Extracellular matrix and cell adhesion molecules

ABSTRACT

The invention provides human extracellular matrix and cell adhesion molecules (ECMCAD) and polynucleotides which identity and encode ECMCAD. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with aberrant expression of ECMCAD.

TECHNICAL FIELD

[0001] This invention relates to nucleic acid and amino acid sequences of extracellular matrix and cell adhesion molecules and to the use of these sequences in the diagnosis, treatment, and prevention of genetic, immune/inflammatory, developmental, neurological, connective tissue, and cell proliferative disorders, including cancer and in the assessment of the effects of exogenous compounds on the expression of nucleic acid and amino acid sequences of extracellular matrix and cell adhesion molecules.

BACKGROUND OF THE INVENTION Extracellular Matrix Proteins

[0002] The extracellular matrix (ECM) is a complex network of glycoproteins, polysaccharides, proteoglycans, and other macromolecules that are secreted from the cell into the extracellular space. The ECM remains in close association with the cell surface and provides a supportive meshwork that profoundly influences cell shape, motility, strength, flexibility, and adhesion. In fact, adhesion of a cell to its surrounding matrix is required for cell survival except in the case of metastatic tumor cells, which have overcome the need for cell-ECM anchorage. This phenomenon suggests that the ECM plays a critical role in the molecular mechanisms of growth control and metastasis. (Reviewed in Ruoslahti, E. (I 996) Sci. Am. 275:72-77.) Furthermore, the ECM determines the structure and physical properties of connective tissue and is particularly important for morphogenesis and other processes associated with embryonic development and pattern formation.

[0003] The collagens comprise a family of ECM proteins that provide structure to bone, teeth, skin, ligaments, tendons, cartilage, blood vessels, and basement membranes. Multiple collagen proteins have been identified. Three collagen molecules fold together in a triple helix stabilized by interchain disulfide bonds. Bundles of these triple helices then associate to form fibrils.

[0004] Elastin and related proteins confer elasticity to tissues such as skin, blood vessels, and lungs. Elastin is a highly hydrophobic protein of about 750 amino acids that is rich in proline and glycine residues. Elastin molecules are highly cross-linked, forming an extensive extracellular network of fibers and sheets. Elastin fibers are surrounded by a sheath of microfibrilins which are composed of a number of glycoproteins, including fibrillin.

[0005] Fibronectin is a large ECM glycoprotein found in all vertebrates. Fibronectin exists as a dimer of two subunits, each containing about 2,500 amino acids. Each subunit folds into a rod-like structure containing multiple domains. The domains each contain multiple repeated modules, the most common of which is the type III fibronectin repeat. The type III fibronectin repeat is about 90 amino acids in length and is also found in other ECM proteins and in some plasma membrane and cytoplasmic proteins. Furthermore, some type III fibronectin repeats contain a characteristic tripeptide consisting of Arginine-Glycine-Aspartic acid (RGD). The RGD sequence is recognized by the integrin family of cell surface receptors and is also found in other ECM proteins. (Reviewed in Alberts, et al. (1994) Molecular Biology of the Cell, Garland Publishing, New York, N.Y., pp. 986-987.)

[0006] Laminin is a major glycoprotein component of the basal lamina which underlies and supports epithelial cell sheets. Laminin is one of the first ECM proteins synthesized in the developing embryo. Laminin is an 850 kilodalton protein composed of three polypeptide chains joined in the shape of a cross by disulfide bonds. Laminin is especially important for angiogenesis and, in particular, for guiding the formation of capillaries. (Reviewed in Alberts, supra, pp. 990-991.)

[0007] Many proteinaceous ECM components are proteoglycans. Proteoglycans are composed of unibranched polysaccharide chains (glycosaminoglycans) attached to protein cores. Common proteoglycans include aggrecan, betaglycan, decorin, perlecan, serglycin, and syndecan-1. Some of these molecules not only provide mechanical support, but also bind to extracellular signaling molecules, such as fibroblast growth factor and transforming growth factor β, suggesting a role for proteoglycans in cell-cell communication. (Reviewed in Alberts, supra, pp. 973-978.)

[0008] Dentin phosphoryn (DPP) is a major component of the dentin ECM. DPP is a proteoglycan that is synthesized and expressed by odontoblasts (Gu, K., et al. (1998) Eur. J. Oral Sci. 106:1043-1047). DPP is believed to nucleate or modulate the formation of hydroxyapatite crystals.

[0009] Mucins are highly glycosylated glycoproteins that are the major structural component of the mucus gel. The physiological functions of mucins are cytoprotection, mechanical protection, maintenance of viscosity in secretions, and cellular recognition. MUC6 is a human gastric mucin that is also found in gall bladder, pancreas, seminal vesicles, and female reproductive tract (Toribara, N. W., et al. (1997) J. Biol. Chem. 272:16398-16403). The MUC6 gene has been mapped to human chromosome 11 (Toribara, N. W., et al. (1993) J. Biol. Chem. 268:5879-5885). Hemomucin is a novel Drosophila surface mucin that may be involved in the induction of antibacterial effector molecules (Theopold, U., et al. (1996) J. Biol. Chem. 217:12708-12715).

[0010] Olfactomedin was originally identified as the major component of the mucus layer surrounding the chemosensory dendrites of olfactory neurons. Olfactomedin-related proteins are secreted glycoproteins with conserved C-terminal motifs. The TIGR/myocilin protein, an olfactomedin-related protein expressed in the eye, is associated with the pathogenesis of glaucoma (Kulkarni, N. H. et al. (2000) Genet. Res. 76:41-50).

[0011] Ankyrin (ANK) repeats mediate protein-protein interactions associated with diverse intracellular functions. ANK repeats are composed of about 33 amino acids that form a helix-turn-helix core preceded by a protruding “tip.” These tips are of variable sequence and may play a role in protein-protein interactions. The helix-turn-helix region of the ANK repeats stack on top of one another and are stabilized by hydrophobic interactions (Yang, Y. et al. (I 998) Structure 6:619-626).

[0012] Sushi repeats, also called short consensus repeats (SCR), are found in a number of proteins that share the common feature of binding to other proteins. For example, in the C-terminal domain of versican, the sushi domain is important for heparin binding. Sushi domains contain basic amino acid residues, which may play a role in binding (Oleszewski, M. et al. (2000) J. Biol. Chem. 275:34478-34485).

[0013] Link, or X-link, modules are hyaluronan-binding domains found in proteins involved in the assembly of extracellular matrix, cell adhesion, and migration. The Link module superfamily includes CD44, cartilage link protein, and aggrecan. There is close similarity between the Link module and the C-type lectin domain, with the predicted hyaluronan-binding site at an analogous position to the carbohydrate-binding pocket in E-selectin (Kohda, D. et al. (1996) Cell, Vol. 86, 767-775).

[0014] Multidomain or mosaic proteins play an important role in the diverse functions of the extracellular matrix (Engel, J. et al. (1994) Development (Camb.) S35-42). ECM proteins are frequently characterized by the presence of one or more domains which may contain a number of potential intracellular disulfide bridge motifs. For example, domains which match the epidermal growth factor (EGF) tandem repeat consensus are present within several known extracellular proteins that promote cell growth, development, and cell signaling. This signature sequence is about forty amino acid residues in length and includes six conserved cysteine residues, and a calcium-binding site near the N-terminus of the signature sequence. The main structure is a two-stranded beta-sheet followed by a loop to a C-terminal short two-stranded sheet. Subdomains between the conserved cysteines vary in length (Davis, C. G. New Biol (1990) May;2(5):410-9). Post-translational hydroxylation of aspartic acid or asparagine residues has been associated with EGF-like domains in several proteins (Prosite PDOC00010 Aspartic acid and asparagine hydroxylation site).

[0015] A number of proteins that contain calcium-binding EGF-like domain signature sequences are involved in growth and differentiation. Examples include bone morphogenic protein 1, which induces the formation of cartilage and bone; crumbs, which is a Drosophila epithelial development protein; Notch and a number of its homologs, which are involved in neural growth and differentiation, and transforming growth factor beta-1 binding protein (Expasy PROSITE document PDOC00913; Soler, C. and Carpenter, G., in Nicola, N. A. (1994) The Cytokine Facts Book, Oxford University Press, Oxford, UK, pp 193-197). EGF-like domains mediate protein-protein interactions for a variety of proteins. For example, EGF-like domains in the ECM glycoprotein fibulin-1 have been shown to mediate both self-association and binding to fibronectin (Tran, H. et al. (1997) J. Biol. Chem. 272:22600-22606). Point mutations in the EGF-like domains of ECM proteins have been identified as the cause of human disorders such as Marfan syndrome and pseudochondroplasia (Maurer, P. et al. (1996) Curr. Opin. Cell Biol. 8:609-617).

[0016] The CUB domain is an extracellular domain of approximately 110 amino acid residues found mostly in developmentally regulated proteins. The CUB domain contains four conserved cysteine residues and is predicted to have a structure similar to that of immunoglobulins. Vertebrate bone morphogenic protein 1, which induces cartilage and bone formation, and fibropellins I and III from sea urchin, which form the apical lamina component of the ECM, are examples of proteins that contain both CUB and EGF domains (PROSITE PDOC00908 CUB domain profile).

[0017] Other ECM proteins are members of the type A domain of von Willebrand factor (vWFA)-like module superfamily, a diverse group of proteins with a module sharing high sequence similarity. The vWFA-like module is found not only in plasma proteins but also in plasma membrane and ECM proteins (Colombatti, A. and Bonaldo, P. (1991) Blood 77:2305-2315). Crystal structure analysis of an integrin vWFA-like module shows a classic “Rossmann” fold and suggests a metal ion-dependent adhesion site for binding protein ligands (Lee, J.-O. et al. (1995) Cell 80:631-638). This family includes the protein matrilin-2, an extracellular matrix protein that is expressed in a broad range of mammalian tissues and organs. Matrilin-2 is thought to play a role in ECM assembly by bridging collagen fibrils and the aggrecan network (Deak, F. et al. (1997) J. Biol. Chem. 272:9268-9274).

[0018] The thrombospondins are multimeric, calcium-binding extracellular glycoproteins found widely in the embryonic extracellular matrix. These proteins are expressed in the developing nervous system or at specific sites in the adult nervous system after injury. Thrombospondins contain multiple EGF-type repeats, as well as a motif known as the thrombospondin type 1 repeat (TSR). The TSR is approximately 60 amino acids in length and contains six conserved cysteine residues. Motifs within TSR domains are involved in mediating cell adhesion through binding to proteoglycans and sulfated glycolipids. Thrombospondin-1 inhibits angiogenesis and modulates endothelial cell adhesion, motility, and growth. TSR domains are found in a diverse group of other proteins, most of which are expressed in the developing nervous system and have potential roles in the guidance of cell and growth cone migration Proteins that share TSRs include the F-spondin gene family, the semapholin 5 family, UNC-5, and SCO-spondin. The TSR superfamily includes the ADAMTS proteins which contain an ADAM (A Disintegin and Metalloproteinase) domain as well as one or more TSRS. The ADAMTS proteins have roles in regulating the turnover of cartilage, matrix, regulation of blood vessel garowth, and possibly development of the nervous system. (Reviewed in Adams, J. C. and Tucker, R. P. (2000) Dev. Dyn. 218:280-299).

[0019] Fibrinogen, the principle protein of vertebrate blood clotting, is a hexamer consisting of two sets of three different chains (alpha, beta, and gamma). The C-terminal domain of the beta and gamma chains comprises about 270 amino acid residues and contains four cysteines involved in two disulfide bonds. This domain has also been found in mammalian tenascin-X, an ECM protein that appears to be involved in cell adhesion (Pro site PDOC00445 Fibrinogen beta and gamma chains C-terminal domain signature).

Adhesion-Associated Proteins

[0020] The surface of a cell is rich in transmembrane proteoglycans, glycoproteins, glycolipids, and receptors. These macromolecules mediate adhesion with other cells and with components of the ECM. The interaction of the cell with its surroundings profoundly influences cell shape, strength, flexibility, motility, and adhesion. These dynamic properties are intimately associated with signal transduction pathways controlling cell proliferation and differentiation, tissue construction, and embryonic development. Families of cell adhesion molecules include the cadherins, integrins, lectins, neural cell adhesion proteins, and some members of the proline-rich proteins.

[0021] Cadherins comprise a family of calcium-dependent glycoproteins that function in mediating cell-cell adhesion in virtually all solid tissues of multicellular organisms. These proteins share multiple repeats of a cadherin-specific motif, and the repeats form the folding units of the cadherin extracellular domain. Cadherin molecules cooperate to form focal contacts, or adhesion plaques, between adjacent epithelial cells. The cadherin family includes the classical cadherins and protoeadherins. Classical cadherins include the E-cadherin, N-cadherin, and P-cadherin subfamilies. E-cadherin is present on many types of epithelial cells and is especially important for embryonic

[0022] Integrins are ubiquitous transmembrane adhesion molecules that link the ECM to the internal cytoskeleton. Integrins are composed of two noncovalently associated transmembrane glycoprotein subunits called α and β. Integrins function as receptors that play a role in signal transduction. For example, binding of integrin to its extracellular ligand may stimulate changes in intracellular calcium levels or protein kinase activity (Sjaastad, M. D. and Nelson, W. J. (1997) BioEssays 19:47-55). At least ten cell surface receptors of the integrin family recognize the ECM component fibronectin, which is involved in many different biological processes including cell migration and embryogenesis (Johansson, S. et al. (1997) Front. Biosci. 2:D126-D146).

[0023] Lectins comprise a ubiquitous family of extracellular glycoproteins which bind cell surface carbohydrates specifically and reversibly, resulting in the agglutination of cells (reviewed in Drickamer, K. and Taylor, M. E. (1993) Annu. Rev. Cell Biol. 9:237-264). This function is particularly important for activation of the immune response. Lectins mediate the agglutination and mitogenic stimulation of lymphocytes at sites of inflammation (Lasky, L. A. (1991) J. Cell. Biochem. 45:139-146; Paietta, E. et al. (1989) J. Immunol. 143:2850-2857).

[0024] Lectins are further classified into subfamilies based on carbohydrate-binding specificity and other criteria. The galectin subfamily, in particular, includes lectins that bind β-galactoside carbohydrate moieties in a thiol-dependent manner (reviewed in Hadari, Y. R. et al. (1998) J. Biol. Chem. 270:3447-3453). Galectins are widely expressed and developmentally regulated. Galectins contain a characteristic carbohydrate recognition domain (CRD). The CRD is about 140 amino acids and contains several stretches of about 1 - 10 amino acids which are highly conserved among all galectins. A particular 6-amino acid motif within the CRD contains conserved tryptophan and arginine residues which are critical for carbohydrate binding. The CRD of some galectins also contains cysteine residues which may be important for disulfide bond formation. Secondary structure predictions indicate that the CRD forms several β-sheets.

[0025] Galectins play a number of roles in diseases and conditions associated with cell-cell and cell-matrix interactions. For example, certain galectins associate with sites of inflammation and bind to cell surface immunoglobulin E molecules. In addition, galectins may play an important role in cancer metastasis. Galectin overexpression is correlated with the metastatic potential of cancers in humans and mice. Moreover, anti-galectin antibodies inhibit processes associated with cell transformation, such as cell aggregation and anchorage-independent growth (see, for example, Su, Z.-Z. et al. (1996) Proc. Natl. Acad. Sci. USA 93:7252-7257).

[0026] Selectins, or LEC-CAMs, comprise a specialized lectin subfamily involved primarily in inflammation and leukocyte adhesion (Reviewed in Lasky, supra). Selectins mediate the recruitment of leukocytes from the circulation to sites of acute inflammation and are expressed on the surface of vascular endothelial cells in response to cytokine signaling. Selectins bind to specific ligands on the leukocyte cell membrane and enable the leukocyte to adhere to and migrate along the endothelial surface. Binding of selectin to its ligand leads to polarized rearrangement of the actin cytoskeleton and stimulates signal transduction within the leukocyte (Breiner, B. et al. (1997) Biochem. Biophys. Res. Commun. 231:802-807; Hidati, K. I. et al. (1997) J. Biol. Chem. 272:28750-28756). Members of the selectin family possess three characteristic motifs: a lectin or carbohydrate recognition domain; an epidermal growth factor-like domain; and a variable number of short consensus repeats (scr or “sushi” repeats) which are also present in complement regulatory proteins.

[0027] Neural cell adhesion proteins (NCAPs) play roles in the establishment of neural networks during development and regeneration of the nervous system (Uyemura et al. (1996) Essays Biochem. 31:37-48; Blummendorf and Rathjen (1996) Curr. Opin. Neurobiol. 6:584-593). NCAP participates in neuronal cell migration, cell adhesion, neurite outgrowth, axonal fasciculation, pathfinding, synaptic target-recognition. synaptic formation, myelination and regeneration. NCAPs are expressed on the surfaces of neurons associated with learning and memory. Mutations in genes encoding NCAPS are linked with neurological diseases, including hereditary neuropathy Charcot-Marie-Tooth disease, Dejerine-Sottas disease, X-linked hydrocephalus, MASA syndrome (mental retardation, aphasia, shuffling gait and adducted thumbs), and spastic paraplegia type I. In some cases, expression of NCAP is not restricted to the nervous system. L1, for example, is expressed in melanoma cells and hematopoiatic tumor cells where it is implicated in cell spreading and migration, and may play a role in tumor progression (Montgomery et al. (1996) J. Cell Biol. 132:475-485).

[0028] NCAPs have at least one immunoglobulin constant or variable domain (Uyemura et al., supra). They are generally linked to the plasma membrane through a transmembrane domain and/or a glycosyl-phosphatidylinositol (GPI) anchor. The GPI linkage can be cleaved by GPI phospholipase C. Most NCAPs consist of an extracellular region made up of one or more immunoglobulin domains, a membrane spanning domain, and an intracellular region. Many NCAPs contain post-translational modifications including covalently attached oligosaccharide, glucuronic acid, and sulfate. NCAPs fall into three subgroups: simple-type, complex-type, and mixed-type. Simple-type NCAPs contain one or more variable or constant immunoglobulin domains, but lack other types of domains. Members of the simple-type subgroup include Schwann cell myclin protein (SMP), limbic system-associated membrane protein (LAMP), opiate-binding cell-adhesion molecule (OBCAM), and myelin-associated glycoprotein (MAG). The complex-type NCAPs contain fibronectin type III domains in addition to the immunoglobulin domains. The complex-type subgroup includes neural cell-adhesion molecule (NCAM), axonin-1, F11, Bravo, and L1. Mixed-type NCAPs contain a combination of immunoglobulin domains and other motifs such as tyrosine kinase and epidermal growth factor-like domains. This subgroup includes Trk receptors of nerve growth factors such as nerve growth factor (NGF) and neurotropin 4 (NT4), Neu differentiation factors such as glial growth factor II (GGFUI) and acctylcholinc receptor-inducing factor (ARIA), and the semaphorin/collapsin family such as semaphorin B and collapsin.

[0029] Semaphorins are a large group of axonal guidance molecules consisting of at least 30 different members and are found in vertebrates, invertebrates, and even certain viruses. All semaphorins contain the soma domain which is approximately 500 amino acids in length. Neuropilin, a semaphorin receptor has been shown to promote neurite outgrowth in vitro. The extracellular region of neuropilins consists of three different domains: CUB, discoidin, and MAM domains. The CUB and the MAM motifs of neuropilin have been suggested as having roles in protein-protein interactions and are suggested to be involved in the binding of semaphorins through the sema and the C-terminal domains (reviewed in Raper, J. A. (2000) Curr. Opin. Neurobiol. 10:88-94).

[0030] An NCAP subfamily, the NCAP-LON subgroup, includes cell adhesion proteins expressed on distinct subpopulations of brain neurons. Members of the NCAP-LON subgroup possess three immunoglobulin domains and bind to cell membranes through GPI anchors. Kilon (a kindred of NCAP-LON), for example, is expressed in the brain cerebral cortex and hippocampus (Funatsu et al. (1999) J. Biol. Chem. 274:8224-8230). Immunostaining localizes Kilon to the dendrites and soma of pyramidal neurons. Kilon has three C2 type immunoglobulin-like domains, six predicted glycosylation sites, and a GPI anchor. Expression of Kilon is developmentally regulated. It is expressed at higher levels in adult brain in comparison to embryonic and early postnatal brains. Confocal microscopy shows the presence of Kilon in dendrites of hypothalamic magnocellular neurons secreting neuropeptides, oxytocin or arginine vasopressin (Miyata et al. (2000) J. Comp. Neurol. 424:74-85). Arginine vasopressin regulates body fluid homeostasis, extracellular osmolarity and intravascular volume. Oxytocin induces contractions of uterine smooth muscle during child birth and of myoepithelial cells in mammary glands during lactation. In magnocellular neurons, Kilon is proposed to play roles in the reorganization of dendritic connections during neuropeptide secretion.

[0031] Cell adhesion proteins also include some members of the proline-rich proteins (PRPs). PRPs are defined by a high frequency of proline, ranging from 20-50% of the total amuino acid content. Some PRPs have short domains which are rich in proline. These proline-rich regions are associated with protein-protein interactions. One family of PRPs are the proline-rich synapse-associated proteins (ProSAPs) which have been shown to bind to members of the postsynaptic density (PSD) protein family and subtypes of the somatostatin receptor (Yao, I. et al. (1999) J. Biol. Chem. 274: 27463-27466; Zitzer, H. et al. (1999) J. Biol. Chem. 274:32997-33001). Members of ProSAP contain at the N-terminus six to seven ankyrin repeats, followed by an SH3 domain, a PDZ domain, then by seven proline-rich regions and a SAM domain at the C terminus. Several groups of ProSAP are important structural constituents of synaptic structures in human brain (Ziter et al., supra). Another member of PRP is the HLA-B-associated transcript 2 protein (BAT2) which is rich in proline and include short tracts of polyproline, polyglycine, and charged amino acids. BAT2 also contains four RGD (Arg-Gly-Asp) motifs typical of integrins (Bancrji, J. et al. (1990) Proc. Natl. Acad. Sci. USA 87:2374-2378).

[0032] There are additional specific domains characteristic of cell adhesion proteins. One such domain is the MAM domain, a domain of about 170 amino acids found in the extracellular region of diverse proteins. These proteins all share a receptor-like architecture comprising a signal peptide, followed by a large N-terminal extracellular domain, a transmembrane region, and an intracellular domain. (PROSITE document PDOC00604 MAM domain signature and profile). MAM domain proteins include zonadhesin, a sperm-specific membrane protein that binds to the zona pellucida of the egg; neuropilin, a cell adhesion molecule that functions during the formation of certain neuronal circuits, and Xenonus laevis thyroid hormone induced protein B, which contains four MAM domains and is involved in metamorphosis (Brown, D. D. et al. (1996) Proc. Natl. Acad. Sci. USA 93:1924-1929).

[0033] The WSC domain was originally found in the yeast WSC (cell-wall integrity and stress response component) proteins which act as sensors of environmental stress. The WSC domains are extracellular and are thought to possess a carbohydrate binding role (Ponting, C. P. et al. (1999) Curr. Biol. 9:S1-S2). A WSC domain has recently been identified in polycystin-1, a human plasma membrane protein. Mutations in polycystin-1 are the cause of the commonest form of autosonial dominant polycystic kidney disease (Ponting, C. P. et al. (1999) Curr. Biol. 9:R585-R588).

[0034] Toposome is a cell-adhesion glycoprotein isolated from mesenchyme-blastula embryos. Toposome precursors including vitellogenin promote cell adhesion of dissociated blastula cells.

[0035] Leucine rich repeats (LRR) are short motifs found in numerous proteins from a wide range of species. LRR motifs are of variable length, most commonly 20-29 amino acids and multiple repeats are typically present in tandem. LRR is important for protein/protein interactions and cell adhesion, and LRR proteins are involved in cell/cell interactions, morphogenesis, and development (Kobe, B. and Deisenhofer, J. (1 995) Curr. Opin. Struct. Biol. 5:409-416). The human ISLR (immunoglobulin superfamnily containing leucine-rich repeat) protein contains a C2-type immunoglobulin domain as well as LRR. The ISLR gene is linked to the critical region for Bardet-Biedl syndrome, a developmental disorder of which the most common feature is retinal dystrophy (Nagasawa, A. et al. (1999) Genomics 61:37-43).

[0036] The sterile alpha motif (SAM) domain is a conserved protein binding domain, approximately 70 amino acids in length, and is involved in the regulation of many developmental processes in many eukaryotes. The SAM domain can potentially function as a protein interaction module through its ability to form homo- or hetero-oligomers with other SAM domains (Schultz, J. et al. (1997) Protein Sci. 6:249-253).

[0037] The discovery of new extracellular matrix and cell adhesion molecules and the polynucleotides encoding them satisfies a need in the art by providing new compositions which are useful in the diagnosis, prevention, and treatment of genetic, immune/inflammatory, developmental, neurological, connective tissue, and cell proliferative disorders, including cancer, and in the assessment of the effects of exogenous compounds on the expression of nucleic acid and amino acid sequences of extracellular matrix and cell adhesion molecules.

SUMMARY OF THE INVENTION

[0038] The invention features purified polypeptides, extracellular matrix and cell adhesion molecules, referred to collectively as “ECMCAD” and individually as “ECMCAD-1,” “ECMCAD-2,” “ECMCAD-3,” “ECMCAD-4,” “ECMCAD-5,” “ECMCAD-6,” “ECMCAD-7,” “ECMCAD-8,” “ECMCAD-9,” “ECMCAD-10,” “ECMCAD-11,” “ECMCAD-12,” “ECMCAD-13,” “ECMCAD-14,” “ECMCAD-15,” “ECMCAD-16,” “ECMCAD-17,” “ECMCAD-18,” “ECMCAD-19,” “ECMCAD-20,” “ECMCAD-21,” “ECMCAD-22,” “ECMCAD-23,” “ECMCAD-24,” “ECMCAD-25,” “ECMCAD-26,” “ECMCAD-27,” “ECMCAD-28,” “ECMCAD-29,” “ECMCAD-30,” “ECMCAD-31,” “ECMCAD-32,” “ECMCAD-33,” “ECMCAD-34,” “ECMCAD-35,” and “ECMCAD-36.” In one aspect, the invention provides an isolated polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-36, b) a naturally occurring polypeptide comprising an amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-36, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-36, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-36. In one alternative, the invention provides an isolated polypeptide comprising the amino acid sequence of SEQ ID NO:1-36.

[0039] The invention further provides an isolated polynucleotide encoding a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-36, b) a naturally occurring polypeptide comprising an amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-36, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-36, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-36. In one alternative, the polynucleotide encodes a polypeptide selected from the group consisting of SEQ ID NO:1-36. In another alternative, the polynucleotide is selected from the group consisting of SEQ ID NO:37-72.

[0040] Additionally, the invention provides a recombinant polynucleotide comprising a promoter sequence operably linked to a polynucleotide encoding a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-36, b) a naturally occurring polypeptide comprising an amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-36, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-36, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-36. In one alternative, the invention provides a cell transformed with the recombinant polynucleotide. In another alternative, the invention provides a transgenic organism comprising the recombinant polynucleotide.

[0041] The invention also provides a method for producing a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-36, b) a naturally occurring polypeptide comprising an amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-36, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-36, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-36. The method comprises a) culturing a cell under conditions suitable for expression of the polypeptide, wherein said cell is transformed with a recombinant polynucleotide comprising a promoter sequence operably linked to a polynucleotide encoding the polypeptide, and b) recovering the polypeptide so expressed.

[0042] Additionally, the invention provides an isolated antibody which specifically binds to a polypeptide selected from ide group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 1-36, b) a naturally occurring polypeptide comprising an amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-36, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-36, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-36.

[0043] The invention further provides an isolated polynucleotide selected from the group consisting of a) a polynucleotide comprising a polynucleotide sequence selected forms the group consisting of SEQ ID NO:37-72, b) a naturally occurring polynucleotide comprising a polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO:37-72, c) a polynucleotide complementary to the polynucleotide of a), d) a polynucleotide complementary to the polynucleotide of b), and e) an RNA equivalent of a)-d). In one alternative, the polynucleotide comprises at least 60 contiguous nucleotides.

[0044] Additionally, the invention provides a method for detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide selected from the group consisting of a) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID, NO:37-72, b) a naturally occurring polynucleotide comprising a polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO:37-72, c) a polynucleotide complementary to the polynucleotide of a), d) a polynucleotide complementary to the polynucleotide of b), and c) an RNA equivalent of a)-d). The method comprises a) hybridizing the sample with a probe comprising at least 20 contiguous nucleotides comprising a sequence complementary to said target polynucleotide in the sample, and which probe specifically hybridizes to said target polynucleotide, under conditions whereby a hybridization complex is formed between said probe and said target polynucleotide or fragments thereof, and b) detecting the presence or absence of said hybridization complex, and optionally, if present, the amount thereof. In one alternative, the probe comprises at least 60 contiguous nucleotides.

[0045] The invention further provides a method for detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide selected from the group consisting of a) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:37-72, b) a naturally occurring polynucleotide comprising a polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO:37-72, c) a polynucleotide complementary to the polynucleotide of a), d) a polynucleotide complementary to the polynucleotide of b), and e) an RNA equivalent of a)-d). The method comprises a) amplifying said target polynucleotide or fragment thereof using polymerase chain reaction amplification, and b) detecting the presence or absence of said amplified target polynucleotide or fragment thereof, and, optionally, if present, the amount thereof.

[0046] The invention further provides a composition comprising an effective amount of a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 1-36, b) a naturally occurring polypeptide comprising an amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-36, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1 -36, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO: 1 -36, and a pharmaceutically acceptable excipient. In one embodiment, the composition comprises an amino acid sequence selected from the group consisting of SEQ ID NO:1-36. The invention additionally provides a method of treating a disease or condition associated with decreased expression of functional ECMCAD, comprising administering to a patient in need of such treatment the composition.

[0047] The invention also provides a method for screening a compound for effectiveness as an agonist of a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-36, b) a naturally occurring polypeptide comprising an amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-36, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1 -36, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-36. The method comprises a) exposing a sample comprising the polypeptide to a compound, and b) detecting agonist activity in the sample. In one alternative, the invention provides a composition comprising an agonist compound identified by the method and a pharmaceutically acceptable excipient. In another alternative, the invention provides a method of treating a disease or condition associated with decreased expression of functional ECMCAD, comprising administering to a patient in need of such treatment the composition.

[0048] Additionally, the invention provides a method for screening a compound for effectiveness as an antagonist of a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-36, b) a naturally occurring polypeptide comprising an amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-36, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-36, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-36. The method comprises a) exposing a sample comprising the polypeptide to a compound, and b) detecting antagonist activity in the sample. In one alternative, the invention provides a composition comprising an antagonist compound identified by the method and a pharmaceutically acceptable excipient. In another alternative, the invention provides a method of treating a disease or condition associated with overexpression of functional ECMCAD, comprising administering to a patient in need of such treatment the composition.

[0049] The invention further provides a method of screening for a compound that specifically binds to a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the, group consisting of SEQ ID NO: 1-36, b) a naturally occurring polypeptide comprising an amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-36, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-36, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-36. The method comprises a) combining the polypeptide with at least one test compound under suitable conditions, and b) detecting binding of the polypeptide to the test compound, thereby identifying a compound that specifically binds to the polypeptide.

[0050] The invention further provides a method of screening for a compound that modulates the activity of a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 1-36, b) a naturally occurring polypeptide comprising an amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-36, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-36, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-36. The method comprises a) combining the polypeptide with at least one test compound under conditions permissive for the activity of the polypeptide, b) assessing the activity of the polypeptide in the presence of the test compound, and c) comparing the activity of the polypeptide in the presence of the test compound with the activity of the polypeptide in the absence of the test compound, wherein a change in the activity of the polypeptide in the presence of the test compound is indicative of a compound that modulates the activity of the polypeptide.

[0051] The invention further provides a method for screening a compound for effectiveness in altering expression of a target polynucleotide, wherein said target polynucleotide comprises a sequence selected from the group consisting of SEQ ID NO:37-72, the method comprising a) exposing a sample comprising the target polynucleotide to a compound, and b) detecting altered expression of the target polynucleotide.

[0052] The invention further provides a method for assessing toxicity of a test compound, said method comprising a) treating a biological sample containing nucleic acids with the test compound; b) hybridizing the nucleic acids of the treated biological sample with a probe comprising at least 20 contiguous nucleotides of a polynucleotide selected from the group consisting of i) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:37-72, ii) a naturally occurring polynucleotide comprising a polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO:37-72, iii) a polynucleotide having a sequence complementary to i), iv) a polynucleotide complementary to the polynucleotide of ii), and v) an RNA equivalent of i)-iv). Hybridization occurs under conditions whereby a specific hybridization complex is formed between said probe and a target polynucleotide in the biological sample, said target polynucleotide selected from the group consisting of i) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:37-72, ii) a naturally occurring polynucleotide comprising a polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO:37-72, iii) a polynucleotide complementary to the polynucleotide of i), iv) a polynucleotide complementary to the polynucleotide of ii), and v) an RNA equivalent of i)-iv). Alternatively, the target polynucleotide comprises a fragment of a polynucleotide sequence selected from the group consisting of i)-v) above; c) quantifying the amount of hybridization complex; and d) comparing the amount of hybridization complex in the treated biological sample with the amount of hybridization complex in an untreated biological sample, wherein a difference in the amount of hybridization complex in the treated biological sample is indicative of toxicity of the test compound.

BRIEF DESCRIPTION OF THE TABLES

[0053] Table 1 summarizes the nomenclature for the full length polynucleotide and polypeptide sequences of the present invention.

[0054] Table 2 shows the GenBank identification number and annotation of the nearest GenBank homolog for polypeptides of the invention. The probability score for the match between each polypeptide and its GenBank homolog is also shown.

[0055] Table 3 shows structural features of polypeptide sequences of the invention, including predicted motifs and domains, along with the methods, algorithms, and searchable databases used for analysis of the polypeptides.

[0056] Table 4 lists the cDNA and/or genomic DNA fragments which were used to assemble polynucleotide sequences of the invention, along with selected fragments of the polynucleotide sequences.

[0057] Table 5 shows the representative cDNA library for polynucleotides of the invention.

[0058] Table 6 provides an appendix which describes the tissues and vectors used for construction of the cDNA libraries shown in Table 5.

[0059] Table 7 shows the tools, programs, and algorithims used to analyze the polynucleotides and polypeptides of the invention, along with applicable descriptions, references, and threshold parameters.

DESCRIPTION OF THE INVENTION

[0060] Before the present proteins, nucleotide sequences, and methods are described, it is understood that this invention is not limited to the particular machines, materials and methods described, as these may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present invention which will be limited only by the appended claims.

[0061] It must be noted that as used herein and in the appended claims, the singular forms “a,” “an,” and “the” include plural reference unless the context clearly dictates otherwise. Thus, for example, a reference to “a host cell” includes a plurality of such host cells, and a reference to “an antibody” is a reference to one or more antibodies and equivalents thereof known to those skilled in the art, and so forth.

[0062] Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any machines, materials, and methods similar or equivalent to those described herein can be used to practice or test the present invention, the preferred machines, materials and methods are now described. All publications mentioned herein are cited for the purpose of describing and disclosing the cell lines, protocols, reagents and vectors which are reported in the publications and which might be used in connection with the invention. Nothing herein is to be construed as an admission that the invention is not entitled to antedate such disclosure by virtue of prior invention.

DEFINITIONS

[0063] “ECMCAD” refers to the amino acid sequences of substantially purified ECMCAD obtained from any species, particularly a mammalian species, including bovine, ovine, porcine, murine, equine, and human, and from any source, whether natural, synthetic, semi-synthetic, or recombinant.

[0064] The term “agonist” refers to a molecule which intensifies or mimics the biological activity of ECMCAD. Agonists may include proteins, nucleic acids, carbohydrates, small molecules, or any other compound or composition which modulates the activity of ECMCAD either by directly interacting with ECMCAD or by acting oil components of the biological pathway in which ECMCAD participates.

[0065] An “allelic variant” is an alternative form of the gene encoding ECMCAD. Allelic variants may result from at least one mutation in the nucleic acid sequence and may result in altered mRNAs or in polypeptidcs whose structure or function may or may not be altered. A gene may have none, one, or many allelic variants of its naturally occurring form. Common mutational changes which give rise to allelic variants are generally ascribed to natural deletions, additions, or substitutions of nucleotides. Each of these types of changes may occur alone, or in combination with the others, one or more times in a given sequence.

[0066] “Altered” nucleic acid sequences encoding ECMCAD include those sequences with deletions, insertions, or substitutions of different nucleotides, resulting in a polypeptide the same as ECMCAD or a polypeptide with at least one functional characteristic of ECMCAD. Included within this definition are polymorphisms which may or may not be readily detectable using a particular oligonucleotide probe of the polynucleotide encoding ECMCAD, and improper or unexpected hybridization to allelic variants, with a locus other than the normal chromosomal locus for the polynucleotide sequence encoding ECMCAD. The encoded protein may also be “altered,” and may contain deletions, insertions, or substitutions of amino acid residues which produce a silent change and result in a functionally equivalent ECMCAD. Deliberate amino acid substitutions may be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues, as long as the biological or immunological activity of ECMCAD is retained. For example, negatively charged amino acids may include aspailtic acid and glutamic acid, and positively charged amino acids may include lysine and arginine. Amino acids with uncharged polar side chains having similar hydrophilicity values may include: asparagine and glutamine; and serine and threonine. Amino acids with uncharged side chains having similar hydrophilicity values may include: leucine, isoleucine, and valine; glycine and alanine; and phenylalanine and tyrosine.

[0067] The terms “amino acid” and “amino acid sequence” refer to an oligopeptide, peptide, polypeptide, or protein sequence, or a fragment of any of these, and to naturally occurring or synthetic molecules. Where “amino acid sequence” is recited to refer to a sequence of a naturally occurring protein molecule, “amino acid sequence” and like terms are not meant to limit the amino acid sequence to the complete native amino acid sequence associated with the recited protein molecule.

[0068] “Amplification” relates to the production of additional copies of a nucleic acid sequence. Amplification is generally carried out using polymerase chain reaction (PCR) technologies well known in the art.

[0069] The term “antagonist” refers to a molecule which inhibits or attenuates the biological activity of ECMCAD. Antagonists may include proteins such as antibodies, nucleic acids, carbohydrates, small molecules, or any other compound or composition which modulates the activity of ECMCAD either by directly interacting with ECMCAD or by acting on components of the biological pathway in which ECMCAD participates.

[0070] The term “antibody” refers to intact immunoglobulin molecules as well as to fragments thereof, such as Fab, F(ab′)₂, and Fv fragments, which are capable of binding an epitopic determinant. Antibodies that bind ECMCAD polypeptides can be prepared using intact polypeptides or using fragments containing small peptides of interest as the immunizing antigen. The polypeptide or oligopeptide used to immunize an animal (e.g., a mouse, a rat, or a rabbit) can be derived from the translation of RNA, or synthesized chemically, and can be conjugated to a carrier protein if desired. Commonly used carriers that are chemically coupled to peptides include bovine serum albumin, thyroglobulin, and keyhole limpet hemocyanin (KLH). The coupled peptide is then used to immunize the animal.

[0071] The term “antigenic determinant” refers to that region of a molecule (i.e., an epilope) that makes contact with a particular antibody. When a protein or a fragment of a protein is used to immunize a host animal, numerous regions of the protein may induce the production of antibodies which bind specifically to antigenic determinants (particular regions or three-dimensional structures on the protein). An antigenic determinant may compete with the intact antigen (i.e., the immunogen used to elicit the immune response) for binding to an antibody.

[0072] The term “antisense” refers to any composition capable of base-pairing with the “sense” (coding) strand of a specific nucleic acid sequence. Antisense compositions may include DNA; RNA; peptide nucleic acid (PNA); oligonucleotides having modified backbone linkages such as phosphorothioates, methylphosphonates, or benzylphosphonates; oligonucleotides having modified sugar groups such as 2′-methoxyethyl sugars or 2′-methoxyethoxy sugars; or oligonucleotides having modified bases such as 5-methyl cytosine, 2′-deoxyuracil, or 7-deaza-2′-deoxyguanosine. Antisense molecules may be produced by any method including chemical synthesis or transcription. Once introduced into a cell, the complementary antisense molecule base-pairs with a naturally occurring nucleic acid sequence produced by the cell to form duplexes which block either transcription or translation. The designation “negative” or “minus” can refer to the antisense strand, and the designation “positive” or “plus” can refer to the sense strand of a reference DNA molecule.

[0073] The term “biologically active” refers to a protein having structural, regulatory, or biochemical functions of a naturally occurring molecule. Likewise, “immunologically active” or “immunogenic” refers to the capability of the natural, recombinant, or synthetic ECMCAD, or of any oligopeptide thereof, to induce a specific immune response in appropriate animals or cells and to bind with specific antibodies.

[0074] “Complementary” describes the relationship between two single-stranded nucleic acid sequences that anneal by base-pairing. For example, 5′-AGT-3′ pairs with its complement, 3′-TCA-5′.

[0075] A “composition comprising a given polynucleotide sequence” and a “composition comprising a given amino acid sequence” refer broadly to any composition containing the given polynucleotide or amino acid sequence. The composition may comprise a dry formulation or an aqueous solution. Compositions comprising polynucleotide sequences encoding ECMCAD or fragments of ECMCAD may be employed as hybridization probes. The probes may be stored in freeze-dried form and may be associated with a stabilizing agent such as a carbohydrate. In hybridizations, the probe may be deployed in an aqueous solution containing salts (e.g., NaCl), detergents (e.g., sodium dodecyl sulfate; SDS), and other components (e.g., Denhardt's solution, dry milk, salmon sperm DNA, etc.).

[0076] “Consensus sequence” refers to a nucleic acid sequence which has been subjected to repeated DNA sequence analysis to resolve uncalled bases, extended using the XL-PCR kit (Applied Biosystems, Foster City Calif.) in the 5′ and/or the 3′ direction, and resequenced, or which has been assembled from one or more overlapping cDNA, EST, or genomic DNA fragments using a computer program for fragment assembly, such as the GELVIEW fragment assembly system (GCG, Madison Wis.) or Phrap (University of Washington, Seattle Wash.). Some sequences have been both extended and assembled to produce the consensus sequence.

[0077] “Conservative amino acid substitutions” are those substitutions that are predicted to least interfere with the properties of the original protein, i.e., the structure and especially the function of the protein is conserved and not significantly changed by such substitutions. The table below shows amino acids which may be substituted for an original amino acid in a protein and which are regarded as conservative amino acid substitutions. Original Residue Conservative Substitution Ala Gly, Ser Arg His, Lys Asn Asp, Gln, His Asp Asn, Glu Cys Ala, Ser Gln Asn, Glu, His Glu Asp, Gln, His Gly Ala His Asn, Arg, Gln, Glu Ile Leu, Val Leu Ile, Val Lys Arg, Gln, Glu Met Leu, Ile Phe His, Met, Leu, Trp, Tyr Ser Cys, Thr Thr Ser, Val Trp Phe, Tyr Tyr His, Phe, Trp Val Ile, Leu, Thr

[0078] Conservative amino acid substitutions generally maintain (a) the structure of the polypeptide backbone in the area of the substitution, for example, as a beta sheet or alpha helical conformation, (b) the charge or hydrophobicity of the molecule at the site of the substitution, and/or (c) the bulk of the side chain.

[0079] A “deletion” refers to a change in the amino acid or nucleotide sequence that results in the absence of one or more amino acid residues or nucleotides.

[0080] The term “derivative” refers to a chemically modified polynucleotide or polypeptide. Chemical modifications of a polynucleotide can include, for example, replacement of hydrogen by an alkyl, acyl, hydroxyl, or amino group. A derivative polynucleotide encodes a polypeptide which retains at least one biological or immunological function of the natural molecule. A derivative polypeptide is one modified by glycosylation, pegylation, or any similar process that retains at least one biological or immunological function of the polypeptide from which it was derived.

[0081] A “detectable label” refers to a reporter molecule or enzyme that is capable of generating a measurable signal and is covalently or noncovalently joined to a polynucleotide or polypeptide.

[0082] “Differential expression” refers to increased or upregulated; or decreased, downregulated, or absent gene or protein expression, determined by comparing at least two different samples. Such comparisons may be carried out between, for example, a treated and an untreated sample, or a diseased and a normal sample.

[0083] A “fragment” is a unique portion of ECMCAD or the polynucleotide encoding ECMCAD which is identical in sequence to but shorter in length than the parent sequence. A fragment may comprise up to the entire length of the defined sequence, minus one nucleotide/amino acid residue. For example, a fragment may comprise from 5 to 1000 continuous nucleotides or amino acid residues. A fragment used as a probe, primer, antigen, therapeutic molecule, or for other purposes, may be at least 5, 10, 15, 16, 20, 25, 30, 40, 50, 60, 75, 100, 150, 250 or at least 500 contiguous nucleotides or amino acid residues in length. Fragments may be preferentially selected from certain regions of a molecule. For example, a polypeptide fragment may comprise a certain length of contiguous amino acids selected from the first 250 or 500 amino acids (or first 25% or 50%) of a polypeptide as shown in a certain defined sequence. Clearly these lengths are exemplary, and any length that is supported by the specification, including the Sequence Listing, tables, and figures, may be encompassed by the present embodiments.

[0084] A fragment of SEQ ID NO:37-72 comprises a region of unique polynucleotide sequence that specifically identifies SEQ ID NO :37-72, for example, as distinct from any other sequence in the genome from which the fragment was obtained. A fragment of SEQ ID NO:37-72 is useful, for example, in hybridization and amplification technologies and in analogous methods that distinguish SEQ ID NO:37-72 from related polynucleotide sequences. The precise length of a fragment of SEQ ID NO:37-72 and the region of SEQ ID NO:37-72 to which the fragment corresponds are routinely determinable by one of ordinary skill in the art based on the intended purpose for the fragment.

[0085] A fragment of SEQ ID NO:1-36 is encoded by a fragment of SEQ ID NO:37-72. A fragment of SEQ ID NO:1-36 comprises a region of unique amino acid sequence that specifically identifies SEQ ID NO:1-36. For example, a fragment of SEQ ID NO:1-36 is useful as an immunogenic peptide for the development of antibodies that specifically recognize SEQ ID NO :1-36. The precise length of a fragment of SEQ ID NO:1-36 and the region of SEQ ID NO:1-36 to which the fragment corresponds are routinely determinable by one of ordinary skill in the art based on the intended purpose for the fragment.

[0086] A “full length” polynucleotide sequence is one containing at least a translation initiation codon (e.g., methionine) followed by an open reading frame and a translation termination codon. A “full length” polynucleotide sequence encodes a “full length” polypeptide sequence.

[0087] “Homology” refers to sequence similarity or, interchangeably, sequence identity, between two or more polynucleotide sequences or two or more polypeptide sequences.

[0088] The terms “percent identity” and “% identity,” as applied to polynucleotide sequences, refer to the percentage of residue matches between at least two polynucleotide sequences aligned using a standardized algorithm. Such an algorithm may insert, in a standardized and reproducible way, gaps in the sequences being compared in order to optimize alignment between two sequences, and therefore achieve a more meaningful comparison of the two sequences.

[0089] Percent identity between polynucleotide sequences may be determined using the default parameters of the CLUSTAL V algorithm as incorporated into the MEGALIGN version 3.12e sequence alignment program. This program is part of the LASERGENE software package, a suite of molecular biological analysis programs (DNASTAR, Madison Wis.). CLUSTAL V is described in Higgins, D. G. and P. M. Sharp (1989) CABIOS 5:151-153 and in Higgins, D. G. et al. (1992) CABIOS 8:189-191. For pairwise alignments of polynucleotide sequences, the default parameters are set as follows: Ktuple=2, gap penalty=5, window=4, and “diagonals saved”=4. The “weighied” residue weight table is selected as the default. Percent identity is reported by CLUSTAL V as the “percent similarity” between aligned polynucleotide sequences.

[0090] Alternatively, a suite of commonly used and freely available sequence comparison algorithms is provided by the National Center for Biotechnology Information (NCBI) Basic Local Alignment Search Tool (BLAST) (Altschul, S. F. et al. (1990) J. Mol. Biol. 215:403-410), which is available from several sources, including the NCBI, Bethesda, Md., and on the Internet at http://www.ncbi.nlm.nih.gov/BLAST/. The BLAST software suite includes various sequence analysis programs including “blastn,” that is used to align a known polynucleotide sequence with other polynucleotide sequences from a variety of databases. Also available is a tool called “BLAST 2 Sequences” that is used for direct pairwise comparison of two nucleotide sequences. “BLAST 2 Sequences” can be accessed and used interactively at http://www.ncbi.nlm.nih.gov/gorf/bl2.html. The “BLAST 2 Sequences” tool can be used for both blastn and blastp (discussed below). BLAST programs are commonly used with gap and other parameters set to default settings. For example, to compare two nucleotide sequences, one may use blastn with the “BLAST 2 Sequences” tool Version 2.0.12 (Apr. 21, 2000) set at default parameters. Such default parameters may be, for example:

[0091] Matrix: BLOSUM62

[0092] Reward for match: 1

[0093] Penalty for mismatch: −2

[0094] Open Gap: 5 and Extension Gap: 2 penalties

[0095] Gap x drop-off: 50

[0096] Expect: 10

[0097] Word Size: 11

[0098] Filter: on

[0099] Percent identity may be measured over the length of an entire defined sequence, for example, as defined by a particular SEQ ID number, or may be measured over a shorter length, for example, over the length of a fragment taken from a larger, defined sequence, for instance, a fragment of at least 20, at least 30, at least 40, at least 50, at least 70, at least 100, or at least 200 contiguous nucleotides. Such lengths are exemplary only, and it is understood that any fragment length supported by the sequences shown herein, in the tables, figures, or Sequence Listing, may be used to describe a length over which percentage identity may be measured.

[0100] Nucleic acid sequences that do not show a high degree of identity may nevertheless encode similar amino acid sequences due to the degeneracy of the genetic code. It is understood that changes in a nucleic acid sequence can be made using this degeneracy to produce multiple nucleic acid sequences that all encode substantially the same protein.

[0101] The phrases “percent identity” and “% identity,” as applied to polypeptide sequences, refer to the percentage of residue matches between at least two polypeptide sequences aligned using a standardized algorithm. Methods of polypeptide sequence alignment are well-known. Some alignment methods take into account conservative amino acid substitutions. Such conservative substitutions, explained in more detail above, generally preserve the charge and hydrophobicity at the site of substitution, thus preserving the structure (and therefore function) of the polypeptide.

[0102] Percent identity between polypeptide sequences may be determined using the default parameters of the CLUSTAL V algorithm as incorporated into the MEGALIGN version 3.12e sequence alignment program (described and referenced above). For pairwise alignments of polypeptide sequences using CLUSTAL V, the default parameters are set as follows: Ktuple=1, gap penalty=3, window=5, and “diagonals saved”=5. The PAM250 matrix is selected as the default residue weight table. As with polynucleotide alignments, the percent identity is reported by CLUSTAL V as the “percent similarity” between aligned polypeptide sequence pairs.

[0103] Alternatively the NCBI BLAST software suite may be used. For example, for a pairwise comparison of two polypeptide sequences, one may use the “BLAST 2 Sequences” tool Version 2.0.12 (Apr. 21, 2000) with blastp set at default parameters. Such default parameters may be, for example:

[0104] Matrix: BLOSUM62

[0105] Open Gap: 11 and Extension Gap: 1 penalties

[0106] Gap x drop-off: 50

[0107] Expect: 10

[0108] Word Size: 3

[0109] Filter: on

[0110] Percent identity may be measured over the length of an entire defined polypeptide sequence, for example, as defined by a particular SEQ ID number, or may be measured over a shorter length, for example, over the length of a fragment taken from a larger, defined polypeptide sequence, for instance, a fragment of at least 15, at least 20, at least 30, at least 40, at least 50, at least 70 or at least 150 contiguous residues. Such lengths are exemplary only, and it is understood that any fragment length supported by the sequences shown herein, in the tables, figures or Sequence Listing, may be used to describe a length over which percentage identity may be measured.

[0111] “Human artificial chromosomes” (HACs) are linear microchromosomes which may contain DNA sequences of about 6 kb to 10 Mb in size and which contain all of the elements required for chromosome replication, segregation and maintenance.

[0112] The term “humanized antibody” refers to an antibody molecule in which the amino acid sequence in the non-antigen binding regions has been altered so that the antibody more closely resembles a human antibody, and still retains its original binding ability.

[0113] “Hybridization” refers to the process by which a polynucleotide strand anneals with a complementary strand through base pairing under defined hybridization conditions. Specific hybridization is an indication that two nucleic acid sequences share a high degree of complementarity. Specific hybridization complexes form under permissive annealing conditions and remain hybridized after the “washing” step(s). The washing step(s) is particularly important in determining the stringency of the hybridization process, with more stringent conditions allowing less non-specific binding, i.e., binding between pairs of nucleic acid strands that are not perfectly matched. Permissive conditions for annealing of nucleic acid sequences are routinely determinable by one of ordinary skill in the art and may be consistent among hybridization experiments, whereas wash conditions may be varied among experiments to achieve the desired stringency, and therefore hybridization specificity. Permissive annealing conditions occur, for example, at 68° C. in the presence of about 6×SSC, about 1% (w/v) SDS, and about 100 μg/ml sheared, denatured salmon sperm DNA.

[0114] Generally, stringency of hybridization is expressed, in part, with reference to the temperature under which the wash step is carried out. Such wash temperatures are typically selected to be about 5° C. to 20° C. lower than the thermal melting point (T_(m)) for the specific sequence at a defined ionic strength and pH. The T_(m) is the temperature (under defined ionic strength and pH) at which 50% of the target sequence hybridizes to a perfectly matched probe. An equation for calculating T_(m) and conditions for nucleic acid hybridization are well known and can be found in Sambrook, J. et al. (1989) Molecular Cloning: A Laboratory Manual, 2^(nd) ed., vol. 1-3, Cold Spring Harbor Press, Plainview N.Y.; specifically see volume 2, chapter 9.

[0115] High stringency conditions for hybridization between polynucleotides of the present invention include wash conditions of 68° C. in the presence of about 0.2×SSC and about 0.1% SDS, for 1 hour. Alternatively, temperatures of about 65° C., 60° C., 55° C., or 42° C. may be used. SSC concentration may be varied from about 0.1 to 2×SSC, with SDS being present at about 0.1%. Typically, blocking reagents are used to block non-specific hybridization. Such blocking reagents include, for instance, sheared and denatured salmon sperm DNA at about 100-200 μg/ml. Organic solvent, such as formaride at a concentration of about 35-50% v/v, may also be used under particular circumstances, such as for RNA:DNA hybridizations. Useful variations on these wash conditions will be readily apparent to those of ordinary skill in the art. Hybridization, particularly under high stringency conditions, may be suggestive of evolutionary similarity between the nucleotides. Such similarity is strongly indicative of a similar role for the nucleotides and their encoded potypeptides.

[0116] The term “hybridization complex” refers to a complex formed between two nucleic acid sequences by virtue of the formation of hydrogen bonds between complementary bases. A hybridization complex may be formed in solution (e.g., C₀t or R₀t analysis) or formed between one nucleic acid sequence present in solution and another nucleic acid sequence immobilized on a solid support (e.g., paper, membranes, filters, chips, pins or glass slides, or any other appropriate substrate to which cells or their nucleic acids have been fixed).

[0117] The words “insertion” and “addition” refer to changes in an amino acid or nucleotide sequence resulting in the addition of one or more amino acid residues or nucleotides, respectively.

[0118] “Immune response” can refer to conditions associated with inflammation, trauma, immune disorders, or infectious or genetic disease, etc. These conditions can be characterized by expression of various factors, e.g., cytokines, chemokines, and other signaling molecules, which may affect cellular and systemic defense systems.

[0119] An “immunogenic fragment” is a polypeptide or oligopeptide fragment of ECMCAD which is capable of eliciting an immune response when introduced into a living organism, for example, a mammal. The term “immunogenic fragment” also includes any polypeptide or oligopeptide fragment of ECMCAD which is useful in any of the antibody production methods disclosed herein or known in the art.

[0120] The term “microarray” refers to an arrangement of a plurality of polynucleotides, polypeptides, or other chemical compounds on a substrate.

[0121] The terms “element” and “array element” refer to a polynucleotide, polypeptide, or other chemical compound having a unique and defined position on a microarray.

[0122] The term “modulate” refers to a change in the activity of ECMCAD. For example, modulation may cause an increase or a decrease in protein activity, binding characteristics, or any other biological, functional, or immunological properties of ECMCAD.

[0123] The phrases “nucleic acid” and “nucleic acid sequence” refer to a nucleotide, oligonucleotide, polynucleotide, or any fragment thereof. These phrases also refer to DNA or RNA of genomic or synthetic origin which may be single-stranded or double-stranded and may represent the sense or the antisense strand, to peptide nucleic acid (PNA), or to any DNA-like or RNA-like material.

[0124] “Operably linked” refers to the situation in which a first nucleic acid sequence is placed in a functional relationship with a second nucleic acid sequence. For instance, a promoter is operably linked to a coding sequence if the promoter affects the transcription or expression of the coding sequence. Operably linked DNA sequences may be in close proximity or contiguous and, where necessary to join two protein coding regions in the same reading frame.

[0125] “Peptide nucleic acid” (PNA) refers to an antisense molecule or anti-gene agent which comprises an oligonucleotide of at least about 5 nucleotides in length linked to a peptide backbone of amino acid residues ending in lysine. The terminal lysine confers solubility to the composition. PNAs preferentially bind complementary single stranded DNA or RNA and stop transcript elongation, and may be pegylated to extend their lifespan in the cell.

[0126] “Post-translational modification” of an ECMCAD may involve lipidation, glycosylation, phosphorylation, acetylation, racemization, proteolytic cleavage, and other modifications known in the art. These processes may occur synthetically or biochemically. Biochemical modifications will vary by cell type depending on the enzymatic milieu of ECMCAD.

[0127] “Probe” refers to nucleic acid sequences encoding ECMCAD, their complements, or fragments thereof, which are used to detect identical, allelic or related nucleic acid sequences. Probes are isolated oligonucleotides or polynucleotides attached to a detectable label or reporter molecule. Typical labels include radioactive isotopes, ligands, chemiluminescent agents, and enzymes. “Primers” are short nucleic acids, usually DNA oligonucleotides, which may be annealed to a target polynucleotide by complementary base-pairing. The primer may then be extended along the target DNA strand by a DNA polymerase enzyme. Primer pairs can be used for amplification (and identification) of a nucleic acid sequence, e.g., by the polymerase chain reaction (PCR). Probes and primers as used in the present invention typically comprise at least 15 contiguous nucleotides of a known sequence. In order to enhance specificity, longer probes and primers may also be employed, such as probes and primers that comprise at least 20, 25, 30, 40, 50, 60, 70, 80, 90, 100, or at least 150 consecutive nucleotides of the disclosed nucleic acid sequences. Probes and primers may be considerably longer than these examples, and it is understood that any length supported by the specification, including the tables, figures, and Sequence Listing, may be used.

[0128] Methods for preparing and using probes and primers are described in the references, for example Sambrook, J. et al. (1989) Molecular Cloning: A Laboratory Manual, 2^(nd) ed., vol. 1-3, Cold Spring Harbor Press, Plainview N.Y.; Ausubel, F. M. et al. (1987) Current Protocols in Molecular Biolog, Greene Publ. Assoc. & Wiley-Intersciences, New York N.Y.; Innis, M. et al. (1990) PCR Protocols, A Guide to Methods and Applications, Academic Press, San Diego Calif. PCR primer pairs can be derived from a known sequence, for example, by using computer programs intended for that purpose such as Primer (Version 0.5, 1991, Whitehead Institute for Biomedical Research, Cambridge Mass.).

[0129] Oligonucleotides for use as primers are selected using software known in the art for such purpose. For example, OLIGO 4.06 software is useful for the selection of PCR primer pairs of up to 100 nucleotides each, and for the analysis of oligonucleotides and larger polynucleotides of up to 5,000 nucleotides from an input polynucleotide sequence of up to 32 kilobases. Similar primer selection programs have incorporated additional features for expanded capabilities. For example, the PrimOU primer selection program (available to the public from the Genome Center at University of Texas South West Medical Center, Dallas Tex.) is capable of choosing specific primers from megabase sequences and is thus useful for designing primers on a genome-wide scope. The Primer3 primer selection program (available to the public from the Whitehead Institute/MIT Center for Genonie Research, Cambridge Mass.) allows the user to input a “mispriming library,” in which sequences to avoid as primer binding sites are user-specified. Primer3 is useful, in particular, for the selection of oligonucleotides for microarrays. (The source code for the latter two primer selection programs may also be obtained from their respective sources and modified to meet the user's specific needs.) The PrimeGen program (available to the public from the UK Human Genome Mapping Project Resource Centre, Cambridge UK) designs primers based on multiple sequence alignments, thereby allowing selection of primers that hybridize to either the most conserved or least conserved regions of aligned nucleic acid sequences. Hence, this program is useful for identification of both unique and conserved oligonucleotides and polynucleotide fragments. The oligonucleotides and polynucleotide fragments identified by any of the above selection methods are useful in hybridization technologies, for example, as PCR or sequencing primers, microarray elements, or specific probes to identify fully or partially complementary polynucleotides in a sample of nucleic acids. Methods of oligonucleotide selection are not limited to those described above.

[0130] A “recombinant nucleic acid” is a sequence that is not naturally occurring or has a sequence that is made by an artificial combination of two or more otherwise separated segments of sequence. This artificial combination is often accomplished by chemical synthesis or, more commonly, by the artificial manipulation of isolated segments of nucleic acids, e.g., by genetic engineering techniques such as those described in Sambrook, supra. The term recombinant includes nucleic acids that have been altered solely by addition, substitution, or deletion of a portion of the nucleic acid. Frequently, a recombinant nucleic acid may include a nucleic acid sequence operably linked to a promoter sequence. Such a recombinant nucleic acid may be part of a vector that is used, for example, to transform a cell.

[0131] Alternatively, such recombinant nucleic acids may be part of a viral vector, e.g., based on a vaccinia virus, that could be use to vaccinate a mammal wherein the recombinant nucleic acid is expressed, inducing a protective immunological response in the mammal.

[0132] A “regulatory element” refers to a nucleic acid sequence usually derived from untranslated regions of a gene and includes enhancers, promoters, introns, and 5′ and 3′ untranslated regions (UTRs). Regulatory elements interact with host or viral proteins which control transcription, translation, or RNA stability.

[0133] “Reporter molecules” are chemical or biochemical moieties used for labeling a nucleic acid, amino acid, or antibody. Reporter molecules include radionuclides; enzymes; fluorescent, chemiluminescent, or chromogenic agents; substrates; cofactors; inhibitors; magnetic particles; and other moieties known in the art.

[0134] An “RNA equivalent,” in reference to a DNA sequence, is composed of the same linear sequence of nucleotides as the reference DNA sequence with the exception that all occurrences of the nitrogenous base thymine are replaced with uracil, and the sugar backbone is composed of ribose instead of deoxyribose.

[0135] The term “sample” is used in its broadest sense. A sample suspected of containing ECMCAD, nucleic acids encoding ECMCAD, or fragments thereof may comprise a bodily fluid; an extract from a cell, chromosome, organelle, or membrane isolated from a cell; a cell; genomic DNA, RNA, or cDNA, in solution or bound to a substrate; a tissue; a tissue print; etc.

[0136] The terms “specific binding” and “specifically binding” refer to that interaction between a protein or peptide and an agonist, an antibody, an antagonist, a small molecule, or any natural or synthetic binding composition. The interaction is dependent upon the presence of a particular structure of the protein, e.g., the antigenic determinant or epitope, recognized by the binding molecule. For example, if an antibody is specific for epitope “A,” the presence of a polypeptide comprising the epitope A, or the presence of free unlabeled A, in a reaction containing free labeled A and the antibody will reduce the amount of labeled A that binds to the antibody.

[0137] The term “substantially purified” refers to nucleic acid or amino acid sequences that are removed from their natural environment and are isolated or separated, and are at least 60% free, preferably at least 75% free, and most preferably at least 90% free from other components with which they are naturally associated.

[0138] A “substitution” refers to the replacement of one or more amino acid residues or nucleotides by different amino acid residues or nucleotides, respectively.

[0139] “Substrate” refers to any suitable rigid or semi-rigid support including membranes, filters, chips, slides, wafers, fibers, magnetic or nonmagnetic beads, gels, tubing, plates, polymers, microparticles and capillaries. The substrate can have a variety of surface forms, such as wells, trenches, pins, channels and pores, to which polynucleotides or polypeptides are bound.

[0140] A “transcript image” refers to the collective pattern of gene expression by a particular cell type or tissue under given conditions at a given time.

[0141] “Transformation” describes a process by which exogenous DNA is introduced into a recipient cell. Transformation may occur under natural or artificial conditions according to various methods well known in the art, and may rely on any known method for the insertion of foreign nucleic acid sequences into a prokaryotic or eukaryotic host cell. The method for transformation is selected based on the type of host cell being transformed and may include, but is not limited to, bacteriophage or viral infection, electroporation, heat shock, lipofection, and particle bombardment. The term “transformed cells” includes stably transformed cells in which the inserted DNA is capable of replication either as an autonomously replicating plasmid or as part of the host chromosome, as well as transiently transformed cells which express the inserted DNA or RNA for limited periods of time.

[0142] A “transgenic organism,” as used herein, is any organism. including but not limited to animals and plants, in which one or more of the cells of the organism contains heterologous nucleic acid introduced by way of human intervention, such as by transgenic techniques well known in the art. The nucleic acid is introduced into the cell, directly or indirectly by introduction into a precursor of the cell, by way of deliberate genetic manipulation, such as by microinjection or by infection with a recombinant virus. The term genetic manipulation does not include classical cross-breeding, or in vitro fertilization, but rather is directed to the introduction of a recombinant DNA molecule. The transgenic organisms contemplated in accordance with the present invention include bacteria, cyanobacteria, fungi, plants and animals. The isolated DNA of the present invention can be introduced into the host by methods known in the art for example infection, transfection, transformation or transconjugation. Techniques for transferring the DNA of the present invention into such organisms are widely known and provided in references such as Sambrook et al. (1989), supra.

[0143] A “variant” of a particular nucleic acid sequence is defined as a nucleic acid sequence having at least 40% sequence identity to the particular nucleic acid sequence over a certain length of one of the nucleic acid sequences using blastn with the “BLAST 2 Sequences” tool Version 2.0.9 (May 7, 1999) set at default parameters. Such a pair of nucleic acids may show, for example, at least 50%, at least 60%, at least 70%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% or greater sequence identity over a certain defined length. A variant may be described as, for example, an “allelic” (as defined above), “splice,” “species,” or “polymorphic” variant. A splice variant may have significant identity to a reference molecule, but will generally have a greater or lesser number of polynucleotides due to alternative splicing of exons during mRNA processing. The corresponding polypeptide may possess additional functional domains or lack domains that are present in the reference molecule. Species variants arc polynucleotide sequences that vary from one species to another. The resulting polypeptides will generally have significant amino acid identity relative to each other. A polymorphic variant is a variation in the polynucleotide sequence of a particular gene between individuals of a given species. Polymorphic variants also may encompass “single nucleotide polymorphisms” (SNPs) in which the polynucleotide sequence varies by one nucleotide base. The presence of SNPs may be indicative of, for example, a certain population, a disease state, or a propensity for a disease state.

[0144] A “variant” of a particular polypeptide sequence is defined as a polypeptide sequence having at least 40% sequence identity to the particular polypeptidc sequence over a certain length of one of the polypeptide sequences using blastp with the “BLAST 2 Sequences” tool Version 2.0.9 (May 7, 1999) set at default parameters. Such a pair of polypeptides may show, for example, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 91 %, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% or greater sequence identity over a certain defined length of one of the polypeptides.

THE INVENTION

[0145] The invention is based on the discovery of new human extracellular matrix and cell adhesion molecules (ECMCAD), the polynucleotides encoding ECMCAD, and the use of these compositions for the diagnosis, treatment, or prevention of genetic, immune/inflammatory, developmental, neurological, connective tissue, and cell proliferative disorders, including cancer.

[0146] Table 1 summarizes the nomenclatrre for the full length polynucleotide and polypeptide sequences of the invention. Each polynucleotide and its corresponding polypeptide are correlated to a single Incyte project identification number (Incyte Project ID). Each polypeptide sequence is denoted by both a polypeptide sequence identification number (Polypeptide SEQ ID NO:) and an Incyte polypeptide sequence number (Incyte Polypeptide ID) as shown. Each polynucleotide sequence is denoted by both a polynucleotide sequence identification number (Polynucleotide SEQ ID NO:) and an Incyte polynucleotide consensus sequence number (Incyte Polynucleotide ID) as shown.

[0147] Table 2 shows sequences with homology to the polypeptides of the invention as identified by BLAST analysis against the GenBank protein (genpept) database. Columns 1 and 2 show the polypeptide sequence identification number (Polypeptide SEQ ID NO:) and the corresponding Incyte polypeptide sequence number (Incyte Polypeptide ID) for polypeptides of the invention. Column 3 shows the GenBank identification number (Genbank ID NO:) of the nearest GenBank homolog. Column 4 shows the probability score for the match between each polypeptide and its GenBank homolog. Column 5 shows the annotation of the GenBank homolog along with relevant citations where applicable, all of which are expressly incorporated by reference herein.

[0148] Table 3 shows various structural features of the polypeptides of the invention. Columns 1 and 2 show the polypeptide sequence identification number (SEQ ID NO:) and the corresponding Incyte polypeptide sequence number (Incyte Polypeptide ID) for each polypeptide of the invention. Column 3 shows the number of amino acid residues in each polypeptide. Column 4 shows potential phosphorylation sites, and column 5 shows potential glycosylation sites, as determined by the MOTIFS program of the GCG sequence analysis software package (Genetics Computer Group, Madison Wis.). Column 6 shows amino acid residues comprising signature sequences, domains, and motifs. Column 7 shows analytical methods for protein structure/function analysis and in some cases, searchable databases to which the analytical methods were applied.

[0149] Together, Tables 2 and 3 summarize the properties of polypeptides of the invention, and these properties establish that the claimed polypeptides are extracellular matrix and cell adhesion molecules. For example, SEQ ID NO:2 is 48% identical over 46% of its length to mouse procollagen type I alpha chain, (GenBank ID g192264) as determined by the Basic Local Alignment Search Tool (BLAST). (See Table 2.) The BLAST probability score is 6.9e-46, which indicates the probability of obtaining the observed polypeptide sequence alignment by chance. SEQ ID NO:2 also contains a collagen triple helix repeat, as determined by searching for statistically significant matches in the PFAM database. (See Table 3.) HMMER and SPSCAN analyses indicate the presence of a signal peptide at the N-terminus of SEQ ID NO:2. Data from BLAST analysis of the PRODOM and DOMO databases, as well as MOTIFS analysis, provide further corroborative evidence that SEQ ID NO:2 is a cellular matrix protein associated with cell adhesion. In an alternative example, SEQ ID NO:6 is 64% identical to frog MAM domain protein (GenBank ID g1234793) as determined by the Basic Local Alignment Search Tool (BLAST). (See Table 2.) The BLAST probability score is 4.2e-254, which indicates the probability of obtaining the observed polypeptide sequence alignment by chance. SEQ ID NO:6 also contains four MAM domains as determined by searching for statistically significant matches in the hidden Markov model (HMM)-based PFAM database of conserved protein family domains. (See Table 3.) Data from MOTIFS analysis provide further corroborative evidence that SEQ ID NO:6 is a MAM domain cell adhesion protein. In an alternative example, SEQ ID NO:10 is 80% identical to murine semaphorin B (GenBank ID g854326) as determined by the Basic Local Alignment Search Tool (BLAST). (See Table 2.) The BLAST probability score is 6.0e-66, which indicates the probability of obtaining the observed polypeptide sequence alignment by chance. SEQ ID NO:10 also contains a soma domain as determined by searching for statistically significant matches in the hidden Markov model (HMM)-based PFAM database of conserved protein family domains. (See Table 3.) The BLAST and HMMER analyses provide evidence that SEQ ID NO:10 is a semaphorin. SEQ ID NO:12 is 44% identical to human cadherin superfamily protein VR4-11 (GenBank ID g9622240) as determined by the Basic Local Alignment Search Tool (BLAST). (See Table 2.) The BLAST probability score is 9.9e-170, which indicates the probability of obtaining the observed polypeptide sequence alignment by chance. SEQ ID NO:12 also contains a cadherin domain as determined by searching for statistically significant matches in the hidden Markov model (HMM)-based PFAM database of conserved protein family domains. (See Table 3.) Data from BLIMPS, MOTIFS, and PROFLES CAN analyses provide further corroborative evidence that SEQ ID NO: 12 is a cadherin. SEQ ID NO: 14 is 91% identical to mutin neuronal glycoprotein (GenBank ID g200057) as determined by the Basic Local Alignment Search Tool (BLAST). (See Table 2.) The BLAST probability score is 0.0, which indicates the probability of obtaining the observed polypeptide sequence alignment by chance, SEQ ID NO: 14 also contains fibronectin type III and immunoglobulin domains as determined by searching for statistically significant matches in the hidden Markov model (HMM)-based PFAM database of conserved protein family domains. (See Table 3.) The BLAST and HMMER analyses provide evidence that SEQ ID NO:14 is a cell adhesion molecule. In an alternative example, SEQ ID NO:22 is 79% identical to mouse lamidn 5 alpha chain (GenBank ID g2599232) as determined by the Basic Local Alignment Search Tool (BLAST), (See Table 2.) The BLAST probability score is 0.0, which indicates the probability of obtaining the observed polypeptide sequence alignment by chance. SEQ ID NO:22 also contains a laminin N-terminal domain, multiple laminin EGF-like domains, a laminin B domain, and laminin G domains, as determined by searching for statistically significant matches in the hidden Markov model (HMM)-based PFAM database of conserved protein family domains. (See Table 3.) Data from BLIMPS, and MOTIFS analyses provide further corroborative evidence that SEQ ID NO:22 is a laminin. In an alternative example, SEQ ID NO:24 is 89% identical to Bos taurus brevican (GenBank ID g452821) as determined by the Basic Local Alignment Search Tool (BLAST). (See Table 2.) The BLAST probability score is 0.0, which indicates the probability of obtaining the observed polypeptide sequence alignment by chance. SEQ ID NO:24 also contains a lectin C-type domain, an extracellular link domain, an EGF-fike domain, a sushi domain, and an immunoglobulin domain as determined by searching for statistically significant matches in the hidden Markov model (HMM)-based PFAM database of conserved protein family domains. (See Table 3.) Data from BLIMPS, MOTIFS, and PROFILESCAN analyses provide further corroborative evidence that SEQ ID NO:24 is a c-type lectin. In an alternative example, SEQ ID NO:31 is 87% identical lo a mouse semaphorin homolog (GenBank ID g1110599) as determined by the Basic Local Alignment Search Tool (BLAST). (See Table 2.) The BLAST probability score is 0.0, which indicates the probability of obtaining the observed polypeptide sequence alignment by chance. SEQ ID NO:31 also contains a Sema domain and a plexin repeat as determined by searching for statistically significant matches in the hidden Markov model (HMM)-based PFAM database of conserved protein family domains. (See Table 3.) Data from BLAST analyses against the DOMO and PRODOM databases provide further corroborative evidence that SEQ ID NO:31 is a semaphorin. In an alternative example, SEQ ID NO:35 is 61% identical to murine C-type lectin (GenBank ID g4159801) as determined by the Basic local Alignment Search Tool (BLAST). (See Table 2.) The BLAST probability score is 2.9e-75, which indicates the probability of obtaining the observed polypeptide sequence alignment by chance. SEQ ID NO:35 also contains a lectin C-type domain as determined by searching for statistically significant matches in the hidden Markov model (HMM)-based PFAM database of conserved protein family domains. (See Table 3.) Data from BLIMPS and PROFILESCAN analyses provide further corroborative evidence that SEQ ID NO:35 is a lectin. SEQ ID NO:1, SEQ ID NO:3-5, SEQ ID NO:7-9, SEQ ID NO:11, SEQ ID NO: 13, SEQ ID NO:15-21, SEQ ID NO:23, SEQ ID NO:25-30, SEQ ID NO:32-34 and SEQ ID NO:36 were analyzed and annotated in a similar manner. The algorithims and parameters for the analysis of SEQ ID NO:1-36 are described in Table 7.

[0150] As shown in Table 4, the full length polynucleotide sequences of the present invention were assembled using cDNA sequences or coding (exon) sequences derived from genomic DNA, or any combination of these two types of sequences. Columns 1 and 2 list the polynucleotide sequence identification number (Polynucleotide SEQ ID NO:) and the corresponding Incyte polynucleotide consensus sequence number (Incyte Polynucleotide ID) for each polynucleotide of the invention. Column 3 shows the length of each polynucleotide sequence in basepairs. Column 4 lists fragments of the polynucleotide sequences which are useful, for example, in hybridization or amplification technologies that identify SEQ ID NO:37-72 or that distinguish between SEQ ID NO:37-72 and related polynucleotide sequences. Column 5 shows identification numbers corresponding to cDNA sequences, coding sequences (exons) predicted from genomic DNA, and/or sequence assemblages comprised of both cDNA and genomic DNA. These sequences were used to assemble the full length polynucleotide sequences of the invention. Columns 6 and 7 of Table 4 show the nucleotide start (5′) and stop (3′) positions of the cDNA and/or genomic sequences in column 5 relative to their respective full length sequences.

[0151] The identification numbers in Column 5 of Table 4 may refer specifically, for example, to Incyte cDNAs along with their corresponding cDNA libraries. For example, 7347284H1 is the identification number of an Incyte cDNA sequence, and LUNLTUE01 is the cDNA library from which it is derived. Incyte cDNAs for which cDNA libraries are not indicated were derived from pooled cDNA libraries (e.g., 71699406V1). Alternatively, the identification numbers in column 5 may refer to GenBank cDNAs or ESTs (e.g., g1242437) which contributed to the assembly of the full length polynucleotide sequences. Alternatively, the identification numbers in column 5 may refer to coding regions predicted by Genscan analysis of genomic DNA. For example, GNN.g7923864_(—)002 is the identification number of a Genscan-predicted coding sequence, with g7923864 being the GenBank identification number of the sequence to which Genscan was applied. The Genscan-predicted coding sequences may have been edited prior to assembly. (See Example IV.) Alternatively, the identification numbers in column 5 may refer to assemblages of both cDNA and Genscan-predicted exons brought together by an “exon stitching” algorithm. (See Example V.) Alternatively, the identification numbers in column 5 may refer to assemblages of both cDNA and Genscan-predicted exons brought together by an “exon-stretching” algorithm. For example, FL2428715_g6815043_(—)000026_g8052237_(—)1_(—)3_(—)4.edit is the identification number of a “stretched” sequence, with 2428715 being the Incyte project identification number, g6815043 being the GenBank identification number of the human genomic sequence to which the “exon-stretching” algorithm was applied, and g8052237 being the GenBank identification number of the nearest GenBank protein homolog. (See Example V.) In some cases, Incyte cDNA coverage redundant with the sequence coverage shown in column 5 was obtained to confirm the final consensus polynucleotide sequence, but the relevant Incyte cDNA identification numbers are not shown.

[0152] Table 5 shows the representative cDNA libraries for those fill length polynucleotide sequences which were assembled using Incyte cDNA sequences. The representative cDNA library is the Incyte cDNA library which is most frequently represented by the Incyte cDNA sequences which were used to assemble and confirm the above polynucleotide sequences. The tissues and vectors which were used to construct the cDNA libraries shown in Table 5 are described in Table 6.

[0153] The invention also encompasses ECMCAD variants. A preferred ECMCAD variant is one which has at least about 80%, or alternatively at least about 90%, or even at least about 95% amnino acid sequence identity to the ECMCAD amino acid sequence, and which contains at least one functional or structural characteristic of ECMCAD.

[0154] The invention also encompasses polynucleotides which encode ECMCAD. In a particular embodiment, the invention encompasses a polynucleotide sequence comprising a sequence selected from the group consisting of SEQ ID NO:37-72, which encodes ECMCAD. The polynucleotide sequences of SEQ ID NO:37-72, as presented in the Sequence Listing, embrace the equivalent RNA sequences, wherein occurrences of the nitrogenous base thymine are replaced with uracil, and the sugar backbone is composed of ribose instead of deoxyribose.

[0155] The invention also encompasses a variant of a polynucleotide sequence encoding ECMCAD. In particular, such a variant polynucleotide sequence will have at least about 70%, or alternatively at least about 85%, or even at least about 95% polynucleotide sequence identity to the polynucleotide sequence encoding ECMCAD. A particular aspect of the invention encompasses a variant of a polynucleotide sequence comprising a sequence selected from the group consisting of SEQ ID NO:37-72 which has at least about 70%, or alternatively at least about 85%, or even at least about 95% polynuclcotidc sequence identity to a nucleic acid sequence selected from the group consisting of SEQ ID NO:37-72. Any one of the polynucleotide variants described above can encode an amino acid sequence which contains at least one functional or structural characteristic of ECMCAD.

[0156] It will be appreciated by those skilled in the art that as a result of the degeneracy of the genetic code, a multitude of polynucleotide sequences encoding ECMCAD, some bearing minimal similarity to the polynucleotide sequences of any known and naturally occurring gene, may be produced. Thus, the invention contemplates each and every possible variation of polynucleotide sequence that could be made by selecting combinations based on possible codon choices. These combinations are made in accordance with the standard triplet genetic code as applied to the polynucleotide sequence of naturally occurring ECMCAD, and all such variations arc to be considered as being specifically disclosed.

[0157] Although nucleotide sequences which encode ECMCAD and its variants are generally capable of hybridizing to the nucleotide sequence of the naturally occurring ECMCAD under appropriately selected conditions of stringency, it may be advantageous to produce nucleotide sequences encoding ECMCAD or its derivatives possessing a substantially different codon usage, e.g., inclusion of non-naturally occurring codons. Codons may be selected to increase the rate at which expression of the peptide occurs in a particular prokaryotic or eukaryotic host in accordance with the frequency with which particular codons are utilized by the host. Other reasons for substantially altering the nucleotide sequence encoding ECMCAD and its derivatives without altering the encoded amino acid sequences include the production of RNA transcripts having more desirable properties, such as a greater half-life, than transcripts produced from the naturally occurring sequence.

[0158] The invention also encompasses production of DNA sequences which encode ECMCAD and ECMCAD derivatives, or fragments thereof, entirely by synthetic chemistry. After production, the synthetic sequence may be inserted into any of the many available expression vectors and cell systems using reagents well known in the art. Moreover, synthetic chemistry may be used to introduce mutations into a sequence encoding ECMCAD or any fragment thereof.

[0159] Also encompassed by the invention are polynucleotide sequences that are capable of hybridizing to the claimed polynucleotide sequences, and, in particular, to those shown in SEQ ID NO:37-72 and fragments thereof under various conditions of stringency. (See, e.g., Wahl, G. M. and S. L. Berger (1987) Methods Enzymol. 152:399407; Kimmel, A. R. (1987) Methods Enzymol. 152:507-511.) Hybridization conditions, including annealing and wash conditions, are described in “Definitions.”

[0160] Methods for DNA sequencing are well known in the art and may be used to practice any of the embodiments of the invention. The methods may employ such enzymes as the Klenow fragment of DNA polymerase 1, SEQUENASE (US Biochemical, Cleveland Ohio), Taq polymerase (Applied Biosystems), thermostable T7 polymerase (Amersham Pharmacia Biotech, Piscataway N.J.), or combinations of polymerases and proofreading exonucleases such as those found in the ELONGASE amplification system (Life Technologies, Gaithersburg Md.). Preferably, sequence preparation is automated with machines such as the MICROLAB 2200 liquid transfer system (Hamilton, Reno Nev.), PTC200 thermal cycler (MJ Research, Watertown Mass.) and ABI CATALYST 800 thermal cycler (Applied Biosystems), Sequencing is then carried out using either the ABI 373 or 377 DNA sequencing system (Applied Biosystems), the MEGABACE 1000 DNA sequencing system (Molecular Dynamics, Sunnyvale Calif.), or other systems known in the art. The resulting sequences are analyzed using a variety of algorithms which are well known in the art. (See, e.g., Ausubel, F. M. (1997) Short Protocols in Molecular Biology, John Wiley & Sons, New York N.Y., unit 7.7; Meyers, R. A. (1995) Molecular Biology and Biotechnology, Wiley VCH, New York N.Y., pp. 856-853.)

[0161] The nucleic acid sequences encoding ECMCAD may be extended utilizing a partial nucleotide sequence and employing various PCR-based methods known in the art to detect upstream sequences, such as promoters and regulatory elements. For example, one method which may be employed, restriction-site PCR, uses universal and nested primers to amplify unknown sequence from genomic DNA within a cloning vector. (See, e.g., Sarkar, G. (1993) PCR Methods Applic. 2:318-322.) Another method, inverse PCR, uses primers that extend in divergent directions to amplify unknown sequence from a circularized template. The template is derived from restriction fragments comprising a known genomic locus and surrounding sequences. (See, e.g., Triglia, T. et al. (1988) Nucleic Acids Res. 16:8186.) A third method, capture PCR, involves PCR amplification of DNA fragments adjacent to known sequences in human and yeast artificial chromosome DNA. (See, e.g., Lagerstrom, M. et al. (1991) PCR Methods Applic. 1: 111-119.) In this method, multiple restriction enzyme digestions and ligations may be used to insert an engineered double-stranded sequence into a region of unknown sequence before performing PCR. Other methods which may be used to retrieve unknown sequences are known in the art. (See, e.g., Parker, J. D. et al. (1991) Nucleic Acids Res. 19:3055-3060). Additionally, one may use PCR, nested primers, and PROMOTERFINDER libraries (Clontech, Palo Alto Calif.) to walk genomic DNA. This procedure avoids the need to screen libraries and is useful in finding intron/exon junctions. For all PCR-based methods, primers may be designed using commercially available software, such as OLIGO 4.06 primer analysis software (National Biosciences, Plymouth Minn.) or another appropriate program, to be about 22 to 30 nucleotides in length, to have a GC content of about 50% or more, and to anneal to the template at temperatures of about 68° C. to 72° C.

[0162] When screening for full length cDNAs, it is preferable to use libraries that have been size-selected to include larger cDNAs. In addition, random-primed libraries, which often include sequences containing the 5′ regions of genes, are preferable for situations in which an oligo d(T) library does not yield a full-length cDNA. Genornic libraries may be useful for extension of sequence into 5′ non-transcribed regulatory regions.

[0163] Capillary electrophoresis systems which are commercially available may be used to analyze the size or confirm the nucleotide sequence of sequencing or PCR products. In particular, capillary sequencing may employ flowable polymers for electrophoretic separation, four different nucleotide-specific, laser-stimulated fluorescent dyes, and a charge coupled device camera for detection of the emitted wavelengths. Output/light intensity may be converted to electrical signal using appropriate software (e.g., GENOTYPER and SEQUENCE NAVIGATOR, Applied Biosystems), and the entire process from loading of samples to computer analysis and electronic data display may be computer controlled. Capillary electrophoresis is especially preferable for sequencing small DNA fragments which may be present in limited amounts in a particular sample.

[0164] In another embodiment of the invention, polynucleotide sequences or fragments thereof which encode ECMCAD may be cloned in recombinant DNA molecules that direct expression of ECMCAD, or fragments or functional equivalents thereof, in appropriate host cells. Due to the inherent degeneracy of the genetic code, other DNA sequences which encode substantially the same or a functionally equivalent amino acid sequence may be produced and used to express ECMCAD.

[0165] The nucleotide sequences of the present invention can be engineered using methods generally known in the art in order to alter ECMCAD-encoding sequences for a variety of purposes including, but not limited to, modification of the cloning, processing, and/or expression of the gene product. DNA shuffling by random fragmentation and PCR reassembly of gene fragments and synthetic oligonucleotides may be used to engineer the nucleotide sequences. For example, oligonucleotide-mediated site-directed mutagenesis may be used to introduce mutations that create new restriction sites, alter glycosylation patterns, change codon preference, produce splice variants, and so forth.

[0166] The nucleotides of the present invention may be subjected to DNA shuffling techniques such as MOLECULARBREEDING (Maxygen Inc., Santa Clara Calif.; described in U.S. Pat. No. 5,837,458: Chang, C.-C. et al. (1999) Nat. Biotechnol. 17:793-797; Christians, F. C. et al. (1999) Nat. Biotechnol. 17:259-264; and Crameri, A. et al. (1996) Nat. Biotechnol. 14:315-319) to alter or improve the biological properties of ECMCAD, such as its biological or enzymatic activity or its ability to bind to other molecules or compounds. DNA shuffling is a process by which a library of gene variants is produced using PCR-moediated recombination of gene fragments. The library is then subjected to selection or screening procedures that identify those gene variants with the desired properties. These preferred variants may then be pooled and further subjected to recursive rounds of DNA shuffling and selection/screening. Thus, genetic diversity is created through “artificial” breeding and rapid molecular evolution. For example, fragments of a single gene containing random point mutations may be recombined, screened, and then reshuffled until the desired properties are optimized. Alternatively, fragments of a given gene may be recombined with fragments of homologous genes in the same gene family, either from the same or different species, thereby maximizing the genetic diversity of multiple naturally occurring genes in a directed and controllable manner.

[0167] In another embodiment, sequences encoding ECMCAD may be synthesized, in whole or in part, using chemical methods well known in the art. (See, e.g., Caruthers, M. H. et al. (1980) Nucleic Acids Symp. Ser. 7:215-223; and Horn, T. et al. (1980) Nucleic Acids Symp. Ser. 7:225-232.) Alternatively, ECMCAD itself or a fragment thereof may be synthesized using chemical methods. For example, peptide synthesis can be performed using various solution-phase of solid-phase techniques. (See, e.g., Creighton, T. (1984) Proteins, Structures and Molecular Properties, WH, Freeman, New York N.Y., pp. 55-60; and Roberge, J. Y. et al. (1995) Science 269:202-204.) Automated synthesis may be achieved using the ABI 431A peptide synthesizer (Applied Biosystems). Additionally, the amino acid sequence of ECMCAD, or any part thereof, may be altered during direct synthesis and/or combined with sequences from other proteins, or any part thereof, to produce a variant polypeptide or a polypeptide having a sequence of a naturally occurring polypeptide.

[0168] The peptide may be substantially purified by preparative high performance liquid chromatography. (See, e.g., Chiez, R. M. and F. Z. Regnier (1990) Methods Enzymol. 182:392-421.) The composition of the synthetic peptides may be confirmed by amino acid analysis or by sequencing. (See, e.g., Creighton, supra, pp. 28-53.)

[0169] In order to express a biologically active ECMCAD, the nucleotide sequences encoding ECMCAD or derivatives thereof may be inserted into an appropriate expression vector, i.e., a vector which contains the necessary elements for transcriptional and translational control of the inserted coding sequence in a suitable host. These elements include regulatory sequences, such as enhancers, constitutive and inducible promoters, and 5′ and 3′untranslated regions in the vector and in polynucleotide sequences encoding ECMCAD. Such elements may vary in their strength and specificity. Specific initiation signals may also be used to achieve more efficient translation of sequences encoding ECMCAD. Such signals include the ATG initiation codon and adjacent sequences, e.g. the Kozak sequence. In cases where sequences encoding ECMCAD and its initiation codon and upstream regulatory sequences are inserted into the appropriate expression vector, no additional transcriptional or translational control signals may be needed. However, in cases where only coding sequence, or a fragment thereof, is inserted, exogenous translational control signals including an in-frame ATG initiation codon should be provided by the vector. Exogenous translational elements and initiation codons may be of various origins, both natural and synthetic. The efficiency of expression may be enhanced by the inclusion of enhancers appropriate for the particular host cell system used. (See, e.g., Scharf, D. et al. (1994) Results Probl. Cell Differ. 20:125-162.)

[0170] Methods which are well known to those skilled in the art may be used to construct expression vectors containing sequences encoding ECMCAD and appropriate transcriptional and translational control elements. These methods include in vitro recombinant DNA tecluiques, synthetic techniques, and in vivo genetic recombination. (See, e.g., Sambrook J. et al. (1989) Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Press, Plainview N.Y., ch. 4, 8, and 16-17; Ausubel, F. M. et al. (1995) Current Protocols in Molecular Biology, John Wiley & Sons, New York N.Y., ch. 9, 13, and 16.)

[0171] A variety of expression vector/host systems may be utilized to contain and express sequences encoding ECMCAD. These include, but are not limited to, microorganisms such as bacteria transformed with recombinant bacteriophage, plasmid, or cosmid DNA expression vectors; yeast transformed with yeast expression vectors; insect cell systems infected with viral expression vectors (e.g., baculovirus); plan( cell systems transformed with viral expression vectors (e.g., cauliflower mosaic virus, CaMV, or tobacco mosaic virus, TMV) or with bacterial expression vectors (e.g., Ti or pBR322 plasmids); or animal cell systems. (See, e.g., Sambrook, supra; Ausubel, supra; Van Heeke, G. and S. M. Schuster (1989) J. Biol. Chem. 264:5503-5509; Engelhard, E. K. et al. (1994) Proc. Natl. Acad. Sci. USA 91:3224-3227; Sandig, V. et al. (1996) Hum. Gene Ther. 7:1937-1945; Takamatsu, N. (1987) EMBO J. 6:307-311; The McGraw Hill Yearbook of Science and Technology (1992) McGraw Hill, New York N.Y., pp. 191-196; Logan, J. and T. Shenk (1984) Proc. Natl. Acad. Sci. USA 81:3655-3659; and Harrington, J. J. et al. (1997) Nat. Genet. 15:345-355.) Expression vectors derived from retroviruses, adenoviruses, or herpes or vaccinia viruses, or from various bacterial plasmids, may be used for delivery of nucleotide sequences to the targeted organ, tissue, or cell population. (See, e.g., Di Nicola, M. et al. (1998) Cancer Gen. Ther. 5(6):350-356; Yu, M. et al. (1993) Proc. Natl. Acad. Sci. USA 90(13):6340-6344; Buller, R. M. et al. (1985) Nature 317(6040):813-815; McGregor, D. P. et al. (1994) Mol. Immunol. 31(3):219-226; and Verma, I. M. and N. Somia (1997) Nature 389:239-242.) The invention is not limited by the host cell employed.

[0172] In bacterial systems, a number of cloning and expression vectors may be selected depending upon the use intended for polynucleotide sequences encoding ECMCAD. For example, routine cloning, subcloning, and propagation of polynucleotide sequences encoding ECMCAD can be achieved using a multifunctional E. coli vector such as PBLUESCRIPT (Stratagene, La Jolla Calif.) or PSPORT1 plasmid (Life Technologies). Ligation of sequences encoding ECMCAD into the vector's multiple cloning site disrupts the lacZ gene, allowing a calorimetric screening procedure for identification of transformed bacteria containing recombinant molecules. In addition, these vectors may be useful for in vitro transcription, didcoxy sequencing, single strand rescue with helper phage, and creation of nested deletions in the cloned sequence. (See, e.g., Van Heeke, G. and S. M. Schuster (1989) J. Biol. Chem. 264:5503-5509.) When large quantities of ECMCAD are needed, e.g. for the production of antibodies, vectors which direct high level expression of ECMCAD may be used. For example, vectors containing the strong, inducible SP6 or T7 bacteriophage promoter may be used.

[0173] Yeast expression systems may be used for production of ECMCAD. A number of vectors containing constitutive or inducible promoters, such as alpha factor, alcohol oxidase, and PGH promoters, may be used in the yeast Saccharomyces cerevisiae or Pichia pastoris. In addition, such vectors direct either the secretion or intracellular retention of expressed proteins and enable integration of foreign sequences into the host genome for stable propagation. (See, e.g., Ausubel, 1995, supra; Bitter, G. A. et al. (1987) Methods Enzymol. 153:516-544; and Scorer, C. A. et al. (1994) Bio/Technology 12:181-184.)

[0174] Plant systems may also be used for expression of ECMCAD. Transcription of sequences encoding ECMCAD may be driven by viral promoters, e.g., the 35S and 19S promoters of CaMV used alone or in combination with the omega leader sequence from TMV (Takamatsu, N. (1987) EMBO J. 6:307-311). Alternatively, plant promoters such as the small subunit of RUBISCO or heat shock promoters may be used. (See, e.g., Coruzzi, G. et al. (1984) EMBO J. 3:1671-1680; Broglie, R. et al. (1984) Science 224:838-843; and Winter, J. et al. (1991) Results Probl. Cell Differ. 17:85-105.) These constructs can be introduced into plant cells by direct DNA transformation or pathogen-mediated transfection. (See, e.g., The McGraw Hill Yearbook of Science and Technology (1992) McGraw Hill, New York N.Y., pp. 191-196.)

[0175] In mammalian cells, a number of viral-based expression systems may be utilized. In cases where an adenovirus is used as an expression vector, sequences encoding ECMCAD may be ligated into an adenovirus transcription/translation complex consisting of the late promoter and tripartite leader sequence. Insertion in a non-essential E1 or E3 region of the viral genome may be used to obtain infective virus which expresses ECMCAD in host cells. (See, e.g., Logan, J. and T. Shenk (1984) Proc. Natl. Acad. Sci. USA 81:3655-3659.) In addition, transcription enhancers, such as the Rous sarcoma virus (RSV) enhancer, may be used to increase expression in mammalian host cells. SV40 or EBV-based vectors may also be used for high-level protein expression.

[0176] Human artificial chromosomes (HACs) may also be employed to deliver larger fragments of DNA than can be contained in and expressed from a plasmid. RACs of about 6 kb to 10 Mb are constructed and delivered via conventional delivery methods (liposomes, polycationic amino polymers, or vesicles) for therapeutic purposes. (See, e.g., Harrington, J. J. et al. (I 997) Nat. Genet. 15:345-355.)

[0177] For long term production of recombinant proteins in mammalian systems, stable expression of ECMCAD in cell lines is preferred. For example, sequences encoding ECMCAD can be transformed into cell lines using expression vectors which may contain viral origins of replication and/or endogenous expression elements and a selectable marker gene on the same or on a separate vector. Following the introduction of the vector, cells may be allowed to grow for about 1 to 2 days in enriched media before being switched to selective media. The purpose of the selectable marker is to confer resistance to a selective agent, and its presence allows growth and recovery of cells which successfully express the introduced sequences. Resistant clones of stably transformed cells may be propagated using tissue culture techniques appropriate to the cell type.

[0178] Any number of selection systems may be used to recover transformed cell lines. These include, but are not limited to, the herpes simplex virus thymidine kinase and adenine phosphoribosyltransferase genes, for use in tk and apr cells, respectively. (See, e.g., Wigler, M. et al. (1977) Cell 11:223-232; Lowy, I. et al. (1980) Cell 22:817-823.) Also, antimetabolite, antibiotic, or herbicide resistance can be used as the basis for selection. For example, dhfr confers resistance to methotrexate; neo confers resistance to the aminoglycosides neomycin and G-418; and als and pat confer resistance to chlorsulfluon and phosphinotricin acetyltransferase, respectively. (See, e.g., Wigler, M. et al. (1980) Proc. Natl. Acad. Sci. USA 77:3567-3570; Colbere-Garapin, F. et al. (1981) J. Mol. Biol. 150:1-14.) Additional selectable genes have been described, e.g., trpB and hisD, which alter cellular requirements for metabolites. (See, e.g., Haitman, S. C. and R. C. Mulligan (1988) Proc. Natl. Acad. Sci. USA 85:8047-8051.) Visible markers, e.g., anthocyanins, green fluorescent proteins (GFP; Clontech), β glucuronidase and its substrate β-glucuronide, or luciferase and its substrate luciferin may be used. These markers can be used not only to identify transformants, but also to quantify the amount of transient or stable protein expression attributable to a specific vector system. (See, e.g., Rhodes, C. A. (1995) Methods Mol. Biol. 55:121-131.)

[0179] Although the presence/absence of marker gene expression suggests that the gene of interest is also present, the presence and expression of the gene may need to be confirmed. For example, if the sequence encoding ECMCAD is inserted within a marker gene sequence, transformed cells containing sequences encoding ECMCAD can be identified by the absence of marker gene function. Alternatively, a marker gene can be placed in tandem with a sequence encoding ECMCAD under the control of a single promoter. Expression of the marker gene in response to induction or selection usually indicates expression of the tandem gene as well.

[0180] In general, host cells that contain the nucleic acid sequence encoding ECMCAD and that express ECMCAD may be identified by a variety of procedures known to those of skill in the art. These procedures include, but are not limited to, DNA-DNA or DNA-RNA hybridizations, PCR amplification, and protein bioassay or immunoassay techniques which include membrane, solution, or chip based technologies for the detection and/or quantification of nucleic acid or protein sequences.

[0181] Immunological methods for detecting and measuring the expression of ECMCAD using either specific polyclonal or monoclonal antibodies are known in the art. Examples of such techniques include enzyme-linked immunosorbent assays (ELISAs), radioimmunoassays (RfAs), and fluorescence activated cell sorting (FACS). A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering epitopes on ECMCAD is preferred, but a competitive binding assay may be employed. These and other assays are well known in the art. (See, e.g., Hampton, R. et al. (1990) Serological Methods, a Laboratory Manual, APS Press, St. Paul Minn., Sect. IV; Coligan, J. E. et al. (1997) Current Protocols in Immunology, Greene Pub. Associates and Wiley-Interscience, New York N.Y.; and Pound, J. D. (1998) Immunochemical Protocols, Humana Press, Totowa N.J.)

[0182] A wide variety of labels and conjugation techniques are known by those skilled in the art and may be used in various nucleic acid and amino acid assays. Means for producing labeled hybridization or PCR probes for detecting sequences related to polynucleotides encoding ECMCAD include oligolabeling, nick translation, end-labeling, or PCR amplification using a labeled nucleotide. Alternatively, the sequences encoding ECMCAD, or any fragments thereof, may be cloned into a vector for the production of an mRNA probe. Such vectors are known in the art, are commercially available, and may be used to synthesize RNA probes in vitro by addition of an appropriate RNA polymerase such as T7, T3, or SP6 and labeled nucleotides. These procedures may be conducted using a variety of commercially available kits, such as those provided by Amersham Pharmacia Biotech, Promega (Madison Wis.), and US Biochemical. Suitable reporter molecules or labels which may be used for ease of detection include radionuclides, enzymes, fluorescent, chemiluminescent, or chromogenic agents, as well as substrates, cofactors, inhibitors, magnetic particles, and the like.

[0183] Host cells transformed with nucleotide sequences encoding ECMCAD may be cultured under conditions suitable for the expression and recovery of the protein from cell culture. The protein produced by a transformed cell may be secreted or retained intracellularly depending on the sequence and/or the vector used. As will be understood by those of skill in the art, expression vectors containing polynucleotides which encode ECMCAD may be designed to contain signal sequences which direct secretion of ECMCAD through a prokaryotic or eukaryotic cell membrane.

[0184] In addition, a host cell strain may be chosen for its ability to modulate expression of the inserted sequences or to process the expressed protein in the desired fashion. Such modifications of the polypeptide include, but are not limited to, acetylation, carboxylation, glycosylation, phosphorylation, lipidation, and acylation. Post-translational processing which cleaves a “prepro” or “pro” form of the protein may also be used to specify protein targeting, folding, and/or activity. Different host cells which have specific cellular machinery and characteristic mechanisms for post-translational activities (e.g., CHO, HeLa, MDCK, HEK293, and W138) are available from the American Type Culture Collection (ATCC, Manassas Va.) and may be chosen to ensure the correct modification and processing of the foreign protein.

[0185] In another embodiment of the invention, natural, modified, or tecombinant nucleic acid sequences encoding ECMCAD may be ligated to a heterologous sequence resulting in translation of a fusion protein in any of the aforementioned host systems. For example, a chimeric ECMCAD protein containing a heterologous moiety that can be recognized by a commercially available antibody may facilitate the screening of peptide libraries for inhibitors of ECMCAD activity. Heterologous protein and peptide moieties may also facilitate purification of fusion proteins using commercially available affinity matrices. Such moieties include, but are not limited to, glutathione S-transferase (GST), maltose binding protein (MBP), tioredoxin (Trx), calmodulin binding peptide (CBP), 6-His, FLAG, c-myc, and hemagglutinin (HA). GST, MBP, Trx, CBP, and 6-His enable purification of their cognate fusion proteins on immobilized glutathione, maltose, phenylarsine oxide, calmodulin, and metal-chelate resins, respectively. FLAG, c-myc, and hemagglutinin (HA) enable immunoaffinity purification of fusion proteins using commercially available monoclonal and polyclonal antibodies that specifically recognize these epitope tags. A fusion protein may also be engineered to contain a proteolytic cleavage site located between the ECMCAD encoding sequence and the heterologous protein sequence, so that ECMCAD may be cleaved away from the heterologous moiety following purification. Methods for fusion protein expression and purification are discussed in Ausubel (1995, supra, ch. 10). A variety of commercially available kits may also be used to facilitate expression and purification of fusion proteins.

[0186] In a further embodiment of the invention, synthesis of radiolabeled ECMCAD may be achieved in vitro using the TNT rabbit reticulocyte lysate or wheat germ extract system (Promega). These systems couple transcription and translation of protein-coding sequences operably associated with the T7, T3, or SP6 promoters. Translation takes place in the presence of a radiolabeled amino acid precursor, for example, ³⁵S-methionine.

[0187] ECMCAD of the present invention or fragments thereof may be used to screen for compounds that specifically bind to ECMCAD. At least one and up to a plurality of test compounds may be screened for specific binding to ECMCAD. Examples of test compounds include antibodies, oligonucleotides, proteins (e.g., receptors), or small molecules.

[0188] In one embodiment, the compound thus identified is closely related to the natural ligand of ECMCAD. e.g., a ligand or fragment thereof, a natural substrate, a structural or functional mimetic, or a natural binding partner. (See, e.g., Coligan, J. E. et al. (1991) Current Protocols in Immunology 1(2): Chapter 5.) Similarly, the compound can be closely related to the natural receptor to which ECMCAD binds, or to at least a fragment of the receptor, e.g., the ligand binding site. In either case, the compound can be rationally designed using known techniques. In one embodiment, screening for these compounds involves producing appropriate cells which express ECMCAD, either as a secreted protein or on the cell membrane. Preferred cells include cells from mammals, yeast, Drosophila, or E. coli. Cells expressing ECMCAD or cell membrane fractions which contain ECMCAD are then contacted with a test compound and binding, stimulation, or inhibition of activity of either ECMCAD or the compound is analyzed.

[0189] An assay may simply test binding of a test compound to the polypeptide, wherein binding is detected by a fluorophore, radioisotope, enzyme conjugate, or other detectable label. For example, the assay may comprise the steps of combining at least one test compound with ECMCAD, either in solution or affixed to a solid support, and detecting the binding of ECMCAD to the compound. Alternatively, the assay may detect or measure binding of a test compound in the presence of a labeled competitor. Additionally, the assay may be carried out using cell-free preparations, chemical libraries, or natural product mixtures, and the test compound(s) may be free in solution or affixed to a solid support.

[0190] ECMCAD of the present invention or fragments thereof may be used to screen for compounds that modulate the activity of ECMCAD. Such compounds may include agonists, antagonists, or partial or inverse agonists. In one embodiment, an assay is performed under conditions permissive for ECMCAD activity, wherein ECMCAD is combined with at least one test compound, and the activity of ECMCAD in the presence of a test compound is compared with the activity of ECMCAD in the absence of the test compound. A change in the activity of ECMCAD in the presence of the test compound is indicative of a compound that modulates the activity of ECMCAD. Alternatively, a test compound is combined with an in vitro or cell-free system comprising ECMCAD under conditions suitable for ECMCAD activity, and the assay is performed. In either of these assays, a test compound which modulates the activity of ECMCAD may do so indirectly and need not come in direct contact with the test compound. At least one and up to a plurality of test compounds may be screened.

[0191] In another embodiment, polynucleotides encoding ECMCAD or their mammalian homologs may be “knocked out” in an animal model system using homologous recombination in embryonic stem (ES) cells. Such techniques arc well known in the art and are useful for the generation of animal models of human disease. (See, e.g., U.S. Pat. No. 5,175,383 and U.S. Pat. No. 5,767,337.) For example, mouse ES cells, such as the mouse 129/SvJ cell line, are derived from the early mouse embryo and grown in culture. The ES cells are transformed with a vector containing the gene of interest disrupted by a marker gene, e.g., the neomycin phosphotransferase gene (neo; Capecchi, M. R. (1989) Science 244:1288-1292). The vector integrates into the corresponding region of the host genome by homologous recombination. Alternatively, homologous recombination takes place using the Cre-loxP system to knockout a gene of interest in a tissue- or developmental stage-specific manner (Maith, J. D. (1996) Clin. Invest. 97:1999-2002; Wagner, K. U. et al. (1997) Nucleic Acids Res. 25:4323-4330). Transformed ES cells are identified and microinjected into mouse cell blastocysts such as those from the C57BL/6 mouse strain. The blastocysts are surgically transferred to pseudopregnant dams, and the resulting chimeric progeny are genotyped and bred to produce heterozygous or homozygous strains. Transgenic animals thus generated may be tested with potential therapeutic or toxic agents.

[0192] Polynucleotides encoding ECMCAD may also be manipulated in vitro in ES cells derived from human blastocysts. Human ES cells have the potential to differentiate into at least eight separate cell lineages including endoderm, mesoderm, and ectodermal cell types. These cell lineages differentiate into, for example, neural cells, hematopoietic lineages, and cardiomyocytes (Thomson, J. A. et al. (1998) Science 282:1145-1147).

[0193] Polynucleotides encoding ECMCAD can also be used to create “knockin” humanized animals (pigs) or transgenic animals (mice or rats) to model human disease. With knockin technology, a region of a polynucleotide encoding ECMCAD is injected into animal ES cells, and the injected sequence integrates into the animal cell genome. Transformed cells are injected into blastulae, and the blastulae are implanted as described above. Transgenic progeny or inbred lines are studied and treated with potential pharmaceutical agents to obtain information on treatment of a human disease. Alternatively, a mammal inbred to overexpress ECMCAD, e.g., by secreting ECMCAD in its milk, may also serve as a convenient source of that protein (Janne, J. et al. (1998) Biotechnol. Annu. Rev. 4:55-74).

THERAPEUTICS

[0194] Chemical and structural similarity, e.g., in the context of sequences and motifs, exists between regions of ECMCAD and extracellular matrix and cell adhesion molecules In addition, the expression of ECMCAD is closely associated with brain, prostate, atrial myxoma, cerebellum, cervical dorsal root ganglion, cardiac muscle, mesentel fat, kidney epithelium, thymus, endothelium, ovary, placenta, smooth muscle, fallopian tube, breast, cartilage, bladder, rib, colon, spine, gall bladder, blood granulocytes, submandibular gland, seminal vesicle, and intestine tissues; with tumors of the brain, prostate, rib, and fallopian tube; and with dermal microvascular endothelial cells, hNT2 cells derived from a human teratocarcinoma, and 293-EBNA transformed embryonal cells derived from kidney epithelial tissue. Therefore, ECMCAD appears to play a role in genetic, immune/inflammatory, developmental, neurological, connective tissue, and cell proliferative disorders, including cancer. In the treatment of disorders associated with increased ECMCAD expression or activity, it is desirable to decrease the expression or activity of ECMCAD. In the treatment of disorders associated with decreased ECMCAD expression or activity, it is desirable to increase the expression or activity of ECMCAD.

[0195] Therefore, in one embodiment, ECMCAD or a fragment or derivative thereof may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of ECMCAD. Examples of such disorders include, but are not limited to, a genetic disorder such as adrenoleukodystrophy, Alport's syndrome, choroideremia, Duchenne and Becker muscular dystrophy, Down's syndrome, cystic fibrosis, chronic granulomatous disease, Gaucher's disease, Huntington's chorea, Marfan's syndrome, muscular dystrophy, myotonic dystrophy, pyenodysostosis, Refsum's syndrome, retinoblastoma, sickle cell anemia, thalassemia, Werner syndrome, von Willebrand's disease, Wilms' tumor, Zellweger syndrome, peroxisomal acyl-CoA oxidase deficiency, peroxisomal thiolase deficiency, peroxisomal bifunctional protein deficiency, mitochondrial carnitine palmitoyl transferase and carnitine deficiency, mitochondrial very-long-chain acyl-CoA dehydrogenase deficiency, mitochondrial medium-chain acyl-CoA dehydrogenase deficiency, mitochondrial short-chain acyl-CoA dehydrogenase deficiency, mitochondrial electron transport flavoprotein and electron transport flavoprotein:ubiquinone oxidoreductase deficiency, mitochondrial trifunctional protein deficiency, and mitochondrial short-chain 3-hydroxyacyl-CoA dehydrogenase deficiency; an immune/inflammatory disorder such as acquired immunodeficiency syndrome (AIDS), X-linked agammaglobinemia of Bruton, common variable immunodeficiency (CVI), DiGeorge's syndrome (thymic hypoplasia), thymic dysplasia, isolated IgA deficiency, severe combined immunodeficiency disease (SCID), immunodeficiency with thrombocytopenia and eczema (Wiskott-Aldrich syndrome), Chediak-Higashi syndrome, chronic granulomatous diseases, hereditary angioneurotic edema, immunodeficiency associated with Cushing's disease, Addison's disease, adult respiratory distress syndrome, allergies, ankylosinig spondylitis, aimyloidosis, anemia, asthma, atherosclerosis, autoimmune hemolytic anemia, autoimmune thyroiditis, autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), bronchitis, cholecystitis, contact dermatitis, Crohn's disease, atopic dermatitis, dermatomyositis, diabetes mellitus, emphysema, episodic lymphopenia with lymphocytotoxins, eiytlioblastosis fetalis, erythema nodosum, atrophic gasthitis, glomerulonephritis, Goodpasture's syndrome, gout, Graves' disease, Hashimoto's thyroiditis, hypereosinophilia, irritable bowel syndrome, multiple sclerosis, myasthenia gravis, myocardial or pericardial inflammation, osteoarthritis, osteoporosis, pancreatitis, polymyositis, psoriasis, Reiter's syndrome, rheumatoid arthritis, scleroderma, Sjogren's syndrome, systemic anaphylaxis, systemic lupus erythematosus, systernic sclerosis, thrombocytopenic purpura, ulcerative colitis, uveitis, Werner syndrome, complications of cancer, hemodialysis, and extracorporeal circulation, viral, bacterial, fungal, parasitic, protozoal, and helminthic infections, and trauma; a developmental disorder such as renal tubular acidosis, anemia, Cushing's syndrome, achondroplastic dwarfism, Duchenne and Becker muscular dystrophy, epilepsy, gonadal dysgenesis, WAGR syndrome (Wilms' tumor, aniridia, genitourinary abnormalities, and mental retardation), Smith-Magenis syndrome, myelodysplastic syndrome, hereditary mucoepithelial dysplasia, hereditary keratodermas, hereditary neuropathies such as Charcot-Marie-Tooth disease and neurofibromatosis, hypothyroidism, hydrocephalus, seizure disorders such as Syndenham's chorea and cerebral palsy, spina bifida, anencephaly, craniorachischisis, congenital glaucoma, cataract, and sensorineural hearing loss; a neurological disorder such as epilepsy, ischemic cerebrovascular disease, stroke, cerebral neoplasms, Alzheimer's disease, Pick's disease, Huntinigton's disease, dementia, Parkinson's disease and other extrapyramidal disorders, amyotrophic lateral sclerosis and other motor neuron disorders, progressive neural muscular atrophy, retinitis pigmentosa, hereditary ataxias, multiple sclerosis and other demyelinating diseases, bacterial and viral meningitis, brain abscess, subdural empyoma, epidural abscess, suppurative intracranial thrombophlebitis, myelitis and radiculitis, viral central nervous system disease, prion diseases including kuru, Creutzfeldt-Jakob disease, and Gerstmann-Straussler-Scheiniker syndrome, fatal familial insomnia, nutritional and metabolic diseases of the nervous system, neurofibromatosis, tuberous sclerosis, cerebelloretinal hemangioblastomatosis, encephalotrigeminal syndrome, mental retardation and other developmental disorders of the central nervous system including Down syndrome, cerebral palsy, neuroskeletal disorders autonomic nervous system disorders, cranial nerve disorders, spinal cord diseases, muscular dystrophy and other neuromuscular disorders, peripheral nervous system disorders, dermatomyositis and polymyositis, inherited, metabolic, endocrine, and toxic myopathies, myasthenia gravis, periodic paralysis, mental disorders including mood, anxiety, and schizophrenic disorders, seasonal affective disorder (SAD), akathesia, amnesia, catatonia, diabetic neuropathy, tardive dyskinesia, dystonias, paranoid psychoses, postheipetic neuralgia, Tourette's disorder, progressive supranuclear palsy, corticobasal degeneration, and familial frontotemporal dementia; a connective tissue disorder such as osteogenesis imperfecta, Ehlers-Danlos syndrome, chondrodysplasias, Marfan syndrome, Alport syndrome, familial aortic aneurysm, achondroplasia, mucopolysaccharidoses, osteoporosis, osteopetrosis, Paget's disease, rickets, osteomalacia, hyperparathyroidism, renal osteodystrophy, osteoneciosis, osteomyelitis, osteoma, osteoid osteoma, osteoblastoma, osteosarcoma, osteochondroma, chondroma, chondroblastoma, chondromyxoid fibroma, chondrosarcoma, fibrous cortical defect, nonossifying fibroma, fibrous dysplasia, fibrosarcoma, malignant fibrous histiocytoma, Ewing's sarcoma, primitive neuroectodermal tumor, giant cell tumor, osteoarthritis, rheumatoid arthritis, ankylosing spondyloarthritis, Reiter's syndrome, psoriatic arthritis, enteropathic arthritis, infectious arthritis, gout, gouty arthritis, calcium pyrophosphate crystal deposition disease, ganglion, synovial cyst, villonodular synovitis, systemic sclerosis, Dupuytren's contracture, hepatic fibrosis, lupus erythematosus, mixed connective tissue disease, epidermolysis bullosa simplex, bullous congenital ichthyosiform erythroderma (epiderniolytic hyperkeratosis), non-epidermolytic and epidermolytic palmoplantar keratoderina, ichthyosis bullosa of Siemens, pachyonychia congenital and white sponge nevus; and a cell proliferative disorder such as actinic keratosis, arteriosclerosis, atherosclerosis, bursitis, cirrhosis, hepatitis, mixed connective tissue disease (MCTD), myelofibrosis, paroxysmal nocturnal hemoglobinuria, polycytheima vera, psoriasis, primary thrombocythemia, and cancers including adenocarcinoma, leukemia, lymphoma, melanoma, myeloma, sarcoma, teratocarcinoma, and, in particular, cancers of the adrenal gland, bladder, bone, bone marrow, brain, breast, cervix, gall bladder, ganglia, gastrointestinal tract, heart, kidney, liver, lung, muscle, ovaty, pancreas, parathyroid, penis, prostate, salivary glands, skin, spleen, testis, thymus, thyroid, and uterus.

[0196] In another embodiment, a vector capable of expressing ECMCAD or a fragment or derivative thereof may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of ECMCAD including, but not limited to, those described above.

[0197] In a further embodiment, a composition comprising a substantially purified ECMCAD in conjunction with a suitable pharmaceutical carrier may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of ECMCAD including, but not limited to, those provided above.

[0198] In still another embodiment, an agonist which modulates the activity of ECMCAD may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of ECMCAD including, but not limited to, those listed above.

[0199] In a further embodiment, an antagonist of ECMCAD may be administered to a subject to treat or prevent a disorder associated with increased expression or activity of ECMCAD. Examples of such disorders include, but are not limited to, those genetic, immunelinflammatory, developmental, neurological, connective tissue, and cell proliferative disorders, including cancer described above. In one aspect, an antibody which specifically binds ECMCAD may be used directly as an antagonist or indirectly as a targeting or delivery mechanism for bringing a pharmaceutical agent to cells or tissues which express ECMCAD.

[0200] In an additional embodiment, a vector expressing the complement of the polynucleotide encoding ECMCAD may be administered to a subject to treat or prevent a disorder associated with increased expression or activity of ECMCAD including, but not limited to, those described above.

[0201] In other embodiments, any of the proteins, antagonists, antibodies, agonists, complementary sequences, or vectors of the invention may be administered in combination with other appropriate therapeutic agents. Selection of the appropriate agents for use in combination therapy may be made by one of ordinary skill in the art, according to conventional pharmaceutical principles. The combination of therapeutic agents may act synergistically to effect the treatment or prevention of the various disorders described above. Using this approach, one may be able to aclueve therapeutic efficacy with lower dosages of each agent, thus reducing the potential for adverse side effects.

[0202] An antagonist of ECMCAD may be produced using methods which are generally known in the art. In particular, purified ECMCAD may be used to produce antibodies or to screen libraries of pharmaceutical agents to identify those which specifically bind ECMCAD. Antibodies to ECMCAD may also be generated using methods that are well known in the art. Such antibodies may include, but are not limited to, polyclonal, monoclonal, chimeric, and single chain antibodies, Fab fragments, and fragments produced by a Fab expression library. Neutralizing antibodies (i.e., those which inhibit dimer formation) are generally preferred for therapeutic use.

[0203] For the production of antibodies, various hosts including goats, rabbits, rats, mice, humans, and others may be immunized by injection with ECMCAD or with any fragment or oligopeptide thereof which has immunogenic properties. Depending on the host species, various adjuvants may be used to increase immunological response. Such adjuvants include, but are not limited to, Freund's, mineral gels such as aluminum hydroxide, and surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, KLH, and dinitrophenol. Among adjuvants used in humans, BCG (bacilli Calmette-Guerin) and Cornebacterium parvum are especially preferable.

[0204] It is preferred that the oligopeptides, peptides, or fragments used to induce antibodies to ECMCAD have an amino acid sequence consisting of at least about 5 amino acids, and generally will consist of at least about 10 amino acids. It is also preferable that these oligopeptides, peptides, or fragments are identical to a portion of the amino acid sequence of the natural protein. Short stretches of ECMCAD amino acids may be fused with those of another protein, such as KLH, and antibodies to the chimeric molecule may be produced.

[0205] Monoclonal antibodies to ECMCAD may be prepared using any technique which provides for the production of antibody molecules by continuous cell lines in culture. These include, but are not limited to, the hybridoma technique, the human B-cell hybridoma technique, and the EBV-hybridoma technique. (See, e.g., Kohler, G. et al. (1975) Nature 256:495-497; Kozbor, D. et al. (1985) J. Immunol. Methods 81:31-42; Cote, R. J. et al. (1983) Proc. Natl. Acad. Sci. USA 80:2026-2030; and Cole, S. P. et al. (1984) Mol. Cell Biol. 62:109-120.)

[0206] In addition, techniques developed for the production of “chimeric antibodies,” such as the splicing of mouse antibody genes to human antibody genes to obtain a molecule with appropriate antigen specificity and biological activity, can be used. (See, e.g., Morrison, S. L. et al. (1984) Proc. Natl. Acad. Sci. USA 81:6851-6855; Neuberger, M. S. et al. (1984) Nature 312:604-608; and Takeda, S. et al. (1985) Nature 314:452-454.) Alternatively, techniques described for the production of single chain antibodies may be adapted, using methods known in the art, to produce ECMCAD-specific single chain antibodies. Antibodies with related specificity, but of distinct idiotypic composition, may be generated by chain shuffling from random combinatorial immunoglobulin libraries. (See, e.g., Burton, D. R. (1991) Proc. Natl. Acad. Sci. USA 88:10134-10137.)

[0207] Antibodies may also be produced by inducing in vivo production in the lymphocyte population or by screening immunoglobulin libraries or panels of highly specific binding reagents as disclosed in the literature. (See, e.g., Orlandi, R. et al. (1989) Proc. Natl. Acad. Sci. USA 86:3833-3837; Winter, G. et al. (1991) Nature 349:293-299.)

[0208] Antibody fragments which contain specific binding sites for ECMCAD may also be generated. For example, such fragments include, but are not limited to, F(ab′)₂ fragments produced by pepsin digestion of the antibody molecule and Fab fragments generated by reducing the disulfide bridges of the F(ab)2 fragments. Alternatively, Fab expression libraries may be constructed to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity. (See, e.g., Huse, W. D. et al. (1989) Science 246:1275-1281.)

[0209] Various immunoassays may be used for screening to identify antibodies having the desired specificity. Numerous protocols for competitive binding or immunoradiometric assays using either polyclonal or monoclonal antibodies with established specificities are well known in the art. Such immunoassays typically involve the measurement of complex formation between ECMCAD and its specific antibody. A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering ECMCAD epitopes is generally used, but a competitive binding assay may also be employed (Pound, supra).

[0210] Various methods such as Scatchard analysis in conjunction with radioimmunoassay techniques may be used to assess the affinity of antibodies for ECMCAD. Affinity is expressed as an association constant K_(a), which is defined as the molar concentration of ECMCAD-antibody complex divided by the molar concentrations of free antigen and free antibody under equilibrium conditions. The K_(a) determined for a preparation of polyclonal antibodies, which are heterogeneous in their affinitics for multiple ECMCAD epitopes, represents the average affinity, or avidity, of the antibodies for ECMCAD. The K_(a) determined for a preparation of monoclonal antibodies, which are monospecific for a particular ECMCAD epitope, represents a true measure of affinity. High-affinity antibody preparations with K_(a) ranging from about 10⁹ to 10¹² L/mole are preferred for use in immunoassays in which the ECMCAD-antibody complex must withstand rigorous manipulations. Low-affinity antibody preparations with K_(a) ranging from about 10⁶ to 10⁷ L/mole are preferred for use in immunopurification and similar procedures which ultimately require dissociation of ECMCAD, preferably in active form, from the antibody (Catty, D. (1988) Antibodies, Volume I: A Practical Approach, IRL Press, Washington D.C.; Liddell, J. E. and A. Ciyer (1991) A Practical Guide to Monoclonal Antibodies, John Wiley & Sons, New York N.Y.).

[0211] The titer and avidity of polyclonal antibody preparations may be further evaluated to determine the quality and suitability of such preparations for certain downstream applications. For example, a polyclonal antibody preparation containing at least 1-2 mg specific antibody/ml, preferably 5-10 mg specific antibody/ml, is generally employed in procedures requiring precipitation of ECMCAD-antibody complexes. Procedures for evaluating antibody specificity, titer, and avidity, and guidelines for antibody quality and usage in various applications, are generally available. (See, e.g., Catty, supra, and Coligan et al. supra.)

[0212] In another embodiment of the invention, the polynucleotides encoding ECMCAD, or any fragment or complement thereof, may be used for therapeutic purposes. In one aspect, modifications of gene expression can be achieved by designing complementary sequences or antisense molecules (DNA, RNA, PNA, or modified oligonucleotides) to the coding or regulatory regions of the gene encoding ECMCAD. Such technology is well known in the all, and antisense oligonucleotides or larger fragments can be designed from various locations along the coding or control regions of sequences encoding ECMCAD. (See, e.g., Agrawal, S., ed. (1996) Antisense Therapeutics, Humana Press Inc., Totawa N.J.)

[0213] In therapeutic use, any gene delivery system suitable for introduction of the antisense sequences into appropriate target cells can be used. Antisense sequences can be delivered intracellularly in the form of an expression plasmid which, upon transcription, produces a sequence complementary to at least a portion of the cellular sequence encoding the taret protein. (See, e.g., Slater, J. E. et al. (1998) J. Allergy Cli. Immunol. 102(3):469-475; and Scanlon, K. J. et al. (1995) 9(13): 1288-1296.) Antisense sequences can also be introduced intracellularly through the use of viral vectors, such as retrovirus and adeno-associated virus vectors. (See, e.g., Miller, A. D. (1990) Blood 76:271; Ausubel, supra; Uckert, W. and W. Walther (1994) Pharmacol. Ther. 63(3):323-347.) Other gene delivery mechanisms include liposome-derived systems, artificial viral envelopes, and other systems known in the alt. (See, e.g., Rossi, J. J. (1995) Br. Med. Bull. 51(1):217-225; Boado, R. J. et al. (1998) J. Pharm. Sci. 87(11):1308-1315; and Morris, M. C. et al. (1997) Nucleic Acids Res. 25(14):2730-2736.)

[0214] In another embodiment of the invention, polynucleotides encoding ECMCAD may be used for somatic or germline gene therapy. Gene therapy may be performed to (i) correct a genetic deficiency (e.g., in the cases of severe combined immunodeficiency (SCID)-X1 disease characterized by X-linked inheritance (Cavazzana-Calvo, M. et al. (2000) Science 288:669-672), severe combined immunodeficiency syndrome associated with an inherited adenosine deaminase (ADA) deficiency (Blaese, R. M. et al. (1995) Science 270:475-480; Bordignon. C. et al. (1995) Science 270:470-475), cystic fibrosis (Zabner, J. et al. (1993) Cell 75:207-216; Crystal, R. G. et al. (1995) Hum. Gene Therapy 6:643-666; Crystal, R. G. et al. (1995) Hum. Gene Therapy 6:667-703). thalassamias, familial hypercholesterolemia, and hemophilia resulting from Factor VIII or Factor IX deficiencies (Crystal, R. G. (1995) Science 270:404-410; Verma, I. M. and N. Somia (1997) Nature 389:239-242)), (ii) express a conditionally lethal gene product (e.g., in the case of cancers which result from unregulated cell proliferation), or (iii) express a protein which affords protection against intracellular parasites (e.g., against human retroviruses, such as human immunodeficiency virus (HIV) (Baltimore, D. (1988) Nature 335:395-396; Poeschla, E. et al. (1996) Proc. Natl. Acad. Sci. USA. 93:1 1395-11399), hepatitis B or C virus (HBV, HCV); fungal parasites, such as Candida albicans and Paracoccidioides brasiliensis; and protozoan parasites such as Plasmodium falciparum and Trypanosoma cruzi). In the case where a genetic deficiency in ECMCAD expression or regulation causes disease, the expression of ECMCAD from an appropriate population of transduced cells may alleviate the clinical manifestations caused by the genetic deficiency.

[0215] In a further embodiment of the invention, diseases or disorders caused by deficiencies in ECMCAD are treated by constructing mammalian expression vectors encoding ECMCAD and introducing these vectors by mechanical means into ECMCAD-deficient cells. Mechanical transfer technologies for use with cells in vivo or ex vitro include (i) direct DNA microinjection into individual cells, (ii) ballistic gold particle delivery, (iii) liposome-mediated transfection, (iv) receptor-mediated gene transfer, and (v) the use of DNA transposons (Morgan, R. A. and W. F. Anderson (1993) Annu. Rev. Biochem. 62:191-217; Ivics, Z. (1997) Cell 91:501-510; Boulay, J-L. and H. Récipon (1998) Curr. Opin. Biotechnol. 9:445-450).

[0216] Expression vectors that may be effective for the expression of ECMCAD include, but are not limited to, the PCDNA 3.1, EPITAG, PRCCMV2, PREP, PVAX vectors (Invitrogen, Carlsbad Calif.), PCMV-SCRIPT, PCMV-TAG, PEGSLYPERV (Stratagene, La Jolla Calif.), and PTET-OFF, PTET-ON, PTRE2, PTRE2-LUC, PTK-HYG (Clontech, Palo Alto Calif.). ECMCAD may be expressed using (i) a constitutively active promoter, (e.g., from cytomegalovirus (CMV), Rous sarcoma virus (RSV), SV40 virus, thymidine kinase (TK), or β-actin genes), (ii) an inducible promoter (e.g., the tetracycime-regulated promoter (Gossen, M. and H. Bujard (1992) Proc. Natl. Acad. Sci. USA 89:5547-5551; Gossen, M. et al. (1995) Science 268:1766-1769; Rossi, F. M. V. and H. M. Blau (1998) Curr. Opin. Biotechnol. 9:451-456), commercially available in the T-REX plasmid (Invitrogen)); the ecdysone-inducible promoter (available in the plasmids PVGRXR and PIND; Invitrogen); the FK506/rapamycin inducible promoter; or the RU486/mifepristone inducible promoter (Rossi, F. M. V. and Blau, H. M. supra)), or (iii) a tissue-specific promoter or the native promoter of the endogenous gene encoding ECMCAD from a normal individual.

[0217] Commercially available liposome transformation kits (e.g., the PERFECT LIPID TRANSFECTION KIT, available from Invitrogen) allow one with ordinary skill in the art to deliver polynucleotides to target cells in culture and require minimal effort to optimize experimental parameters. In the alternative, transformation is performed using the calcium phosphate method (Graham, F. L. and A. J. Eb (1973) Virology 52:456-467), or by electroporation (Neumann, E. et al. (1982) EMBO J. 1:841-845). The introduction of DNA to primary cells requires modification of these standardized mammalian transfection protocols.

[0218] In another embodiment of the invention, diseases or disorders caused by genetic defects with respect to ECMCAD expression are treated by constructing a retrovirus vector consisting of (i) the polynucleotide encoding ECMCAD under the control of an independent promoter or the retrovirus long terminal repeat (LTR) promoter, (ii) appropriate RNA packaging signals, and (iii) a Rev-responsive element (RRE) along with additional retrovirus cis-acting RNA sequences and coding sequences required for efficient vector propagation. Retrovirus vectors (e.g., PFB and PFBNEO) are commercially available (Stratagene) and are based on published data (Riviere, I. et al. (1995) Proc. Natl. Acad. Sci. USA 92:6733-6737), incorporated by reference herein. The vector is propagated in an appropriate vector producing cell line (VPCL) that expresses an envelope gene with a tropism for receptors on the target cells or a promiscuous envelope protein such as VSVg (Armentano. D. et al. (1987) J. Virol. 61:1647-1650; Bender, M. A. et al. (1987) J. Virol. 61:1639-1646; Adam, M. A. and A. D. Miller(I988) J. Virol. 62:3802-3806: Dull, T. et al. (1998) J. Virol. 72:8463-8471; Zufferey, R. et al. (1998) J. Virol. 72:9873-9880). U.S. Pat. No. 5,910,434 to Rigg (“Method for obtaining retrovirus packaging cell lines producing high transducing efficiency retroviral supernatant”) discloses a method for obtaining retrovirus packaging cell lines and is hereby incorporated by reference. Propagation of retrovirus vectors, transduction of a population of cells (e.g., CD4⁺ T-cells), and the return of transduced cells to a patient are procedures well known to persons skilled in the art of gene therapy and have been well documented (Ranga, U. et al. (1997) J. Virol. 71:7020-7029; Bauer, G. et al. (1997) Blood 89:2259-2267; Bonyhadi, M. L. (1997) J. Virol. 71:47074716; Ranga, U. et al. (1998) Proc. Natl. Acad. Sci. USA 95:1201-1206; Su, L. (1997) Blood 89:2283-2290).

[0219] In the alternative, an adenovirus-based gene therapy delivery system is used to deliver polynucleotides encoding ECMCAD to cells which have one or more genetic abnormalities with respect to the expression of ECMCAD. The construction and packaging of adenovirus-based vectors are well known to those with ordinary skill in the art. Replication defective adenovirus vectors have proven to be versatile for importing genes encoding immunoregulatory proteins into intact islets in the pancreas (Csete, M. E. et al. (1995) Transplantation 27:263-268). Potentially useful adenoviral vectors are described in U.S. Pat. No. 5,707,618 to Armentano (“Adenoviius vectors for gene therapy”), hereby incorporated by reference. For adenoviral vectors, see also Antinozzi, P. A. et al. (1999) Annu. Rev. Nutr. 19:511-544 and Verma, I. M. and N. Somia (1997) Nature 18:389:239-242, both incorporated by reference herein.

[0220] In another alterative, a herpes-based, gene therapy delivery system is used to deliver polynucleotides encoding ECMCAD to target cells which have one or more genetic abnormalities with respect to the expression of ECMCAD. The use of herpes simplex virus (HSV)-based vectors may be especially valuable for introducing ECMCAD to cells of the central nervous system, for which HSV has a tropism. The construction and packaging of herpes-based vectors are well known to those with ordinary skill in the art. A replication-competent herpes simplex virus (HSV) type 1 -based vector has been used to deliver a reporter gene to the eyes of primates (Liu, X. et al. (1999) Exp. Eye Res. 169:385-395). The construction of a HSV-1 virus vector has also been disclosed in detail in U.S. Pat. No. 5,804,413 to DeLuca (“Herpes simplex virus strains for gene transfer”), which is hereby incorporated by reference. U.S. Pat. No. 5,804,413 teaches the use of recombinant HSV d92 which consists of a genome containing at least one exogenous gene to be transferred to a cell under the control of the appropriate promoter for purposes including human gene therapy. Also taught by this patent are the construction and use of recombinant HSV strains deleted for ICP4, ICP27 and ICP22. For HSV vectors, see also Goins, W. F. et al. (1999) J. Virol. 73:519-532 and Xu, H. et al. (1994) Dev. Biol. 163:152-161, hereby incorporated by reference. The manipulation of cloned herpesvirus sequences the generation of recombinant virus following the transfection of multiple plasmids containing different segments of the large herpesvirus genomes, the growth and propagation of herpesvirus, and the infection of cells with herpesvirus are techniques well known to those of ordinary skill in the art.

[0221] In another alternative, an alphavirus (positive, single-stranded RNA virus) vector is used to deliver polynucleotides encoding ECMCAD to target cells. The biology of the prototypic alphavirus, Semliki Forest Virus (SFV), has been studied extensively and gene transfer vectors have been based on the SFV genome (Garoff, H. and K.-J. Li (1998) Curr. Opin. Biotechnol. 9:464469). During alphavirus RNA replication, a subgenomic RNA is generated that normally encodes the viral capsid proteins. This subgenomic RNA replicates to higher levels than the full length genomic RNA, resulting in the overproduction of capsid proteins relative to the viral proteins with enzymatic activity (e.g., protease and polymerase). Similarly, inserting the coding sequence for ECMCAD into the alphavirus genome in place of the capsid-coding region results in the production of a large number of ECMCAD-coding RNAs and the synthesis of high levels of ECMCAD in vector transduced cells. While alphavirus infection is typically associated with cell lysis within a few days, the ability to establish a persistent infection in hamster normal kidney cells (BHK-21) with a variant of Sindbis virus (SET) indicates that the lytic replication of alphaviruses can be altered to suit the needs of the gene therapy application (Dryga, S. A. et al. (1997) Virology 228:74-83). The wide host range of alphaviruses will allow the introduction of ECMCAD into a variety of cell types. The specific transduction of a subset of cells in a population may require the sorting of cells prior to transduction. The methods of manipulating infectious cDNA clones of alphaviruses, performing alphavirus cDNA and RNA transfections, and performing alphavirus infections, are well known to those with ordinary skill in the art.

[0222] Oligonucleotides derived from the transcription initiation site, e.g., between about positions −10 and +10 from the start site, may also be employed to inhibit gene expression. Similarly, inhibition can be achieved using triple helix base-pairing methodology. Triple helix pairing is useful because it causes inhibition of the ability of the double helix to open sufficiently for the binding of polymerases, transcription factors, or regulatory molecules. Recent therapeutic advances using triplex DNA have been described in the literature. (See, e.g., Gee. J. E. et al. (1994) in Huber, B. E. and B. I. Carr, Molecular and Immunologic Approaches, Futura Publishing, Mt. Kisco N.Y., pp. 163-177.) A complementary sequence or antisense molecule may also be designed to block translation of mRNA by preventing the transcript from binding to ribosomes.

[0223] Ribozymes, enzymatic RNA molecules, may also be used to catalyze the specific cleavage of RNA. The mechanism of ribozyme action involves sequence-specific hybridization of the ribozyme molecule to complementary target RNA followed by endonucleolytic cleavage. For example, engineered hammerhead motif ribozyme molecules may specifically and efficiently catalyze endonucleolytic cleavage of sequences encoding ECMCAD.

[0224] Specific ribozyme cleavage sites within any potential RNA target are initially identified by scanning the target molecule for ribozyme cleavage sites, including the following sequences: GUA, GUU, and GUC. Once identified, short RNA sequences of between 15 and 20 ribonucleotides, corresponding to the region of the target gene containing the cleavage site, may be evaluated for secondary structural features which may render the oligonucleotide inoperable. The suitability of candidate targets may also be evaluated by testing accessibility to hybridization with complementary oligonucleotides using ribonuclease protection assays.

[0225] Complementary ribonucleic acid molecules and ribozymes of the invention may be prepared by any method known in the ant for the synthesis of nucleic acid molecules. These include techniques for chemically synthesizing oligonucleotides such as solid phase phosphoramidite chemical synthesis. Alternatively, RNA molecules may be generated by in vitro and in vivo transcription of DNA sequences encoding ECMCAD. Such DNA sequences may be incorporated into a wide variety of vectors with suitable RNA polymerase promoters such as T7 or SP6. Alternatively, these cDNA constructs that synthesize complementary RNA, constitutively or inducibly, can be introduced into cell lines, cells, or tissues.

[0226] RNA molecules may be modified to increase intracellular stability and half-life. Possible modifications include, but are not limited to, the addition of flanking sequences at the 5′ and/or 3′ ends of the molecule, or the use of phosphorothioate or 2′O-methyl rather than phospliodiesterase linkages within the backbone of the molecule. This concept is inherent in the production of PNAs and can be extended in all of these molecules by the inclusion of nontraditional bases such as inosine, queosine, and wybutosine, as well as acetyl-, methyl-, thio-, and similarly modified forms of adenine, cytidine, guanine, thymine, and uridine which are not as easily recognized by endogenous endonucleases.

[0227] An additional embodiment of the invention encompasses a method for screening for a compound which is effective in altering expression of a polynucleotide encoding ECMCAD. Compounds which may be effective in altering expression of a specific polynucleotide may include, but are not limited to, oligonucleotides, antisense oligonucleotides, triple helix-forming oligonucleotides. transcription factors and other polypeptide transcriptional regulators, and non-macromolecular chemical entities which are capable of interacting with specific polynucleotide sequences. Effective compounds may alter polynucleotide expression by acting as either inhibitors or promoters of polynucleotide expression. Thus, in the treatment of disorders associated with increased ECMCAD expression or activity, a compound which specifically inhibits expression of the polynucleotide encoding ECMCAD may be therapeutically useful, and in the treatment of disorders associated with decreased ECMCAD expression or activity, a compound which specifically promotes expression of the polynucleotide encoding ECMCAD may be therapeutically useful.

[0228] At least one, and up to a plurality, of test compounds may be screened for effectiveness in altering expression of a specific polynucleotide. A test compound may be obtained by any method commonly known in the art, including chemical modification of a compound known to be effective in altering polynucleotide expression; selection from an existing, commercially-available or proprietary library of naturally-occurring or non-natural chemical compounds; rational design of a compound based on chemical and/or structural properties of the target polynucleotide; and selection from a, library of chemical compounds created combinatorially or randomly. A sample comprising a polynucleotide encoding ECMCAD is exposed to at least one test compound thus obtained. The sample may comprise, for example, an intact or permeabilized cell, or an in vitro cellfree or reconstituted biochemical system. Alterations in the expression of a polynucleotide encoding ECMCAD are assayed by any method commonly known in the art. Typically, the expression of a specific nucleotide is detected by hybridization with a probe having a nucleotide sequence complementary to the sequence of the polynucleotide encoding ECMCAD. The amount of hybridization may be quantified, thus forming the basis for a comparison of the expression of the polynucleotide both with and without exposure to one or more test compounds. Detection of a change in the expression of a polynucleotide exposed to a test compound indicates that the test compound is effective in altering the expression of the polynucleotide. A screen for a compound effective in altering expression of a specific polynucleotide can be carried out, for example, using a Schizosaccharomyces pombe gene expression system (Atkins, D. et al. (1999) U.S. Pat. No. 5,932,435: Arndt, G. M. et al. (2000) Nucleic Acids Res. 28:E15) or a human cell line such as HeLa cell (Clarke, M. L. et al. (2000) Biochem. Biophys. Res. Commun. 268:8-13). A particular embodiment of the present invention involves screening a combinatorial library of oligonucleotides (such as deoxyribonucleotides, ribonucleotides, peptide nucleic acids, and modified oligonucleotides) for antisense activity against a specific polynucleotide sequence (Bruice, T. W. et al. (1997) U.S. Pat. No. 5,686,242; Bruice, T. W. et al. (2000) U.S. Pat. No. 6,022,691).

[0229] Many methods for introducing vectors into cells or tissues are available and equally suitable for use in vivo, in vitro, and ex vivo. For ex vivo therapy, vectors may be introduced into stem cells taken from the patient and clonally propagated for autologous transplant back into that same patient. Delivery by transfection, by liposome injections, or by polycationic amino pollers may be achieved using methods which are well known in the art. (See, e.g., Goldman, C. K. et al. (1997) Nat. Biotechnol. 15:462-466.)

[0230] Any of the therapeutic methods described above may be applied to any subject in need of such therapy, including, for example, mammals such as humans, dogs, cats, cows, horses, rabbits, and monkeys.

[0231] An additional embodiment of the invention relates to the administration of a composition which generally comprises an active ingredient formulated with a pharmaceutically acceptable excipient. Excipients may include, for example, sugars, starches, celluloses, gums, and proteins. Various formulations are commonly known and are thoroughly discussed in the latest edition of Remington's Pharmaceutical Sciences (Maack Publishing, Easton Pa.). Such compositions may consist of ECMCAD, antibodies to ECMCAD, and mimetics, agonists, antagonists, or inhibitors of ECMCAD.

[0232] The compositions utilized in this invention may be administered by any number of routes including, but not limited to, oral, intravenous, intramuscular, intra-aterial, intramedullaty, intrathecal, intravetitricular, pulmonary, transdermal, subcutaneous, intraperitoneal, intranasal, enteral, topical, sublingual, or rectal means.

[0233] Compositions for pulmonary administration may be prepared in liquid or dry powder form. These compositions are generally aerosolized immediately prior to inhalation by the patient. In the case of small molecules (e.g. traditional low molecular weight organic drugs), aerosol delivery of fast-acting formulations is well-known in the art. In the case of macromolecules (e.g. larger peptides and proteins), recent developments in the field of pulmonary delivery via the alveolar region of the lung have enabled the practical delivery of drugs such as insulin to blood circulation (see, e.g., Patton, J. S. et al., U.S. Pat. No. 5,997,848). Pulmonary delivery has the advantage of administration without needle injection, and obviates the need for potentially toxic penetration enhancers.

[0234] Compositions suitable for use in the invention include compositions wherein the active ingredients are contained in an effective amount to achieve the intended purpose. The determination of an effective dose is well within the capability of those skilled in the art.

[0235] Specialized forms of compositions may be prepared for direct intracellular delivery of macromolecules comprising ECMCAD or fragments thereof. For example, liposome preparations containing a cell-impermeable macromolecule may promote cell fusion and intracellular delivery of the macromolecule. Alternatively, ECMCAD or a fragment thereof may be joined to a short cationic N-terminal portion from the HIV Tat-1 protein. Fusion proteins thus generated have been found to transduce into the cells of all tissues, including the brain, in a mouse model system (Schwarze, S. R. et al (1999) Science 285:1569-1572).

[0236] For any compound, the therapeutically effective dose can be estimated initially either in cell culture assays, e.g., of neoplastic cells, or in animal models such as mice. rats, rabbits, dogs, monkeys, or pigs. An animal model may also be used to determine the appropriate concentration range and route of administration. Such information can then be used to determine useful doses and routes for administration in humans.

[0237] A therapeutically effective dose refers to that amount of active ingredient, for example ECMCAD or fragments thereof, antibodies of ECMCAD, and agonists, antagonists or inhibitors of ECMCAD, which ameliorates the symptoms or condition. Therapeutic efficacy and toxicity may be determined by standard pharmaceutical procedures in cell cultures or with experimental animals, such as by calculating the ED50 (the dose therapeutically effective in 50% of the population) or LD₅₀ (the dose lethal to 50% of the population) statistics. The dose ratio of toxic to therapeutic effects is the therapeutic index, which can be expressed as the LD₅₀/ED₅₀ ratio. Compositions which exhibit large therapeutic indices are preferred. The data obtained from cell culture assays and animal studies are used to formulate a range of dosage for human use. The dosage contained in such compositions is preferably within a range of circulating concentrations that includes the ED₅₀ with little or no toxicity. The dosage varies within this range depending upon the dosage form employed the sensitivity of the patient, and the route of administration.

[0238] The exact dosage will be determined by the practitioner, in light of factors related to the subject requiring treatment. Dosage and administration are adjusted to provide sufficient levels of the active moiety or to maintain the desired effect. Factors which may be taken into account include the severity of the disease state, the general health of the subject, the age, weight, and gender of the subject, time and frequency of administration, drug combination(s), reaction sensitivities, and response to therapy. Long-acting compositions may be administered every 3 to 4 days, every week, or biweekly depending on the half-life and clearance rate of the particular formulation.

[0239] Normal dosage amounts may vary from about 0.1 μg to 100,000 μg, up to a total dose of about 1 gram, depending upon the route of administration. Guidance as to particular dosages and methods of delivery is provided in the literature and generally available to practitioners in the art. Those skilled in the art will employ different formulations for nucleotides than for proteins or their inhibitors. Similarly, delivery of polynucleotides or polypeptides will be specific to particular cells, conditions, locations, etc.

DIAGNOSTICS

[0240] In another embodiment, antibodies which specifically bind ECMCAD may be used for the diagnosis of disorders characterized by expression of ECMCAD, or in assays to monitor patients being treated with ECMCAD or agonists, antagonists, or inhibitors of ECMCAD. Antibodies useful for diagnostic purposes may be prepared in the same manner as described above for therapeutics. Diagnostic assays for ECMCAD include methods which utilize the antibody and a label to detect ECMCAD in human body fluids or in extracts of cells or tissues. The antibodies may be used with or without modification, and may be labeled by covalent or non-covalent attachment of a reporter molecule. A wide variety of reporter molecules, several of which are described above, are known in the art and may be used.

[0241] A variety of protocols for measuring ECMCAD, including ELISAs, RIAs, and FACS, are known in the art and provide a basis for diagnosing altered or abnormal levels of ECMCAD expression. Normal or standard values for ECMCAD expression are established by combining body fluids or cell extracts taken from normal mammalian subjects, for example, human subjects, with antibodies to ECMCAD under conditions suitable for complex formation. The amount of standard complex formation may be quantitated by various methods, such as photometric means. Quantities of ECMCAD expressed in subject, control, and disease samples from biopsied tissues are compared with the standard values. Deviation between standard and subject values establishes the parameters for diagnosing disease.

[0242] In another embodiment of the invention, the polynucleotides encoding ECMCAD may be used for diagnostic purposes. The polynucleotides which may be used include oligonucleotide sequences, complementary RNA and DNA molecules, and PNAs. The polynucleotides may be used to detect and quantify gene expression in biopsied tissues in which expression of ECMCAD may be correlated with disease. The diagnostic assay may be used to determine absence, presence, and excess expression of ECMCAD, and to monitor regulation of ECMCAD levels during therapeutic intervention.

[0243] In one aspect, hybridization with PCR probes which are capable of detecting polynucleotide sequences, including genomic sequences, encoding ECMCAD or closely related molecules may be used to identify nucleic acid sequences which encode ECMCAD. The specificity of the probe, whether it is made from a highly specific region, e.g., the 5′ regulatory region, or from a less specific region, e.g., a conserved motif, and the stringency of the hybridization or amplification will determine whether the probe identifies only naturally occurring sequences encoding ECMCAD, allelic variants, or related sequences.

[0244] Probes may also be used for the detection of related sequences, and may have at least 50% sequence identity to any of the ECMCAD encoding sequences. The hybridization probes of the subject invention may be DNA or RNA and may be derived from the sequence of SEQ ID NO:37-72 or from genomic sequences including promoters, enhancers, and introns of the ECMCAD gene.

[0245] Means for producing specific hybridization probes for DNAs encoding ECMCAD include the cloning of polynucleotide sequences encoding ECMCAD or ECMCAD derivatives into vectors for the production of mRNA probes. Such vectors are known in the art, are commercially available, and may be used to synthesize RNA probes in vitro by means of the addition of the appropriate RNA polymerases and the appropriate labeled nucleotides. Hybridization probes may be labeled by a variety of reporter groups, for example, by radionuclides such as ³²P or ³⁵S, or by enzymatic labels, such as alkaline phosphatase coupled to the probe via avidin/biotin coupling systems, and the like.

[0246] Polynucleotide sequences encoding ECMCAD may be used for the diagnosis of disorders associated with expression of ECMCAD. Examples of such disorders include, but are not limited to, a genetic disorder such as adrenoleukodystrophy, Alport's syndrome, choroideremia, Duchenne and Becker muscular dystrophy, Down's syndrome, cystic fibrosis, chronic granulomatous disease, Gaucher's disease, Huntington's chorea, Marfan's syndrome, muscular dystrophy, myotonic dystrophy, pycnodysostosis, Refsum's syndrome, retinoblastoma, sickle cell anemia, thalassenia, Werner syndrome., von Willebrand's disease, Wilms' tumor, Zellweger syndrome, peroxisomal acyl-CoA oxidase deficiency, peroxisomal thiolase deficiency, peroxisomal bifunctional protein deficiency, mitochondrial carnitine palmitoyl transferase and carnitine deficiency, mitochondrial very-long-chain acyl-CoA dehydrogenase deficiency, mitochondrial medium-chain acyl-CoA dehydrogenase deficiency, mitochondrial short-chain acyl-CoA dehydrogenase deficiency, mitochondnial electron transport flavoprotein and electron transport flavoprotein:ubiquinone oxidoreductase deficiency, mitochondrial trifunctional protein deficiency, and mitochondrial short-chain 3-hydroxyacyl-CoA dehydrogenase deficiency; an immune/inflammatory disorder such as acquired immunodeficiency syndrome (AIDS), X-linked agammaglobinemia of Bruton, common variable immunodeficiency (CVI), DiGeorge's syndrome (thymic hypoplasia), thynic dysplasia, isolated IgA deficiency, severe combined immunodeficiency disease (SCID), immunodeficiency with thrombocytopenia and eczema (Wiskott-Aldrich syndrome), Chediak-Higashi syndrome, chronic granulomatous diseases, hereditary angioneurotic edema, immunodeficiency associated with Cushing's disease, Addison's disease, adult respiratory distress syndrome, allergies, ankrylosing spondylitis, amyloidosis, anemia, asthma, atherosclerosis, autoimmune hemolytic anemia, autoimmune thyroiditis, autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), bronchitis, cholecystitis, contact dermatitis, Crohn's disease, atopic dermatitis, dermatomyositis, diabetes mellitus, emphysema, episodic lymphopenia with lymuphocytotoxins, erythoblastosis fetalis, erythema nodosum, atrophic gastritis, glomerulonephritis, Goodpasture's syndrome, gout, Graves' disease, Hashimoto's thyroiditis, hypereosinophilia, irritable bowel syndrome, multiple sclerosis, myasthenia gravis, myocardial or pericardial inflammation, osteoarthritis, osteoporosis, pancreatitis, polymyositis, psoriasis, Reiter's syndrome, rheumatoid arthritis, scleroderma, Sjogren's syndrome, systemic anaphylaxis, systemic lupus erythematosus, systemic sclerosis, thrombocytopenia puipura, ulcerative colitis, uveitis, Werner syndrome, complications of cancer, hemodialysis, and extracorporeal circulation, viral, bacterial, fungal, parasitic, protozoal, and helminthic infections, and trauma; a developmental disorder such as renal tubular acidosis, anemia, Cushing's syndrome, achondroplastic dwarfism, Duchenne and Becker muscular dystrophy, epilepsy, gonadal dysgenesis, WAGR syndrome (Wilms' tumor, anriridia, geritourinary abnornalities, and mental retardation), Smith-Magenis syndrome, myelodysplastic syndrome, hereditary mucoepithelial dysplasia, hereditary keratodermas, hereditary neuropathies such as Charcot-Marie-Tooth disease and neurofibromatosis, hypothyroidism, hydrocephalus, seizure disorders such as Syndenham's chorea and cerebral palsy, spina bifida, anelncephaly, craniorachischisis, congenital glaucoma, cataract, and sensorineural hearing loss; a neurological disorder such as epilepsy, ischemic cerebrovascular disease, stroke, cerebral neoplasms, Alzheimer's disease, Pick's disease, Huntington's disease, dementia, Parkinson's disease and other extrapyramidal disorders, amyotrophic lateral sclerosis and other motor neuron disorders, progressive neural muscular atrophy, retinitis pigmentosa, hereditary ataxias, multiple sclerosis and other demyelinating diseases, bacterial and viral meningitis, brain abscess, subdural empyema, epidural abscess, suppurative intracranial thrombopwlebitis, myelitis and radiculitis, viral central nervous system disease, prion diseases including kuru, Creutzfeldt-Jakob disease, and Gerstmann-Straussler-Scheinker syndrome, fatal familial insomnia, nutritional and metabolic diseases of the nervous system, neurofibromatosis, tuberous sclerosis, cerebelloretinal hemangioblastomatosis, encephalotigerinal syndrome, mental retardation and other developmental disorders of the central nervous system including Down syndrome, cerebral palsy, neuroskeletal disorders, autonomic nervous system disorders, cranial nerve disorders, spinal cord diseases, muscular dystrophy and other neuromuscular disorders, peripheral nervous system disorders, dermatomyositis and polymyositis, inherited, metabolic, endocrine, and toxic myopathies, myasthenia gravis, periodic paralysis, mental disorders including mood, anxiety, and schizophrenic disorders, seasonal affective disorder (SAD), akathesia, amnesia, catatonia, diabetic neuropathy, tardive dyskinesia, dystonias, paranoid psychoses, postherpetic neuralgia, Tourette's disorder, progressive supranuclear palsy, coilticobasal degeneration, and familial frontotemporal dementia; a connective tissue disorder such as osteogenesis imperfecta, Ehlers-Danlos syndrome, chondrodysplasias, Marfan syndrome, Alport syndrome, familial aortic aneurysm, achondroplasia, mucopolysaccharidoses, osteoporosis, osteopetrosis, Paget's disease, rickets, osteomalacia, hyperparathyroidism, renal osieodystrophy, osteonecrosis, osteomyelitis, osteoma, osteoid osteoma, osteoblastoma, osteosarcoma, osteochondroma, chondroma, chondroblastoma, chondromyxoid fibroma, chondrosarcoma, fibrous cortical defect, nonossifying fibroma, fibrous dysplasia, fibrosarcoma, malignant fibrous histiocetoma, Ewing's sarcoma, primitive neuroectodermal tumor, giant cell tumor, osteoartbritis, rheumatoid arthritis, ankylosing spondyloartluitis, Reiter's syndrome, psoriatic arthritis, enteropathic arthritis, infectious arthritis, gout, gouty arthritis, calcium pyrophosphate crystal deposition disease, ganglion, synovial cyst, villonodular synovitis, systemic sclerosis, Dupuytren's contracture, hepatic fibrosis, lupus erythematosus, mixed connective tissue disease, epidermolysis bullosa simplex, bullous congenital ichthyosiform eiythrodenna (epidermolytic hyperkeratosis), non-epidermlolytic and epidermolytic palmoplantar keratoderma, ichthyosis bullosa of Siemens, pachyonychia congenita, and white sponge nevus; and a cell proliferative disorder such as actinic keratosis, arteriosclerosis, atherosclerosis, bursitis, cirrhosis, hepatitis, mixed connective tissue disease (MCTD), myelofibrosis, paroxysmal nocturnal hemoglobinuria, polycytheinia vera, psoriasis, primary thrombocythemia, and cancers including adenocarcinoma, leukemia, lymphoma, melanoma, myeloma, sarcoma, teratocarcinoma, and, in particular, cancers of the adrenal gland, bladder, bone, bone marrow, brain, breast, cervix, gall bladder, ganglia, gastrointestinal tract, heart, kidney, liver, lung, muscle, ovary, pancreas, parathyroid, penis, prostate, salivary glands, skin, spleen, testis, thymus, thyroid, and uterus. The polynucleotide sequences encoding ECMCAD may be used in Southern or northern analysis, dot blot, or other membrane-based technologies; in PCR technologies; in dipstick, pin, and multiformat ELISA-like assays; and in microarrays utilizing fluids or tissues from patients to detect altered ECMCAD expression. Such qualitative or quantitative methods are well known in the art.

[0247] In a particular aspect, the nucleotide sequences encoding ECMCAD may be useful in assays that detect the presence of associated disorders, particularly those mentioned above. The nucleotide sequences encoding ECMCAD may be labeled by standard methods and added to a fluid or tissue sample from a patient under conditions suitable for the formation of hybridization complexes. After a suitable incubation period, the sample is washed and the signal is quantified and compared with a standard value. If the amount of signal in the patient sample is significantly altered in comparison to a control sample then the presence of altered levels of nucleotide sequences encoding ECMCAD in the sample indicates the presence of the associated disorder. Such assays may also be used to evaluate the efficacy of a particular therapeutic treatment regimen in animal studies, in clinical trials, or to monitor the treatment of an individual patient.

[0248] In order to provide a basis for the diagnosis of a disorder associated with expression of ECMCAD, a normal or standard profile for expression is established. This may be accomplished by combining body fluids or cell extracts taken from normal subjects, either animal or human, with a sequence, or a fragment thereof, encoding ECMCAD, under conditions suitable for hybridization or amplification. Standard hybridization may be quantified by comparing the values obtained from normal subjects with values from an experiment in which a known amount of a substantially purified polynucleotide is used. Standard values obtained in this manner may be compared with values obtained from samples from patients who are symptomatic for a disorder. Deviation from standard values is used to establish the presence of a disorder.

[0249] Once the presence of a disorder is established and a treatment protocol is initiated, hybridization assays may be repeated on a regular basis to determine if the level of expression in the patient begins to approximate that which is observed in the normal subject. The results obtained from successive assays may be used to show the efficacy of treatment over a period ranging from several days to months.

[0250] With respect to cancer, the presence of an abnormal amount of transcript (either under- or overexpressed) in biopsied tissue from an individual may indicate a predisposition for the development of the disease, or may provide a means for detecting the disease prior to the appearance of actual clinical symptoms. A more definitive diagnosis of this type may allow health professionals to employ preventative measures or aggressive treatment earlier thereby preventing the development or further progression of the cancer.

[0251] Additional diagnostic uses for oligonucleotides designed from the sequences encoding ECMCAD may involve the use of PCR. These oligomers may be chemically synthesized, generated enzymatically, or produced in vitro. Oligomers will preferably contain a fragment of a polynucleotide encoding ECMCAD, or a fragment of a polynucleotide complementary to the polynucleotide encoding ECMCAD, and will be employed under optimized conditions for identification of a specific gene or condition. Oligomers may also be employed under less stringent conditions for detection or quantification of closely related DNA or RNA sequences.

[0252] In a particular aspect, oligonucleotide primers derived from the polynucleotide sequences encoding ECMCAD may be used to detect single nucleotide polytheism (SNPs). SNPs are substitutions, insertions and deletions that are a frequent cause of inherited or acquired genetic disease in humans. Methods of SNP detection include, but are not limited to, single-stranded conformation polymorphism (SSCP) and fluorescent SSCP (fSSCP) methods. In SSCP, oligonucleotide primers derived from the polynucleotide sequences encoding ECMCAD are used to amplify DNA using the polymerase chain reaction (PCR). The DNA may be derived, for example, from diseased or normal tissue, biopsy samples, bodily fluids, and the like. SNPs in the DNA cause differences in the secondary and tertiary structures of PCR products in single-stranded form, and these differences are detectable using gel electrophoresis in non-denaturing gels. In fSCCP, the oligonucleotide primers are fluorescently labeled, which allows detection of the amplifiers in high-throughput equipment such as DNA sequencing machines. Additionally, sequence database analysis methods, termed in silico SNP (isSNP), are capable of identifying polymorphisms by comparing the sequence of individual overlapping DNA fragments which assemble into a common consensus sequence. These computer-based methods filter out sequence variations due to laboratory preparation of DNA and sequencing errors using statistical models and automated analyses of DNA sequence chromatogram. In the alterative. SNPs may be detected and characterized by mass spectrometry using, for example, the high throughput MASSARRAY system (Sequenom, Inc., San Diego Calif.).

[0253] Methods which may also be used to quantify the expression of ECMCAD include radiolabeling or biotinylating nucleotides, coamplification of a control nucleic acid, and interpolating results from standard curves. (See, e.g., Melby, P. C. et al. (1993) J. Immunol. Methods 159:235-244; Duplaa, C. et al. (1993) Anal. Biochem. 212:229-236.) The speed of quantitation of multiple samples may be accelerated by running the assay in a high-throughput format where the oligomer or polynucleotide of interest is presented in various dilutions and a spectrophotometic or calorimetric response gives rapid quantitation.

[0254] In further embodiments, oligonucleotides or longer fragments derived from any of the polynucleotide sequences described herein may be used as elements on a microarray. The microarray can be used in transcript imaging techniques which monitor the relative expression levels of large numbers of genes simultaneously as described below. The microarray may also be used to identify genetic variants, mutations, and polymorphisms. This information may be used to determine gene function, to understand the genetic basis of a disorder, to diagnose a disorder, to monitor progression/regression of disease as a function of gene expression, and to develop and monitor the activities of therapeutic agents in the treatment of disease. In particular, this information may be used to develop a pharmacogenomic profile of a patient in order to select the most appropriate and effective treatment regimen for that patient. For example, therapeutic agents which are highly effective and display the fewest side effects may be selected for a patient based on his/her pharmacogenomic profile.

[0255] In another embodiment, ECMCAD, fragments of ECMCAD, or antibodies specific for ECMCAD may be used as elements on a microarray. The microarray may be used to monitor or measure protein-protein interactions, drug-target interactions, and gene expression profiles, as described above.

[0256] A particular embodiment relates to the use of the polynucleotides of the present invention to generate a transcript image of a tissue or cell type. A transcript image represents the global pattern of gene expression by a particular tissue or cell type. Global gene expression patterns are analyzed by quantifying the number of expressed genes and their relative abundance under given conditions and at a given time. (See Seilhamer et al., “Comparative Gene Transcript Analysis,” U.S. Pat. No. 5,840,484, expressly incorporated by reference herein.) Thus a transcript image may be generated by hybridizing the polynucleotides of the present invention or their complements to the totality of transcripts or reverse transcripts of a particular tissue or cell type. In one embodiment, the hybridization takes place in high-throughput format, wherein the polynucleotides of the present invention or their complements comprise a subset of a plurality of elements on a microarray. The resultant transcript image would provide a profile of gene activity.

[0257] Transcript images may be generated using transcripts isolated from tissues, cell lines, biopsies, or other biological samples. The transcript image may thus reflect gene expression in vivo, as in the case of a tissue or biopsy sample, or in vitro, as in the case of a cell line.

[0258] Transcript images which profile the expression of the polynucleotides of the present invention may also be used in conjunction with in vitro model systems and preclinical evaluation of pharmaceuticals, as well as toxicological testing of industrial and naturally-occurring environmental compounds. All compounds induce characteristic gene expression patterns, frequently termed molecular fingerprints or toxicant signatures, which are indicative of mechanisms of action and toxicity (Nuwaysir, E. F. et al. (1999) Mol. Carcinog. 24:153-159; Steiner, S. and N. L. Anderson (2000) Toxicol. Lett. 112-113:467-471, expressly incorporated by reference herein). If a test compound has a signature similar to that of a compound with known toxicity, it is likely to share those toxic properties. These fingerprints or signatures are most useful and refined when they contain expression information from a large number of genes and gene families. Ideally, a genome-wide measurement of expression provides the highest quality signature. Even genes whose expression is not altered by any tested compounds are important as well, as the levels of expression of these genes are used to normalize the rest of the expression data. The normalization procedure is useful for comparison of expression data after treatment with different compounds. While the assignment of gene function to elements of a toxicant signature aids in interpretation of toxicity mechanisms, knowledge of gene function is not necessary for the statistical matching of signatures which leads to prediction of toxicity. (See, for example, Press Release 00-02 from the National Institute of Environmental Health Sciences, released Feb. 29, 2000, available at http://www.niehs.nii.gov/oc/news/toxchip.htm.) Therefore, it is important and desirable in toxicological screening using toxicant signatures to include all expressed gene sequences.

[0259] In one embodiment, the toxicity of a test compound is assessed by treating a biological sample containing nucleic acids with the test compound. Nucleic acids that are expressed in the treated biological sample are hybridized with one or more probes specific to the polynucleotides of the present invention, so that transcript levels corresponding to the polynucleotides of the present invention may be quantified. The transcript levels in the treated biological sample are compared with levels in an untreated biological sample. Differences in the transcript levels between the two samples are indicative of a toxic response caused by the test compound in the treated sample.

[0260] Another particular embodiment relates to the use of the polypeptide sequences of the present invention to analyze the proteome of a tissue or cell type. The term proteome refers to the global pattern of protein expression in a particular tissue or cell type. Each protein component of a proteome can be subjected individually to further analysis. Proteome expression patterns, or profiles, are analyzed by quantifying the number of expressed proteins and their relative abundance under given conditions and at a given time. A profile of a cell's proteome may thus be generated by separating and analyzing the polypeptides of a particular tissue or cell type. In one embodiment, the separation is achieved using two-dimensional gel electropholesis, in which proteins from a sample are separated by isoelectric focusing in the first dimension, and then according to molecular weight by sodium dodecyl sulfate slab gel electrophoresis in the second dimension (Steiner and Anderson, supra). The proteins are visualized in the gel as discrete and uniquely positioned spots, typically by staining the gel with an agent such as Coomassie Blue or silver or fluorescent stains. The optical density of each protein spot is generally proportional to the level of the protein in the sample. The optical densities of equivalently positioned protein spots from different samples, for example, from biological samples either treated or untreated with a test compound or therapeutic agent, are compared to identify any changes in protein spot density related to the treatment. The proteins in the spots are partially sequenced using, for example, standard methods employing chemical or enzymatic cleavage followed by mass spectrometry. The identity of the protein in a spot may be determined by compating its partial sequence, preferably of at least 5 contiguous amino acid residues, to the polypeptide sequences of the present invention. In some cases, further sequence data may be obtained for definitive protein identification.

[0261] A proteornic profile may also be generated using antibodies specific for ECMCAD to quantify the levels of ECMCAD expression. In one embodiment, the antibodies are used as elements on a microarray, and protein expression levels are quantified by exposing the microarray to the sample and detecting the levels of protein bound to each array element (Lueking, A. et al. (1999) Anal. Biochem. 270:103-111; Mendoze, L. G. et al. (1999) Biotechniques 27:778-788). Detection may be performed by a variety of methods known in the art, for example, by reacting the proteins in the sample with a thiol- or amino-reactive fluorescent compound and detecting the amount of fluorescence bound at each array clement.

[0262] Toxicant signatures at the proteome level are also useful for toxicological screening, and should be analyzed in parallel with toxicant signatures at the transcript level. There is a poor correlation between transcript and protein abundances for some proteins in some tissues (Anderson, N. L. and J. Seilhamer (1997) Electrophoresis 18:533-537), so proteome toxicant signatures may be useful in the analysis of compounds which do not significantly affect the transcript image, but which alter the proteotic profile. In addition, the analysis of transcripts in body fluids is difficult, due to rapid degradation of mRNA, so proteomic profiling may be more reliable and informative in such cases.

[0263] In another embodiment, the toxicity of a test compound is assessed by treating a biological sample containing proteins with the test compound. Proteins that are expressed in the treated biological sample are separated so that the amount of each protein can be quantified. The amount of each protein is compared to the amount of the corresponding protein in an untreated biological sample. A difference in the amount of protein between the two samples is indicative of a toxic response to the test compound in the treated sample. Individual proteins are identified by sequencing the amino acid residues of the individual proteins and comparing these partial sequences to the polypeptides of the present invention.

[0264] In another embodiment, the toxicity of a test compound is assessed by treating a biological sample containing proteins with the test compound. Proteins from the biological sample are incubated with antibodies specific to the polypeptides of the present invention. The amount of protein recognized by the antibodies is quantified. The amount of protein in the treated biological sample is compared with the amount in an untreated biological sample. A difference in the amount of protein between the two samples is indicative of a toxic response to the test compound in the treated sample.

[0265] Microarrays may be prepared, used, and analyzed using methods known in the art. (See, e.g., Brennan, T. M. et al. (1995) U.S. Pat. No. 5,474,796; Schena, M. et al. (1996) Proc. Natl. Acad. Sci. USA 93:10614-10619; Baldeschweiler et al. (1995) PCT application WO95/251116; Shalon, D. et al. (1995) PCT application WO95/35505; Heller, R. A. et al. (1997) Proc. Natl. Acad. Sci. USA 94:2150-2155; and Heller, M. J. et al. (1997) U.S. Pat. No. 5,605,662.) Various types of microarrays are well known and thoroughly described in DNA Microarrays: A Practical Approach, M. Schena, ed. (1999) Oxford University Press, London, hereby expressly incorporated by reference.

[0266] In another embodiment of the invention, nucleic acid sequences encoding ECMCAD may be used to generate hybridization probes useful in mapping the naturally occurring genomic sequence. Either coding or noncoding sequences may be used, and in some instances, noncoding sequences may be preferable over coding sequences. For example, conservation of a coding sequence among members of a multi-gene family may potentially cause undesired cross hybridization during chromosomal mapping. The sequences may be mapped to a particular chromosome, to a specific region of a chromosome, or to artificial chromosome constructions, e.g., human artificial chromosomes (HACs), yeast artificial chromosomes (YACs), bacterial artificial chromosomes (BACs), bacterial P1 constructions, or single chromosome cDNA libraries. (See, e.g., Harrington, J. J. et al. (1997) Nat. Genet. 15:345-355; Price, C. M. (1993) Blood Rev. 7:127-134; and Trask, B. J. (1991) Trends Genet. 7:149-154.) Once mapped, the nucleic acid sequences of the invention may be used to develop genetic linkage maps, for example, which correlate the inheritance of a disease state with the inheritance of a particular chromosome region or restiction fragment length polymorphism (RFLP). (See, for example, Lander, E. S. and D. Botstein (1986) Proc. Natl. Acad. Sci. USA 83:7353-7357.)

[0267] Fluorescent in situ hybridization (FISH) may be correlated with other physical and genetic map data. (See, e.g., Heinz-Ulrich, et al. (1995) in Meyers, supra, pp. 965-968.) Examples of genetic map data can be found in various scientific journals or at the Online Mendelian Inheritance in Man (OMIM) World Wide Web site. Correlation between the location of the gene encoding ECMCAD on a physical map and a specific disorder, or a predisposition to a specific disorder, may help define the region of DNA associated with that disorder and thus may further positional cloning efforts. In situ hybridization of chromosomal preparations and physical mapping techniques, such as linkage analysis using established chromosomal markers, may be used for extending genetic maps. Often the placement of a gene on the chromosome of another mammalian species, such as mouse, may reveal associated markers even if the exact chromosomal locus is not known. This information is valuable to investigators searching for disease genes using positional cloning or other gene discovery techniques. Once the gene or genes responsible for a disease or syndrome have been crudely localized by genetic linkage to a particular genomic region, e.g., ataxia-telangiectasia to 11q22-23, any sequences mapping to that area may represent associated or regulatory genes for further investigation (See, e.g., Gatti, R. A. et al. (1988) Nature 336:577-580.) The nucleotide sequence of the instant invention may also be used to detect differences in the chromosomal location due to translocation, inversion, etc., among normal, carrier, or affected individuals.

[0268] In another embodiment of the invention, ECMCAD, its catalytic or immunogenic fragments, or oligopeptides thereof can be used for screening libraries of compounds in any of a variety of drug screening techniques. The fragment employed in such screening may be free in solution, affixed to a solid support, borne on a cell surface, or located intracellularly. The formation of binding complexes between ECMCAD and the agent being tested may be measured.

[0269] Another technique for drug screening provides for high throughput screening of compounds having suitable binding affinity to the protein of interest. (See, e.g., Geysen, et al. (1984) PCT application WO84/03564.) In this method, large numbers of different small test compounds are synthesized on a solid substrate. The test compounds are reacted with ECMCAD, or fragments thereof, and washed. Bound ECMCAD is then detected by methods well known in the art. Purified ECMCAD can also be coated directly onto plates for use in the aforementioned drug screening techniques. Alternatively, non-neutralizing antibodies can be used to capture the peptide and immobilize it on a solid support.

[0270] In another embodiment, one may use competitive drug screening assays in which neutralizing antibodies capable of binding ECMCAD specifically compete with a test compound for binding ECMCAD. In this manner, antibodies can be used to detect the presence of any peptide which shares one or more antigenic determinants with ECMCAD.

[0271] In additional embodiments, the nucleotide sequences which encode ECMCAD may be used in any molecular biology techniques that have yet to be developed, provided the new techniques rely on properties of nucleotide sequences that are currently known, including, but not limited to, such properties as the triplet genetic code and specific base pair interactions.

[0272] Without further elaboration, it is believed that one skilled in the art can, using the preceding description, utilize the present invention to its fullest extent. The following embodiments are, therefore, to be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever.

[0273] The disclosures of all patents, applications, and publications mentioned above and below, including U.S. Ser. No. 60/215,454, U.S. Ser. No. 60/219,462, U.S. Ser. No. 60/240,111, U.S. Ser. No. 60/240,106, U.S. Ser. No. 60/244,021, U.S. Ser. No. 60/248,887, and U.S. Ser. No. 60/249,570 are hereby expressly incorporated by reference.

EXAMPLES I. Construction of cDNA Libraries

[0274] Incyte cDNAs were derived from cDNA libraries described in the LIFESEQ GOLD database (Incyte Genomics, Palo Alto Calif.) and shown in Table 4, column 5. Some tissues were homogenized and lysed in guanidimiuin isothiocyanate, while others were homogenized and lysed in phenol or in a suitable mixture of denaturants, such as TRIZOL (Life Technologies), a monophasic solution of phenol and guanidine isothiocyanate. The resulting lysates were centrifuged over CsCl cushions or extracted with chloroform. RNA was precipitated from the lysates with either isopropanol or sodium acetate and ethanol, or by other routine methods.

[0275] Phenol extraction and precipitation of RNA were repeated as necessary to increase RNA purity. In some cases, RNA was treated with DNase. For most libraries, poly(A)+RNA was isolated using oligo d(T)-coupled paramagnetic particles (Promega), OLIGOTEX latex particles (QIAGEN, Chatsworth Calif.), or an OLIGOTEX mRNA purification kit (QIAGEN). Alternatively, RNA was isolated directly from tissue lysates using other RNA isolation kits, e.g., the POLY(A)PURE mRNA purification kit (Ambion, Austin Tex.).

[0276] In some cases, Stratagene was provided with RNA and constructed the corresponding cDNA libraries. Otherwise, cDNA was synthesized and cDNA libraries were constructed with the UNIZAP vector system (Stratagene) or SUPERSCRIPT plasmid system (Life Technologies), using the recommended procedures or similar methods known in the art. (See, e.g., Ausubel, 1997, supra, units 5.1-6.6.) Reverse transcription was initiated using oligo d(T) or random primers. Synthetic oligonucleotide adapters were ligated to double stranded cDNA, and the cDNA was digested with the appropriate restriction enzyme or enzymes. For most libraries, the cDNA was size-selected (300-1000 bp) using SEPHACRYL S1000, SEPHAROSE CL2B, or SEPHAROSE CL4B column chromatography (Amersham Pharmacia Biotech) or preparative agarose gel electrophoresis. cDNAs were ligated into compatible restriction enzyme sites of the polylinker of a suitable plasmid, e.g., PBLUESCRIPT plasmid (Stratagene), PSPORT1 plasmid (Life Technologies), PCDNA2.1 plasmid (Invitrogen, Carlsbad Calif.), PBK-CMV plasmid (Stratagene), or pINCY (Incyte Genomics, Palo Alto Calif.), or derivatives thereof. Recombinant plasmids were transformed into competent E. coli cells including XL1-Blue, XL1-BlueMRF, or SOLR from Stratagene or DH5α, DH10B, or ElectroMAX DH10 B from Life Technologies.

II. Isolation of cDNA Clones

[0277] Plasmnids obtained as described in Example I were recovered from host cells by in vivo excision using the UNIZAP vector system (Stratagene) or by cell lysis. Plasmids were purified using at least one of the following: a Magic or WIZARD Minipreps DNA purification system (Promega); an AGTC Miniprep purification kit (Edge Biosystems, Gaithersburg Md.); and QIAWELL 8 Plasmid, QIAWELL 8 Plus Plasmid, QIAWELL 8 Ultra Plasmid purification systems or the R.E.A.L. PREP 96 plasmid purification kit from QIAGEN. Following precipitation, plasmids were resuspended in 0.1 ml of distilled water and stored, with or without lyophilization, at 4° C.

[0278] Alternatively, plasmid DNA was amplified from host cell lysates using direct link PCR in a high-throughput format (Rao, V. B. (1994) Anal. Biochem. 216:1-14). Host cell lysis and thermal cycling steps were carried out in a single reaction mixture. Samples were processed and stored in 384-well plates, and the concentration of amplified plasmid DNA was quantified fluorometrically using PICOGREEN dye (Molecular Probes, Eugene Oreg.) and a FLUOROSKAN II fluorescence scanner (Labsystems Oy, Helsinki, Finland).

III. Sequencing and Analysis

[0279] Incyte cDNA recovered in plasmids as described in Example II were sequenced as follows. Sequencing reactions were processed using standard methods or high-throughput instrumentation such as the ABI CATALYST 800 (Applied Biosystems) thermal cycler or the PTC-200 thermal cycler (MJ Research) in conjunction with the HYDRA microdispenser (Robbins Scientific) or the MICROLAB 2200 (Hamilton) liquid transfer system. cDNA sequencing reactions were prepared using reagents provided by Amersham Pharmacia Biotech or supplied in ABI sequencing kits such as the ABI PRISM BIGDYE Terminator cycle sequencing ready reaction kit (Applied Biosystems). Electrophoretic separation of cDNA sequencing reactions and detection of labeled polynucleotides were carried out using the MEGABACE 1000 DNA sequencing system (Molecular Dynamics); the ABI PRISM 373 or 377 sequencing system (Applied Biosystems) in conjunction with standard ABI protocols and base calling software; or other sequence analysis systems known in the art. Reading frames within the cDNA sequences were identified using standard methods (reviewed in Ausubel, 1997, supra, unit 7.7). Some of the cDNA sequences were selected for extension using the techniques disclosed in Example VIII.

[0280] The polynucleotide sequences derived from Incyte cDNAs were validated by removing vector, linker, and poly(A) sequences and by masking ambiguous bases, using algorithms and programs based on BLAST, dynamic programming, and dinucleotide nearest neighbor analysis. The Incyte cDNA sequences or translations thereof were then queried against a selection of public databases such as the GenBank primate, rodent, mammalian, vertebrate, and eukaryote databases, and BLOCKS, PRINTS, DOMO, PRODOM, and hidden Markov model (HMM)-based protein family databases such as PFAM. (HMM is a probabilistic approach which analyzes consensus primary structures of gene families. See, for example, Eddy, S. R. (1996) Curr. Opin. Struct. Biol. 6:361-365.) The queries were performed using programs based on BLAST, FASTA, BLIMPS, and HMMER. The Incyte cDNA sequences were assembled to produce full length polynucleotide sequences. Alternatively, GenBank cDNAs, GenBank ESTs, stitched sequences, stretched sequences, or Genscan-predicted coding sequences (see Examples IV and V) were used to extend Incyte cDNA assemblages to full length. Assembly was performed using programs based on Phred, Phrap, and Consed, and cDNA assemblages were screened for open reading frames using programs based on GeneMark, BLAST, and FASTA. The full length polynucleotide sequences were translated to derive the corresponding full length polypeptide sequences. Alternatively, a polypeptide of the invention may begin at any of the methionine residues of the full length translated polypeptide. Full length polypeptide sequences were subsequently analyzed by querying against databases such as the Genank protein databases (genpcpt), SwissProt, BLOCKS, PRINTS, DOMO, PRODOM, Prosite, and hidden Markov model (HMM)-based protein family databases such as PFAM. Full length polynucleotide sequences are also analyzed using MACDNASIS PRO software (Hitachi Software Engineering, South San Francisco Calif.) and LASERGENE software (DNASTAR). Polynucleotide and polypeptide sequence alignments are generated using default parameters specified by the CLUSTAL algorithm as incorporated into the MEGALIGN multisequence alignment program (DNASTAR), which also calculates the percent identity between aligned sequences.

[0281] Table 7 summarizes the tools, programs, and algorithms used for the analysis and assembly of Incyte cDNA and full length sequences and provides applicable descriptions, references, and threshold parameters. The first column of Table 7 shows the tools, programs, and algorithms used, the second column provides brief descriptions thereof, the third column presents appropriate references, all of which are incorporated by reference herein in their entirety, and the fourth column presents, where applicable, the scores, probability values, and other parameters used to evaluate the strength of a match between two sequences (the higher the score or the lower the probability value, the greater the identity between two sequences).

[0282] The programs described above for the assembly and analysis of full length polynucleotide and polypeptide sequences wore also used to identify polynucleotide sequence fragments from SEQ ID NO:37-72 Fragments from about 20 to about 4000 nucleotides which are useful in hybridization and amplification technologies are described in Table 4, column 4.

IV. Identification and Editing of Coding Sequences from Genomic DNA

[0283] Putative extracellular matrix and cell adhesion molecules were initially identified by running the Genscan gene identification program against public genomic sequence databases (e.g., gbpri and gbhtg). Genscan is a general-purpose gene identification program which analyzes genomic DNA sequences from a variety of organisms (See Burge, C. and S. Karlin (1997) J. Mol. Biol. 268:78-94, and Burge, C. and S. Karlin (1998) Curr. Opin. Struct. Biol. 8:346-354). The program concatenates predicted exons to form an assembled cDNA sequence extending from a methionine to a stop codoe The output of Genscan is a FASTA database of polynucleotide and polypeptide sequences. The maximum range of sequence for Genscan to analyze at once was set to 30 kb. To determine which of these Genscan predicted cDNA sequences encode extracellular matrix and cell adhesion molecules, the encoded polypeptides were analyzed by querying against PFAM models for extracellular matrix and cell adhesion molecules. Potential extracellular matrix and cell adhesion molecules were also identified by homology to Incyte cDNA sequences that had been annotated as extracellular matrix and cell adhesion molecules. These selected Genscan-predicted sequences were then compared by BLAST analysis to the genpept and gbpri public databases. Where necessary, the Genscan-predicted sequences wore then edited by comparison to the top BLAST hit from genpept to correct errors in the sequence predicted by Genscan, such as extra or omitted exons. BLAST analysis was also used to find any Incyte cDNA or public cDNA coverage of the Genscan-predicted sequences, thus providing evidence for transcription. When Incyte cDNA coverage was available, this information was used to correct or confirm the Genscan predicted sequence. Full length polynucleotide sequences were obtained by assembling Genscan-predicted coding sequences with Incyte cDNA sequences and/or public cDNA sequences using the assembly process described in Example III. Alternatively, full length polynucleotide sequences were derived entirely from edited or unedited Genscan-predicted coding sequences.

V. Assembly of Genomic Sequence Data with cDNA Sequence Data “Stitched” Sequences

[0284] Partial cDNA sequences were extended with exons predicted by the Genscan gene identification program described in Example IV. Partial cDNAs assembled as described in Example III were mapped to genomic DNA and parsed into clusters containing related cDNAs and Genscan exon predictions from one or more genomic sequences. Each cluster was analyzed using an algorithm based on graph theory and dynamic programming to integrate cDNA and genomic information, generating possible splice variants that were subsequently confirmed, edited, or extended to create a full length sequence. Sequence intervals in which the entire length of the interval was present on more than one sequence in the cluster were identified, and intervals thus identified were considered to be equivalent by transitivity. For example, if an interval was present on a cDNA and two genomic sequences, then all three intervals were considered to be equivalent. This process allows unrelated but consecutive genomic sequences to be brought together, bridged by cDNA sequence. Intervals thus identified were then “stitched” together by the stitching algorithm in the order that they appear along their parent sequences to generate the longest possible sequence, as well as sequence variants. Linkages between intervals which proceed along one type of parent sequence (cDNA to cDNA or genomic sequence to genomic sequence) were given preference over linkages which change parent type (cDNA to genomic sequence). The resultant stitched sequences were translated and compared by BLAST analysis to the genpept and gbpri public databases. Incorrect exons predicted by Genscan were corrected by comparison to the top BLAST hit from genpept. Sequences were farther extended with additional cDNA sequences, or by inspection of genomic DNA, when necessary.

“Stretched” Sequences

[0285] Partial DNA sequences were extended to full length with an algorithm based on BLAST analysis. First, partial cDNAs assembled as described in Example III were queried against public databases such as the GenBank primate, rodent, mammalian, vertebrate, and cukaryote databases using the BLAST program. The nearest GenBank protein homolog was then compared by BLAST analysis to either Incyte cDNA sequences or GenScan exon predicted sequences described in Example IV. A chimeric protein was generated by using the resultant high-scoring segment pairs (HSPs) to map the translated sequences onto the GenBank protein homolog. Insertions or deletions may occur in the chimeric protein with respect to the original GenBank protein homolog. The GenBank protein homolog, the chimeric protein, or both were used as probes to search for homologous genomic sequences from the public human genome databases. Partial DNA sequences were therefore “stretched” or extended by the addition of homologous genomic sequences. The resultant stretched sequences were examined to determine whether it contained a complete gene.

VI. Chromosomal Mapping of ECMCAD Encoding Polynucleotides

[0286] The sequences which were used to assemble SEQ ID NO:37-72 were compared with sequences from the Incyte LIFESEQ database and public domain databases using BLAST and other implementations of the Smith-Waterman algorithm. Sequences from these databases that matched SEQ ID NO:37-72 were assembled into clusters of contiguous and overlapping sequences using assembly algorithms such as Phrap (Table 7). Radiation hybrid and genetic mapping data available from public resources such as the Stanford Human Genome Center (SHGC), Whitehead Institute for Genome Research (WIGR), and Généthon were used to determine if any of the clustered sequences had been previously mapped. Inclusion of a mapped sequence in a cluster resulted in the assignment of all sequences of that cluster, including its particular SEQ ID NO:, to that map location.

[0287] Map locations are represented by ranges, or intervals, of human chromosomes. The map position of an interval, in centiMorgans, is measured relative to the terminus of the chromosome's p-arm. (The centiMorgan (cM) is a unit of measurement based on recombination frequencies between chromosomal markers. On average, 1 cM is roughly equivalent to 1 megabase (Mb) of DNA in humans, although this can vary widely due to hot and cold spots of recombination.) The cM distances are based on genetic markers mapped by Ginethon which provide boundaries for radiation hybrid markers whose sequences were included in each of the clusters. Human genome maps and other resources available to the public, such as the NCBI “GeneMap'99” World Wide Web site (http://www.ncbi.nlm.nih.gov/genemap/), can be employed to determine if previously identified disease genes map within or in proximity to the intervals indicated above.

[0288] In this manner, SEQ ID NO:47 was mapped to chromosome 3 within the interval from 162.00 to 168.30 centiMorgans. SEQ ID NO:49 was mapped to chromosome 4 within the interval from 63.90 to 88.50 centiMorgans.

VII. Analysis of Polynucleotide Expression

[0289] Northern analysis is a laboratory technique used to detect the presence of a transcript of a gene and involves the hybridization of a labeled nucleotide sequence to a membrane on which RNAs from a particular cell type or tissue have been bound. (See, e.g., Sambrook, supra, ch. 7; Ausubel (1995) supra, ch. 4 and 16.)

[0290] Analogous computer techniques applying BLAST were used to search for identical or related molecules in cDNA databases such as GenBank or LIFESEQ (Incyte Genomics). This analysis is much faster than multiple membrane-based hybridizations. In addition, the sensitivity of the computer search can be modified to determine whether any particular match is categorized as exact or similar. The basis of the search is the product score, which is defined as: $\frac{{BLAST}\quad {Score} \times {Percent}\quad {Identity}}{5 \times {minimum}\quad \left\{ {{{length}\left( {{Seq}.\quad 1} \right)},{{length}\left( {{Seq}.\quad 2} \right)}} \right\}}$

[0291] The product score takes into account both the degree of similarity between two sequences and the length of the sequence match. The product score is a normalized value between 0 and 100, and is calculated as follows: the BLAST score is multiplied by the percent nucleotide identity and the product is divided by (5 times the length of the shorter of the two sequences). The BLAST score is calculated by assigning a score of +5 for every base that matches in a high-scoring segment pair (HSP), and 4 for every mismatch. Two sequences may share more than one HSP (separated by gaps). If there is more than one HSP, then the pair with the highest BLAST score is used to calculate the product score. The product score represents a balance between fractional overlap and quality in a BLAST alignment. For example, a product score of 100 is produced only for 100% identity over the entire length of the shorter of the two sequences being compared. A product score of 70 is produced either by 100% identity and 70% overlap at one end, or by 88% identity and 100% overlap at the other. A product score of 50 is produced either by 100% identity and 50% overlap at one end, of 79% identity and 100% overlap.

[0292] Alternatively, polynucleotide sequences encoding ECMCAD are analyzed with respect to the tissue sources from which they were derived. For example, some full length sequences are assembled, at least in part, with overlapping Incyte cDNA sequences (see Example III). Each cDNA sequence is derived from a cDNA library constructed from a human tissue. Each human tissue is classified into one of the following organ/tissue categories: cardiovascular system; connective tissue; digestive system; embryonic structures; endocrine system; exocrine glands; genitalia, female; genitalia, male; germ cells; hemic and immune system; liver; musculoskeletal system; nervous system; pancreas; respiratory system; sense organs; skin; stomatognathic system; unclassified/mixed; or urinary tract. The number of libraries in each category is counted and divided by the total number of libraries across all categories. Similarly, each human tissue is classified into one of the following disease/condition categories: cancer, cell line, developmental, inflammation, neurological, trauma, cardiovascular, pooled, and other, and the number of libraries in each category is counted and divided by the total number of libraries across all categories. The resulting percentages reflect the tissue- and disease-specific expression of cDNA encoding ECMCAD. cDNA sequences and cDNA library/tissue information are found in the LIFESEQ GOLD database (Incyte Genomics, Palo Alto Calif.).

VIII. Extension of ECMCAD Encoding Polynucleotides

[0293] Full length polynucleotide sequences were also produced by extension of an appropriate fragment of the full length molecule using oligonucleotide primers designed from this fragment. One primer was synthesized to initiate 5′ extension of the known fragment, and the other primer was synthesized to initiate 3′ extension of the known fragment. The initial primers were designed using OLIGO 4.06 software (National Biosciences), or another appropriate program, to be about 22 to 30 nucleotides in length, to have a GC content of about 50% or more, and to anneal to the target sequence at temperatures of about 68° C. to about 72° C. Any stretch of nucleotides which would result in hairpin structures and primer-primer dimerizations was avoided.

[0294] Selected human cDNA libraries were used to extend the sequence. If more than one extension was necessary or desired, additional or nested sets of primers were designed.

[0295] High fidelity amplification was obtained by PCR using methods well known in the art. PCR was performed in 96-well plates using the PTC-200 thermal cycler (MJ Research, Inc.). The reaction mix contained DNA template, 200 nmol of each primer, reaction buffer containing Mg²⁺, (NH₄)₂SO₄, and 2-mercaptoethanol, Taq DNA polymerase (Amersham Pharmacia Biotech), ELONGASE enzyme (Life Technologies), and Pfu DNA polymerase (Stratagene), with the following parameters for primer pair PCI A and PCI B: Step 1: 94° C., 3 nin; Step 2: 94° C., 15 sec; Step 3: 60° C., 1 min; Step 4: 68° C., 2 min; Step 5: Steps 2, 3, and 4 repeated 20 times; Step 6: 68° C., 5 min; Step 7: storage at 4° C. In the alternative, the parameters for primer pair T7 and SK+ were as follows: Step 1: 94° C., 3 min; Step 2: 94° C., 15 sec; Step 3: 57° C., 1 min; Step 4: 68° C., 2 min; Step 5: Steps 2, 3, and 4 repeated 20 times; Step 6: 68° C., 5 min; Step 7: storage at 4° C.

[0296] The concentration of DNA in each well was determined by dispensing 100 μl PICOGREEN quantitation reagent (0.25% (v/v) PICOGREEN; Molecular Probes, Eugene Oreg.) dissolved in 1×TE and 0.5 μl of undiluted PCR product into each well of an opaque fluorimeter plate (Corning Costar, Acton Mass.), allowing the DNA to bind to the reagent. The plate was scanned in a Fluoroskan II (Labsystems Oy, Helsinki, Finland) to measure the fluorescence of the sample and to quantify the concentration of DNA. A 5 μl to 10 μl aliquot of the reaction mixture was analyzed by electrophoresis on a 1% agarose gel to detemine which reactions were successful in extending the sequence.

[0297] The extended nucleotides were desalted and concentrated, transferred to 384-well plates, digested with CviJI cholera virus endonuclease (Molecular Biology Research, Madison Wis.), and sonicated or sheared prior to relegation into pUC 18 vector (Amersham Pharmacia Biotech). For shotgun sequencing, the digested nucleotides were separated on low concentration (0.6 to 0.8%) agarose gels, fragments were excised, and agar digested with Agar ACE (Promega). Extended clones were religated using T4 ligase (New England Biolabs, Beverly Mass.) into pUC 18 vector (Amersham Pharmacia Biotech), treated with Pfu DNA polymerase (Stratagene) to fill-in restriction site overhangs, and transfected into competent E. coli cells. Transformed cells were selected on antibiotic-containing media, and individual colonies were picked and cultured overnight at 37° C. in 384-well plates in LB/2×carb liquid media.

[0298] The cells were lysed, and DNA was amplified by PCR using Taq DNA polymerase (Amersham Pharmacia Biotech) and Pfu DNA polymerase (Stratagene) with the following parameters: Step 1: 94° C., 3 min; Step 2: 94° C., 15 sec; Step 3: 60° C., 1 min; Step 4: 72° C., 2 min; Step 5: steps 2, 3, and 4 repeated 29 times; Step 6: 72° C., 5 min; Step 7: storage at 4° C. DNA was quantified by PICOGREEN reagent (Molecular Probes) as described above. Samples with low DNA recoveries were reamplified using the same conditions as described above. Samples were diluted with 20% dimethysulfoxide (1:2, v/v), and sequenced using DYENAMIC energy transfer sequencing primers and the DYENAMIC DIRECT kit (Amersham Pharmacia Biotech) or the ABI PRISM BIGDYE Trminator cycle sequencing ready reaction kit (Applied Biosystems).

[0299] In like manner, full length polynucleotide sequences are verified using the above procedure or are used to obtain 5 regulatory sequences using the above procedure along with oligonucleotides designed for such extension, and an appropriate genomic library.

IX. Labeling and Use of Individual Hybridization Probes

[0300] Hybridization probes derived from SEQ ID NO:37-72 are employed to screen cDNAs, gelioulic DNAs, or mRNAs. Although the labeling of oligonicleotides, consisting of about 20 base pairs, is specifically described, essentially the same procedure is used with larger nucleotide fragments. Oligonucleotides are designed using state-of-the-art software such as OLIGO 4.06 software (National Bioscicnces) and labeled by combining 50 pmol of each oligomer, 250 μCi of [γ-³²P] adenosine tiphosphate (Amersham Pharmacia Biotech), and T4 polynucleotide kinase (DuPont NEN, Boston Mass.). The labeled oligonucleotides are substantially purified using a SEPHADEX G-25 superfine size exclusion dextran bead column (Amersham Pharmacia Biotech). An aliquot containing 10⁷ counts per minute of the labeled probe is used in a typical membrane-based hybridization analysis of human genomic DNA digested with one of the following endonucleases: Ase I, Bgl II, Eco RI, Pst I, Xba I, or Pvu II (DuPont NEN).

[0301] The DNA from each digest is fractionated on a 0.7% agarose gel and transferred to nylon membranes (Nytran Plus, Schleicher & Schuell, Durham N.H.). Hybridization is carried out for 16 hours at 40° C. To remove nonspecific signals, blots are sequentially washed at room temperature under conditions of up to, for example, 0.1× saline sodium citrate and 0.5% sodium dodecyl sulfate. Hybridization patterns are visualized using autoradiography or an alternative imaging means and compared.

X. Microarrays

[0302] The linkage or synthesis of array elements upon a microarray can be achieved utilizing photolithography, piezoelectric printing (ink-jet printing, See, e.g., Baldeschweiler, supra.), mechanical microspotting technologies, and derivatives thereof. The substrate in each of the aforementioned technologies should be uniform and solid with a non-porous surface (Schena (1999), supra). Suggested substrates include silicon, silica, glass slides, glass chips, and silicon wafers. Alternatively, a procedure analogous to a dot or slot blot may also be used to arrange and link elements to the surface of a substrate using thermal, UV, chemical, or mechanical bonding procedures. A typical array may be produced using available methods and machines well known to those of ordinary skill in the art and may contain any appropriate number of elements. (See, e.g., Schena, M. et al. (1995) Science 270:467-470; Shalon, D. et al. (1996) Genome Res. 6:639-645; Marshall, A. and J. Hodgson (1998) Nat. Biotechnol. 16:27-31.)

[0303] Full length cDNAs, Expressed Sequence Tags (ESTs), or fragments or oligomers thereof may comprise the elements of the microarray. Fragments or oligomers suitable for hybridization can be selected using software well known in the art such as LASERGENE software (DNASTAR). The array elements are hybridized with polynucleotides in a biological sample. The polynucleotides in the biological sample are conjugated to a fluorescent label or other molecular tag for ease of detection. After hybridization, nonhybridized nucleotides from the biological sample are removed, and a fluorescence scanner is used to detect hybridization at each array element. Alternatively, laser desorption and mass spectrometry may be used for detection of hybridization. The degree of complementarity and the relative abundance of each polynucleotide which hybridizes to an element on the microarray may be assessed. In one embodiment, microarray preparation and usage is described in detail below.

Tissue or Cell Sample Preparation

[0304] Total RNA is isolated from tissue samples using the guanidinium thiocyanate method and poly(A)⁺RNA is purified using the oligo-(dT) cellulose method. Each poly(A)⁺RNA sample is reverse transcribed using MMLV reverse-transcriptase, 0.05 pg/μl oligo-(dT) primer (21mer), 1×first strand buffer, 0.03 units/μl RNase inhibitor, 500 μM dATP, 500 μM dGTP, 500 μM dTTP, 40 μM dCTP, 40 μM dCTP-Cy3 (BDS) or dCTP-Cy5 (Amersham Pharmacia Biotech). The reverse transcription reaction is performed in a 25 ml volume containing 200 ng poly(A)⁺RNA with GEMBRIGHT kits (Incyte). Specific control poly(A)⁺RNAs are synthesized by in vitro transcription from non-coding yeast genomic DNA. After incubation at 37° C. for 2 hr, each reaction sample (one with Cy3 and another with Cy5 labeling) is treated with 2.5 ml of 0.5M sodium hydroxide and incubated for 20 minutes at 85° C. to the stop the reaction and degrade the RNA. Samples are purified using two successive CHROMA SPIN 30 gel filtration spin columns (CLONTECH Laboratories, Inc. (CLONTECH), Palo Alto Calif.) and after combining, both reaction samples are ethanol precipitated using 1 ml of glycogen (1 mg/ml), 60 ml sodium acetate, and 300 ml of 100% ethanol. The sample is then dried to completion using a SpeedVAC (Savant Instruments Inc., Holbrook N.Y.) and resuspended in 14 μl 5×SSC/0.2% SDS.

Microarray Preparation

[0305] Sequences of the present invention are used to generate array elements. Each array element is amplified from bacterial cells containing vectors with cloned cDNA inserts. PCR amplification uses primers complementary to the vector sequences flanking the cDNA insert. Array elements are amplified in thirty cycles of PCR from an initial quantity of 1-2 ng to a final quantity greater than 5 μg. Amplified array elements are then purified using SEPHACRYL400 (Amersham Pharmacia Biotech).

[0306] Purified array elements are immobilized on polymer-coated glass slides. Glass microscope slides (Corning) are cleaned by ultrasound in 0.1% SDS and acetone, with extensive distilled water washes between and after treatments. Glass slides are etched in 4% hydroIluoric acid (VWR Scientific Products Corporation (VWR), West Chester Pa.), washed extensively in distilled water, and coated with 0.05% aminopropyl silane (Sigma) in 95% ethanol. Coated slides are cured in a 110° C. oven.

[0307] Array elements are applied to the coated glass substrate using a procedure described in U.S. Pat. No. 5,807,522, incorporated herein by reference. 1 μl of the array element DNA, at an average concentration of 100 ng/μl, is loaded into the open capillary printing element by a high-speed robotic apparatus. The apparatus then deposits about 5 nl of array element sample per slide.

[0308] Microarrays are UV-crosslinked using a STRATALINKER UV-crosslinker (Stratagene). Microarrays are washed at room temperature once in 0.2% SDS and three times in distilled water. Non-specific binding sites are blocked by incubation of microarrays in 0.2% casein in phosphate buffered saline (PBS) (Tropix, Inc., Bedford Mass.) for 30 minutes at 60° C. followed by washes in 0.2% SDS and distilled water as before.

Hybridization

[0309] Hybridization reactions contain 9 μl of sample mixture consisting of 0.2 μg each of Cy3 and Cy5 labeled cDNA synthesis products in 5×SSC, 0.2% SDS hybridization buffer. The sample mixture is heated to 65° C. for 5 minutes and is aliquoted onto the microarray surface and covered with an 1.8 cm² coverslip. The arrays are transferred to a waterproof chamber having a cavity just slightly larger than a microscope slide. The chamber is kept at 100% humidity internally by the addition of 140 μl of 5×SSC in a corner of the chamber. The chamber containing the arrays is incubated for about 6.5 hours at 60° C. The arrays are washed for 10 min at 45° C. in a first wash buffer (1×SSC, 0.1% SDS), three times for 10 minutes each at 45° C. in a second wash buffer (0.1×SSC), and dried.

Detection

[0310] Reporter-labeled hybridization complexes are detected with a microscope equipped with an Innova 70 mixed gas 10 W laser (Coherent, Inc., Santa Clara Calif.) capable of generating spectral lines at 488 nm for excitation of Cy3 and at 632 nm for excitation of Cy5. The excitation laser light is focused on the array using a 20× microscope objective (Nikon, Inc., Melville N.Y.). The slide containing the array is placed on a computer-controlled X-Y stage on the microscope and raster-scanned past the objective. The 1.8 cm×1.8 cm array used in the present example is scanned with a resolution of 20 micrometers.

[0311] In two separate scans, a mixed gas multiline laser excites the two fluorophores sequentially. Emitted light is split, based on wavelength, into two photomultiplier tube detectors (PMT R1477, Hamamatsu Photonics Systems, Bridgewater N.J.) corresponding to the two fluorophores. Appropriate filters positioned between the array and the photomultiplier tubes are used to filter the signals. The emission maxima of the fluorophores used are 565 nm for Cy3 and 650 nm for Cy5. Each array is typically scanned twice, one scan per fluorophore using the appropriate filters at the laser source, although the apparatus is capable of recording the spectra from both fluorophores simultaneously.

[0312] The sensitivity of the scans is typically calibrated using the signal intensity generated by a cDNA control species added to the sample mixture at a known concentration. A specific location on the array contains a complementary DNA sequence, allowing the intensity of the signal at that location to be correlated with a weight ratio of hybridizing species of 1:100,000. When two samples from different sources (e.g., representing test and control cells), each labeled with a different fluorophore, are hybridized to a single array for the purpose of identifying genes that are differentially expressed, the calibration is done by labeling samples of the calibrating cDNA with the two fluorophores and adding identical amounts of each to the hybridization mixture.

[0313] The output of the photomultiplier tube is digitized using a 12-bit RTI-835H analog-to-digital (A/D) conversion board (Analog Devices, Inc., Norwood Mass.) installed in an IBM-compatible PC computer. The digitized data are displayed as an image where the signal intensity is mapped using a linear 20-color transformation to a pseudocolor scale ranging from blue (low signal) to red (high signal). The data is also analyzed quantitatively. Where two different fluorophores are excited and measured simultaneously, the data are first corrected for optical crosstalk (due to overlapping emission spectra) between the fluorophores using each fluorophore's emission spectrum.

[0314] A grid is superimposed over the fluorescence signal image such that the signal from each spot is centered in each element of the grid. The fluorescence signal within each element is then integrated to obtain a numerical value corresponding to the average intensity of the signal. The software used for signal analysis is the GEMTOOLS gene expression analysis program (Incyte).

XI. Complementary Polynucleotides

[0315] Sequences complementary to the ECMCAD-encoding sequences, or any parts thereof, are used to detect, decrease, or inhibit expression of naturally occurring ECMCAD. Although use of oligonucleotides comprising from about 15 to 30 base pairs is described, essentially the same procedure is used with smaller or with larger sequence fragments. Appropriate oligonucleotides are designed using OLIGO 4.06 software (National Biosciences) and the coding sequence of ECMCAD. To inhibit transcription, a complementary oligonucleotide is designed from the most unique 5′ sequence and used to prevent promoter binding to the coding sequence. To inhibit translation, a complementary oligonucleotide is designed to prevent ribosomal binding to the ECMCAD-encoding transcript.

XII. Expression of ECMCAD

[0316] Expression and purification of ECMCAD is achieved using bacterial or vitus-based expression systems. For expression of ECMCAD in bacteria, cDNA is subcloned into an appropriate vector containing an antibiotic resistance gene and an inducible promoter that directs high levels of cDNA transcription. Examples of such promoters include, but are not limited to, the trp-lac (tac) hybrid promoter and the T5 or T7 bacteriophage promoter in conjunction with the lac operator regulatory element. Recombinant vectors are transformed into suitable bacterial hosts, e.g., BL21(DE3). Antibiotic resistant bacteria express ECMCAD upon induction with isopropyl beta-D-thiogalactopyranoside (IPTG). Expression of ECMCAD in eukaryotic cells is achieved by infecting insect or mammalian cell lines with recombinant Autographica californica nuclear polyhedrosis virus (AcMNPV), commonly known as baculovirus. The nonessential polyhedrin gene of baculovirus is replaced with cDNA encoding ECMCAD by either homologous recombination or bacterial-mediated transposition involving transfer plasmid intermediates. Viral infectivity is maintained and the strong polyhedrin promoter drives high levels of cDNA transcription. Recombinant baculovirus is used to infect Spodoptera frugiperda (Sf9) insect cells in most cases, or human hepatocytes, in some cases. Infection of the latter requires additional genetic modifications to baculovirus. (See Engelhard, E. K. et al. (1994) Proc. Natl. Acad. Sci. USA 91:3224-3227; Sandig, V. et al. (1996) Hum. Gene Ther. 7:1937-1945.)

[0317] In most expression systems, ECMCAD is synthesized as a fusion protein with, e.g., glutathione S-transferase (GST) or a peptide epitope tag, such as FLAG or 6-His, permitting rapid, single-step, affinity-based purification of recombinant fusion protein from crude cell lysates. GST, a 26-kilodalton enzyme from Schistosoma japonicum, enables the purification of fusion proteins on immobilized glutathione under conditions that maintain protein activity and antigenicity (Amersham Pharmacia Biotech). Following purification, the GST moiety can be proteolytically cleaved from ECMCAD at specifically engineered sites. FLAG, an 8-amino acid peptide, enables immunoaffinity purification using commercially available monoclonal and polyclonal anti-FLAG antibodies (Eastman Kodak). 6-His, a stretch of six consecutive histidine residues, enables purification on metal-chelate resins (QIAGEN). Methods for protein expression and purification are discussed in Ausubel (1995, supra, ch. 10 and 16). Purified ECMCAD obtained by these methods can be used directly in the assays shown in Examples XVI and XVI where applicable.

XIII. Functional Assays

[0318] ECMCAD function is assessed by expressing the sequences encoding ECMCAD at physiologically elevated levels in mammalian cell culture systems. cDNA is subcloned into a mammalian expression vector containing a strong promoter that drives high levels of cDNA expression. Vectors of choice include PCMV SPORT (Life Technologies) and PCR3.1 (Invitrogen, Carlsbad Calif.), both of which contain the cytomegalovirus promoter. 5-10 μg of recombinant vector are transiently transfected into a human cell line, for example, an endothelial or hematopoietic cell line, using either liposome formulations or electroporation. 1-2 μg of an additional plasmid containing sequences encoding a marker protein are co-transfected. Expression of a marker protein provides a means to distinguish transfected cells from nontransfected cells and is a reliable predictor of cDNA expression from the recombinant vector. Marker proteins of choice include, e.g., Green Fluorescent Protein (GFP; Clontech), CD64, or a CD64-GFP fusion protein. Flow cytometry (FCM), an automated, laser optics-based technique, is used to identify transfected cells expressing GFP or CD64-GFP and to evaluate the apoptotic state of the cells and other cellular properties. FCM detects and quantifies the uptake of fluorescent molecules that diagnose events preceding or coincident with cell death. These events include changes in nuclear DNA content as measured by staining of DNA with propidium iodide; changes in cell size and granularity as measured by forward light scatter and 90 degree side light scatter; down-regulation of DNA synthesis as measured by decrease in bromodeoxyuridine uptake; alterations in expression of cell surface and intracellular proteins as measured by reactivity with specific antibodies; and alterations in plasma membrane composition as measured by the binding of fluorescein-conjugated Annexin V protein to the cell surface. Methods in flow cytometry are discussed in Ormerod, M. G. (1994) Flow Cytometry, Oxford, New York N.Y.

[0319] The influence of ECMCAD on gene expression can be assessed using highly purified populations of cells transfected with sequences encoding ECMCAD and either CD64 or CD64-GFP. CD64 and CD64-GFP are expressed on the surface of transfected cells and bind to conserved regions of human immunoglobulin G (IgG). Transfected cells are efficiently separated from nontransfected cells using magnetic heads coated with either human IgG or antibody against CD64 (DYNAL, Lake Success N.Y.). mRNA can be purified from the cells using methods well known by those of skill in the art. Expression of mRNA encoding ECMCAD and other genes of interest can be analyzed by northern analysis or microarray techniques.

XIV. Production of ECMCAD Specific Antibodies

[0320] ECMCAD substantially purified using polyacrylamide gel electrophoresis (PAGE; see, e.g., Harrington. M. G. (1990) Methods Enzymol. 182:488-495), or other purification techniques, is used to immunize rabbits and to produce antibodies using standard protocols.

[0321] Alternatively, the ECMCAD amino acid sequence is analyzed using LASERGENE software (DNASTAR) to detentine regions of high immunogenicity, and a corresponding oligopeptide is synthesized and used to raise antibodies by means known to those of skill in the art. Methods for selection of appropriate epitopes, such as those near the C-terminus or in hydrophilic regions are well described in the art. (See, e.g., Ausubel, 1995, supra, ch. 11.)

[0322] Typically, oligopeptides of about 15 residues in length are synthesized using an ABI 431 A peptide synthesizer (Applied Biosystems) using FMOC chemistry and coupled to KLH (Sigma-Aldrich, St. Louis Mo.) by reaction with N-maleimidobenzoyl-N-hydroxysuccinimide ester (MBS) to increase immunogenicity. (See, e.g., Ausubel, 1995, supra.) Rabbits are immunized with the oligopeptide-KLH complex in complete Freund's adjuvant. Resulting antisera are tested for antipeptide and anti-ECMCAD activity by, for example, binding the peptide or ECMCAD to a substrate, blocking with 1% BSA, reacting with rabbit antisera, washing, and reacting with radio-iodinated goat anti-rabbit IgG.

XV. Purification of Naturally Occurring ECMCAD Using Specific Antibodies

[0323] Naturally occurring or recombinant ECMCAD is substantially purified by immunoaffinity chromatography using antibodies specific for ECMCAD. An immunoaffinity column is constructed by covalently coupling anti-ECMCAD antibody to an activated chromatographic resin, such as CNBr-activated SEPHAROSE (Amersham Pharmacia Biotech). After the coupling, the resin is blocked and washed according to the manufacturer's instructions.

[0324] Media containing ECMCAD are passed over the immunoaffinity column, and the column is washed under conditions that allow the preferential absorbance of ECMCAD (e.g., high ionic strength buffers in the presence of detergent). The column is eluted under conditions that disrupt antibody/ECMCAD binding (e.g., a buffer of pH 2 to pH 3, or a high concentration of a chaotrope, such as urea or thiocyanate ion), and ECMCAD is collected.

XVI. Identification of Molecules Which Interact with ECMCAD

[0325] ECMCAD, or biologically active fragments thereof, are labeled with ¹²⁵Bolton-Hunter reagent. (See, e.g., Bolton A. E. and W. M. Hunter (1973) Biochem. J. 133:529-539.) Candidate molecules previously arrayed in the wells of a multi-well plate are incubated with the labeled ECMCAD, washed, and any wells with labeled ECMCAD complex are assayed. Data obtained using different concentrations of ECMCAD are used to calculate values for the number, affinity, and association of ECMCAD with the candidate molecules.

[0326] Alternatively, molecules interacting with ECMCAD are analyzed using the yeast two-hybrid system as described in Fields, S. and O. Song (1989) Nature 340:245-246, or using commercially available kits based on the two-hybrid system, such as the MATCHMAKER system (Clontech).

[0327] ECMCAD may also be used in the PATHCALLING process (CuraGen Corp., New Haven Conn.) which employs the yeast two-hybrid system in a high-throughput manner to determine all interactions between the proteins encoded by two large libraries of genes (Nandabalan, K. et al. (2000) U.S. Pat. No. 6,057,101).

XVII. Demonstration of ECMCAD Activity

[0328] An assay for ECMCAD activity measures the expression of ECMCAD on the cell surface. cDNA encoding ECMCAD is transfected into a non-leukocytic cell line. Cell surface proteins are labeled with biotin (de la Fuente, M. A. et al. (1997) Blood 90:2398-2405). Immunoprecipitations are performed using ECMCAD-specific antibodies, and immunoprecipitated samples are analyzed using SDS-PAGE and immunoblotting techniques. The ratio of labeled immunoprecipitant to unlabeled immunoprecipitant is proportional to the amount of ECMCAD expressed on the cell surface.

[0329] Alternatively, an assay for ECMCAD activity measures the amount of cell aggregation induced by overexpression of ECMCAD. In this assay, cultured cells such as NIH3T3 are transfected with cDNA encoding ECMCAD contained within a suitable mammalian expression vector under control of a strong promoter. Cotransfection with cDNA encoding a fluorescent marker protein, such as Green Fluorescent Protein (CLONTECH), is useful for identifying stable transfectants. The amount of cell agglutination, or clumping, associated with transfected cells is compared with that associated with untransfected cells. The amount of cell agglutination is a direct measure of ECMCAD activity.

[0330] Alternatively, an assay for ECMCAD activity measures the disruption of cytoskeletal filament networks upon overexpression of ECMCAD in cultured cell lines (Rezniczek, G. A. et al. (1998) J. Cell Biol. 141:209-225). cDNA encoding ECMCAD is subcloned into a mammalian expression vector that drives high levels of cDNA expression. This construct is transfected into cultured cells, such as rat kangaroo PtK2 or rat bladder carcinoma 804G cells. Actin filaments and intermediate filaments such as keratin and vimentin are visualized by immunofluorescence microscopy using antibodies and techniques well known in the art. The configuration and abundance of cyoskeletal filaments can be assessed and quantified using confocal imaging techniques. In particular, the bundling and collapse of cytoskeletal filament networks is indicative of ECMCAD activity.

[0331] Alternatively, cell adhesion activity in ECMCAD is measured in a 96-well microtiter assay in which wells are first coated with ECMCAD by adding solutions of ECMCAD of varying concentrations to the wells. Excess ECMCAD is washed off with saline, and the wells incubated with a solution of 1% bovine serum albumin to block non-specific cell binding. Aliquots of a cell suspension of a suitable cell type are then added to the microtiter wells and incubated for a period of time at 37° C. Non-adhered cells are washed off with saline and the cells stained with a suitable cell stain such as Coomassie blue. The intensity of staining is measured using a variable wavelength microtiter plate reader and compared to a standard curve to determine the number of cells adhering to the ECMCAD coated plates. The degree of cell staining is proportional to the cell adhesion activity of ECMCAD in the sample.

[0332] Various modifications and variations of the described methods and systems of the invention wilt be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in collection with certain embodiments, it should be understood that the invention as claimed should not he unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention which are obvious to those skilled in molecular biology or related fields are intended to be within the scope of the following claims. TABLE 1 Polynucleo- Incyte Polypeptide Incyte tide SEQ Incyte Poly- Project ID SEQ ID NO: Polypeptide ID ID NO: nucleotide ID 1888682 1 1888682CD1 37 1888682CB1 1794980 2 1794980CD1 38 1794980CB1 5533958 3 5533958CD1 39 5533958CB1 60210196 4 60210196CD1 40 60210196CB1 815125 5 815125CD1 41 815125CB1 1386915 6 1386915CD1 42 1386915CB1 1344495 7 1344495CD1 43 1344495CB1 1485774 8 1485774CD1 44 1485774CB1 7289372 9 7289372CD1 45 7289372CB1 1672338 10 1672338CD1 46 1672338CB1 184661 11 184661CD1 47 184661CB1 3719737 12 3719737CD1 48 3719737CB1 5773251 13 5773251CD1 49 5773251CB1 5426470 14 5426470CD1 50 5426470CB1 7087904 15 7087904CD1 51 7087904CB1 7477312 16 7477312CD1 52 7477312CB1 2739431 17 2739431CD1 53 2739431CB1 7473606 18 7473606CD1 54 7473606CB1 3534918 19 3534918CD1 55 3534918CB1 2428715 20 2428715CD1 56 2428715CB1 3351332 21 3351332CD1 57 3351332CB1 6382722 22 6382722CD1 58 6382722CB1 55022490 23 55022490CD1 59 55022490CB1 6755002 24 6755002CD1 60 6755002CB1 7350907 25 7350907CD1 61 7350907CB1 7474411 26 7474411CD1 62 7474411CB1 4755911 27 4755911CD1 63 4755911CB1 379766 28 379766CD1 64 379766CB1 553744 29 553744CD1 65 553744CB1 1825473 30 1825473CD1 66 1825473CB1 7950094 31 7950094CD1 67 7950094CB1 7479484 32 7479484CD1 68 7479484CB1 6780147 33 6780147CD1 69 6780147CB1 7204554 34 7204554CD1 70 7204554CB1 6833247 35 6833247CD1 71 6833247CB1 4148119 36 4148119CD1 72 4148119CB1

[0333] TABLE 2 Polypeptide Incyte GenBank Probability SEQ ID NO: Polypeptide ID ID NO: score GenBank Homolog 2 1794980CD1 g192264 6.9e−46 procollagen type I alpha chain Grant, S. F. et al. (1996) Nat. Genet. 14: 203-205 3 5533958CD1 g4091819 2.2e−54 glioma-inactivated protein precursor Chernova, O. B. et al. (1998) Oncogene 17: 2873-2882 4 60210196CD1 g3132522  8.0e−144 carcinogenesis-associated protein ICB-1 (induced by cell-matrix interactions) Treeck, O. et al. (1998) FEBS Lett. 425: 426-430 5 815125CD1 g9652103 0 [Mus musculus] netrin 4 Yin, Y. et al. (2000) Identification and expression of mouse netrin-4 Mech. Dev. 96: 115-119 g4388541 3.3e−96 laminin B1 chain Durkin, M. E. et al. (1988) Biochemistry 27: 5198-5204 6 1386915CD1 g1234793  4.2e−254 [Xenopus laevis] MAM domain protein Brown, D. D. et al. (1996) The thyroid hormone-induced tail resorption program during Xenopus laevis metamorphosis. Proc. Natl. Acad. Sci. U.S.A. 93, 1924-1929 9 7289372CD1 g2554604 6.1e−88 [Homo sapiens] ISLR Nagasawa, A. et al. (1997) Cloning of the cDNA for a new member of the immunoglobulin superfamily (ISLR) containing leucine-rich repeat (LRR). Genomics 44, 273-279 10 1672338CD1 g854326 6.0e−66 [Mus musculus] semaphorin B (Puschel, A. W. et al. (1995) Neuron 14: 941-948) 11 184661CD1 g2367641 2.9e−26 [Rattus norvegicus] neuropilin-2 (Kolodkin, A. L. et al. (1997) Cell 90: 753-762) 12 3719737CD1 g9622242 0 [Homo sapiens] [5′ incom] protocadherin 13 g6978935  9.9e−170 [Homo sapiens] protocadherin-Xa (Yoshida, K. and Sugano, S. (1999) Genomics 62: 540-543) 13 5773251CD1 g1304387 5.4e−27 [Saccharomyces cerevisiae var. diastaticus] Glucoamylase (Lambrechts, M. G. et al. (1996) Proc. Natl. Acad. Sci. U.S.A. 93: 8419-8424) 14 5426470CD1 g200057 0.0 [Mus musculus] neuronal glycoprotein Connelly, M. A. et al. (1994) Proc. Natl. Acad. Sci. U.S.A. 91: 1337-1341 15 7087904CD1 g4519558  1.4e−181 [Rattus norvegicus] Kilon Funatsu, N. et al. (1999) J. Biol. Chem. 274: 8224-8230 16 7477312CD1 g5262748 0.0 [Rattus norvegicus] Proline rich synapse associated protein 2 Boeckers, T. M. et al. (1999) Biochem. Biophys. Res. Commun. 264: 2476-2528; Boeckers, T. M. et al. (1999) J. Neurosci. 19: 6506-6518 17 2739431CD1 g2708626 5.7e−34 [Mus musculus] fibrinogen-like protein 18 7473606CD1 g3928000 3.5e−07 [Homo sapiens] procollagen I N- proteinase 19 3534918CD1 g13872813 0 [5′ incom] [Homo sapiens] (AJ306906) fibulin-6 g2947314 8.6e−63 [Gallus gallus] fibulin-1, isoform D precursor 20 2428715CD1 g10998440 0 [Mus musculus] EGF-related protein SCUBE1 Grimmond, S. et al. (2000) Cloning, Mapping, and Expression Analysis of a Gene Encoding a Novel Mammalian EGF-Related Protein (SCUBE1) Genomics 70: 74-81 g2072792 3.1e−64 [Mus musculus] matrilin-2 precursor Deak, F. et al. (1997) Primary structure and expression of matrilin-2, the closest relative of cartilage matrix protein within the von Willebrand factor type A-like module superfamily. J. Biol. Chem. 272, 9268-9274 21 3351332CD1 g3449294 0 [Rattus norvegicus] MEGF6 Nakayama, M. et al. (1998) Identification of high-molecular- weight proteins with multiple EGF- like motifs by motif-trap screening Genomics 51, 27-34 g483581  1.1e−111 [Mus musculus] Notch 3 Lardelli, M. et al. (1994) The novel Notch homologue mouse Notch 3 lacks specific epidermal growth factor- repeats and is expressed in proliferating Neuroepithelium. Mech. Dev. 46, 123-136 22 6382722CD1 g2599232 0.0 [Mus musculus] laminin alpha 5 chain Miner, J. H. et al. (1995) Molecular cloning of a novel laminin chain, alpha 5, and widespread expression in adult mouse tissues. J. Biol. Chem. 270, 28523-28526 23 55022490CD1 g8977890  9.3e−256 [Homo sapiens] ADAMTS7, alternatively spliced product 24 6755002CD1 g452821 0.0 [Bos taurus] Brevican Yamada, H. et al. (1994) J. Biol. Chem. 269: 10119-10126 25 7350907CD1 g442368  4.1e−246 [Rattus norvegicus] Neuronal olfactomedin-related ER localized protein Danielson, P. E. et al. (1994) J. Neurosci. Res. 38: 468-478 26 7474411CD1 g6164595 4.0e−95 [Manduca sexta] Lacunin (Extracellular matrix protein) Nardi, J. B. et al. (1999) Insect Biochem. Mol. Biol. 29: 883-897 27 4755911CD1 g1504038 7.1e−41 [Homo sapiens] Similar to human ankyrin 1 28 379766CD1 g13183078 1.00E−163 [3′ incom] [Homo sapiens] a disintegrin-like and metalloprotease domain with thrombospondin type I motifs-like 3 g5923786 1.4e−44 [Homo sapiens] Zinc metalloprotease ADAMTS6 Hurskainen, T. L. et al. (1999) J. Biol. Chem. 274: 25555-25563 29 553744CD1 g8572538 7.0e−14 [Homo sapiens] Mucin Gerard, C. et al. (1990) J. Clin. Invest. 86: 1921-1927 30 1825473CD1 g188864 9.2e−47 [Homo sapiens] Mucin Toribara, N. W. et al. (1991) J. Clin. Invest. 88: 1005-1013 31 7950094CD1 g1110599 0.0 [Mus sp.] Semaphorin homolog Inagaki, S. et al. (1995) FEBS Lett. 370: 269-272 32 7479484CD1 g4322670 l.7e−28 [Homo sapiens] Dentin phosphoryn Gu, K. et al. (1998) Eur. J. Oral Sci. 106: 1043-1047 33 6780147CD1 g5805194 0.0 [Rattus norvegicus] Leprecan Wassenhove-McCarthy, D. J. and K. J. McCarthy (1999) J. Biol. Chem. 274: 25004-25017 34 7204554CD1 g1665757 0.0 [Mus musculus] Plexin 1 Kameyama, T. et al. (1996) Biochem. Biophys. Res. Commun. 226: 524-529 35 6833247CD1 g4159801 2.9e−75 [Mus musculus] C-type lectin Balch, S. G. et al. (1998) J. Biol. Chem. 273: 18656-18664 36 4148119CD1 g6579191 6.5e−35 [Rattus norvegicus] SLIT-2 Liang Y. et al. (1999) J. Biol. Chem. 274: 17885-17892

[0334] TABLE 3 SEQ Incyte Amino Potential Potential Analytical ID Polypeptide Acid Phosphorylation Glycosylation Signature Sequences, Methods and NO: ID Residues Sites Sites Domains and Motifs Databases 1 1888682CD1 234 S141 S150 T137 N147 N197 N52 Signal cleavage: M1-A44 SPSCAN T99 N97 Transmembrane domain: G168-F187 HMMER Rgd cell surface interaction motif: R14-D16 MOTIFS Fibronectin type III domain: P47-G130 HMMER_PFAM Fibronectin type III PR00014: BLIMPS_PRINTS N61-P70, V96-Y114, Y114-P128 2 1794980CD1 443 S103 S188 S31 N138 N51 Signal cleavage: M1-A21 SPSCAN S438 S72 T122 Signal peptide: M1-A22 HMMER T146 T160 T172 Glycosaminoglycan attchment site: S407-G410 MOTIFS T242 T282 T80 Transmembrane domain: A8-F30 HMMER T89 Collagen triple helix repeat: HMMER_PFAM G208-P267 G299-R358 COLLAGEN ALPHA PRECURSOR CHAIN BLAST_PRODOM REPEAT PD000007: G223-G332 FIBRILLAR COLLAGEN CARBOXYL-TERMINAL BLAST_DOMO DM00019/P20908/1300-1524): P176-G374 3 5533958CD1 261 S243 S89 T151 N177 Leucine_Zipper: L129-L150 MOTIFS T203 Atp_Gtp binding site: A239-T246 MOTIFS Signal cleavage: M1-A19 SPSCAN Signal peptide: M1-A19 HMMER Leucine rich repeat: T53-Q171 HMMER_PFAM Leucine rich repeat C-terminal domain: HMMER_PFAM N158-R207 Leucine-rich repeat signature PR00019: BLIMPS_PRINTS L126-L139 NEUROGENIC TRKB RECEPTOR DM01983| BLAST_DOMO B39667|24-197: W20-L169 4 60210196CD1 643 S103 S143 S162 ICB1 membrane carcinogenesis-associated BLAST_PRODOM S225 S237 S304 protein PD121395: M150-G403 S33 S38 S388 S429 S437 S441 S45 S567 T114 T333 T527 T593 T92 5 815125CD1 628 S108 S136 S212 N163 N353 Signal cleavage: M1-L20 SPSCAN S27 S28 S387 N483 N56 Egf (epidermal growth factor) motif: MOTIFS S416 S465 S503 C293-C304, C420-C431 S534 S554 S570 Signal peptide: M1-G25 HMMER S98 T153 T182 Transmembrane domain: M1-V23 HMMER T192 T331 T411 Laminin N-terminal (Domain VI) HMMER_PFAM T467 T540 T572 laminin_Nterm: C34-G260 T597 T71 Laminin EGF-like (Domains III and V): HMMER_PFAM C262-C329, C332-C392, C395-C446 Laminin-type EGF-like domain BL01248: BLIMPS_BLOCKS C295-C307 Type III EGF-like signature PR00011: BLIMPS_PRINTS C413-C431 EGFLIKE LAMININ PRECURSOR DOMAIN BLAST_PRODOM REPEAT PD002082: C34-G260, C262-A319 LAMININ CHAIN B1 DM01003|P07942|27-259: BLAST_DOMO E31-K230 6 1386915CD1 686 S117 S135 S136 N134 N329 Signal peptide: HMMER; SPSCAN S196 S336 S445 N524 M1-A18 S449 S477 S497 MAM domains: HMMER_PFAM S499 S578 S647 C26-E169; C170-N329; C342-S498; S93 T209 T460 C509-E666 T89 PRECURSOR GLYCOPROTEIN SIGNAL BLAST_PRODOM TRANSMEMBRANE HYDROLASE PROTEIN REPEAT RECEPTOR PHOSPHATASE NEUROPILIN PD001482: C170-C327; C509-E666 MAM DM01344|A55620|618-796: BLAST_DOMO C509-R644 MAM domain motif: MOTIFS G551-F585 7 1344495CD1 296 S115 S38 S39 N253 N259 N30 Transmembrane domain: HMMER S43 T129 T207 W218-F235 T282 Putative peptidoglycan binding domain: HMMER_PFAM R76-P119 8 1485774CD1 575 S240 S281 S402 N257 N270 Signal peptide: SPSCAN S413 S511 S527 N348 N509 M1-P45 T157 T170 T245 N564 WSC domain: HMMER_PFAM T247 T301 T341 Y145-A224 T500 9 7289372CD1 592 S151 S19 S198 N121 N337 Signal peptide: HMMER; SPSCAN S202 S289 S346 N364 N474 N52 M1-P21 S367 S395 S411 N563 Leucine rich repeat N-terminal domain: HMMER_PFAM S440 S544 S587 S19-P50 T267 T329 T354 Leucine Rich Repeats: HMMER_PFAM T400 T431 T433 N52-T75; Q76-S99; Q100-S123; A124-P147; D148-S171 Leucine rich repeat C-terminal domain: HMMER_PFAM N181-A231 Immunoglobulin domain: HMMER_PFAM G253-A357 ISLR PRECURSOR SIGNAL PD103127: BLAST_PRODOM P229-P286; P321-I417 ISLR PRECURSOR SIGNAL PD167884: BLAST_PRODOM S19-V74 10 1672338CD1 255 S106 S111 S119 N120 N135 signal peptide: M1-A31 HMMER S180 T233 Sema domain: F64-V155 HMMER_PFAM SEMAPHORIN B IMMUNOGLOBULIN FOLD BLAST_PRODOM NEUROGENESIS DEVELOPMENTAL PROTEIN PD107003: M1-D63 SEMAPHORIN PROTEIN RECEPTOR KINASE BLAST_PRODOM SIGNAL TYROSINE FAMILY HEPATOCYTE PD001844: L67-H167 SEMAPHORIN; FASCICLIN; COLLAPSIN; II BLAST_DOMO DM01606|I48745|1-619: M1-I154, C217-L255 DM01606|I48748|1-589: G34-I154 DM01606|I48747|1-646: L24-I154 DM01606|A49069|1-646: F64-I154 11 184661CD1 641 S103 S139 S226 N124 N277 signal_cleavage: M1-A34 SPSCAN S242 S244 S275 N351 N418 signal peptide: M1-A34 HMMER S427 S433 S488 N455 N64 transmembrane domain: T458-F480 HMMER S556 S615 S634 F5/8 type C domain (discoidin (DS) domain HMMER_PFAM T129 T157 T325 family): S258-L409 T357 T434 T46 CUB domain: C41-Y147 HMMER_PFAM T527 T54 T552 GLYCOPROTEIN NEUROPILIN COAGULATION BLAST_PRODOM T557 T563 T600 PD000875: D264-L409 T66 GLYCOPROTEIN EGF-LIKE FACTORB12 BLAST_PRODOM PD000165: C41-Y147 DISCOIDIN I N-TERMINAL BLAST_DOMO DM00516|P12259|2095-2223: H284-I414 DM00516|A42580|2085-2210: P287-I414 DM00516|P00451|2221-2347: W285-Q413 DM00516|A44258|86-212: W285-Q413 12 3719737CD1 924 S116 S12 S144 N108 N299 signal_cleavage: M1-G33 SPSCAN S333 S362 S366 N305 N653 transmembrane domain: L866-I884 HMMER S44 S57 S609 N721 N776 Cadherin domain: HMMER_PFAM S635 S767 S824 N817 N822 I187-S284, I298-I390, I513-L603, T219 T428 T464 F617-L706, Y724-N817 T516 T533 T568 Cadherin: MOTIFS T581 T601 T637 I170-P180 I281-P291 V496-P506 T662 T698 T778 L600-P610 I703-P713 T82 T850 Y43 Cadherins extracellular repeated domain PROFILESCAN Y436 Y580 Y802 signature: V260-I312, T581-I631, V685-P733 CADHERIN SIGNATURE BLIMPS_PRINTS PR00205: Q678-P693, S696-P713, V168-F182 CADHERIN REPEAT BLAST_DOMO DM00030|P33450|1079-1181: E539-D640 DM00030|P33450|187-298: N215-L322 DM00030|P33450|1952-2055: E539-A641 DM00030|P34616|1682-1783: G642-D746 13 5773251CD1 987 S111 S115 S15 N14 N213 N337 KH domain: K113-G161 HMMER_PFAM S16 S165 S32 N391 N404 OTOGELIN ALPHA POLYPEPTIDE ALPHANAC BLAST_PRODOM S324 S33 S377 N410 N478 MUSCLESPECIFIC FORM GP220 S443 S457 S459 N581 N628 PD147940: A206-S772 S5 S52 S56 S662 N729 N770 MUCIN; MUC5; TRACHEOBRONCHIAL BLAST_DOMO S669 S795 S816 N800 N833 DM05454|S55316|1-317: I287-P530, S93 S959 T158 V384-S666, S317-P530, T246 T249 T417 T355-S617, F311-S583 T554 T62 T640 EPSTEIN; BARR; MEMBRANE BLAST_DOMO T686 T813 DM06222|P03200|1-906: G203-S588, S339-A768 14 5426470CD1 1028 S133 S164 S170 N193 N375 Fibronectin type III domain: HMMER_PFAM S184 S270 S279 N468 N489 N65 P598-S687, P700-S790, P802-S891, S342 S348 S377 N765 N860 P903-S986 S397 S406 S436 N895 N913 Immunoglobulin domain: HMMER_PFAM S442 S449 S507 N931 N956 D43-A102, G137-V198, G242-A299, S512 S549 S558 C339-A388, G424-A481, G514-V579 S572 S588 S617 CONTACTIN CELL ADHESION NEUROFASCIN BLAST_PRODOM S67 S678 S690 GLYCOPROTEIN GP135 IMMUNOGLOBULIN S713 S772 S797 PD001890: L688-P802 S815 S817 S852 ADHESION IMMUNOGLOBULIN BLAST_PRODOM S863 T244 T364 GLYCOPROTEIN GPI ANCHOR REPEAT T47 T470 T581 CONTACTIN PD005229: V894-I991 T648 T661 T754 FIBRONECTIN TYPEIII BLAST_PRODOM T758 T897 T898 PD073047: N301-G560 T955 T958 T984 NEURAL CELL ADHESION MOLECULE CLOSE BLAST_PRODOM T995 Y98 HOMOLOGUE OF L1 L1LIKE PROTEIN PD066559: E482-G596 IMMUNOGLOBULIN BLAST_DOMO DM00001|A53449|497-587: T497-S588 DM00001|A53449|405-495: A405-V496 DM00001|A53449|32-110: P32-S111 DM00001|A53449|126-206: T126-V207 15 7087904CD1 354 S171 S178 S210 N155 N275 signal_cleavage: M1-P33 SPSCAN S277 T125 T149 N286 N294 Immunoglobulin domain: HMMER_PFAM T163 T226 Y187 N307 N73 G53-V120, G153-A205, G238-A299 Receptor tyrosine kinase class III PROFILESCAN signature: V135-A198 PRECURSOR SIGNAL GLYCOPROTEIN BLAST_PRODOM IMMUNOGLOBULIN FOLD CELL ADHESION GPI ANCHOR ALTERNATIVE PD005605: F40-T128 IMMUNOGLOBULIN BLAST_DOMO DM00001|P32736|39-125: A44-T128 DM00001|P32736|139-212: D143-V214 DM00001|P32736|226-306: I227-A308 16 7477312CD1 1829 S1050 S1124 N122 N239 signal_cleavage: M1-A15 SPSCAN T948 S1150 S124 N358 N531 Ank repeat: HMMER_PFAM S477 S1260 S226-R259 D260-S292 R293-E326 S1285 S57 N327-A359 S360-Y392 S1295 S484 T279 SAM domain (Sterile alpha motif): HMMER_PFAM S1351 S667 Q1764-D1827 S1370 S1371 SH3 domain: R580-V634 HMMER_PFAM S844 S1389 CORTACTINBINDING PROTEIN 1 BLAST_PRODOM S1390 S870 D0148775: P1333-L1765, V768-A1305, S1391 S1436 P912-T1495, P17-R223, E16-A74, S952 S1449 P27-A128, S454-P569, A6-P64, S1453 S996 A60-P94, P1739-W1766, P478-L504, S1462 S1496 P25-S38 S880 S1536 LARGE STRUCTURAL PHOSPHOPROTEIN BLAST_PRODOM S1596 S854 PD145465: R1021-R1560 S1608 S1619 BAT2 (HLA-B-associated transcript 2) BLAST_DOMO S889 S1637 DM05517|S37671|1-1870: P896-D1201, S1660 S900 A12-A79, G1610-P1762 S1664 S1729 PROLINE-RICH PROTEIN 3 BLAST_DOMO S1767 S503 S608 DM00215|S14972|7-90: P912-P941, T1011 T1086 P556-P566 T1125 T415 T1196 T1360 T848 S38 T1395 T443 T1526 T1801 T206 T323 T618 T641 T645 T650 T699 T771 T796 T823 T837 T843 17 N173 N264 N53 Signal peptide: M1-A22 SPSCAN Signal peptide: M1-A22 HMMER Fibrinogen beta and gamma chains, C-term HMMER_PFAM domain: Q115-M317 Fibrinogen beta and gamma chains C-terminal BLIMPS_BLOCKS domain signature BL00514: V116-G152, E157-V169, F206-A220 Fibrinogen beta and gamma chains C-terminal PROFILESCAN domain signature: T237-S303 PRECURSOR GLYCOPROTEIN SIGNAL BLAST_PRODOM FIBRINOGEN BLOOD COAGULATION CHAIN PLASMA PROTEIN PLATELET PD001241: Q115-R315 FIBRINOGEN BETA/GAMMA BLAST_DOMO DM00531|P12804|145-428: N45-P320 S47273|152-435: N26-P320 JN0596|27-305: V116-R315 P12799|106-414: S31-I314 Fibrin_Ag_C_Domain motif: MOTIFS W268-G280 18 7473606CD1 644 S171 S214 S270 N574 Transmembrane domain: HMMER S290 S363 S405 M228-F248 S425 S535 S581 Reprolysin family propeptide domain: HMMER_PFAM S592 S630 T167 Q502-Q615 T266 T315 T377 Glycosaminoglycan attachment sites: MOTIFS T620 Y534 S86-G89, S125-G128 19 3534918CD1 881 S362 S387 S425 N257 N403 EGF-like domains: HMMER_PFAM S447 S533 S548 N630 N861 C682-C716, C722-C762, C474-C508, S552 S60 S658 C514-C553, C559-C591, C597-C633, S8 S91 T199 C639-C676 T259 T300 T322 Thrombospondin type 1 domains: HMMER_PFAM T367 T39 T507 S124-C174, G181-C231 T626 T632 T715 Calcium-binding EGF-like domain BL01187: BLIMPS_BLOCKS T793 T839 T848 C633-H644, C692-Y707 Y849 Type II EGF-like signature PR00010: BLIMPS_PRINTS D593-P604, N630-D637, G697-Y707 HEMICENTIN PRECURSOR SIGNAL BLAST_PRODOM GLYCOPROTEIN EGFLIKE DOMAIN HIM4 PROTEIN ALTERNATIVE SPLICING PD083049: Q725-Y881 EGF-LIKE DOMAIN DM00864|I55476|159-241: BLAST_DOMO N649-C722, C480-E561, D525-N600 THROMBOSPONDIN TYPE 1 REPEAT DM00275| BLAST_DOMO P35440|485-548: Q165-C226 P07996|477-540: Q165-C226 Q03350|479-542: C169-C226 Glycosaminoglycan attachment site: MOTIFS S127-G130 Aspartic acid and asparagine hydroxylation MOTIFS sites: C484-C495, C569-C580, C652-C663, C692-C703 20 2428715CD1 957 S216 S258 S444 N255 N400 Signal peptide: M1-L22 SPSCAN S525 S526 S56 N674 N745 Signal peptide: M1-G25 HMMER S594 S728 S880 N774 N784 EGF-like domains: HMMER_PFAM S894 T101 T180 C37-C72, C78-C115, C121-C156, T240 T285 T309 C166-C202, C206-C241, C275-C310, T350 T434 T505 C316-C351, C357-C390, C396-C431 T520 T53 T551 CUB domain: C793-Y902 HMMER_PFAM T579 T596 T648 Calcium-binding EGF-like signature BL01187: BLIMPS_BLOCKS T721 T748 T775 C115-G126, C407-R422 T777 T862 T877 THROMBOMODULIN SIGNATURE PR00907: BLIMPS_PRINTS T904 C282-P298, L344-C367, G372-S397, C50-D76 GLYCOPROTEIN THYROGLOBULIN BLAST_PRODOM PRECURSOR REPEAT THYROID HORMONE IODINATION SIGNAL EGFLIKE PROTEIN PD009765: C641-C788 EGF-LIKE DOMAIN DM00864|I55476|159-241: BLAST_DOMO N320-C396, N279-C357, N84-C156, C363-C437, I49-N124 EGF DM00003| BLAST_DOMO P98163|1373-1460: C87-C156, C323-L384 P98063|706-753: D117-C156 Glycosaminoglycan attachment site: MOTIFS S894-G897 Aspartic acid and asparagine hydroxylation MOTIFS sites: C50-C61, C91-C102, C132-C143, C327-C338, C367-C378, C407-C418 21 3351332CD1 1393 S1008 S1018 N1098 N1109 Signal peptide: M1-G26 SPSCAN S1158 S1206 N1169 N1204 Signal peptide: M1-A22 HMMER S1255 S1277 N147 N447 EGF-like domains: HMMER_PFAM S1380 S201 S313 N458 N634 C60-C95, C101-C137, C143-C178, S347 S49 S567 N769 N856 C184-C219, C230-C265, C271-C305, T1179 T1214 N867 N893 C311-C346, C415-C446, C459-C489, T1354 T1384 C502-C532, C536-C577, C635-C664, T264 T399 T401 C677-C708, C721-C751, C764-C795, T418 T487 T660 C808-C838, C851-C881, C894-C924, T836 T953 C937-C967, C980-C1010, C1067-C1097, C1110-C1140, C1153-C1183, C1196-C1226, C1239-C1269, C1282-C1312, C1325-C1355, Type III EGF-like signature PR00011: BLIMPS_PRINTS C471-C489, C1337-C1355, Q797-G825, C690-C708 THROMBOMODULIN SIGNATURE PR00907: BLIMPS_PRINTS G758-C777, C237-P253, C108-L130 MEGF6 GLYCOPROTEIN EGFLIKE DOMAIN BLAST_PRODOM PD169326: L349-D414 PD165309: N507-C536 SURFACE ANTIGEN PROTEIN PRECURSOR BLAST_PRODOM SIGNAL REPEAT MEMBRANE GPIANCHOR 156G 168G PD001714: H774-C1215 EGF BLAST_DOMO DM00003|P98163|1373-1460: S229-V308, C143-E223 DM00003|P35556|2219-2292: S274-C346 DM00003|A57278|2213-2286: S274-C346 EGF-LIKE DOMAIN DM00864|I55476|159-241: BLAST_DOMO N234-C311 EGF domain motifs: MOTIFS C435-C446, C478-C489, C521-C532, C566-C577, C653-C664, C697-C708, C740-C751, C784-C795, C827-C838, C870-C881, C913-C924, C956-C967, C999-C1010, C1043-C1054, C1086-C1097, C1129-C1140, C1172-C1183, C1215-C1226, C1258-C1269, C1301-C1312, C1344-C1355 Aspartic acid and asparagine hydroxylation MOTIFS sites: C71-C82, C195-206, C281-292, C322-333 22 6382722CD1 3695 S1093 S111 N1330 N143 Signal peptide: M1-A35 SPSCAN S1172 S164 N1529 N1555 Signal peptide: M1-A35 HMMER S1731 S1779 N2019 N2196 Laminin N-terminal (Domain VI): L45-G298 HMMER_PFAM S1807 S1826 N2209 N2303 S1836 S1841 N2423 N243 Laminin EGF-like (Domains III and V): HMMER_PFAM S1870 S190 N2501 N2568 C300-C356, C359-C426, S1901 S1902 N2707 N3107 C429-C471, C494-C538, C541-C584, S191 S1982 N3209 N3257 C587-C629, C632-C674, C677-C720, S2211 S2358 N3287 N3626 E721-C773, C776-C826, C829-D870, S2626 S2684 N452 N479 C1438-C1481, C1484-C1525, C1528-C1574, S2698 S2798 N900 N921 N95 C1577-C1625, C1864-C1910, S2819 S290 N959 C1913-C1966, C1969-C2020, C2023-C2067, S2934 S2944 C2070-C2114, C2117-C2167 S3035 S3076 Laminin B (Domain IV): Y1693-E1829 HMMER_PFAM S3086 S3155 Laminin G domain; HMMER_PFAM S3316 S3349 F2876-S2911, L2970-D3102, S3374 S3429 V3370-G3502, V3549-A3676 S3478 S352 S380 Laminin-type EGF-like signature BL01248: BLIMPS_BLOCKS S477 S697 S73 C1883-C1895 S768 S810 S828 Type III EGF-like signature PR00011: BLIMPS_PRINTS S902 S943 S947 C1589-C1607, C2033-C2051, C1596-G1624, T1032 T1091 C1543-C1561 T1154 T124 LAMININ DOMAIN BLAST_PRODOM T1269 T1355 PD035152: S2731-C3292, P3301-F3353 T1362 T1557 PD025440: L871-A1435 T1634 T1643 PD002082: H46-G298 T1658 T1711 PD155637: E1687-L1858 T1720 T1745 LAMININ CHAIN B1 DM01003|P25391|14-258: BLAST_DOMO T2021 T2047 L45-Y289 T208 T2128 DM01003|S53868|27-271: L45-Y289 T2288 T2315 DM01003|I49077|27-271: L45-Y289 T2515 T2570 DM01003|S50829|1-208: P94-Y289 T2625 T2749 TNFR/NGFR motif: C2051-C2090 MOTIFS Glycosaminoglycan attachment sites: MOTIFS S1531-G1534, S1972-G1975, S3149-G3152 RGD motifs: MOTIFS R1722-D1724, R1838-D1840 EGF domain motifs: MOTIFS C322-C333, C447-C458, C515-C526, C560-C571, C605-C616, C650-C661, C696-C707, C744-C755, C797-C808, C848-C859, C1457-C1468, C1550-C1561, C1596-C1607, C1831-C1842 C1937-C1948, C2040-C2051, C2070-C2081, C2088-C2099, C2131-C2142 23 55022490CD1 1255 S1009 S1052 N1039 N1129 Signal peptide: M1-G27 SPSCAN S1097 S1188 N262 N347 Thrombospondin type 1 domain: HMMER_PFAM S167 S174 S444 N519 N540 S111-C161, W394-C448, G518-C563, S470 S486 S580 N981 N988 W984-C1032, W1035-C1090, S604 S74 S761 W1093-C1139, T1140-C1197, S877 S939 S954 PROTEIN F25H8.3 F53B6.2 KIAA0605 BLAST_PRODOM S966 T1115 PROCOLLAGEN C37C3.6 SERINE T1130 T1217 PROTEASE INHIBITOR ALTERNATIVE T1228 T138 T272 PD007018: W394-P512, W1093-P1203 T31 T526 T531 PROTEIN PROCOLLAGEN THROMBOSPONDIN BLAST_PRODOM Y316 MOTIFS NPROTEINASE A DISINTEGRIN METALLOPROTEASE WITH ADAMTS1 PD011654: C198-C266 PD014161: V269-E380 Glycosaminoglycan attachment site: MOTIFS S575-G578 24 6755002CD1 911 S116 S165 S29 N130 N337 Signal peptide: M1-A22 HMMER S310 S319 S419 Signal cleavage: M1-A22 SPSCAN S446 S615 S67 C_Type_Lectin C784-C808 MOTIFS S704 S708 S727 Egf C670-C681 MOTIFS S74 T212 T219 Ig_Mhc Y135-H141 MOTIFS T269 T382 T386 Lectin C-type domain lectin_c: T714-C808 HMMER_PFAM T397 T420 T430 Extracellular link domain Xlink: HMMER_PFAM T545 T558 T660 G156-Y251, G257-F353 T705 T728 T807 Immunoglobulin domain ig: G50-V139 HMMER_PFAM Y135 Y459 EGF-like domain EGF: C650-C681 HMMER_PFAM Sushi domain (SCR repeat) sushi: C815-C871 HMMER_PFAM C-type lectin domain signature PROFILESCAN c_type_lectin.prf: P763-G828 C-type lectin domain protein BL00615: BLIMPS_BLOCKS C699-C716, W795-C808 Link domain proteins BL01241: E272-G324 BLIMPS_BLOCKS TYPE II ANTIFREEZE PROTEIN (lectin-like) BLIMPS_PRINTS PR00356: F687-C699, C699-C716, R717-F734, W744-D760, W795-C808 C-TYPE LECTIN DM00035|A54423|689-811: BLAST_DOMO C688-G811 COMPLEMENT FACTOR H REPEAT DM00260 BLAST_DOMO A54423|142-252: G142-E253 BREVICAN CORE PROTEIN PRECURSOR (brain- BLAST_PRODOM specific lectican) PD022317: L479-V651 PD021260: R354-E455 EGFLIKE DOMAIN REPEAT BLAST_PRODOM PD150847: D28-V154, PD000918: K267-F353 25 7350907CD1 467 S124 S194 S261 N169 N270 Signal cleavage: M1-T31 SPSCAN S273 S335 S362 N289 N376 GLYCOPROTEIN OLFACTOMEDIN BLAST_PRODOM S383 S415 S432 N413 N455 N85 MESHWORK-INDUCED RESPONSE SIGNAL S47 T220 T36 PROTEIN PRECURSOR PD006897: E258-I452 T97 Y103 Y323 NEURONAL OLFACTOMEDIN RELATED BLAST_PRODOM ER LOCALIZED PRECURSOR PD037534: A135-R257, PD020721: M11-K134 26 7474411CD1 1018 S117 S195 S206 N373 N441 Signal cleavage: M1-P25 SPSCAN S309 S312 S394 N709 Receptor_Cytokines_2 G57-S63 MOTIFS S458 S557 S648 Transmembrane domain: M1-F20 HMMER S656 S661 S803 Thrombospondin type 1 domain tsp_1: HMMER_PFAM S84 S896 T368 S737-C793 T483 T493 T649 PROCOLLAGEN THROMBOSPONDIN MOTIFS BLAST_PRODOM T665 T843 T851 PD011654: K344-C411, PD014161: Q412-I527 PROCOLLAGEN SERINE PROTEASE INHIBITOR BLAST_PRODOM PD007018: W856-P969 27 4755911CD1 1458 S1014 S1027 N1199 N215 Ankyrin repeat ank: P108-D140, E141-N173, HMMER_PFAM S104 S1073 N354 N958 S174-L204, N215-K247, S248-T279 S1131 S1254 (SAM) protein interaction domain SAM: HMMER_PFAM S1274 S1298 E497-S560, H568-A630 S1391 S1395 PROLINE-RICH PROTEIN DM03894|A39066| BLAST_DOMO S1429 S1437 1-159: P1216-P1358 S1444 S174 S367 S447 S450 S560 S673 S732 S777 S782 S79 S846 S916 S918 S946 S981 T1056 T1092 T1103 T1122 T1150 T1170 T1174 T1203 T1273 T177 T283 T337 T356 T534 T604 T667 T678 T702 T712 T716 T717 T80 T828 T841 T855 Y363 Y594 28 379766CD1 323 Signal peptide: M1-T24 HMMER Thrombospondin type 1 domain: D79-C123 HMMER-PFAM Thrombospondin, procollagen, N-proteinase BLAST-PRODOM A, disintegrin, metalloprotease with ADAMTS1 PD011654: P157-C227, Q133-G203 29 553744CD1 234 S231 T140 30 1825473CD1 377 S120 S140 S18 N128 N135 Signal peptide: M1-S18 HMMER S38 S41 S62 N146 N97 Signal peptide: M1-G22 SPScan T267 T343 Y48 Mucin, MUC5, tracheobronchial: BLAST-DOMO DM05454|S55316|1-317: P91-A350, C70-T348, S150-P351, Q163-A350, P203-A350 Salivary glue protein: BLAST-DOMO DM02055|P02840|17-234: S149-K355, S120-T330, P85-T291 31 7950094CD1 833 S200 S34 S364 N106 N121 Signal peptide: M1-V23 HMMER S382 S46 S480 N310 N419 Transmembrane domain: L667-R687 HMMER S505 S555 S685 N522 N564 Plexin repeat: D499-N551 HMMER-PFAM S742 S826 T229 Sema domain: F53-K481 HMMER-PFAM T276 T302 T418 Semaphorin, fasciclin, collapsin: BLAST-DOMO T429 T523 T561 DM01606|I48747|1-646: L10-W519 T57 T701 Y249 Semaphorin, fasciclin, collapsin: BLAST-DOMO Y345 Y736 DM01606|A49069|1-646: N26-W519 Semaphorin, fasciclin, collapsin: BLAST-DOMO DM01606|I48744|1-639: A12-G592 Semaphorin, fasciclin, collapsin: BLAST-DOMO DM01606|I48748|1-589: D52-G530 Semaphorin I (neural development factor): BLAST-PRODOM PD129812: H540-V833 Semaphorin, receptor, kinase, tyrosin BLAST-PRODOM protein PD001844: F145-E351, R242-S453, L56-E204, P754-G764 Semaphorin I: BLAST-PRODOM PD166847: M1-D52 32 7479484CD1 1291 S1037 S113 N394 N500 N54 Cell attachment sequence: R844-D846 MOTIFS S1279 S216 S224 Tumor recognition, prolyl: BLAST-DOMO S225 S272 S324 DM08077|P30414|230-1403: S380 S396 S434 S613-P1098, E398-P896 S445 S450 S453 Acidic serine cluster repeat: BLAST-DOMO S465 S466 S480 DM03496|P32583|57-405: S481 S489 S508 S539-Q824, N500-K819, S557-V878, S535 S547 S558 S421-S754, A474-R765, S465-W800, S563 S585 S589 A378-Y718 S595 S596 S606 Type B repeat: BLAST-DOMO S618 S635 S652 DM05511|S26650|1-1203: S655 S656 S662 E400-P826, D534-Q791, Q593-D842 S678 S683 S688 Type B repeat: BLAST- DOMO S691 S695 S708 DM05511|P18583|113-1296: S713 S719 S720 S585-P826, D475-D842, D534-S783 S721 S760 S764 S785 S790 S795 S799 S804 S810 S831 S866 S871 S889 S947 S954 S965 S971 T1102 T118 T175 T243 T268 T341 T371 T41 T439 T862 T879 T944 33 6780147CD1 736 S131 S144 S20 N316 N467 Signal peptide: M1-A22 HMMER S361 S369 S409 N540 Signal peptide: M1-A22 SPScan S469 S479 S653 Cell attachment sequence: R48-D50 MOTIFS S683 S699 S726 Leucine zipper pattern: L445-L466 MOTIFS T394 T430 T495 CD4, GNB3, mouse BAC library PD043366: BLAST-PRODOM T508 T542 T570 L445-K733, H176-E412, C79-E234, T608 T630 Y250 Q97-E135 CASP, cartilage-associated PD023886: BLAST-PRODOM Y46-C282, E201-S361 34 7204554CD1 1896 S1004 S1115 S45 N1043 N1098 Signal peptide: M1-A26 SPScan S1271 S1382 N1140 N1187 Signal peptide: M1-A28 HMMER S1435 S1487 N1212 N1609 Transmembrane domains: HMMER S1546 S1621 N1612 N572 V10-A28, P1244-Y1267 S1631 S1635 N597 N660 Plexin repeat: HMMER-PFAM S1767 S1785 N672 N701 S514-V564, N660-P707, K808-T862 S1797 S1811 N761 N769 N77 Sema domain: HMMER-PFAM S1827 S1883 N785 L51-N495 S202 S203 S249 IPT/TIG domain: HMMER-PFAM S294 S454 S542 P864-V959, P961-T1045, P1048-Y1147, S599 S608 S621 P1150-Y1236 S838 S858 S908 ATP/GTP-binding site motif A (P-loop): MOTIFS S929 S952 T1036 G188-S195 S162 T1075 Hepatocyte tyrosine kinase: BLAST-DOMO T1200 T1220 DM03653|P08581|14-526: T1277 T1363 L51-C521, T647-C667 T1574 T1575 Tyrosine kinase: BLAST-DOMO T1739 T1779 DM01368|P51805|796-899: T189 T268 T279 C819-I924 T361 T503 T519 Tyrosine kinase: BLAST-DOMO T604 T647 T957 DM02937|P51805|991-1085: Y1540 Y1817 P1021-V1109 Hepatocyte tyrosine kinase: BLAST-DOMO DM03653|A48196|13-528: L19-E522 Plexin precursor PD008852: BLAST-PRODOM A1262-S1672, T1504-S1896, E482-N495 Receptor, tyrosine kinase PD003981: BLAST-PRODOM R892-N1212, M502-H531 Plexin precursor PD010132: BLAST-PRODOM P570-C843 Plexin precursor PD003973: BLAST-PRODOM R372-Y498 35 6833247CD1 215 S108 S140 S177 N102 N111 N45 signal peptide: SPSCAN S8 T104 T124 M1-C39 T53 Transmembrane domain: HMMER Q17-A37 Lectin C-type domain: HMMER_PFAM R110-C207 C-type lectin domain protein BLIMPS_BLOCKS BL00615A: C95-C112 BL00615B: W194-C207 C-type lectin domain signature: PROFILESCAN Q159-T213 TYPE II ANTIFREEZE PROTEIN BLIMPS_PRINTS PR00356: S113-F130, F142-D158, W194-C207, C83-C95, C95-C112 C-TYPE LECTIN BLAST_DOMO DM00035|A54423|689-811: C83-I209 DM00035|P10716|405-536: D87-K208 DM00035|P16112|2205-2327: C84-K208 DM00035|A46274|248-377: C84-K208 36 4148119CD1 579 S144 S253 S394 N69 signal_cleavage: SPSCAN S485 T162 T472 M1-G24 T521 T570 signal peptide: HMMER M1-G24 Leucine Rich Repeat: HMMER_PFAM Q239-H264, S265-A288, G310-R335, G336-R359, G381-R406, A407-P426, G428-D451, Q452-Q477, A478-P497, A499-P522, R523-P548, A73-S96, G97-T122, Q123-R146, V168-E193, A194-P213, S215-T238 Leucine zipper pattern: MOTIFS L198-L219 L269-L290 L340-L361 L411-L432 L418-L439 L482-L503

[0335] TABLE 4 Polynucleotide Incyte Sequence Selected SEQ ID NO: Polynucleotide ID Length Fragment(s) Sequence Fragments 5′ Position 3′ Position 37 1888682CB1 1211 7347284H1 (LUNLTUE01) 315 905 2110746R6 (BRAITUT03) 749 1211 7016843H1 (KIDNNOC01) 1 625 38 1794980CB1 1523 1403-1523, 1-121, 6775891H1 (OVARDIR01) 1 700 409-454, 4955572H1 (ENDVUNT01) 1202 1523 833-907 6149683H1 (BRANDIT03) 780 1450 2149263F6 (BRAINOT09) 678 1313 39 5533958CB1 1368 1-589 6552411H1 (BRAFNON02) 878 1368 7237564H1 (BRAINOY02) 850 1358 6976222H1 (BRAHTDR04) 579 1333 7182163H1 (BONRFEC01) 1 604 40 60210196CB1 3157 1-2311 71699406V1 2592 3157 71699506V1 2085 2898 71699453V1 1611 2165 7050851H1 (BRACNOK02) 1 792 70810715V1 2310 2955 71699537V1 1393 2080 3767657F7 (BRSTNOT24) 769 1492 5436183F6 (SPLNNOT17) 882 1623 41 815125CB1 3264 1879-1968, 1-938 70506843V1 512 1131 71182375V1 1999 2553 6764263H1 (BRAUNOR01) 1 646 71149313V1 2520 3264 60205342U1 1305 1932 1376122F1 (LUNGNOT10) 2143 2654 6488119H1 (MIXDUNB01) 1453 2026 70483405V1 702 1342 42 1386915CB1 3383 1-1510 6841587H1 (BRSTNON02) 3124 3376 70772013V1 1247 1875 70773009V1 663 1266 1350440F1 (LATRTUT02) 2451 3007 5797946H1 (PLACFET04) 2547 3041 6428723H1 (LUNGNON07) 1 338 6481347H1 (PROSTMC01) 319 991 3326918T6 (HEAONOT04) 2914 3333 843210H1 (PROSTUT05) 3173 3383 70772645V1 1958 2562 70771297V1 1319 1951 70772890V1 1852 2483 43 1344495CB1 2741 1-361, 2693-2741 70267334V1 657 1209 1860069T6 (PROSNOT18) 1944 2667 g2577445 2437 2741 1344495F6 (PROSNOT11) 1 566 1860069F6 (PROSNOT18) 1083 1873 70269146V1 2051 2687 70266807V1 1211 1944 70270212V1 539 1172 70267638V1 1803 2365 44 1485774CB1 2076 524-976, 303-332 1617862H1 (BRAITUT12) 1776 2006 744054R6 (BRAITUT01) 1413 1972 1485774F6 (CORPNOT02) 1028 1467 6904024H1 (MUSLTDR02) 1 703 g3043569_CD 356 1842 1290195H1 (BRAINOT11) 562 837 g1242437 1607 2076 45 7289372CB1 2957 1214-1324, 1-236, 7289157H1 (BRAIFER06) 2467 2957 991-1098, 7252620H2 (BRAIFEE04) 1964 2575 1803-2480, 7675562J2 (NOSETUE01) 972 1527 464-920 g772391 1 495 7290371H1 (BRAIFER06) 1579 2105 7288441H1 (BRAIFER06) 342 788 7292572R8 (BRAIFER06) 747 1443 5090004R8 (UTRSTMR01) 1440 1948 46 1672338CB1 1223 1196-1223, 6609653H1 (EPIGTMC01) 1 609 652-678 71743918V1 558 1223 47 184661CB1 2888 1331-1592, 1-596, 70160946V1 2386 2888 2355-2401 7703219J1 (UTRETUE01) 1520 2162 70160174V1 2176 2810 71401492V1 620 1168 70154040V1 2020 2637 6153426H1 (ENDMUNT04) 1 544 7192494H2 (BRATDIC01) 1062 1709 71142234V1 449 1137 48 3719737CB1 3142 3067-3142, 1-409, 71046117V1 2277 2807 1301-1659, 71047416V1 1375 1784 761-822 71046670V1 1676 2317 70064096V1 2614 3142 4027661F8 (BRAINOT23) 916 1327 7455730H1 (LIVRTUE01) 1156 1582 7431827H1 (UTRMTMR02) 543 1071 7189788H2 (BRATDIC01) 1 603 49 5773251CB1 4749 3194-3442, 1-1545, 71699127V1 1649 2386 4114-4749, 7091322H1 (BRAUTDR03) 963 1558 2497-2543 71698165V1 2430 3198 6981926H1 (BRAIFER05) 1221 1633 594160T6 (BRAVUNT02) 3989 4604 7733307H2 (COLDDIE01) 3460 4056 g3927714 326 712 71698388V1 2348 3102 7733307J2 (COLDDIE01) 4181 4749 70089831V1 3135 3978 71699024V1 1512 2271 7754525J1 (SPLNTUE01) 1 570 7285547H1 (BRAIFEJ01) 650 1140 50 5426470CB1 4155 2222-2681, 6991563H1 (BRAIFER05) 1 478 4067-4086, 1-171, 6122067H1 (BRAHNON05) 3604 4155 3250-3606, 5814755F8 (PROSTUS23) 2969 3555 301-1873 7177748H1 (BRAXDIC01) 2416 3023 g7959252_CD 442 3284 5426470T6 (PROSTMT07) 3210 4048 5426470F6 (PROSTMT07) 2219 2938 7035583R8 (SINTFER03) 1610 1786 4329672H1 (KIDNNOT32) 2110 2361 7178436H1 (BRAXDIC01) 949 1498 51 7087904CB1 1327 943-1327, 7946383H1 (BRABNOE02) 151 976 267-490 7087904H1 (BRAUTDR03) 1 392 6312090H1 (NERDTDN03) 605 1327 52 7477312CB1 5529 4005-4070, 1-246, GNN.g7923864_002 90 2347 3475-3746, 7102261F8 (BRAWTDR02) 5148 5529 688-2835, 7314180H1 (LIVRNOE07) 1803 2384 4856-5529 7719744J1 (SINTFEE02) 2885 3567 8023704J1 (BRABDIE02) 2342 3058 7398367H1 (KIDEUNE02) 596 1224 6953114H1 (BRAITDR02) 3429 4052 7231729H1 (BRAXTDR15) 4267 4889 6772109J1 (BRAUNOR01) 4599 5255 7228637H1 (BRAXTDR15) 3676 4218 6880723J1 (BRAHTDR03) 4193 4837 GBI: g7923864.edit 1 503 7070679R8 (BRAUTDR02) 239 650 6034612H1 (PITUNOT06) 4974 5501 7647642J1 (UTRSTUE01) 1362 1642 53 2739431CB1 1623 1-1302 2819460F6 (BRSTNOT14) 1503 1623 70563142V1 627 1142 1388139T6 (CARGDIT02) 303 1023 1388139F6 (CARGDIT02) 1 587 2737908T6 (OVARNOT09) 975 1599 54 7473606CB1 2242 1053-1326, 2618950T6 (GBLANOT01) 666 863 252-776, 1-167, 5624160R8 (THYMNOR02) 1892 2242 864-955, 2618950F6 (GBLANOT01) 1 667 1401-1490 6770895J1 (BRAUNOR01) 1610 1865 g5545559 1602 2085 GNN.g6454068_000018_002.edit 29 1865 55 3534918CB1 3751 854-1195, 6483020H1 (MIXDUNB01) 1355 1880 593-646, 1-129, 70882296V1 2517 3054 3709-3751, 70880032V1 3139 3751 1706-2129 6819410H1 (OVARDIR01) 513 1170 3736613T6 (SMCCNOS01) 3127 3701 70879201V1 1925 2526 GNN.g6634914_000002_002 1 1672 70879032V1 2483 3011 70879778V1 1833 2470 1404901T6 (LATRTUT02) 2984 3670 56 2428715CB1 3579 1-94, 2957-3167 71902796V1 2452 3184 599-2309 71907111V1 2725 3295 7362261H1 (BRAIFEE05) 2407 2663 GNN.g5911819_008.edit 1051 2966 2428715H1 (SCORNON02) 2359 2590 6925281R8 (PLACFER06) 2767 3579 55037058H2 1632 2403 8186336H1 (EYERNON01) 1 648 GBI.g5911819_000001.edit 600 1412 7287205F8 (BRAIFER06) 984 1517 FL2428715_g6815043_000026_g8052237_1_3-4.edit 466 726 1736320T6 (COLNNOT22) 4260 4888 57 3351332CB1 5178 4912-5178, 1-3036 71990942V1 3479 4113 3143-3274, 72036025V1 2484 3377 3855-4182 71992140V1 2434 3066 8006270H1 (PENIFEC01) 1743 2484 7715524H1 (SINTFEE02) 1197 1736 1736320F6 (COLNNOT22) 4066 4603 8037780H1 (SMCRUNE01) 1715 2099 7715524J1 (SINTFEE02) 666 1078 GNN.g9187279_000012_002.edit 644 1978 1437833F1 (PANCNOT08) 4690 5178 GBI.g9844022_000020_000016_000015.edit 272 766 8037316H1 (SMCRUNE01) 854 1588 71990329V1 3204 4032 8037316J1 (SMCRUNE01) 1 639 58 6382722CB1 11367 1-5178 7104534H1 (BRAWTDR02) 4529 5108 6808001J1 (SKIRNOR01) 5941 6661 7000837H1 (HEALDIR01) 3133 3749 7324406H1 (COLRTUE01) 2301 2916 2778756T6 (OVARTUT03) 10822 11353 1675050F6 (BLADNOT05) 10293 10903 6938286R8 (FTUBTUR01) 834 1498 2951540F6 (KIDNFET01) 10075 10675 6942017H1 (FTUBTUR01) 2091 2548 7663312J1 (UTRSTME01) 8747 9415 7705507H1 (UTRETUE01) 3523 4235 7716415J1 (SINTFEE02) 8632 9160 7755720H1 (SPLNTUE01) 4863 5504 8037265J1 (SMCRUNE01) 3740 4494 8045466H1 (OVARTUE01) 1434 2165 7641932J1 (SEMVTDE01) 9355 10078 7751563H1 (HEAONOE01) 6986 7768 7076128F6 (BRAUTDR04) 121 881 7970390H1 (MIXDDIA01) 10912 11367 7713737H1 (TESTTUE02) 9483 10150 7755720J1 (SPLNTUE01) 4429 5069 8045466J1 (OVARTUE01) 1075 1528 7763930J1 (URETTUE01) 7298 8008 6975271H1 (BRAHTDR04) 6667 7261 GNN.g8670608_000002_002.edit 1 297 7644864J1 (UTRSTUE01) 7987 8616 7699541H1 (KIDPTDE01) 5176 5894 6765766H1 (BRAUNOR01) 2543 3057 6948079H1 (BRAITDR02) 2765 3434 6759347J1 (HEAONOR01) 5801 6513 7699541J1 (KIDPTDE01) 6468 7236 55145718J1 8102 8728 59 55022490CB1 4255 2644-2898, 1-436, 8110806H1 (OSTEUNC01) 1231 1882 1179-1891 7201271F8 (LUNGFER04) 2265 2964 8213356H1 (FIBRTXC01) 3680 4255 7953052H1 (SYNONOC01) 2062 2558 55022495H1 1 645 55022496H1 1316 1961 2939061F6 (THYMFET02) 3185 3774 55022495J1 608 1248 55022496J1 661 1310 7704179H1 (UTRETUE01) 1886 2338 7346573H1 (SYNODIN02) 2630 3219 7577135H1 (ADIPUNS02) 3426 4023 g1382343 3648 4255 60 6755002CB1 3438 1-37, 1548-1618, 5879324F6 (BRAUNOT01) 617 1285 2405-2610 7630423H1 (BRAFTUE03) 177 711 6755102H1 (SINTFER02) 84 702 6337127H1 (BRANDIN01) 1351 1904 5968891H1 (BRAZNOT01) 2185 2887 8126594H1 (SCOMDIC01) 863 1538 1290035H1 (BRAINOT11) 3190 3438 6555447H1 (BRAFNON02) 2732 3317 1305462H1 (PLACNOT02) 1 182 71389138V1 1524 2121 71185765V1 2086 2672 61 7350907CB1 1683 7350907H1 (COLNNON05) 1299 1683 6631669J1 (BMARTXR02) 567 1302 7750841J1 (HEAONOE01) 1 603 6443310H1 (BRAENOT02) 718 1366 62 7474411CB1 6886 6622-6886, 7222381H1 (PLACFEC01) 2499 3017 5389-5509, 1-1582, 7737011J1 (BRAITUE01) 6219 6886 6439-6474, 70870035V1 3823 4452 1894-1951, 7633045H1 (SINTDIE01) 2306 2579 2850-4036 8037283J1 (SMCRUNE01) 1014 1741 2483734F6 (SMCANOT01) 4465 5002 7755056H1 (SPLNTUE01) 3653 4411 1603055T6 (BLADNOT03) 5780 6443 70743936V1 5077 5667 6822892H1 (SINTNOR01) 1766 2503 7931495H1 (COLNDIS02) 4915 5652 8053929J1 (FTUBTUE01) 132 720 7689270H1 (PROSTME06) 1 458 6822892J1 (SINTNOR01) 1481 2273 7644647J1 (UTRSTUE01) 632 1115 7738773H1 (BRAITUE01) 3004 3655 7738657H1 (BRAITUE01) 4306 4946 7688349J1 (PROSTME06) 2589 3035 71230141V1 3125 3768 2695328T6 (UTRSNOT12) 5562 6252 63 4755911CB1 4457 1-324, 750-1798, 6773194J1 (BRAUNOR01) 336 1095 3657-3747, 4755911H1 (BRAHNOT01) 1769 2034 2407-3438, g7242966_CD 913 4457 2273-2326, 6880647J1 (BRAHTDR03) 3285 4044 3912-4457 6773172H1 (BRAUNOR01) 3132 3908 6765836H1 (BRAUNOR01) 1902 2429 7076957H1 (BRAUTDR04) 689 1321 g953650 311 699 7371978H2 (BRAIFEE04) 1207 1591 GNN.g7454228_000009_004.edit 1 4172 64 379766CB1 1943 1-260, 922-1565 71913768V1 1049 1755 71225395V1 529 1072 71912043V1 1122 1769 71910219V1 1291 1943 1672013H1 (BLADNOT05) 1 221 7082633R8 (STOMTMR02) 192 957 65 553744CB1 4111 1-580, 2777-2939 3918424H1 (BRAINOT14) 3588 3876 6610359H2 (MUSTTMC01) 2323 2934 71249585V1 1666 2217 3294472T6 (TLYJINT01) 3163 3801 6338521F7 (BRANDIN01) 1 427 8016583J1 (BMARTXE01) 531 895 7467954H1 (LUNGNOE02) 1059 1601 553744R6 (SCORNOT01) 3799 4110 1799062T6 (COLNNOT27) 2193 2814 7167059H1 (PLACNOR01) 147 755 1304490H1 (PLACNOT02) 3030 3251 71066496V1 1496 2151 2219161H1 (LUNGNOT18) 3947 4111 71065885V1 2537 3206 7608285J1 (COLRTUE01) 807 1308 66 1825473CB1 1604 1186-1222, 1-662, 71671748V1 957 1604 697-1075 7977810H1 (LSUBDMC01) 1 614 7978864H1 (LSUBDMC01) 642 1276 7978667H1 (LSUBDMC01) 482 1181 67 7950094CB1 2646 1887-1962, 7751102H1 (HEAONOE01) 477 1191 1358-1427, 1-716, 71824138V1 1889 2577 2117-2176 1674661F6 (BLADNOT05) 1 503 71495047V1 608 1350 7721119H2 (THYRDIE01) 1991 2646 7675220H1 (NOSETUE01) 1248 1912 6252635H1 (LUNPTUT02) 529 1205 68 7479484CB1 3876 1855-1892, GBI.g8569175_000028.edit 580 3876 1380-1714, GNN.g8569175_000028_002.edit 1 3579 2489-2791 69 6780147CB1 2583 720-1210, 6081718H1 (LUNLTUT11) 1909 2583 2237-2583 2417167F6 (HNT3AZT01) 674 1192 7220328H1 (SPLNDIC01) 586 1176 4603304F8 (BRSTNOT07) 1242 1889 6780147H1 (OVARDIR01) 1111 1709 3282558T6 (HEAONOT05) 1836 2558 8116139H1 (TONSDIC01) 1 630 70 7204554CB1 6147 4831-5200, 6321562F6 (LUNGDIN02) 3284 3732 2698-3091, 1-557, 7655014H1 (UTREDME06) 2035 2634 3609-4067, 8036632H1 (SMCRUNE01) 1 593 1239-2254 7655014J1 (UTREDME06) 1286 1880 6804453H1 (COLENOR03) 762 1352 7631942H1 (BLADTUE01) 5282 5852 7292462H1 (BRAIFER06) 2334 2853 4099025F8 (BRAITUT26) 5241 5762 6832366H1 (BRSTNON02) 3821 4567 GBI.g10518389_000002_CDS_5.edit 162 5852 6814168J1 (ADRETUR01) 4696 5261 7721587H2 (THYRDIE01) 5641 6147 6883267J1 (BRAHTDR03) 3504 4216 7698650J1 (KIDPTDE01) 572 1196 8239939J1 (LIVRTMR01) 2589 3255 8076958J1 (ADRETUE02) 4407 5152 7383235R8 (FTUBTUE01) 1551 2326 71 6833247CB1 888 331-430 498875H1 (NEUTLPT01) 692 888 6128926H1 (BRAHNON05) 1 432 6833247T8 (BRSTNON02) 265 879 72 4148119CB1 3582 1681-1740, 1-1470, g6465050 2274 2694 2944-3582 7412335H1 (BONMTUE02) 2052 2514 70776200V1 1409 2028 1539263R6 (SINTTUT01) 3199 3582 2212958H1 (SINTFET03) 2452 2684 4148119F6 (SINITUT04) 2704 3290 5984846F6 (MCLDTXT02) 1 732 70776601V1 1053 1616 7765150J1 (URETTUE01) 614 1285 70776341V1 1632 2115

[0336] TABLE 5 Polynucleotide Incyte Representative SEQ ID NO: Project ID Library 37 1888682CB1 BRAITUT08 38 1794980CB1 BRAINOT09 39 5533958CB1 CONNTUT04 40 60210196CB1 BRACNOK02 41 815125CB1 BRAENOK01 42 1386915CB1 LATRTUT02 43 1344495CB1 SINTFET03 44 1485774CB1 BRAITUT01 45 7289372CB1 BRAIFER06 46 1672338CB1 CONNNOT01 47 184661CB1 CARDNOT01 48 3719737CB1 KIDETXS02 49 5773251CB1 PLACFER06 50 5426470CB1 PROSTUS23 51 7087904CB1 NERDTDN03 52 7477312CB1 BRABDIE02 53 2739431CB1 OVARNOT09 54 7473606CB1 GBLADIT03 55 3534918CB1 BONRTUT01 56 2428715CB1 PLACFER06 57 3351332CB1 ENDCNOT03 58 6382722CB1 FTUBTUR01 59 55022490CB1 BRAIFEE05 60 6755002CB1 BRAITUT12 61 7350907CB1 BRAENOT02 62 7474411CB1 BRAITUT26 63 4755911CB1 BRAUNOR01 64 379766CB1 NEUTFMT01 65 553744CB1 SEMVNOT01 66 1825473CB1 LSUBDMC01 67 7950094CB1 BLADNOT05 68 7479484CB1 LUNPTUT02 69 6780147CB1 HNT3AZT01 70 7204554CB1 COLENOR03 71 6833247CB1 BRSTNON02 72 4148119CB1 CARGDIT01

[0337] TABLE 6 Library Vector Library Description BLADNOT05 pINCY Library was constructed using RNA isolated from bladder tissue removed from a 60-year- old Caucasian male during a radical cystectomy, prostatectomy, and vasectomy. Pathology for the associated tumor tissue indicated grade 3 transitional cell carcinoma. Carcinoma in-situ was identified in the dome and trigone. Patient history included tobacco use. BONRTUT01 pINCY Library was constructed using RNA isolated from rib tumor tissue removed from a 16-year- old Caucasian male during a rib osteotomy and a wedge resection of the lung. Pathology indicated a metastatic grade 3 (of 4) osteosarcoma, forming a mass involving the chest wall. BRABDIE02 pINCY This 5′ biased random primed library was constructed using RNA isolated from diseased cerebellum tissue removed from the brain of a 57-year-old Caucasian male who died from a cerebrovascular accident. Serologies were negative. Patient history included Huntington's disease, emphysema, and tobacco abuse (3-4 packs per day, for 40 years). BRACNOK02 PSPORT1 This amplified and normalized library was constructed using RNA isolated from posterior cingulate tissue removed from an 85-year-old Caucasian female who died from myocardial infarction and retroperitoneal hemorrhage. Pathology indicated atherosclerosis, moderate to severe, involving the circle of Willis, middle cerebral, basilar and vertebral arteries; infarction, remote, left dentate nucleus; and amyloid plaque deposition consistent with age. There was mild to moderate leptomeningeal fibrosis, especially over the convexity of the frontal lobe. There was mild generalized atrophy involving all lobes. The white matter was mildly thinned. Cortical thickness in the temporal lobes, both maximal and minimal, was slightly reduced. The substantia nigra pars compacta appeared mildly depigmented. Patient history included COPD, hypertension, and recurrent deep venous thrombosis. 6.4 million independent clones from this amplified library were normalized in one round using conditions adapted Soares et al., PNAS (1994) 91: 9228-9232 and Bonaldo et al., Genome Research 6 (1996): 791. BRAENOK01 PSPORT1 This amplified and normalized library was constructed using RNA isolated from inferior parietal cortex tissue removed from a 35-year-old Caucasian male who died from cardiac failure. Pathology indicated moderate leptomeningeal fibrosis and multiple microinfarctions of the cerebral neocortex. There was evidence of shrunken and slightly eosinophilic pyramidal neurons throughout the cerebral hemispheres. There were multiple small microscopic areas of cavitation with surrounding gliosis scattered throughout the cerebral cortex. Patient history included dilated cardiomyopathy, congestive heart failure, and cardiomegaly. Patient medications included simethicone, Lasix, Digoxin, Colace, Zantac, captopril, and Vasotec. 1.08 million independent clones from this amplified library were normalized in one round using conditions adapted from Soares et al., PNAS (1994) 91: 9228-9232 and Bonaldo et al., Genome Research 6 (1996): 791, except that a significantly longer (48 hours/round) reannealing hybridization was used. BRAENOT02 pINCY Library was constructed using RNA isolated from posterior parietal cortex tissue removed from the brain of a 35-year-old Caucasian male who died from cardiac failure. BRAIFEE05 PCDNA2.1 This 5′ biased random primed library was constructed using RNA isolated from brain tissue removed from a Caucasian male fetus who was stillborn with a hypoplastic left heart at 23 weeks' gestation. BRAIFER06 PCDNA2.1 This random primed library was constructed using RNA isolated from brain tissue removed from a Caucasian male fetus who was stillborn with a hypoplastic left heart at 23 weeks' gestation. Serologies were negative. BRAINOT09 pINCY Library was constructed using RNA isolated from brain tissue removed from a Caucasian male fetus, who died at 23 weeks' gestation. BRAITUT01 PSPORT1 Library was constructed using RNA isolated from brain tumor tissue removed from a 50- year-old Caucasian female during a frontal lobectomy. Pathology indicated recurrent grade 3 oligoastrocytoma with focal necrosis and extensive calcification. Patient history included a speech disturbance and epilepsy. The patient's brain had also been irradiated with a total dose of 5,082 cyg (Fraction 8). Family history included a brain tumor. BRAITUT08 pINCY Library was constructed using RNA isolated from brain tumor tissue removed from the left frontal lobe of a 47-year-old Caucasian male during excision of cerebral meningeal tissue. Pathology indicated grade 4 fibrillary astrocytoma with focal tumoral radionecrosis. Patient history included cerebrovascular disease, deficiency anemia, hyperlipidemia, epilepsy, and tobacco use. Family history included cerebrovascular disease and a malignant prostate neoplasm. BRAITUT12 pINCY Library was constructed using RNA isolated from brain tumor tissue removed from the left frontal lobe of a 40-year-old Caucasian female during excision of a cerebral meningeal lesion. Pathology indicated grade 4 gemistocytic astrocytoma. BRAITUT26 pINCY Library was constructed using RNA isolated from brain tumor tissue removed from the right posterior fossa, occipital convexity of a 70-year-old Caucasian male during cerebral meninges lesion excision. Pathology indicated meningioma. Patient history included a benign colon neoplasm and unspecified personality disorder. Family history included chronic proliferative nephritis, acute myocardial infarction, atherosclerotic coronary artery disease, and chronic proliferative nephritis. BRAUNOR01 pINCY This random primed library was constructed using RNA isolated from striatum, globus pallidus and posterior putamen tissue removed from an 81-year-old Caucasian female who died from a hemorrhage and ruptured thoracic aorta due to atherosclerosis. Pathology indicated moderate atherosclerosis involving the internal carotids, bilaterally; microscopic infarcts of the frontal cortex and hippocampus; and scattered diffuse amyloid plaques and neurofibrillary tangles, consistent with age. Grossly, the leptomeninges showed only mild thickening and hyalinization along the superior sagittal sinus. The remainder of the leptomeninges was thin and contained some congested blood vessels. Mild atrophy was found mostly in the frontal poles and lobes, and temporal lobes, bilaterally. Microscopically, there were pairs of Alzheimer type II astrocytes within the deep layers of the neocortex. There was increased satellitosis around neurons in the deep gray matter in the middle frontal cortex. The amygdala contained rare diffuse plaques and neurofibrillary tangles. The posterior hippocampus contained a microscopic area of cystic cavitation with hemosiderin-laden macrophages surrounded by reactive gliosis. Patient history included sepsis, cholangitis, post-operative atelectasis, pneumonia CAD, cardiomegaly due to left ventricular hypertrophy, splenomegaly, arteriolonephrosclerosis, nodular colloidal goiter, emphysema, CHF, hypothyroidism, and peripheral vascular disease. BRSTNON02 pINCY This normalized breast tissue library was constructed from 6.2 million independent clones from a pool of two libraries from two different donors. Starting RNA was made from breast tissue removed from a 46-year-old Caucasian female during a bilateral reduction mammoplasty (donor A), and from breast tissue removed from a 60-year-old Caucasian female during a bilateral reduction mammoplasty (donor B). Pathology indicated normal breast parenchyma, bilaterally (A) and bilateral mammary hypertrophy (B). Patient history included hypertrophy of breast, obesity, lumbago, and glaucoma (A) and joint pain in the shoulder, thyroid cyst, colon cancer, normal delivery and cervical cancer (B). Family history included cataract, osteoarthritis, uterine cancer, benign hypertension, hyperlipidemia, and alcoholic cirrhosis of the liver, cerebrovascular disease, and type II diabetes (A) and cerebrovascular accident, atherosclerotic coronary artery disease, colon cancer, type II diabetes, hyperlipidemia, depressive disorder, and Alzheimer's Disease. The library was normalized in two rounds using conditions adapted from Soares et al., PNAS (1994) 91: 9228-9232 and Bonaldo et al., Genome Research 6 (1996): 791, except that a significantly longer (48 hours/round) reannealing hybridization was used. CARDNOT01 PBLUESCRIPT Library was constructed using RNA isolated from the cardiac muscle of a 65-year-old Caucasian male, who died from a gunshot wound. CARGDIT01 pINCY Library was constructed using RNA isolated from diseased cartilage tissue. Patient history included osteoarthritis. COLENOR03 PCDNA2.1 Library was constructed using RNA isolated from colon epithelium tissue removed from a 13-year-old Caucasian female who died from a motor vehicle accident. CONNNOT01 pINCY Library was constructed using RNA isolated from mesentery fat tissue obtained from a 71- year-old Caucasian male during a partial colectomy and permanent colostomy. Family history included atherosclerotic coronary artery disease, myocardial infarction, and extrinsic asthma. CONNTUT04 pINCY Library was constructed using RNA isolated from tumorous spinal tissue removed from a 35-year-old Caucasian male during an exploratory laparotomy. Pathology indicated schwannoma with degenerative changes. Patient history included anxiety, depression, neurofibromatosis and benign neoplasm of the scrotum. Previously the patient had a spinal fusion. Family history included brain cancer, liver disease, and multiple sclerosis. ENDCNOT03 pINCY Library was constructed using RNA isolated from dermal microvascular endothelial cells removed from a neonatal Caucasian male. FTUBTUR01 PCDNA2.1 This random primed library was constructed using RNA isolated from fallopian tube tumor tissue removed from an 85-year-old Caucasian female during bilateral salpingo- oophorectomy and hysterectomy. Pathology indicated poorly differentiated mixed endometrioid (80%) and serous (20%) adenocarcinoma, which was confined to the mucosa without mural involvement. Endometrioid carcinoma in situ was also present. Pathology for the associated uterus tumor indicated focal endometrioid adenocarcinoma in situ and moderately differentiated invasive adenocarcinoma arising in an endometrial polyp. Metastatic endometrioid and serous adenocarcinoma was present at the cul-de-sac tumor. Patient history included medullary carcinoma of the thyroid and myocardial infarction. GBLADIT03 pINCY Library was constructed using RNA isolated from diseased gallbladder tissue removed from a 53-year-old Caucasian female during cholecystectomy. Pathology indicated mild chronic cholecystitis and cholelithiasis with approximately 150 mixed stones ranging in size from 0.1 cm to 0.5 cm. The patient presented with abdominal pain and nausea and vomiting. Patient history included hyperlipidema and tobacco and alcohol abuse. Previous surgeries included adenotonsillectomy. Patient medications included Zantac, Provera, Premarin, and calcium. Family history included benign hypertension in the mother and the father. HNT3AZT01 pINCY Library was constructed using RNA isolated from the hNT2 cell line (derived from a human teratocarcinoma that exhibited properties characteristic of a committed neuronal precursor). Cells were treated for three days with 0.35 micromolar 5-aza-2′- deoxycytidine (AZ). KIDETXS02 pINCY This subtracted, transformed embryonal cell line library was constructed using 9 million clones from a treated, transformed embryonal cell line (293-EBNA) derived from kidney epithelial tissue and was subjected to two rounds of subtraction hybridization with 1.9 million clones from an untreated transformed embryonal cell line (293-EBNA) derived from a kidney epithelial tissue library. The starting library for subtraction was constructed using RNA isolated from the treated, transformed embryonal cell line (293-EBNA). The cells were treated with 5-aza-2′-deoxycytidine and transformed with adenovirus 5 DNA. The hybridization probe for subtraction was derived from a similarly constructed library from RNA isolated from untreated 293-EBNA cells from the same cell line. Subtractive hybridization conditions were based on the methodologies of Swaroop et al., NAR 19 (1991): 1954 and Bonaldo, et al. Genome Research (1996) 6: 791. LATRTUT02 pINCY Library was constructed using RNA isolated from a myxoma removed from the left atrium of a 43-year-old Caucasian male during annuloplasty. Pathology indicated atrial myxoma. Patient history included pulmonary insufficiency, acute myocardial infarction, atherosclerotic coronary artery disease, hyperlipidemia, and tobacco use. Family history included benign hypertension, acute myocardial infarction, atherosclerotic coronary artery disease, and type II diabetes. LSUBDMC01 PSPORT1 This large size fractionated library was constructed using RNA isolated from submandibular gland tissue removed from a 49-year-old Caucasian female during sialoadenectomy. Pathology indicated unremarkable gland. The patient presented with sialoadenitis. Patient history included vericose veins and normal delivery. Previous surgeries included cholecystectomy and total abdominal hysterectomy. Patient medications included vitamins, phentermine HCL, and Pondimin. Family history included atherosclerotic coronary artery disease and acute myocardial infarction in the mother; benign hypertension, cerebrovascular accident, atherosclerotic coronary artery disease, and hyperlipidemia in the sibling(s); and alcohol abuse and depressive disorder in the grandparent(s). LUNPTUT02 pINCY Library was constructed using RNA isolated from pleura tumor tissue removed from a 55- year-old Caucasian female during complete pneumonectomy. Pathology indicated grade 3 sarcoma most consistent with leiomyosarcoma, uterine primary, forming a bosellated mass replacing the right lower lobe and a portion of the middle lobe. The tumor involved the adjacent parietal pleura and pericardium. Multiple nodules comprising the tumor show near total necrosis. The right upper lobe was atelectic but uninvolved by tumor. Microsections of cellular nodules show brisk mitotic activity. The pericardium shows direct involvement but its margins were tumor free. Smooth muscle actin was positive. Estrogen receptor was negative and progesterone receptor was positive. Patient history included shortness of breath, peptic ulcer disease, lung cancer, uterine cancer, normal delivery, tobacco abuse, and deficiency anemia. Previous surgeries included endoscopic excision of a lung lesion. Family history included atherosclerotic coronary artery disease, breast cancer, type II diabetes, and multiple sclerosis. NERDTDN03 pINCY This normalized dorsal root ganglion tissue library was constructed from 1.05 million independent clones from a dorsal root ganglion tissue library. Starting RNA was made from dorsal root ganglion tissue removed from the cervical spine of a 32-year-old Caucasian male who died from acute pulmonary edema, acute bronchopneumonia, bilateral pleural effusions, pericardial effusion, and malignant lymphoma (natural killer cell type). The patient presented with pyrexia of unknown origin, malaise, fatigue, and gastrointestinal bleeding. Patient history included probable cytomegalovirus infection, liver congestion, and steatosis, splenomegaly, hemorrhagic cystitis, thyroid hemorrhage, respiratory failure, pneumonia of the left lung, natural killer cell lymphoma of the pharynx, Bell's palsy, and tobacco and alcohol abuse. Previous surgeries included colonoscopy, closed colon biopsy, adenotonsillectomy, and nasopharyngeal endoscopy and biopsy. Patient medications included Diflucan (fluconazole), Deltasone (prednisone), hydrocodone, Lortab, Alprazolam, Reazodone, ProMace-Cytabom, Etoposide, Cisplatin, Cytarabine, and dexamethasone. The patient received radiation therapy and multiple blood transfusions. The library was normalized in 2 rounds using conditions adapted from Soares et al., PNAS (1994) 91: 9228-9232 and Bonaldo et al., Genome Research 6 (1996): 791, except that a significantly longer (48 hours/round) reannealing hybridization was used. NEUTFMT01 PBLUESCRIPT Library was constructed using total RNA isolated from peripheral blood granulocytes collected by density gradient centrifugation through Ficoll-Hypaque. The cells were isolated from buffy coat units obtained from unrelated male and female donors. Cells were cultured in 10 nM fMLP for 30 minutes, lysed in GuSCN, and spun through CsCl to obtain RNA for library construction. Because this library was made from total RNA, it has an unusually high proportion of unique singleton sequences, which may not all come from polyA RNA species. OVARNOT09 pINCY Library was constructed using RNA isolated from ovarian tissue removed from a 28-year- old Caucasian female during a vaginal hysterectomy and removal of the fallopian tubes and ovaries. Pathology indicated multiple follicular cysts ranging in size from 0.4 to 1.5 cm in the right and left ovaries, chronic cervicitis and squamous metaplasia of the cervix, and endometrium in weakly proliferative phase. Family history included benign hypertension, hyperlipidemia, and atherosclerotic coronary artery disease. PLACFER06 pINCY This random primed library was constructed using RNA isolated from placental tissue removed from a Caucasian fetus who died after 16 weeks' gestation from fetal demise and hydrocephalus. Patient history included umbilical cord wrapped around the head (3 times) and the shoulders (1 time). Serology was positive for anti-CMV. Family history included multiple pregnancies and live births, and an abortion. PROSTUS23 pINCY This subtracted prostate tumor library was constructed using 10 million clones from a pooled prostate tumor library that was subjected to 2 rounds of subtractive hybridization with 10 million clones from a pooled prostate tissue library. The starting library for subtraction was constructed by pooling equal numbers of clones from 4 prostate tumor libraries using mRNA isolated from prostate tumor removed from Caucasian males at ages 58 (A), 61 (B), 66 (C) , and 68 (D) during prostatectomy with lymph node excision. Pathology indicated adenocarcinoma in all donors. History included elevated PSA, induration and tobacco abuse in donor A; elevated PSA, induration, prostate hyperplasia, renal failure, osteoarthritis, renal artery stenosis, benign HTN, thrombocytopenia, hyperlipidemia, tobacco/alcohol abuse and hepatitis C (carrier) in donor B; elevated PSA, induration, and tobacco abuse in donor C; and elevated PSA, induration, hypercholesterolemia, and kidney calculus in donor D. The hybridization probe for subtraction was constructed by pooling equal numbers of cDNA clones from 3 prostate tissue libraries derived from prostate tissue, prostate epithelial cells, and fibroblasts from prostate stroma from 3 different donors. Subtractive hybridization conditions were based on the methodologies of Swaroop et al., NAR 19 (1991): 1954 and Bonaldo, et al. Genome Research 6 (1996): 791. SEMVNOT01 pINCY Library was constructed using RNA isolated from seminal vesicle tissue removed from a 58-year-old Caucasian male during radical prostatectomy. Pathology for the associated tumor tissue indicated adenocarcinoma (Gleason grade 3 + 2) of the prostate. Adenofibromatous hyperplasia was also present. The patient presented with elevated prostate specific antigen (PSA). Family history included a malignant breast neoplasm. SINTFET03 pINCY Library was constructed using RNA isolated from small intestine tissue removed from a Caucasian female fetus, who died at 20 weeks' gestation. CARGDIT01 pINCY Library was constructed using RNA isolated from diseased cartilage tissue. Patient history included osteoarthritis.

[0338] TABLE 7 Program Description Reference Parameter Threshold ABI A program that removes vector sequences and Applied Biosystems, Foster City, CA. FACTURA masks ambiguous bases in nucleic acid sequences. ABI/ A Fast Data Finder useful in comparing and Applied Biosystems, Foster City, CA; Mismatch < 50% PARACEL annotating amino acid or nucleic acid sequences. Paracel Inc., Pasadena, CA. FDF ABI Auto- A program that assembles nucleic acid sequences. Applied Biosystems, Foster City, CA. Assembler BLAST A Basic Local Alignment Search Tool useful in Altschul, S. F. et al. (1990) J. Mol. Biol. ESTs: Probability value = sequence similarity search for amino acid and 215: 403-410; Altschul, S. F. et al. (1997) 1.0E−8 or less nucleic acid sequences. BLAST includes five Nucleic Acids Res. 25: 3389-3402. Full Length sequences: functions: blastp, blastn, blastx, tblastn, and tblastx. Probability value = 1.0E−10 or less FASTA A Pearson and Lipman algorithm that searches for Pearson, W. R. and D. J. Lipman (1988) Proc. ESTs: fasta E value = similarity between a query sequence and a group of Natl. Acad Sci. USA 85: 2444-2448; Pearson, 1.06E−6 Assembled ESTs: sequences of the same type. FASTA comprises as W. R. (1990) Methods Enzymol. 183: 63-98; fasta Identity = 95% or least five functions: fasta, tfasta, fastx, tfastx, and and Smith, T. F. and M. S. Waterman (1981) greater and Match length = ssearch. Adv. Appl. Math. 2: 482-489. 200 bases or greater; fastx E value = 1.0E−8 or less Full Length sequences: fastx score = 100 or greater BLIMPS A BLocks IMProved Searcher that matches a Henikoff, S. and J. G. Henikoff (1991) Nucleic Probability value = 1.0E−3 sequence against those in BLOCKS, PRINTS, Acids Res. 19: 6565-6572; Henikoff, J. G. and or less DOMO, PRODOM, and PFAM databases to search S. Henikoff (1996) Methods Enzymol. for gene families, sequence homology, and 266: 88-105; and Attwood, T. K. et al. (1997) structural fingerprint regions. J. Chem. Inf. Comput. Sci. 37: 417-424. HMMER An algorithm for searching a query sequence against Krogh, A. et al. (1994) J. Mol. Biol. PFAM hits: Probability hidden Markov model (HMM)-based databases of 235: 1501-1531; Sonnhammer, E. L. L. et al. value = 1.0E−3 or less protein family consensus sequences, such as PFAM. (1988) Nucleic Acids Res. 26: 320-322; Signal peptide hits: Score = 0 Durbin, R. et al. (1998) Our World View, in a or greater Nutshell, Cambridge Univ. Press, pp. 1-350. ProfileScan An algorithm that searches for structural and sequence Gribskov, M. et al. (1988) CABIOS 4: 61-66; Normalized quality score ≧ motifs in protein sequences that match sequence patterns Gribskov, M. et al. (1989) Methods Enzymol. GCG-specified “HIGH” value defined in Prosite. 183: 146-159; Bairoch, A. et al. (1997) for that particular Prosite Nucleic Acids Res. 25: 217-221. motif. Generally, score = 1.4-2.1. Phred A base-calling algorithm that examines automated Ewing, B. et al. (1998) Genome Res. sequencer traces with high sensitivity and probability. 8: 175-185; Ewing, B. and P. Green (1998) Genome Res. 8: 186-194. Phrap A Phils Revised Assembly Program including SWAT and Smith, T. F. and M. S. Waterman (1981) Adv. Score = 120 or greater; CrossMatch, programs based on efficient implementation Appl. Math. 2: 482-489; Smith, T. F. and M. Match length = 56 or greater of the Smith-Waterman algorithm, useful in searching S. Waterman (1981) J. Mol. Biol. 147: 195- sequence homology and assembling DNA sequences. 197; and Green, P., University of Washington, Seattle, WA. Consed A graphical tool for viewing and editing Phrap Gordon, D. et al. (1998) Genome Res. 8: assemblies. 195-202. SPScan A weight matrix analysis program that scans protein Nielson, H. et al. (1997) Protein Engineering Score = 3.5 or greater sequences for the presence of secretory signal peptides. 10: 1-6; Claverie, J. M. and S. Audic (1997) CABIOS 12: 431-439. TMAP A program that uses weight matrices to delineate Persson, B. and P. Argos (1994) J. Mol. Biol. transmembrane segments on protein sequences and 237: 182-192; Persson, B. and P. Argos (1996) determine orientation. Protein Sci. 5: 363-371. TMHMMER A program that uses a hidden Markov model (HMM) to Sonnhammer, E. L. et al. (1998) Proc. Sixth delineate transmembrane segments on protein sequences Intl. Conf. on Intelligent Systems for Mol. and determine orientation. Biol., Glasgow et al., eds., The Am. Assoc. for Artificial Intelligence Press, Menlo Park, CA, pp. 175-182. Motifs A program that searches amino acid sequences for Bairoch, A. et al. (1997) Nucleic Acids Res. patterns that matched those defined in Prosite. 25: 217-221; Wisconsin Package Program Manual, version 9, page M51-59, Genetics Computer Group, Madison, WI.

[0339]

1 72 1 234 PRT Homo sapiens misc_feature Incyte ID No 1888682CD1 1 Met Pro Ser Gly Cys His Ser Ser Pro Pro Ser Gly Leu Arg Gly 1 5 10 15 Asp Met Ala Ser Leu Val Pro Leu Ser Pro Tyr Leu Ser Pro Thr 20 25 30 Val Leu Leu Leu Val Ser Cys Asp Leu Gly Phe Val Arg Ala Asp 35 40 45 Arg Pro Pro Ser Pro Val Asn Val Thr Val Thr His Leu Arg Ala 50 55 60 Asn Ser Ala Thr Val Ser Trp Asp Val Pro Glu Gly Asn Ile Val 65 70 75 Ile Gly Tyr Ser Ile Ser Gln Gln Arg Gln Asn Gly Pro Gly Gln 80 85 90 Arg Val Ile Arg Glu Val Asn Thr Thr Thr Arg Ala Cys Ala Leu 95 100 105 Trp Gly Leu Ala Glu Asp Ser Asp Tyr Thr Val Gln Val Arg Ser 110 115 120 Ile Gly Leu Arg Gly Glu Ser Pro Pro Gly Pro Arg Val His Phe 125 130 135 Arg Thr Leu Lys Gly Ser Asp Arg Leu Pro Ser Asn Ser Ser Ser 140 145 150 Pro Gly Asp Ile Thr Val Glu Gly Leu Asp Gly Glu Arg Pro Leu 155 160 165 Gln Thr Gly Glu Val Val Ile Ile Val Val Val Leu Leu Met Trp 170 175 180 Ala Ala Val Ile Gly Leu Phe Cys Arg Gln Tyr Asp Ile Ile Lys 185 190 195 Asp Asn Asp Ser Asn Asn Asn Pro Lys Glu Lys Gly Lys Gly Pro 200 205 210 Glu Gln Ser Pro Gln Gly Arg Pro Val Gly Thr Arg Gln Lys Lys 215 220 225 Ser Pro Ser Ile Asn Thr Ile Asp Val 230 2 443 PRT Homo sapiens misc_feature Incyte ID No 1794980CD1 2 Met Gly Gly Pro Arg Ala Trp Ala Leu Leu Cys Leu Gly Leu Leu 1 5 10 15 Leu Pro Gly Gly Gly Ala Ala Trp Ser Ile Gly Ala Ala Pro Phe 20 25 30 Ser Gly Arg Arg Asn Trp Cys Ser Tyr Val Val Thr Arg Thr Ile 35 40 45 Ser Cys His Val Gln Asn Gly Thr Tyr Leu Gln Arg Val Leu Gln 50 55 60 Asn Cys Pro Trp Pro Met Ser Cys Pro Gly Ser Ser Tyr Arg Thr 65 70 75 Val Val Arg Pro Thr Tyr Lys Val Met Tyr Lys Ile Val Thr Ala 80 85 90 Arg Glu Trp Arg Cys Cys Pro Gly His Ser Gly Val Ser Cys Glu 95 100 105 Glu Val Ala Ala Ser Ser Ala Ser Leu Glu Pro Met Trp Ser Gly 110 115 120 Ser Thr Met Arg Arg Met Ala Leu Arg Pro Thr Ala Phe Ser Gly 125 130 135 Cys Leu Asn Cys Ser Lys Val Ser Glu Leu Thr Glu Arg Leu Lys 140 145 150 Val Leu Glu Ala Lys Met Thr Met Leu Thr Val Ile Glu Gln Pro 155 160 165 Val Pro Pro Thr Pro Ala Thr Pro Glu Asp Pro Ala Pro Leu Trp 170 175 180 Gly Pro Pro Pro Ala Gln Gly Ser Pro Gly Asp Gly Gly Leu Gln 185 190 195 Asp Gln Val Gly Ala Trp Gly Leu Pro Gly Pro Thr Gly Pro Lys 200 205 210 Gly Asp Ala Gly Ser Arg Gly Pro Met Gly Met Arg Gly Pro Pro 215 220 225 Gly Pro Gln Gly Pro Pro Gly Ser Pro Gly Arg Ala Gly Ala Val 230 235 240 Gly Thr Pro Gly Glu Arg Gly Pro Pro Gly Pro Pro Gly Pro Pro 245 250 255 Gly Pro Pro Gly Pro Pro Ala Pro Val Gly Pro Pro His Ala Arg 260 265 270 Ile Ser Gln His Gly Asp Pro Leu Leu Ser Asn Thr Phe Thr Glu 275 280 285 Thr Asn Asn His Trp Pro Gln Gly Pro Thr Gly Pro Pro Gly Pro 290 295 300 Pro Gly Pro Met Gly Pro Pro Gly Pro Pro Gly Pro Thr Gly Val 305 310 315 Pro Gly Ser Pro Gly His Ile Gly Pro Pro Gly Pro Thr Gly Pro 320 325 330 Lys Gly Ile Ser Gly His Pro Gly Glu Lys Gly Glu Arg Gly Leu 335 340 345 Arg Gly Glu Pro Gly Pro Gln Gly Ser Ala Gly Gln Arg Gly Glu 350 355 360 Pro Gly Pro Lys Gly Asp Pro Gly Glu Lys Ser His Trp Gly Glu 365 370 375 Gly Leu His Gln Leu Arg Glu Ala Leu Lys Ile Leu Ala Glu Arg 380 385 390 Val Leu Ile Leu Glu Thr Met Ile Gly Leu Tyr Glu Pro Glu Leu 395 400 405 Gly Ser Gly Ala Gly Pro Ala Gly Thr Gly Thr Pro Ser Leu Leu 410 415 420 Arg Gly Lys Arg Gly Gly His Ala Thr Asn Tyr Arg Ile Val Ala 425 430 435 Pro Arg Ser Arg Asp Glu Arg Gly 440 3 261 PRT Homo sapiens misc_feature Incyte ID No 5533958CD1 3 Met Gly Gly Ala Gly Ile Leu Leu Leu Leu Leu Ala Gly Ala Gly 1 5 10 15 Val Val Val Ala Trp Arg Pro Pro Lys Gly Lys Cys Pro Leu Arg 20 25 30 Cys Ser Cys Ser Lys Asp Ser Ala Leu Cys Glu Gly Ser Pro Asp 35 40 45 Leu Pro Val Ser Phe Ser Pro Thr Leu Leu Ser Leu Ser Leu Val 50 55 60 Arg Thr Gly Val Thr Gln Leu Lys Ala Gly Ser Phe Leu Arg Ile 65 70 75 Pro Ser Leu His Leu Leu Leu Phe Thr Ser Asn Ser Phe Ser Val 80 85 90 Ile Glu Asp Asp Ala Phe Ala Gly Leu Ser His Leu Gln Tyr Leu 95 100 105 Phe Ile Glu Asp Asn Glu Ile Gly Ser Ile Ser Lys Asn Ala Leu 110 115 120 Arg Gly Leu Arg Ser Leu Thr His Leu Ser Leu Ala Asn Asn His 125 130 135 Leu Glu Thr Leu Pro Arg Phe Leu Phe Arg Gly Leu Asp Thr Leu 140 145 150 Thr His Val Asp Leu Arg Gly Asn Pro Phe Gln Cys Asp Cys Arg 155 160 165 Val Leu Trp Leu Leu Gln Trp Met Pro Thr Val Asn Ala Ser Val 170 175 180 Gly Thr Gly Ala Cys Ala Gly Pro Ala Ser Leu Ser His Met Gln 185 190 195 Leu His His Leu Asp Pro Lys Thr Phe Lys Cys Arg Ala Ile Gly 200 205 210 Gly Gly Leu Ser Arg Trp Gly Gly Arg Arg Glu Ile Trp Gly Lys 215 220 225 Gly Cys Gln Gly Gln Glu Ala Arg Leu Thr Pro Cys Pro Ala Ile 230 235 240 Ser Arg Ser Gly Lys Thr Leu Ser Lys Gln His Cys Leu Pro Glu 245 250 255 Pro Gln Phe Ser His Leu 260 4 643 PRT Homo sapiens misc_feature Incyte ID No 60210196CD1 4 Met Glu Pro Val Pro Leu Gln Asp Phe Val Arg Ala Leu Asp Pro 1 5 10 15 Ala Ser Leu Pro Arg Val Leu Arg Val Cys Ser Gly Val Tyr Phe 20 25 30 Glu Gly Ser Ile Tyr Glu Ile Ser Gly Asn Glu Cys Cys Leu Ser 35 40 45 Thr Gly Asp Leu Ile Lys Val Thr Gln Val Arg Leu Gln Lys Val 50 55 60 Val Cys Glu Asn Pro Lys Thr Ser Gln Thr Met Glu Leu Ala Pro 65 70 75 Asn Phe Gln Gly Tyr Phe Thr Pro Leu Asn Thr Pro Gln Ser Tyr 80 85 90 Glu Thr Leu Glu Glu Leu Val Ser Ala Thr Thr Gln Ser Ser Lys 95 100 105 Gln Leu Pro Thr Cys Phe Met Ser Thr His Arg Ile Val Thr Glu 110 115 120 Gly Arg Val Val Thr Glu Asp Gln Leu Leu Met Leu Glu Ala Val 125 130 135 Val Met His Leu Gly Ile Arg Ser Ala Arg Cys Val Leu Gly Met 140 145 150 Glu Gly Gln Gln Val Ile Leu His Leu Pro Leu Ser Gln Lys Gly 155 160 165 Pro Phe Trp Thr Trp Glu Pro Ser Ala Pro Arg Thr Leu Leu Gln 170 175 180 Val Leu Gln Asp Pro Ala Leu Lys Asp Leu Val Leu Thr Cys Pro 185 190 195 Thr Leu Pro Trp His Ser Leu Ile Leu Arg Pro Gln Tyr Glu Ile 200 205 210 Gln Ala Ile Met His Met Arg Arg Thr Ile Val Lys Ile Pro Ser 215 220 225 Thr Leu Glu Val Asp Val Glu Asp Val Thr Ala Ser Ser Arg His 230 235 240 Val His Phe Ile Lys Pro Leu Leu Leu Ser Glu Val Leu Ala Trp 245 250 255 Glu Gly Pro Phe Pro Leu Ser Met Glu Ile Leu Glu Val Pro Glu 260 265 270 Gly Arg Pro Ile Phe Leu Ser Pro Trp Val Gly Ser Leu Gln Lys 275 280 285 Gly Gln Arg Leu Cys Val Tyr Gly Leu Ala Ser Pro Pro Trp Arg 290 295 300 Val Leu Ala Ser Ser Lys Gly Arg Lys Val Pro Arg His Phe Leu 305 310 315 Val Ser Gly Gly Tyr Gln Gly Lys Leu Arg Arg Arg Pro Arg Glu 320 325 330 Phe Pro Thr Ala Tyr Asp Leu Leu Gly Ala Phe Gln Pro Gly Arg 335 340 345 Pro Leu Arg Val Val Ala Thr Lys Asp Cys Glu Gly Glu Arg Glu 350 355 360 Glu Asn Pro Glu Phe Thr Ser Leu Ala Val Gly Asp Arg Leu Glu 365 370 375 Val Leu Gly Pro Gly Gln Ala His Gly Ala Gln Gly Ser Asp Val 380 385 390 Asp Val Leu Val Cys Gln Arg Leu Ser Asp Gln Ala Gly Glu Asp 395 400 405 Glu Glu Glu Glu Cys Lys Glu Glu Ala Glu Ser Pro Glu Arg Val 410 415 420 Leu Leu Pro Phe His Phe Pro Gly Ser Phe Val Glu Glu Met Ser 425 430 435 Asp Ser Arg Arg Tyr Ser Leu Ala Asp Leu Thr Ala Gln Phe Ser 440 445 450 Leu Pro Cys Glu Val Lys Val Val Ala Lys Asp Thr Ser His Pro 455 460 465 Thr Asp Pro Leu Thr Ser Phe Leu Gly Leu Arg Leu Glu Glu Lys 470 475 480 Ile Thr Glu Pro Phe Leu Val Val Ser Leu Asp Ser Glu Pro Gly 485 490 495 Met Cys Phe Glu Ile Pro Pro Arg Trp Leu Asp Leu Thr Val Val 500 505 510 Lys Ala Lys Gly Gln Pro Asp Leu Pro Glu Gly Ser Leu Pro Ile 515 520 525 Ala Thr Val Glu Glu Leu Thr Asp Thr Phe Tyr Tyr Arg Leu Arg 530 535 540 Lys Leu Pro Ala Cys Glu Ile Gln Ala Pro Pro Pro Arg Pro Pro 545 550 555 Lys Asn Gln Gly Leu Ser Lys Gln Arg Arg His Ser Ser Glu Gly 560 565 570 Gly Val Lys Ser Ser Gln Val Leu Gly Leu Gln Gln His Ala Arg 575 580 585 Leu Pro Lys Pro Lys Ala Lys Thr Leu Pro Glu Phe Ile Lys Asp 590 595 600 Gly Ser Ser Thr Tyr Ser Lys Ile Pro Ala His Arg Lys Gly His 605 610 615 Arg Pro Ala Lys Pro Gln Arg Gln Asp Leu Asp Asp Asp Glu His 620 625 630 Asp Tyr Glu Glu Ile Leu Glu Gln Phe Gln Lys Thr Ile 635 640 5 628 PRT Homo sapiens misc_feature Incyte ID No 815125CD1 5 Met Gly Ser Cys Ala Arg Leu Leu Leu Leu Trp Gly Cys Thr Val 1 5 10 15 Val Ala Ala Gly Leu Ser Gly Val Ala Gly Val Ser Ser Arg Cys 20 25 30 Glu Lys Ala Cys Asn Pro Arg Met Gly Asn Leu Ala Leu Gly Arg 35 40 45 Lys Leu Trp Ala Asp Thr Thr Cys Gly Gln Asn Ala Thr Glu Leu 50 55 60 Tyr Cys Phe Tyr Ser Glu Asn Thr Asp Leu Thr Cys Arg Gln Pro 65 70 75 Lys Cys Asp Lys Cys Asn Ala Ala Tyr Pro His Leu Ala His Leu 80 85 90 Pro Ser Ala Met Ala Asp Ser Ser Phe Arg Phe Pro Arg Thr Trp 95 100 105 Trp Gln Ser Ala Glu Asp Val His Arg Glu Lys Val Gln Leu Asp 110 115 120 Leu Glu Ala Glu Phe Tyr Phe Thr His Leu Ile Val Met Phe Lys 125 130 135 Ser Pro Arg Pro Ala Ala Met Val Leu Asp Arg Ser Gln Asp Phe 140 145 150 Gly Lys Thr Trp Lys Pro Tyr Lys Tyr Phe Ala Thr Asn Cys Ser 155 160 165 Ala Thr Phe Gly Leu Glu Asp Asp Val Val Lys Lys Gly Ala Ile 170 175 180 Cys Thr Ser Lys Tyr Ser Ser Pro Phe Pro Cys Thr Gly Gly Glu 185 190 195 Val Ile Phe Lys Ala Leu Ser Pro Pro Tyr Asp Thr Glu Asn Pro 200 205 210 Tyr Ser Ala Lys Val Gln Glu Gln Leu Lys Ile Thr Asn Leu Arg 215 220 225 Val Gln Leu Leu Lys Arg Gln Ser Cys Pro Cys Gln Arg Asn Asp 230 235 240 Leu Asn Glu Glu Pro Gln His Phe Thr His Tyr Ala Ile Tyr Asp 245 250 255 Phe Ile Val Lys Gly Ser Cys Phe Cys Asn Gly His Ala Asp Gln 260 265 270 Cys Ile Pro Val His Gly Phe Arg Pro Val Lys Ala Pro Gly Thr 275 280 285 Phe His Met Val His Gly Lys Cys Met Cys Lys His Asn Thr Ala 290 295 300 Gly Ser His Cys Gln His Cys Ala Pro Leu Tyr Asn Asp Arg Pro 305 310 315 Trp Glu Ala Ala Asp Gly Lys Thr Gly Ala Pro Asn Glu Cys Arg 320 325 330 Thr Cys Lys Cys Asn Gly His Ala Asp Thr Cys His Phe Asp Val 335 340 345 Asn Val Trp Glu Ala Ser Gly Asn Arg Ser Gly Gly Val Cys Asp 350 355 360 Asp Cys Gln His Asn Thr Glu Gly Gln Tyr Cys Gln Arg Cys Lys 365 370 375 Pro Gly Phe Tyr Arg Asp Leu Arg Arg Pro Phe Ser Ala Pro Asp 380 385 390 Ala Cys Lys Pro Cys Ser Cys His Pro Val Gly Ser Ala Val Leu 395 400 405 Pro Ala Asn Ser Val Thr Phe Cys Asp Pro Ser Asn Gly Asp Cys 410 415 420 Pro Cys Lys Pro Gly Val Ala Gly Arg Arg Cys Asp Arg Cys Met 425 430 435 Val Gly Tyr Trp Gly Phe Gly Asp Tyr Gly Cys Arg Pro Cys Asp 440 445 450 Cys Ala Gly Ser Cys Asp Pro Ile Thr Gly Asp Cys Ile Ser Ser 455 460 465 His Thr Asp Ile Asp Trp Tyr His Glu Val Pro Asp Phe Arg Pro 470 475 480 Val His Asn Lys Ser Glu Pro Ala Trp Glu Trp Glu Asp Ala Gln 485 490 495 Gly Phe Ser Ala Leu Leu His Ser Gly Lys Cys Glu Cys Lys Glu 500 505 510 Gln Thr Leu Gly Asn Ala Lys Ala Phe Cys Gly Met Lys Tyr Ser 515 520 525 Tyr Val Leu Lys Ile Lys Ile Leu Ser Ala His Asp Lys Gly Thr 530 535 540 His Val Glu Val Asn Val Lys Ile Lys Lys Val Leu Lys Ser Thr 545 550 555 Lys Leu Lys Ile Phe Arg Gly Lys Arg Thr Leu Tyr Pro Glu Ser 560 565 570 Trp Thr Asp Arg Gly Cys Thr Cys Pro Ile Leu Asn Pro Gly Leu 575 580 585 Glu Tyr Leu Val Ala Gly His Glu Asp Ile Arg Thr Gly Lys Leu 590 595 600 Ile Val Asn Met Lys Ser Phe Val Gln His Trp Lys Pro Ser Leu 605 610 615 Gly Arg Lys Val Met Asp Ile Leu Lys Arg Glu Cys Lys 620 625 6 686 PRT Homo sapiens misc_feature Incyte ID No 1386915CD1 6 Met Leu Leu Arg Gly Val Leu Leu Ala Leu Gln Ala Leu Gln Leu 1 5 10 15 Ala Gly Ala Leu Asp Leu Pro Ala Gly Ser Cys Ala Phe Glu Glu 20 25 30 Ser Thr Cys Gly Phe Asp Ser Val Leu Ala Ser Leu Pro Trp Ile 35 40 45 Leu Asn Glu Glu Gly His Tyr Ile Tyr Val Asp Thr Ser Phe Gly 50 55 60 Lys Gln Gly Glu Lys Ala Val Leu Leu Ser Pro Asp Leu Gln Ala 65 70 75 Glu Glu Trp Ser Cys Leu Arg Leu Val Tyr Gln Ile Thr Thr Ser 80 85 90 Ser Glu Ser Leu Ser Asp Pro Ser Gln Leu Asn Leu Tyr Met Arg 95 100 105 Phe Glu Asp Glu Ser Phe Asp Arg Leu Leu Trp Ser Ala Lys Glu 110 115 120 Pro Ser Asp Ser Trp Leu Ile Ala Ser Leu Asp Leu Gln Asn Ser 125 130 135 Ser Lys Lys Phe Lys Ile Leu Ile Glu Gly Val Leu Gly Gln Gly 140 145 150 Asn Thr Ala Ser Ile Ala Leu Phe Glu Ile Lys Met Thr Thr Gly 155 160 165 Tyr Cys Ile Glu Cys Asp Phe Glu Glu Asn His Leu Cys Gly Phe 170 175 180 Val Asn Arg Trp Asn Pro Asn Val Asn Trp Phe Val Gly Gly Gly 185 190 195 Ser Ile Arg Asn Val His Ser Ile Leu Pro Gln Asp His Thr Phe 200 205 210 Lys Ser Glu Leu Gly His Tyr Met Tyr Val Asp Ser Val Tyr Val 215 220 225 Lys His Phe Gln Glu Val Ala Gln Leu Ile Ser Pro Leu Thr Thr 230 235 240 Ala Pro Met Ala Gly Cys Leu Ser Phe Tyr Tyr Gln Ile Gln Gln 245 250 255 Gly Asn Asp Asn Val Phe Ser Leu Tyr Thr Arg Asp Val Ala Gly 260 265 270 Leu Tyr Glu Glu Ile Trp Lys Ala Asp Arg Pro Gly Asn Ala Ala 275 280 285 Trp Asn Leu Ala Glu Val Glu Phe Asn Ala Pro Tyr Pro Met Glu 290 295 300 Val Ile Phe Glu Val Ala Phe Asn Gly Pro Lys Gly Gly Tyr Val 305 310 315 Ala Leu Asp Asp Ile Ser Phe Ser Pro Val His Cys Gln Asn Gln 320 325 330 Thr Glu Leu Leu Phe Ser Ala Val Glu Ala Ser Cys Asn Phe Glu 335 340 345 Gln Asp Leu Cys Asn Phe Tyr Gln Asp Lys Glu Gly Pro Gly Trp 350 355 360 Thr Arg Val Lys Val Lys Pro Asn Met Tyr Arg Ala Gly Asp His 365 370 375 Thr Thr Gly Leu Gly Tyr Tyr Leu Leu Ala Asn Thr Lys Phe Thr 380 385 390 Ser Gln Pro Gly Tyr Ile Gly Arg Leu Tyr Gly Pro Ser Leu Pro 395 400 405 Gly Asn Leu Gln Tyr Cys Leu Arg Phe His Tyr Ala Ile Tyr Gly 410 415 420 Phe Leu Lys Met Ser Asp Thr Leu Ala Val Tyr Ile Phe Glu Glu 425 430 435 Asn His Val Val Gln Glu Lys Ile Trp Ser Val Leu Glu Ser Pro 440 445 450 Arg Gly Val Trp Met Gln Ala Glu Ile Thr Phe Lys Lys Pro Met 455 460 465 Pro Thr Lys Val Val Phe Met Ser Leu Cys Lys Ser Phe Trp Asp 470 475 480 Cys Gly Leu Val Ala Leu Asp Asp Ile Thr Ile Gln Leu Gly Ser 485 490 495 Cys Ser Ser Ser Glu Lys Leu Pro Pro Pro Pro Gly Glu Cys Thr 500 505 510 Phe Glu Gln Asp Glu Cys Thr Phe Thr Gln Glu Lys Arg Asn Arg 515 520 525 Ser Ser Trp His Arg Arg Arg Gly Glu Thr Pro Thr Ser Tyr Thr 530 535 540 Gly Pro Lys Gly Asp His Thr Thr Gly Val Gly Tyr Tyr Met Tyr 545 550 555 Ile Glu Ala Ser His Met Val Tyr Gly Gln Lys Ala Arg Leu Leu 560 565 570 Ser Arg Pro Leu Arg Gly Val Ser Gly Lys His Cys Leu Thr Phe 575 580 585 Phe Tyr His Met Tyr Gly Gly Gly Thr Gly Leu Leu Ser Val Tyr 590 595 600 Leu Lys Lys Glu Glu Asp Ser Glu Glu Ser Leu Leu Trp Arg Arg 605 610 615 Arg Gly Glu Gln Ser Ile Ser Trp Leu Arg Ala Leu Ile Glu Tyr 620 625 630 Ser Cys Glu Arg Gln His Gln Ile Ile Phe Glu Ala Ile Arg Gly 635 640 645 Val Ser Ile Arg Ser Asp Ile Ala Ile Asp Asp Val Lys Phe Gln 650 655 660 Ala Gly Pro Cys Gly Glu Met Glu Asp Thr Thr Gln Gln Ser Ser 665 670 675 Gly Tyr Ser Glu Asp Leu Asn Glu Ile Glu Tyr 680 685 7 296 PRT Homo sapiens misc_feature Incyte ID No 1344495CD1 7 Met Arg His Glu Glu Leu Leu Thr Lys Thr Phe Gln Gly Pro Ala 1 5 10 15 Val Val Cys Gly Thr Pro Thr Ser His Val Tyr Met Phe Lys Asn 20 25 30 Gly Ser Gly Asp Ser Gly Asp Ser Ser Glu Glu Glu Ser His Arg 35 40 45 Val Val Leu Arg Pro Arg Gly Lys Glu Arg His Lys Ser Gly Val 50 55 60 His Gln Pro Pro Gln Ala Gly Ala Gly Asp Val Val Leu Leu Gln 65 70 75 Arg Glu Leu Ala Gln Glu Asp Ser Leu Asn Lys Leu Ala Leu Gln 80 85 90 Tyr Gly Cys Lys Val Ala Asp Ile Lys Lys Val Asn Asn Phe Ile 95 100 105 Arg Glu Gln Asp Leu Tyr Ala Leu Lys Ser Val Lys Ile Pro Val 110 115 120 Arg Asn His Gly Ile Leu Met Glu Thr His Lys Glu Leu Lys Pro 125 130 135 Leu Leu Ser Pro Ser Ser Glu Thr Thr Val Thr Val Glu Leu Pro 140 145 150 Glu Ala Asp Arg Ala Gly Ala Gly Thr Gly Ala Gln Ala Gly Gln 155 160 165 Leu Met Gly Phe Phe Lys Gly Ile Asp Gln Asp Ile Glu Arg Ala 170 175 180 Val Gln Ser Glu Ile Phe Leu His Glu Ser Tyr Cys Met Asp Thr 185 190 195 Ser His Gln Pro Leu Leu Pro Ala Pro Pro Lys Thr Pro Met Asp 200 205 210 Gly Ala Asp Cys Gly Ile Gln Trp Trp Asn Ala Val Phe Ile Met 215 220 225 Leu Leu Ile Gly Ile Val Leu Pro Val Phe Tyr Leu Val Tyr Phe 230 235 240 Lys Ile Gln Ala Ser Gly Glu Thr Pro Asn Ser Leu Asn Thr Thr 245 250 255 Val Ile Pro Asn Gly Ser Met Ala Met Gly Thr Val Pro Gly Gln 260 265 270 Ala Pro Arg Leu Ala Val Ala Val Pro Ala Val Thr Ser Ala Asp 275 280 285 Ser Gln Phe Ser Gln Thr Thr Gln Ala Gly Ser 290 295 8 575 PRT Homo sapiens misc_feature Incyte ID No 1485774CD1 8 Met Ala Lys Pro Phe Phe Arg Leu Gln Lys Phe Leu Arg Arg Thr 1 5 10 15 Gln Phe Leu Leu Phe Phe Leu Thr Ala Ala Tyr Leu Met Thr Gly 20 25 30 Ser Leu Leu Leu Leu Gln Arg Val Arg Val Ala Leu Pro Gln Gly 35 40 45 Pro Arg Ala Pro Gly Pro Leu Gln Thr Leu Pro Val Ala Ala Val 50 55 60 Ala Leu Gly Val Gly Leu Leu Asp Ser Arg Ala Leu His Asp Pro 65 70 75 Arg Val Ser Pro Glu Leu Leu Leu Gly Val Asp Met Leu Gln Ser 80 85 90 Pro Leu Thr Arg Pro Arg Pro Gly Pro Arg Trp Leu Arg Ser Arg 95 100 105 Asn Ser Glu Leu Arg Gln Leu Arg Arg Arg Trp Phe His His Phe 110 115 120 Met Ser Asp Ser Gln Gly Pro Pro Ala Leu Gly Pro Glu Ala Ala 125 130 135 Arg Pro Ala Ile His Ser Arg Gly Thr Tyr Ile Gly Cys Phe Ser 140 145 150 Asp Asp Gly His Glu Arg Thr Leu Lys Gly Ala Val Phe Tyr Asp 155 160 165 Leu Arg Lys Met Thr Val Ser His Cys Gln Asp Ala Cys Ala Glu 170 175 180 Arg Ser Tyr Val Tyr Ala Gly Leu Glu Ala Gly Ala Glu Cys Tyr 185 190 195 Cys Gly Asn Arg Leu Pro Ala Val Ser Val Gly Leu Glu Glu Cys 200 205 210 Asn His Glu Cys Lys Gly Glu Lys Gly Ser Val Cys Gly Ala Val 215 220 225 Asp Arg Leu Ser Val Tyr Arg Val Asp Glu Leu Gln Pro Gly Ser 230 235 240 Arg Lys Arg Arg Thr Ala Thr Tyr Arg Gly Cys Phe Arg Leu Pro 245 250 255 Glu Asn Ile Thr His Ala Phe Pro Ser Ser Leu Ile Gln Ala Asn 260 265 270 Val Thr Val Gly Thr Cys Ser Gly Phe Cys Ser Gln Lys Glu Phe 275 280 285 Pro Leu Ala Ile Leu Arg Gly Trp Glu Cys Tyr Cys Ala Tyr Pro 290 295 300 Thr Pro Arg Phe Asn Leu Arg Asp Ala Met Asp Ser Ser Val Cys 305 310 315 Gly Gln Asp Pro Glu Ala Gln Arg Leu Ala Glu Tyr Cys Glu Val 320 325 330 Tyr Gln Thr Pro Val Gln Asp Thr Arg Cys Thr Asp Arg Arg Phe 335 340 345 Leu Pro Asn Lys Ser Lys Val Phe Val Ala Leu Ser Ser Phe Pro 350 355 360 Gly Ala Gly Asn Thr Trp Ala Arg His Leu Ile Glu His Ala Thr 365 370 375 Gly Phe Tyr Thr Gly Ser Tyr Tyr Phe Asp Gly Thr Leu Tyr Asn 380 385 390 Lys Gly Phe Lys Gly Glu Lys Asp His Trp Arg Ser Arg Arg Thr 395 400 405 Ile Cys Val Lys Thr His Glu Ser Gly Arg Arg Glu Ile Glu Met 410 415 420 Ser Asp Ser Ala Ile Leu Leu Ile Arg Asn Pro Tyr Arg Ser Leu 425 430 435 Val Ala Glu Phe Asn Arg Lys Cys Ala Gly His Leu Gly Tyr Ala 440 445 450 Ala Asp Arg Asn Trp Lys Ser Lys Glu Trp Pro Asp Phe Val Asn 455 460 465 Ser Tyr Ala Ser Trp Trp Ser Ser His Val Leu Asp Trp Leu Lys 470 475 480 Tyr Gly Lys Arg Leu Leu Val Val His Tyr Glu Glu Leu Arg Arg 485 490 495 Ser Leu Val Pro Thr Leu Arg Glu Met Val Ala Phe Leu Asn Val 500 505 510 Ser Val Ser Glu Glu Arg Leu Leu Cys Val Glu Asn Asn Lys Glu 515 520 525 Gly Ser Phe Arg Arg Arg Gly Arg Arg Ser His Asp Pro Glu Pro 530 535 540 Phe Thr Pro Glu Met Lys Asp Leu Ile Asn Gly Tyr Ile Arg Thr 545 550 555 Val Asp Gln Ala Leu Arg Asp His Asn Trp Thr Gly Leu Pro Arg 560 565 570 Glu Tyr Val Pro Arg 575 9 592 PRT Homo sapiens misc_feature Incyte ID No 7289372CD1 9 Met Phe Pro Leu Arg Ala Leu Trp Leu Val Trp Ala Leu Leu Gly 1 5 10 15 Val Ala Gly Ser Cys Pro Glu Pro Cys Ala Cys Val Asp Lys Tyr 20 25 30 Ala His Gln Phe Ala Asp Cys Ala Tyr Lys Glu Leu Arg Glu Val 35 40 45 Pro Glu Gly Leu Pro Ala Asn Val Thr Thr Leu Ser Leu Ser Ala 50 55 60 Asn Lys Ile Thr Val Leu Arg Arg Gly Ala Phe Ala Asp Val Thr 65 70 75 Gln Val Thr Ser Leu Trp Leu Ala His Asn Glu Val Arg Thr Val 80 85 90 Glu Pro Gly Ala Leu Ala Val Leu Ser Gln Leu Lys Asn Leu Asp 95 100 105 Leu Ser His Asn Phe Ile Ser Ser Phe Pro Trp Ser Asp Leu Arg 110 115 120 Asn Leu Ser Ala Leu Gln Leu Leu Lys Met Asn His Asn Arg Leu 125 130 135 Gly Ser Leu Pro Arg Asp Ala Leu Gly Ala Leu Pro Asp Leu Arg 140 145 150 Ser Leu Arg Ile Asn Asn Asn Arg Leu Arg Thr Leu Ala Pro Gly 155 160 165 Thr Phe Asp Ala Leu Ser Ala Leu Ser His Leu Gln Leu Tyr His 170 175 180 Asn Pro Phe His Cys Gly Cys Gly Leu Val Trp Leu Gln Ala Trp 185 190 195 Ala Ala Ser Thr Arg Val Ser Leu Pro Glu Pro Asp Ser Ile Ala 200 205 210 Cys Ala Ser Pro Pro Ala Leu Gln Gly Val Pro Val Tyr Arg Leu 215 220 225 Pro Ala Leu Pro Cys Ala Pro Pro Ser Val His Leu Ser Ala Glu 230 235 240 Pro Pro Leu Glu Ala Pro Gly Thr Pro Leu Arg Ala Gly Leu Ala 245 250 255 Phe Val Leu His Cys Ile Ala Asp Gly His Pro Thr Pro Arg Leu 260 265 270 Gln Trp Gln Leu Gln Ile Pro Gly Gly Thr Val Val Leu Glu Pro 275 280 285 Pro Val Leu Ser Gly Glu Asp Asp Gly Val Gly Ala Glu Glu Gly 290 295 300 Glu Gly Glu Gly Asp Gly Asp Leu Leu Thr Gln Thr Gln Ala Gln 305 310 315 Thr Pro Thr Pro Ala Pro Ala Trp Pro Ala Pro Pro Ala Thr Pro 320 325 330 Arg Phe Leu Ala Leu Ala Asn Gly Ser Leu Leu Val Pro Leu Leu 335 340 345 Ser Ala Lys Glu Ala Gly Val Tyr Thr Cys Arg Ala His Asn Glu 350 355 360 Leu Gly Ala Asn Ser Thr Ser Ile Arg Val Ala Val Ala Ala Thr 365 370 375 Gly Pro Pro Lys His Ala Pro Gly Ala Gly Gly Glu Pro Asp Gly 380 385 390 Gln Ala Pro Thr Ser Glu Arg Lys Ser Thr Ala Lys Gly Arg Gly 395 400 405 Asn Ser Val Leu Pro Ser Lys Pro Glu Gly Lys Ile Lys Gly Gln 410 415 420 Gly Leu Ala Lys Val Ser Ile Leu Gly Glu Thr Glu Thr Glu Pro 425 430 435 Glu Glu Asp Thr Ser Glu Gly Glu Glu Ala Glu Asp Gln Ile Leu 440 445 450 Ala Asp Pro Ala Glu Glu Gln Arg Cys Gly Asn Gly Asp Pro Ser 455 460 465 Arg Tyr Val Ser Asn His Ala Phe Asn Gln Ser Ala Glu Leu Lys 470 475 480 Pro His Val Phe Glu Leu Gly Val Ile Ala Leu Asp Val Ala Glu 485 490 495 Arg Glu Ala Arg Val Gln Leu Thr Pro Leu Ala Ala Arg Trp Gly 500 505 510 Pro Gly Pro Gly Gly Ala Gly Gly Ala Pro Arg Pro Gly Arg Arg 515 520 525 Pro Leu Arg Leu Leu Tyr Leu Cys Pro Ala Gly Gly Gly Ala Ala 530 535 540 Val Gln Trp Ser Arg Val Glu Glu Gly Val Asn Ala Tyr Trp Phe 545 550 555 Arg Gly Leu Arg Pro Gly Thr Asn Tyr Ser Val Cys Leu Ala Leu 560 565 570 Ala Gly Glu Ala Cys His Val Gln Val Val Phe Pro Pro Arg Arg 575 580 585 Ser Ser His Arg Cys Trp Ser 590 10 255 PRT Homo sapiens misc_feature Incyte ID No 1672338CD1 10 Met Ala Leu Pro Ala Leu Gly Leu Asp Pro Trp Ser Leu Leu Gly 1 5 10 15 Leu Phe Leu Phe Gln Leu Leu Gln Leu Leu Leu Pro Thr Thr Thr 20 25 30 Ala Gly Gly Gly Gly Gln Gly Pro Met Pro Arg Val Arg Tyr Tyr 35 40 45 Ala Gly Asp Glu Arg Arg Ala Leu Ser Phe Phe His Gln Lys Gly 50 55 60 Leu Gln Asp Phe Asp Thr Leu Leu Leu Ser Gly Asp Gly Asn Thr 65 70 75 Leu Tyr Val Gly Ala Arg Glu Ala Ile Leu Ala Leu Asp Ile Gln 80 85 90 Asp Pro Gly Val Pro Arg Leu Lys Asn Met Ile Pro Trp Pro Ala 95 100 105 Ser Asp Arg Lys Lys Ser Glu Cys Ala Phe Lys Lys Lys Ser Asn 110 115 120 Glu Thr Gln Cys Phe Asn Phe Ile Arg Val Leu Val Ser Tyr Asn 125 130 135 Val Thr His Leu Tyr Thr Cys Gly Thr Phe Ala Phe Ser Pro Ala 140 145 150 Cys Thr Phe Ile Val Ser Ser Leu Val Pro Ser Ala Gln Ala Pro 155 160 165 Lys His Pro Phe Ser His Leu Pro Thr Thr Phe Leu Cys Ser Ser 170 175 180 Gly Lys Leu Trp Pro Ser Arg Cys Arg Thr Leu Met Asn Phe Leu 185 190 195 Ala Pro Asp Gln Phe Pro Ser Met Ser Leu Ser Leu Pro Ser Ser 200 205 210 Ser Pro Ser Phe Pro Arg Cys Glu Thr Leu Ala Phe Trp Pro Pro 215 220 225 Ser Leu Ser Pro His Leu Gly Thr Ser Arg Phe Leu Pro Val Ala 230 235 240 His Leu Gly Gly Gln Gly His Gly Gly Lys Arg Pro Lys Pro Leu 245 250 255 11 641 PRT Homo sapiens misc_feature Incyte ID No 184661CD1 11 Met Val Pro Gly Ala Arg Gly Gly Gly Ala Leu Ala Arg Ala Ala 1 5 10 15 Gly Arg Gly Leu Leu Ala Leu Leu Leu Ala Val Ser Ala Pro Leu 20 25 30 Arg Leu Gln Ala Glu Glu Leu Gly Asp Gly Cys Gly His Leu Val 35 40 45 Thr Tyr Gln Asp Ser Gly Thr Met Thr Ser Lys Asn Tyr Pro Gly 50 55 60 Thr Tyr Pro Asn His Thr Val Cys Glu Lys Thr Ile Thr Val Pro 65 70 75 Lys Gly Lys Arg Leu Ile Leu Arg Leu Gly Asp Leu Asp Ile Glu 80 85 90 Ser Gln Thr Cys Ala Ser Asp Tyr Leu Leu Phe Thr Ser Ser Ser 95 100 105 Asp Gln Tyr Gly Pro Tyr Cys Gly Ser Met Thr Val Pro Lys Glu 110 115 120 Leu Leu Leu Asn Thr Ser Glu Val Thr Val Arg Phe Glu Ser Gly 125 130 135 Ser His Ile Ser Gly Arg Gly Phe Leu Leu Thr Tyr Ala Ser Ser 140 145 150 Asp His Pro Asp Leu Ile Thr Cys Leu Glu Arg Ala Ser His Tyr 155 160 165 Leu Lys Thr Glu Tyr Ser Lys Phe Cys Pro Ala Gly Cys Arg Asp 170 175 180 Val Ala Gly Asp Ile Ser Gly Asn Met Val Asp Gly Tyr Arg Asp 185 190 195 Thr Ser Leu Leu Cys Lys Ala Ala Ile His Ala Gly Ile Ile Ala 200 205 210 Asp Glu Leu Gly Gly Gln Ile Ser Val Leu Gln Arg Lys Gly Ile 215 220 225 Ser Arg Tyr Glu Gly Ile Leu Ala Asn Gly Val Leu Ser Arg Asp 230 235 240 Gly Ser Leu Ser Asp Lys Arg Phe Leu Phe Thr Ser Asn Gly Cys 245 250 255 Ser Arg Ser Leu Ser Phe Glu Pro Asp Gly Gln Ile Arg Ala Ser 260 265 270 Ser Ser Trp Gln Ser Val Asn Glu Ser Gly Asp Gln Val His Trp 275 280 285 Ser Pro Gly Gln Ala Arg Leu Gln Asp Gln Gly Pro Ser Trp Ala 290 295 300 Ser Gly Asp Ser Ser Asn Asn His Lys Pro Arg Glu Trp Leu Glu 305 310 315 Ile Asp Leu Gly Glu Lys Lys Lys Ile Thr Gly Ile Arg Thr Thr 320 325 330 Gly Ser Thr Gln Ser Asn Phe Asn Phe Tyr Val Lys Ser Phe Val 335 340 345 Met Asn Phe Lys Asn Asn Asn Ser Lys Trp Lys Thr Tyr Lys Gly 350 355 360 Ile Val Asn Asn Glu Glu Lys Val Phe Gln Gly Asn Ser Asn Phe 365 370 375 Arg Asp Pro Val Gln Asn Asn Phe Ile Pro Pro Ile Val Ala Arg 380 385 390 Tyr Val Arg Val Val Pro Gln Thr Trp His Gln Arg Ile Ala Leu 395 400 405 Lys Val Glu Leu Ile Gly Cys Gln Ile Thr Gln Gly Asn Asp Ser 410 415 420 Leu Val Trp Arg Lys Thr Ser Gln Ser Thr Ser Val Ser Thr Lys 425 430 435 Lys Glu Asp Glu Thr Ile Thr Arg Pro Ile Pro Ser Glu Glu Thr 440 445 450 Ser Thr Gly Ile Asn Ile Thr Thr Val Ala Ile Pro Leu Val Leu 455 460 465 Leu Val Val Leu Val Phe Ala Gly Met Gly Ile Phe Ala Ala Phe 470 475 480 Arg Lys Lys Lys Lys Lys Gly Ser Pro Tyr Gly Ser Ala Glu Ala 485 490 495 Gln Lys Thr Asp Cys Trp Lys Gln Ile Lys Tyr Pro Phe Ala Arg 500 505 510 His Gln Ser Ala Glu Phe Thr Ile Ser Tyr Asp Asn Glu Lys Glu 515 520 525 Met Thr Gln Lys Leu Asp Leu Ile Thr Ser Asp Met Ala Asp Tyr 530 535 540 Gln Gln Pro Leu Met Ile Gly Thr Gly Thr Val Thr Arg Lys Gly 545 550 555 Ser Thr Phe Arg Pro Met Asp Thr Asp Ala Glu Glu Ala Gly Val 560 565 570 Ser Thr Asp Ala Gly Gly His Tyr Asp Cys Pro Gln Arg Ala Gly 575 580 585 Arg His Glu Tyr Ala Leu Pro Trp Arg Pro Arg Ser Pro Ser Thr 590 595 600 Pro Arg Pro Ser Trp Ser Gly Thr Cys Cys Ala Pro Thr Arg Ser 605 610 615 Leu Arg Arg Ala Ala Thr Ala Ser Gln Gly Pro Ser Pro Ala Thr 620 625 630 Asn Thr Pro Ser Pro Arg Ala Ala Ser Pro Pro 635 640 12 924 PRT Homo sapiens misc_feature Incyte ID No 3719737CD1 12 Met Gly Arg Leu His Arg Pro Arg Ser Ser Thr Ser Tyr Arg Asn 1 5 10 15 Leu Pro His Leu Phe Leu Phe Phe Leu Phe Val Gly Pro Phe Ser 20 25 30 Cys Leu Gly Ser Tyr Ser Arg Ala Thr Glu Leu Leu Tyr Ser Leu 35 40 45 Asn Glu Gly Leu Pro Ala Gly Val Leu Ile Gly Ser Leu Ala Glu 50 55 60 Asp Leu Arg Leu Leu Pro Arg Ser Ala Gly Arg Pro Asp Pro Gln 65 70 75 Ser Gln Leu Pro Glu Arg Thr Gly Ala Glu Trp Asn Pro Pro Leu 80 85 90 Ser Phe Ser Leu Ala Ser Arg Gly Leu Ser Gly Gln Tyr Val Thr 95 100 105 Leu Asp Asn Arg Ser Gly Glu Leu His Thr Ser Ala Gln Glu Ile 110 115 120 Asp Arg Glu Ala Leu Cys Val Glu Gly Gly Gly Gly Thr Ala Trp 125 130 135 Ser Gly Ser Val Ser Ile Ser Ser Ser Pro Ser Asp Ser Cys Leu 140 145 150 Leu Leu Leu Asp Val Leu Val Leu Pro Gln Glu Tyr Phe Arg Phe 155 160 165 Val Lys Val Lys Ile Ala Ile Arg Asp Ile Asn Asp Asn Ala Pro 170 175 180 Gln Phe Pro Val Ser Gln Ile Ser Val Trp Val Pro Glu Asn Ala 185 190 195 Pro Val Asn Thr Arg Leu Ala Ile Glu His Pro Ala Val Asp Pro 200 205 210 Asp Val Gly Ile Asn Gly Val Gln Thr Tyr Arg Leu Leu Asp Tyr 215 220 225 His Gly Met Phe Thr Leu Asp Val Glu Glu Asn Glu Asn Gly Glu 230 235 240 Arg Thr Pro Tyr Leu Ile Val Met Gly Ala Leu Asp Arg Glu Thr 245 250 255 Gln Asp Gln Tyr Val Ser Ile Ile Ile Ala Glu Asp Gly Gly Ser 260 265 270 Pro Pro Leu Leu Gly Ser Ala Thr Leu Thr Ile Gly Ile Ser Asp 275 280 285 Ile Asn Asp Asn Cys Pro Leu Phe Thr Asp Ser Gln Ile Asn Val 290 295 300 Thr Val Tyr Gly Asn Ala Thr Val Gly Thr Pro Ile Ala Ala Val 305 310 315 Gln Ala Val Asp Lys Asp Leu Gly Thr Asn Ala Gln Ile Thr Tyr 320 325 330 Ser Tyr Ser Gln Lys Val Pro Gln Ala Ser Lys Asp Leu Phe His 335 340 345 Leu Asp Glu Asn Thr Gly Val Ile Lys Leu Phe Ser Lys Ile Gly 350 355 360 Gly Ser Val Leu Glu Ser His Lys Leu Thr Ile Leu Ala Asn Gly 365 370 375 Pro Gly Cys Ile Pro Ala Val Ile Thr Ala Leu Val Ser Ile Ile 380 385 390 Lys Val Ile Phe Arg Pro Pro Glu Ile Val Pro Arg Tyr Ile Ala 395 400 405 Asn Glu Ile Asp Gly Val Val Tyr Leu Lys Glu Leu Glu Pro Val 410 415 420 Asn Thr Pro Ile Ala Phe Phe Thr Ile Arg Asp Pro Glu Gly Lys 425 430 435 Tyr Lys Val Asn Cys Tyr Leu Asp Gly Glu Gly Pro Phe Arg Leu 440 445 450 Ser Pro Tyr Lys Pro Tyr Asn Asn Glu Tyr Leu Leu Glu Thr Thr 455 460 465 Lys Pro Met Asp Tyr Glu Leu Gln Gln Phe Tyr Glu Val Ala Val 470 475 480 Val Ala Trp Asn Ser Glu Gly Phe His Val Lys Arg Val Ile Lys 485 490 495 Val Gln Leu Leu Asp Asp Asn Asp Asn Ala Pro Ile Phe Leu Gln 500 505 510 Pro Leu Ile Glu Leu Thr Ile Glu Glu Asn Asn Ser Pro Asn Ala 515 520 525 Phe Leu Thr Lys Leu Tyr Ala Thr Asp Ala Asp Ser Glu Glu Arg 530 535 540 Gly Gln Val Ser Tyr Phe Leu Gly Pro Asp Ala Pro Ser Tyr Phe 545 550 555 Ser Leu Asp Ser Val Thr Gly Ile Leu Thr Val Ser Thr Gln Leu 560 565 570 Asp Arg Glu Glu Lys Glu Lys Tyr Arg Tyr Thr Val Arg Ala Val 575 580 585 Asp Cys Gly Lys Pro Pro Arg Glu Ser Val Ala Thr Val Ala Leu 590 595 600 Thr Val Leu Asp Lys Asn Asp Asn Ser Pro Arg Phe Ile Asn Lys 605 610 615 Asp Phe Ser Phe Phe Val Pro Glu Asn Phe Pro Gly Tyr Gly Glu 620 625 630 Ile Gly Val Ile Ser Val Thr Asp Ala Asp Ala Gly Arg Asn Gly 635 640 645 Trp Val Ala Leu Ser Val Val Asn Gln Ser Asp Ile Phe Val Ile 650 655 660 Asp Thr Gly Lys Gly Met Leu Arg Ala Lys Val Ser Leu Asp Arg 665 670 675 Glu Gln Gln Ser Ser Tyr Thr Leu Trp Val Glu Ala Val Asp Gly 680 685 690 Gly Glu Pro Ala Leu Ser Ser Thr Ala Lys Ile Thr Ile Leu Leu 695 700 705 Leu Asp Ile Asn Asp Asn Pro Pro Leu Val Leu Phe Pro Gln Ser 710 715 720 Asn Met Ser Tyr Leu Leu Val Leu Pro Ser Thr Leu Pro Gly Ser 725 730 735 Pro Val Thr Glu Val Tyr Ala Val Asp Lys Asp Thr Gly Met Asn 740 745 750 Ala Val Ile Ala Tyr Ser Ile Ile Gly Arg Arg Gly Pro Arg Pro 755 760 765 Glu Ser Phe Arg Ile Asp Pro Lys Thr Gly Asn Ile Thr Leu Glu 770 775 780 Glu Ala Leu Leu Gln Thr Asp Tyr Gly Leu His Arg Leu Leu Val 785 790 795 Lys Val Ser Asp His Gly Tyr Pro Glu Pro Leu His Ser Thr Val 800 805 810 Met Val Asn Leu Phe Val Asn Asp Thr Val Ser Asn Glu Ser Tyr 815 820 825 Ile Glu Ser Leu Leu Arg Lys Glu Pro Glu Ile Asn Ile Glu Glu 830 835 840 Lys Glu Pro Gln Ile Ser Ile Glu Pro Thr His Arg Lys Val Glu 845 850 855 Ser Val Ser Cys Met Pro Thr Leu Val Ala Leu Ser Val Ile Ser 860 865 870 Leu Gly Ser Ile Thr Leu Val Thr Gly Met Gly Ile Tyr Ile Cys 875 880 885 Leu Arg Lys Gly Glu Lys His Pro Arg Glu Asp Glu Asn Leu Glu 890 895 900 Val Gln Ile Pro Leu Lys Gly Lys Ile Asp Leu His Met Arg Glu 905 910 915 Arg Lys Pro Met Asp Ile Ser Asn Ile 920 13 987 PRT Homo sapiens misc_feature Incyte ID No 5773251CD1 13 Met Arg Ile Ser Ser Cys Ser Asp Glu Ser Ser Asn Ser Asn Ser 1 5 10 15 Ser Arg Lys Ser Asp Asn His Ser Pro Ala Val Val Thr Thr Thr 20 25 30 Val Ser Ser Lys Lys Gln Pro Ser Val Leu Val Thr Phe Pro Lys 35 40 45 Glu Glu Arg Lys Ser Val Ser Gly Lys Ala Ser Ile Lys Leu Ser 50 55 60 Glu Thr Ile Ser Glu Gly Thr Ser Asn Ser Leu Ser Thr Cys Thr 65 70 75 Lys Ser Gly Pro Ser Pro Leu Ser Ser Pro Asn Gly Lys Leu Thr 80 85 90 Val Ala Ser Pro Lys Arg Gly Gln Lys Arg Glu Glu Gly Trp Lys 95 100 105 Glu Val Val Arg Arg Ser Lys Lys Val Ser Val Pro Ser Thr Val 110 115 120 Ile Ser Arg Val Ile Gly Arg Gly Gly Cys Asn Ile Asn Ala Ile 125 130 135 Arg Glu Phe Thr Gly Ala His Ile Asp Ile Asp Lys Gln Lys Asp 140 145 150 Lys Thr Gly Asp Arg Ile Ile Thr Ile Arg Gly Gly Thr Glu Ser 155 160 165 Thr Arg Gln Ala Thr Gln Leu Ile Asn Ala Leu Ile Lys Asp Pro 170 175 180 Asp Lys Glu Ile Asp Glu Leu Ile Pro Lys Asn Arg Leu Lys Ser 185 190 195 Ser Ser Ala Asn Ser Lys Ile Gly Ser Ser Ala Pro Thr Thr Thr 200 205 210 Ala Ala Asn Thr Ser Leu Met Gly Ile Lys Met Thr Thr Val Ala 215 220 225 Leu Ser Ser Thr Ser Gln Thr Ala Thr Ala Leu Thr Val Pro Ala 230 235 240 Ile Ser Ser Ala Ser Thr His Lys Thr Ile Lys Asn Pro Val Asn 245 250 255 Asn Val Arg Pro Gly Phe Pro Val Ser Leu Pro Leu Ala Tyr Pro 260 265 270 Pro Pro Gln Phe Ala His Ala Leu Leu Ala Ala Gln Thr Phe Gln 275 280 285 Gln Ile Arg Pro Pro Arg Leu Pro Met Thr His Phe Gly Gly Thr 290 295 300 Phe Pro Pro Ala Gln Ser Thr Trp Gly Pro Phe Pro Val Arg Pro 305 310 315 Leu Ser Pro Ala Arg Ala Thr Asn Ser Pro Lys Pro His Met Val 320 325 330 Pro Arg His Ser Asn Gln Asn Ser Ser Gly Ser Gln Val Asn Ser 335 340 345 Ala Gly Ser Leu Thr Ser Ser Pro Thr Thr Thr Thr Ser Ser Ser 350 355 360 Ala Ser Thr Val Pro Gly Thr Ser Thr Asn Gly Ser Pro Ser Ser 365 370 375 Pro Ser Val Arg Arg Gln Leu Phe Val Thr Val Val Lys Thr Ser 380 385 390 Asn Ala Thr Thr Thr Thr Val Thr Thr Thr Ala Ser Asn Asn Asn 395 400 405 Thr Ala Pro Thr Asn Ala Thr Tyr Pro Met Pro Thr Ala Lys Glu 410 415 420 His Tyr Pro Val Ser Ser Pro Ser Ser Pro Ser Pro Pro Ala Gln 425 430 435 Pro Gly Gly Val Ser Arg Asn Ser Pro Leu Asp Cys Gly Ser Ala 440 445 450 Ser Pro Asn Lys Val Ala Ser Ser Ser Glu Gln Glu Ala Gly Ser 455 460 465 Pro Pro Val Val Glu Thr Thr Asn Thr Arg Pro Pro Asn Ser Ser 470 475 480 Ser Ser Ser Gly Ser Ser Ser Ala His Ser Asn Gln Gln Gln Pro 485 490 495 Pro Gly Ser Val Ser Gln Glu Pro Arg Pro Pro Leu Gln Gln Ser 500 505 510 Gln Val Pro Pro Pro Glu Val Arg Met Thr Val Pro Pro Leu Ala 515 520 525 Thr Ser Ser Ala Pro Val Ala Val Pro Ser Thr Ala Pro Val Thr 530 535 540 Tyr Pro Met Pro Gln Thr Pro Met Gly Cys Pro Gln Pro Thr Pro 545 550 555 Lys Met Glu Thr Pro Ala Ile Arg Pro Pro Pro His Gly Thr Thr 560 565 570 Ala Pro His Lys Asn Ser Ala Ser Val Gln Asn Ser Ser Val Ala 575 580 585 Val Leu Ser Val Asn His Ile Lys Arg Pro His Ser Val Pro Ser 590 595 600 Ser Val Gln Leu Pro Ser Thr Leu Ser Thr Gln Ser Ala Cys Gln 605 610 615 Asn Ser Val His Pro Ala Asn Lys Pro Ile Ala Pro Asn Phe Ser 620 625 630 Ala Pro Leu Pro Phe Gly Pro Phe Ser Thr Leu Phe Glu Asn Ser 635 640 645 Pro Thr Ser Ala His Ala Phe Trp Gly Gly Ser Val Val Ser Ser 650 655 660 Gln Ser Thr Pro Glu Ser Met Leu Ser Gly Lys Ser Ser Tyr Leu 665 670 675 Pro Asn Ser Asp Pro Leu His Gln Ser Asp Thr Ser Lys Ala Pro 680 685 690 Gly Phe Arg Pro Pro Leu Gln Arg Pro Ala Pro Ser Pro Ser Gly 695 700 705 Ile Val Asn Met Asp Ser Pro Tyr Gly Ser Val Thr Pro Ser Ser 710 715 720 Thr His Leu Gly Asn Phe Ala Ser Asn Ile Ser Gly Gly Gln Met 725 730 735 Tyr Gly Pro Gly Ala Pro Leu Gly Gly Ala Pro Ala Ala Ala Asn 740 745 750 Phe Asn Arg Gln His Phe Ser Pro Leu Ser Leu Leu Thr Pro Cys 755 760 765 Ser Ser Ala Ser Asn Asp Ser Ser Ala Gln Ser Val Ser Ser Gly 770 775 780 Val Arg Ala Pro Ser Pro Ala Pro Ser Ser Val Pro Leu Gly Ser 785 790 795 Glu Lys Pro Ser Asn Val Ser Gln Asp Arg Lys Val Pro Val Pro 800 805 810 Ile Gly Thr Glu Arg Ser Ala Arg Ile Arg Gln Thr Gly Thr Ser 815 820 825 Ala Pro Ser Val Ile Gly Ser Asn Leu Ser Thr Ser Val Gly His 830 835 840 Ser Gly Ile Trp Ser Phe Glu Gly Ile Gly Gly Asn Gln Asp Lys 845 850 855 Val Asp Trp Cys Asn Pro Gly Met Gly Asn Pro Met Ile His Arg 860 865 870 Pro Met Ser Asp Pro Gly Val Phe Ser Gln His Gln Ala Met Glu 875 880 885 Arg Asp Ser Thr Gly Ile Val Thr Pro Ser Gly Thr Phe His Gln 890 895 900 His Val Pro Ala Gly Tyr Met Asp Phe Pro Lys Val Gly Gly Met 905 910 915 Pro Phe Ser Val Tyr Gly Asn Ala Met Ile Pro Pro Val Ala Pro 920 925 930 Ile Pro Asp Gly Ala Gly Gly Pro Ile Phe Asn Gly Pro His Ala 935 940 945 Ala Asp Pro Ser Trp Asn Ser Leu Ile Lys Met Val Ser Ser Ser 950 955 960 Thr Glu Asn Asn Gly Pro Gln Thr Val Trp Thr Gly Pro Trp Ala 965 970 975 Pro His Met Asn Ser Val His Met Asn Gln Leu Gly 980 985 14 1028 PRT Homo sapiens misc_feature Incyte ID No 5426470CD1 14 Met Met Phe Pro Trp Lys Gln Leu Ile Leu Leu Ser Phe Ile Gly 1 5 10 15 Cys Leu Gly Gly Glu Leu Leu Leu Gln Gly Pro Val Phe Ile Lys 20 25 30 Glu Pro Ser Asn Ser Ile Phe Pro Val Gly Ser Glu Asp Lys Lys 35 40 45 Ile Thr Leu His Cys Glu Ala Arg Gly Asn Pro Ser Pro His Tyr 50 55 60 Arg Trp Gln Leu Asn Gly Ser Asp Ile Asp Met Ser Met Glu His 65 70 75 Arg Tyr Lys Leu Asn Gly Gly Asn Leu Val Val Ile Asn Pro Asn 80 85 90 Arg Asn Trp Asp Thr Gly Thr Tyr Gln Cys Phe Ala Thr Asn Ser 95 100 105 Leu Gly Thr Ile Val Ser Arg Glu Ala Lys Leu Gln Phe Ala Tyr 110 115 120 Leu Glu Asn Phe Lys Thr Lys Met Arg Ser Thr Val Ser Val Arg 125 130 135 Glu Gly Gln Gly Val Val Leu Leu Cys Gly Pro Pro Pro His Ser 140 145 150 Gly Glu Leu Ser Tyr Ala Trp Ile Phe Asn Glu Tyr Pro Ser Phe 155 160 165 Val Glu Glu Asp Ser Arg Arg Phe Val Ser Gln Glu Thr Gly His 170 175 180 Leu Tyr Ile Ser Lys Val Glu Pro Ser Asp Val Gly Asn Tyr Thr 185 190 195 Cys Val Val Thr Ser Met Val Thr Asn Ala Arg Val Leu Gly Ser 200 205 210 Pro Thr Pro Leu Val Leu Arg Ser Asp Gly Val Met Gly Glu Tyr 215 220 225 Glu Pro Lys Ile Glu Val Gln Phe Pro Glu Thr Leu Pro Ala Ala 230 235 240 Lys Gly Ser Thr Val Lys Leu Glu Cys Phe Ala Leu Gly Asn Pro 245 250 255 Ile Pro Gln Ile Asn Trp Arg Arg Ser Asp Gly Leu Pro Phe Ser 260 265 270 Ser Lys Ile Lys Leu Arg Lys Phe Ser Gly Val Leu Glu Ile Pro 275 280 285 Asn Phe Gln Gln Glu Asp Ala Gly Ser Tyr Glu Cys Ile Ala Glu 290 295 300 Asn Ser Arg Gly Lys Asn Val Ala Arg Gly Arg Leu Thr Tyr Tyr 305 310 315 Ala Lys Pro His Trp Val Gln Leu Ile Lys Asp Val Glu Ile Ala 320 325 330 Val Glu Asp Ser Leu Tyr Trp Glu Cys Arg Ala Ser Gly Lys Pro 335 340 345 Lys Pro Ser Tyr Arg Trp Leu Lys Asn Gly Ala Ala Leu Val Leu 350 355 360 Glu Glu Arg Thr Gln Ile Glu Asn Gly Ala Leu Thr Ile Ser Asn 365 370 375 Leu Ser Val Thr Asp Ser Gly Met Phe Gln Cys Ile Ala Glu Asn 380 385 390 Lys His Gly Leu Val Tyr Ser Ser Ala Glu Leu Lys Val Val Ala 395 400 405 Ser Ala Pro Asp Phe Ser Lys Asn Pro Met Lys Lys Leu Val Gln 410 415 420 Val Gln Val Gly Ser Leu Val Ser Leu Asp Cys Lys Pro Arg Ala 425 430 435 Ser Pro Arg Ala Leu Ser Ser Trp Lys Lys Gly Asp Val Ser Val 440 445 450 Gln Glu His Glu Arg Ile Ser Leu Leu Asn Asp Gly Gly Leu Lys 455 460 465 Ile Ala Asn Val Thr Lys Ala Asp Ala Gly Thr Tyr Thr Cys Met 470 475 480 Ala Glu Asn Gln Phe Gly Lys Ala Asn Gly Thr Thr His Leu Val 485 490 495 Val Thr Glu Pro Thr Arg Ile Thr Leu Ala Pro Ser Asn Met Asp 500 505 510 Val Ser Val Gly Glu Ser Val Ile Leu Pro Cys Gln Val Gln His 515 520 525 Asp Pro Leu Leu Asp Ile Ile Phe Thr Trp Tyr Phe Asn Gly Ala 530 535 540 Leu Ala Asp Phe Lys Lys Asp Gly Ser His Phe Glu Lys Val Gly 545 550 555 Gly Ser Ser Ser Gly Asp Leu Met Ile Arg Asn Ile Gln Leu Lys 560 565 570 His Ser Gly Lys Tyr Val Cys Met Val Gln Thr Gly Val Asp Ser 575 580 585 Val Ser Ser Ala Ala Asp Leu Ile Val Arg Gly Ser Pro Gly Pro 590 595 600 Pro Glu Asn Val Lys Val Asp Glu Ile Thr Asp Thr Thr Ala Gln 605 610 615 Leu Ser Trp Lys Glu Gly Lys Asp Asn His Ser Pro Val Ile Ser 620 625 630 Tyr Ser Ile Gln Ala Arg Thr Pro Phe Ser Val Gly Trp Gln Thr 635 640 645 Val Thr Thr Val Pro Glu Val Ile Asp Gly Lys Thr His Thr Ala 650 655 660 Thr Val Val Glu Leu Asn Pro Trp Val Glu Tyr Glu Phe Arg Val 665 670 675 Val Ala Ser Asn Lys Ile Gly Gly Gly Glu Pro Ser Leu Pro Ser 680 685 690 Glu Lys Val Arg Thr Glu Glu Ala Val Pro Glu Val Pro Pro Ser 695 700 705 Glu Val Asn Gly Gly Gly Gly Ser Arg Ser Glu Leu Val Ile Thr 710 715 720 Trp Asp Pro Val Pro Glu Glu Leu Gln Asn Gly Glu Gly Phe Gly 725 730 735 Tyr Val Val Ala Phe Arg Pro Leu Gly Val Thr Thr Trp Ile Gln 740 745 750 Thr Val Val Thr Ser Pro Asp Thr Pro Arg Tyr Val Phe Arg Asn 755 760 765 Glu Ser Ile Val Pro Tyr Ser Pro Tyr Glu Val Lys Val Gly Val 770 775 780 Tyr Asn Asn Lys Gly Glu Gly Pro Phe Ser Pro Val Thr Thr Val 785 790 795 Phe Ser Ala Glu Glu Glu Pro Thr Val Ala Pro Ser Gln Val Ser 800 805 810 Ala Asn Ser Leu Ser Ser Ser Glu Ile Glu Val Ser Trp Asn Thr 815 820 825 Ile Pro Trp Lys Leu Ser Asn Gly His Leu Leu Gly Tyr Glu Val 830 835 840 Arg Tyr Trp Asn Gly Gly Gly Lys Glu Glu Ser Ser Ser Lys Met 845 850 855 Lys Val Ala Gly Asn Glu Thr Ser Ala Arg Leu Arg Gly Leu Lys 860 865 870 Ser Asn Leu Ala Tyr Tyr Thr Ala Val Arg Ala Tyr Asn Ser Ala 875 880 885 Gly Ala Gly Pro Phe Ser Ala Thr Val Asn Val Thr Thr Lys Lys 890 895 900 Thr Pro Pro Ser Gln Pro Pro Gly Asn Val Val Trp Asn Ala Thr 905 910 915 Asp Thr Lys Val Leu Leu Asn Trp Glu Gln Val Lys Ala Met Glu 920 925 930 Asn Glu Ser Glu Val Thr Gly Tyr Lys Val Phe Tyr Arg Thr Ser 935 940 945 Ser Gln Asn Asn Val Gln Val Leu Asn Thr Asn Lys Thr Ser Ala 950 955 960 Glu Leu Val Leu Pro Ile Lys Glu Asp Tyr Ile Ile Glu Val Lys 965 970 975 Ala Thr Thr Asp Gly Gly Asp Gly Thr Ser Ser Glu Gln Ile Arg 980 985 990 Ile Pro Arg Ile Thr Ser Met Asp Ala Arg Gly Ser Thr Ser Ala 995 1000 1005 Ile Ser Asn Val His Pro Met Ser Ser Tyr Met Pro Ile Val Leu 1010 1015 1020 Phe Leu Ile Val Tyr Val Leu Trp 1025 15 354 PRT Homo sapiens misc_feature Incyte ID No 7087904CD1 15 Met Asp Met Met Leu Leu Val Gln Gly Ala Cys Cys Ser Asn Gln 1 5 10 15 Trp Leu Ala Ala Val Leu Leu Ser Leu Cys Cys Leu Leu Pro Ser 20 25 30 Cys Leu Pro Ala Gly Gln Ser Val Asp Phe Pro Trp Ala Ala Val 35 40 45 Asp Asn Met Met Val Arg Lys Gly Asp Thr Ala Val Leu Arg Cys 50 55 60 Tyr Leu Glu Asp Gly Ala Ser Lys Gly Ala Trp Leu Asn Arg Ser 65 70 75 Ser Ile Ile Phe Ala Gly Gly Asp Lys Trp Ser Val Asp Pro Arg 80 85 90 Val Ser Ile Ser Thr Leu Asn Lys Arg Asp Tyr Ser Leu Gln Ile 95 100 105 Gln Asn Val Asp Val Thr Asp Asp Gly Pro Tyr Thr Cys Ser Val 110 115 120 Gln Thr Gln His Thr Pro Arg Thr Met Gln Val His Leu Thr Val 125 130 135 Gln Val Pro Pro Lys Ile Tyr Asp Ile Ser Asn Asp Met Thr Val 140 145 150 Asn Glu Gly Thr Asn Val Thr Leu Thr Cys Leu Ala Thr Gly Lys 155 160 165 Pro Glu Pro Ser Ile Ser Trp Arg His Ile Ser Pro Ser Ala Lys 170 175 180 Pro Phe Glu Asn Gly Gln Tyr Leu Asp Ile Tyr Gly Ile Thr Arg 185 190 195 Asp Gln Ala Gly Glu Tyr Glu Cys Ser Ala Glu Asn Asp Val Ser 200 205 210 Phe Pro Asp Val Arg Lys Val Lys Val Val Val Asn Phe Ala Pro 215 220 225 Thr Ile Gln Glu Ile Lys Ser Gly Thr Val Thr Pro Gly Arg Ser 230 235 240 Gly Leu Ile Arg Cys Glu Gly Ala Gly Val Pro Pro Pro Ala Phe 245 250 255 Glu Trp Tyr Lys Gly Glu Lys Lys Leu Phe Asn Gly Gln Gln Gly 260 265 270 Ile Ile Ile Gln Asn Phe Ser Thr Arg Ser Ile Leu Thr Val Thr 275 280 285 Asn Val Thr Gln Glu His Phe Gly Asn Tyr Thr Cys Val Ala Ala 290 295 300 Asn Lys Leu Gly Thr Thr Asn Ala Ser Leu Pro Leu Asn Pro Pro 305 310 315 Ser Thr Ala Gln Tyr Gly Ile Thr Gly Ser Ala Asp Val Leu Phe 320 325 330 Ser Cys Trp Tyr Leu Val Leu Thr Leu Ser Ser Phe Thr Ser Ile 335 340 345 Phe Tyr Leu Lys Asn Ala Ile Leu Gln 350 16 1829 PRT Homo sapiens misc_feature Incyte ID No 7477312CD1 16 Met Gln Leu Ser Arg Ala Ala Ala Ala Ala Ala Ala Ala Pro Ala 1 5 10 15 Glu Pro Pro Glu Pro Leu Ser Pro Ala Pro Ala Pro Ala Pro Ala 20 25 30 Pro Pro Gly Pro Leu Pro Arg Ser Ala Ala Asp Gly Ala Pro Ala 35 40 45 Gly Gly Lys Gly Gly Pro Gly Arg Arg Ala Arg Ser Pro Arg Ala 50 55 60 Leu Arg Ser Pro Ala Arg Ala Ala Pro Ala Arg Ala Pro Ala Arg 65 70 75 Gly Trp Thr Ala Pro Gly Pro Gly Ala Ser Ala Val Val Val Arg 80 85 90 Val Gly Ile Pro Asp Leu Gln Gln Thr Lys Cys Leu Arg Leu Asp 95 100 105 Pro Ala Ala Pro Val Trp Ala Ala Lys Gln Arg Val Leu Cys Ala 110 115 120 Leu Asn His Ser Leu Gln Asp Ala Leu Asn Tyr Gly Leu Phe Gln 125 130 135 Pro Pro Ser Arg Gly Arg Ala Gly Lys Phe Leu Asp Glu Glu Arg 140 145 150 Leu Leu Gln Glu Tyr Pro Pro Asn Leu Asp Thr Pro Leu Pro Tyr 155 160 165 Leu Glu Phe Arg Tyr Lys Arg Arg Val Tyr Ala Gln Asn Leu Ile 170 175 180 Asp Asp Lys Gln Phe Ala Lys Leu His Thr Lys Ala Asn Leu Lys 185 190 195 Lys Phe Met Asp Tyr Val Gln Leu His Ser Thr Asp Lys Val Ala 200 205 210 Arg Leu Leu Asp Lys Gly Leu Asp Pro Asn Phe His Asp Pro Asp 215 220 225 Ser Gly Glu Cys Pro Leu Ser Leu Ala Ala Gln Leu Asp Asn Ala 230 235 240 Thr Asp Leu Leu Lys Val Leu Lys Asn Gly Gly Ala His Leu Asp 245 250 255 Phe Arg Thr Arg Asp Gly Leu Thr Ala Val His Cys Ala Thr Arg 260 265 270 Gln Arg Asn Ala Ala Ala Leu Thr Thr Leu Leu Asp Leu Gly Ala 275 280 285 Ser Pro Asp Tyr Lys Asp Ser Arg Gly Leu Thr Pro Leu Tyr His 290 295 300 Ser Ala Leu Gly Gly Gly Asp Ala Leu Cys Cys Glu Leu Leu Leu 305 310 315 His Asp His Ala Gln Leu Gly Thr Thr Asp Glu Asn Gly Trp Gln 320 325 330 Glu Ile His Gln Ala Cys Arg Phe Gly His Val Gln His Leu Glu 335 340 345 His Leu Leu Phe Tyr Gly Ala Asp Met Gly Ala Gln Asn Ala Ser 350 355 360 Gly Asn Thr Ala Leu His Ile Cys Ala Leu Tyr Asn Gln Glu Ser 365 370 375 Cys Ala Arg Val Leu Leu Phe Arg Gly Ala Asn Arg Asp Val Arg 380 385 390 Asn Tyr Asn Ser Gln Thr Ala Phe Gln Val Ala Ile Ile Ala Gly 395 400 405 Asn Phe Glu Leu Ala Glu Val Ile Lys Thr His Lys Asp Ser Asp 410 415 420 Val Gly Gln Asp Ser His Asp Leu Leu His Pro Met Pro Thr Gly 425 430 435 Val Pro Glu Trp Gly Leu Tyr Thr Glu Glu Glu Leu Glu Gly Gly 440 445 450 Ala Ala Phe Ser Val Pro Phe Arg Glu Thr Pro Ser Tyr Ala Lys 455 460 465 Arg Arg Arg Leu Ala Gly Pro Ser Gly Leu Ala Ser Pro Arg Pro 470 475 480 Leu Gln Arg Ser Ala Ser Asp Ile Asn Leu Lys Gly Glu Ala Gln 485 490 495 Pro Ala Ala Ser Pro Gly Pro Ser Leu Arg Ser Leu Pro His Gln 500 505 510 Leu Leu Leu Gln Arg Leu Gln Glu Glu Lys Asp Arg Asp Arg Asp 515 520 525 Ala Asp Gln Glu Ser Asn Ile Ser Gly Pro Leu Ala Gly Arg Ala 530 535 540 Gly Gln Ser Lys Ile Arg Ser Cys Ile Arg Ile Arg Ala Arg Phe 545 550 555 Pro Ala Pro Pro Ala Pro Pro Ala Pro Pro Pro Arg Gly Pro Lys 560 565 570 Arg Lys Leu Tyr Ser Ala Val Pro Gly Arg Lys Phe Ile Ala Val 575 580 585 Lys Ala His Ser Pro Gln Gly Glu Gly Glu Ile Pro Leu His Arg 590 595 600 Gly Glu Ala Val Lys Val Leu Ser Ile Gly Glu Gly Gly Phe Trp 605 610 615 Glu Gly Thr Val Lys Gly Arg Thr Gly Trp Phe Pro Ala Asp Cys 620 625 630 Val Glu Glu Val Gln Met Arg Gln His Asp Thr Arg Pro Glu Thr 635 640 645 Arg Glu Asp Arg Thr Lys Arg Leu Phe Arg His Tyr Thr Val Gly 650 655 660 Ser Tyr Asp Ser Leu Thr Ser His Ser Asp Tyr Val Ile Asp Asp 665 670 675 Lys Val Ala Val Leu Gln Lys Arg Asp His Glu Gly Phe Gly Phe 680 685 690 Val Leu Arg Gly Ala Lys Ala Glu Thr Pro Ile Glu Glu Phe Thr 695 700 705 Pro Thr Pro Ala Phe Pro Ala Leu Gln Tyr Leu Glu Ser Val Asp 710 715 720 Val Glu Gly Val Ala Trp Arg Ala Gly Leu Arg Thr Gly Asp Phe 725 730 735 Leu Ile Glu Val Asn Gly Val Asn Val Val Lys Val Gly His Lys 740 745 750 Gln Val Val Ala Leu Ile Arg Gln Gly Gly Asn Arg Leu Val Met 755 760 765 Lys Val Val Ser Val Thr Arg Lys Pro Glu Glu Asp Gly Ala Arg 770 775 780 Arg Arg Ala Pro Pro Pro Pro Lys Arg Ala Pro Ser Thr Thr Leu 785 790 795 Thr Leu Arg Ser Lys Ser Met Thr Ala Glu Leu Glu Glu Leu Glu 800 805 810 Lys Leu Asp Glu Met Leu Ala Ala Ala Ala Glu Pro Thr Leu Arg 815 820 825 Pro Asp Ile Ala Asp Ala Asp Ser Arg Ala Ala Thr Val Lys Gln 830 835 840 Arg Pro Thr Ser Arg Arg Ile Thr Pro Ala Glu Ile Ser Ser Leu 845 850 855 Phe Glu Arg Gln Gly Leu Pro Gly Pro Glu Lys Leu Pro Gly Ser 860 865 870 Leu Arg Lys Gly Ile Pro Arg Thr Lys Ser Val Gly Glu Asp Glu 875 880 885 Lys Leu Ala Ser Leu Leu Glu Gly Arg Phe Pro Arg Ser Thr Ser 890 895 900 Met Gln Asp Pro Val Arg Glu Gly Arg Gly Ile Pro Pro Pro Pro 905 910 915 Gln Thr Ala Pro Pro Pro Pro Pro Ala Pro Tyr Tyr Phe Asp Ser 920 925 930 Gly Pro Pro Pro Ala Phe Ser Pro Pro Pro Pro Pro Gly Arg Ala 935 940 945 Tyr Asp Thr Val Arg Ser Ser Phe Lys Pro Gly Leu Glu Ala Arg 950 955 960 Leu Gly Ala Gly Ala Ala Gly Leu Tyr Glu Pro Gly Ala Ala Leu 965 970 975 Gly Pro Leu Pro Tyr Pro Glu Arg Gln Lys Arg Ala Arg Ser Met 980 985 990 Ile Ile Leu Gln Asp Ser Ala Pro Glu Ser Gly Asp Ala Pro Arg 995 1000 1005 Pro Pro Pro Ala Ala Thr Pro Pro Glu Arg Pro Lys Arg Arg Pro 1010 1015 1020 Arg Pro Pro Gly Pro Asp Ser Pro Tyr Ala Asn Leu Gly Ala Phe 1025 1030 1035 Ser Ala Ser Leu Phe Ala Pro Ser Lys Pro Gln Arg Arg Lys Ser 1040 1045 1050 Pro Leu Val Lys Gln Leu Gln Val Glu Asp Ala Gln Glu Arg Ala 1055 1060 1065 Ala Leu Ala Val Gly Ser Pro Gly Pro Gly Gly Gly Ser Phe Ala 1070 1075 1080 Arg Glu Pro Ser Pro Thr His Arg Gly Pro Arg Pro Gly Gly Leu 1085 1090 1095 Asp Tyr Gly Ala Gly Asp Gly Pro Gly Leu Ala Phe Gly Gly Pro 1100 1105 1110 Gly Pro Ala Lys Asp Arg Arg Leu Glu Glu Arg Arg Arg Ser Thr 1115 1120 1125 Val Phe Leu Ser Val Gly Ala Ile Glu Gly Ser Ala Pro Gly Ala 1130 1135 1140 Asp Leu Pro Ser Leu Gln Pro Ser Arg Ser Ile Asp Glu Arg Leu 1145 1150 1155 Leu Gly Thr Gly Pro Thr Ala Gly Arg Asp Leu Leu Leu Pro Ser 1160 1165 1170 Pro Val Ser Ala Leu Lys Pro Leu Val Ser Gly Pro Ser Leu Gly 1175 1180 1185 Pro Ser Gly Ser Thr Phe Ile His Pro Leu Thr Gly Lys Pro Leu 1190 1195 1200 Asp Pro Ser Ser Pro Leu Ala Leu Ala Leu Ala Ala Arg Glu Arg 1205 1210 1215 Ala Leu Ala Ser Gln Ala Pro Ser Arg Ser Pro Thr Pro Val His 1220 1225 1230 Ser Pro Asp Ala Asp Arg Pro Gly Pro Leu Phe Val Asp Val Gln 1235 1240 1245 Ala Arg Asp Pro Glu Arg Gly Ser Leu Ala Ser Pro Ala Phe Ser 1250 1255 1260 Pro Arg Ser Pro Ala Trp Ile Pro Val Pro Ala Arg Arg Glu Ala 1265 1270 1275 Glu Lys Val Pro Arg Glu Glu Arg Lys Ser Pro Glu Asp Lys Lys 1280 1285 1290 Ser Met Ile Leu Ser Val Leu Asp Thr Ser Leu Gln Arg Pro Ala 1295 1300 1305 Gly Leu Ile Val Val His Ala Thr Ser Asn Gly Gln Glu Pro Ser 1310 1315 1320 Arg Leu Gly Gly Ala Glu Glu Glu Arg Pro Gly Thr Pro Glu Leu 1325 1330 1335 Ala Pro Ala Pro Met Gln Ser Ala Ala Val Ala Glu Pro Leu Pro 1340 1345 1350 Ser Pro Arg Ala Gln Pro Pro Gly Gly Thr Pro Ala Asp Ala Gly 1355 1360 1365 Pro Gly Gln Gly Ser Ser Glu Glu Glu Pro Glu Leu Val Phe Ala 1370 1375 1380 Val Asn Leu Pro Pro Ala Gln Leu Ser Ser Ser Asp Glu Glu Thr 1385 1390 1395 Arg Glu Glu Leu Ala Arg Ile Gly Leu Val Pro Pro Pro Glu Glu 1400 1405 1410 Phe Ala Asn Gly Val Leu Leu Ala Thr Pro Leu Ala Gly Pro Gly 1415 1420 1425 Pro Ser Pro Thr Thr Val Pro Ser Pro Ala Ser Gly Lys Pro Ser 1430 1435 1440 Ser Glu Pro Pro Pro Ala Pro Glu Ser Ala Ala Asp Ser Gly Val 1445 1450 1455 Glu Glu Ala Asp Thr Arg Ser Ser Ser Asp Pro His Leu Glu Thr 1460 1465 1470 Thr Ser Thr Ile Ser Thr Val Ser Ser Met Ser Thr Leu Ser Ser 1475 1480 1485 Glu Ser Gly Glu Leu Thr Asp Thr His Thr Ser Phe Ala Asp Gly 1490 1495 1500 His Thr Phe Leu Leu Glu Lys Pro Pro Val Pro Pro Lys Pro Lys 1505 1510 1515 Leu Lys Ser Pro Leu Gly Lys Gly Pro Val Thr Phe Arg Asp Pro 1520 1525 1530 Leu Leu Lys Gln Ser Ser Asp Ser Glu Leu Met Ala Gln Gln His 1535 1540 1545 His Ala Ala Ser Ala Gly Leu Ala Ser Ala Ala Gly Pro Ala Arg 1550 1555 1560 Pro Arg Tyr Leu Phe Gln Arg Arg Ser Lys Leu Trp Gly Asp Pro 1565 1570 1575 Val Glu Ser Arg Gly Leu Pro Gly Pro Glu Asp Asp Lys Pro Thr 1580 1585 1590 Val Ile Ser Glu Leu Ser Ser Arg Leu Gln Gln Leu Asn Lys Asp 1595 1600 1605 Thr Arg Ser Leu Gly Glu Glu Pro Val Gly Gly Leu Gly Ser Leu 1610 1615 1620 Leu Asp Pro Ala Lys Lys Ser Pro Ile Ala Ala Ala Arg Leu Phe 1625 1630 1635 Ser Ser Leu Gly Glu Leu Ser Ser Ile Ser Ala Gln Arg Ser Pro 1640 1645 1650 Gly Gly Pro Gly Gly Gly Ala Ser Tyr Ser Val Arg Pro Ser Gly 1655 1660 1665 Arg Tyr Pro Val Ala Arg Arg Ala Pro Ser Pro Val Lys Pro Ala 1670 1675 1680 Ser Leu Glu Arg Val Glu Gly Leu Gly Ala Gly Ala Gly Gly Ala 1685 1690 1695 Gly Arg Pro Phe Gly Leu Thr Pro Pro Thr Ile Leu Lys Ser Ser 1700 1705 1710 Ser Leu Ser Ile Pro His Glu Pro Lys Glu Val Arg Phe Val Val 1715 1720 1725 Arg Ser Val Ser Ala Arg Ser Arg Ser Pro Ser Pro Ser Pro Leu 1730 1735 1740 Pro Ser Pro Ala Ser Gly Pro Gly Pro Gly Ala Pro Gly Pro Arg 1745 1750 1755 Arg Pro Phe Gln Gln Lys Pro Leu Gln Leu Trp Ser Lys Phe Asp 1760 1765 1770 Val Gly Asp Trp Leu Glu Ser Ile His Leu Gly Glu His Arg Asp 1775 1780 1785 Arg Phe Glu Asp His Glu Ile Glu Gly Ala His Leu Pro Ala Leu 1790 1795 1800 Thr Lys Asp Asp Phe Val Glu Leu Gly Val Thr Arg Val Gly His 1805 1810 1815 Arg Met Asn Ile Glu Arg Ala Leu Arg Gln Leu Asp Gly Ser 1820 1825 17 323 PRT Homo sapiens misc_feature Incyte ID No 2739431CD1 17 Met Met Ser Pro Ser Gln Ala Ser Leu Leu Phe Leu Asn Val Cys 1 5 10 15 Ile Phe Ile Cys Gly Glu Ala Val Gln Gly Asn Cys Val His His 20 25 30 Ser Thr Asp Ser Ser Val Val Asn Ile Val Glu Asp Gly Ser Asn 35 40 45 Ala Lys Asp Glu Ser Lys Ser Asn Asp Thr Val Cys Lys Glu Asp 50 55 60 Cys Glu Glu Ser Cys Asp Val Lys Thr Lys Ile Thr Arg Glu Glu 65 70 75 Lys His Phe Met Cys Arg Asn Leu Gln Asn Ser Ile Val Ser Tyr 80 85 90 Thr Arg Ser Thr Lys Lys Leu Leu Arg Asn Met Met Asp Glu Gln 95 100 105 Gln Ala Ser Leu Asp Tyr Leu Ser Asn Gln Val Met Cys Asp Met 110 115 120 Asp Tyr Arg Gly Gly Gly Trp Thr Val Ile Gln Lys Arg Ile Asp 125 130 135 Gly Ile Ile Asp Phe Gln Arg Leu Trp Cys Asp Tyr Leu Asp Gly 140 145 150 Phe Gly Asp Leu Leu Gly Glu Phe Trp Leu Gly Leu Lys Lys Ile 155 160 165 Phe Tyr Ile Val Asn Gln Lys Asn Thr Ser Phe Met Leu Tyr Val 170 175 180 Ala Leu Glu Ser Glu Asp Asp Thr Leu Ala Tyr Ala Ser Tyr Asp 185 190 195 Asn Phe Trp Leu Glu Asp Glu Thr Arg Phe Phe Lys Met His Leu 200 205 210 Gly Arg Tyr Ser Gly Asn Ala Gly Asp Ala Phe Arg Gly Leu Lys 215 220 225 Lys Glu Asp Asn Gln Asn Ala Met Pro Phe Ser Thr Ser Asp Val 230 235 240 Asp Asn Asp Gly Cys Arg Pro Ala Cys Leu Val Asn Gly Gln Ser 245 250 255 Val Lys Ser Cys Ser His Leu His Asn Lys Thr Gly Trp Trp Phe 260 265 270 Asn Glu Cys Gly Leu Ala Asn Leu Asn Gly Ile His His Phe Ser 275 280 285 Gly Lys Leu Leu Ala Thr Gly Ile Gln Trp Gly Thr Trp Thr Lys 290 295 300 Asn Asn Ser Pro Val Lys Ile Lys Ser Val Ser Met Lys Ile Arg 305 310 315 Arg Met Tyr Asn Pro Tyr Phe Lys 320 18 644 PRT Homo sapiens misc_feature Incyte ID No 7473606CD1 18 Met Asp Gly Arg Gly Ala Phe Trp Thr Val Ala Ile Pro Arg Ala 1 5 10 15 Arg Gln Glu Gly Leu Gly Arg Leu Gly Leu Pro Phe Pro Val Lys 20 25 30 Arg Thr Pro Pro Ala Pro Gln Asn Pro Gly Gly Ser Thr Gln Ala 35 40 45 Pro Gln Arg Val Val Gly Lys Ser His Ser Gly Ile Arg Met Pro 50 55 60 Ala Lys Ser Arg Asn Leu Arg Leu Glu Ser Lys Leu Asn Arg Lys 65 70 75 Val Val Lys Tyr Lys Trp Gly Lys Gln Gly Ser Gly Ala Gly Arg 80 85 90 Glu Leu Val Pro Ala Phe Pro Thr Asn Ala Gly Leu Gly Arg Arg 95 100 105 Asp Arg Cys Arg Pro Pro Pro Ala Gly Gly Asp Val Ala Ser His 110 115 120 Gly Leu Pro Gly Ser Gly Val Gly Tyr Ser Cys Asn Gln Arg Glu 125 130 135 Glu Gly Leu Arg Gly Gly Cys Gly Gly Ile Pro His Val Pro Leu 140 145 150 Phe Leu Ser Pro Leu Pro Leu Asp Ala Ser Gly Gln Arg Pro Ser 155 160 165 Ser Thr Tyr Arg Gln Ser Leu Arg Arg Gly Leu Gly Thr Arg Ala 170 175 180 His Gln Ser Pro Ala Asn Glu Ile Pro Glu Leu Gly Asp Leu Arg 185 190 195 Gly Ser Arg Leu Ala Gln Glu Pro Ala Val Leu Phe Gly Leu Arg 200 205 210 Pro Ser Ile Ser Lys Arg Gly Leu Leu Ala Arg Arg Leu Trp Ala 215 220 225 Gln Pro Met Leu Leu Ser Gly Trp Val Val Ser Thr Thr Thr Thr 230 235 240 Ile Ile Thr Val Thr Val Thr Phe Thr Pro Thr Gly Leu Leu Cys 245 250 255 Val Lys His Ser Arg Gly Pro Leu Gln Pro Thr Cys Gln Glu Ser 260 265 270 Ala Pro Glu Asn Arg Val Gly Lys Ala Leu Ile Thr Phe Ser Lys 275 280 285 Gly Trp Arg Ala Ser Leu Arg Leu Ala Pro Pro Pro Ser Ala Leu 290 295 300 Leu Leu Arg Arg His Gly Pro Gly Gly Leu Pro Val Pro Gly Thr 305 310 315 Met Cys Asp Gly Ala Leu Leu Pro Pro Leu Val Leu Pro Val Leu 320 325 330 Leu Leu Leu Val Trp Gly Leu Asp Pro Gly Thr Gly Ser Ala Pro 335 340 345 Ser His Ser Pro Leu His Pro Ala Ser Cys Gly Tyr Leu Pro Ser 350 355 360 Ala Phe Ser Arg Arg Pro Gly Gly Pro Gly Ala Ala Ala Gly Pro 365 370 375 Leu Thr Ala Pro Glu Arg Arg Arg Arg Gly Pro Arg Pro Glu Tyr 380 385 390 Gly Asn Arg Val Ala Pro Trp Gln Ala Arg Arg Arg Arg Val Ser 395 400 405 Ala Arg Arg Cys Ala Ala Pro Phe Arg Glu Val Leu Ala Arg Leu 410 415 420 Arg Arg Arg Pro Ser Pro Gly Gly Ala Gly Gln Arg Gly Ala Val 425 430 435 Gly Asp Ala Ala Ala Asp Val Glu Val Val Leu Pro Trp Arg Val 440 445 450 Arg Pro Asp Asp Val His Leu Pro Pro Leu Pro Ala Ala Pro Gly 455 460 465 Pro Arg Arg Arg Arg Arg Pro Arg Thr Pro Pro Ala Ala Pro Arg 470 475 480 Ala Arg Pro Gly Glu Arg Ala Leu Leu Leu His Leu Pro Ala Phe 485 490 495 Gly Arg Asp Leu Tyr Leu Gln Leu Arg Arg Asp Leu Arg Phe Leu 500 505 510 Ser Arg Gly Phe Glu Val Glu Glu Ala Gly Ala Ala Arg Arg Arg 515 520 525 Gly Arg Pro Ala Glu Leu Cys Phe Tyr Ser Gly Arg Val Leu Gly 530 535 540 His Pro Gly Ser Leu Val Ser Leu Ser Ala Cys Gly Ala Ala Gly 545 550 555 Gly Leu Val Gly Leu Ile Gln Leu Gly Gln Glu Gln Val Leu Ile 560 565 570 Gln Pro Leu Asn Asn Ser Gln Gly Pro Phe Ser Gly Arg Glu His 575 580 585 Leu Ile Arg Arg Lys Trp Ser Leu Thr Pro Ser Pro Ser Ala Glu 590 595 600 Ala Gln Arg Pro Glu Gln Leu Cys Lys Val Leu Thr Val Pro Gln 605 610 615 Cys Leu Gly Leu Thr Trp Glu Asp Leu Lys Ser Gly Gly Trp Ser 620 625 630 Asp Leu Glu Val Pro His Ser Cys Val Trp Pro Gly Gly Gly 635 640 19 881 PRT Homo sapiens misc_feature Incyte ID No 3534918CD1 19 Met Glu His Gly Ala Leu Gly Ser Leu Gly Glu His Ala Ala Lys 1 5 10 15 Val Val Gly Lys Val Leu Arg Gln Glu Gln Asp Phe Val Ile Thr 20 25 30 His His Gln Arg Leu Val Gly Pro Thr Val Met Glu Gln Lys His 35 40 45 Arg Cys Lys Phe Ala Met Lys Glu Ile Val Gln Phe Met Ala Ser 50 55 60 Gly Arg Leu Gly Pro Val Gly Val Pro Val Leu Cys His Val Glu 65 70 75 Glu Val Pro Asp Arg Glu Gln Gly Ala Ala Pro Thr Leu Cys Pro 80 85 90 Ser Met Glu Glu Gly Asn Ala Lys Gly Val Met Ser Arg Val Ile 95 100 105 Phe Ala Thr Val Thr Leu Ala Gln Val Ser Val Gly Asn Thr His 110 115 120 Gly Asn Trp Ser Pro Trp Ser Gly Trp Gly Thr Cys Ser Arg Thr 125 130 135 Cys Asn Gly Gly Gln Met Arg Arg Tyr Arg Thr Cys Asp Asn Pro 140 145 150 Pro Pro Ser Asn Gly Gly Arg Ala Cys Gly Gly Pro Asp Ser Gln 155 160 165 Ile Gln Arg Cys Asn Thr Asp Met Cys Pro Val Asp Gly Ser Trp 170 175 180 Gly Ser Trp His Ser Trp Ser Gln Cys Ser Ala Ser Cys Gly Gly 185 190 195 Gly Glu Lys Thr Arg Lys Arg Leu Cys Asp His Pro Val Pro Val 200 205 210 Lys Gly Gly Arg Pro Cys Pro Gly Asp Thr Thr Gln Val Thr Arg 215 220 225 Cys Asn Val Gln Ala Cys Pro Gly Gly Pro Gln Arg Ala Arg Gly 230 235 240 Ser Val Ile Gly Asn Ile Asn Asp Val Glu Phe Gly Ile Ala Phe 245 250 255 Leu Asn Ala Thr Ile Thr Asp Ser Pro Asn Ser Asp Thr Arg Ile 260 265 270 Ile Arg Ala Lys Ile Thr Asn Val Pro Arg Ser Leu Gly Ser Ala 275 280 285 Met Arg Lys Ile Val Ser Ile Leu Asn Pro Ile Tyr Trp Thr Thr 290 295 300 Ala Lys Glu Ile Gly Glu Ala Val Asn Gly Phe Thr Leu Thr Asn 305 310 315 Ala Val Phe Lys Arg Glu Thr Gln Val Glu Phe Ala Thr Gly Glu 320 325 330 Ile Leu Gln Met Ser His Ile Ala Arg Gly Leu Asp Ser Asp Gly 335 340 345 Ser Leu Leu Leu Asp Ile Val Val Ser Gly Tyr Val Leu Gln Leu 350 355 360 Gln Ser Pro Ala Glu Val Thr Val Lys Asp Tyr Thr Glu Asp Tyr 365 370 375 Ile Gln Thr Gly Pro Gly Gln Leu Tyr Ala Tyr Ser Thr Arg Leu 380 385 390 Phe Thr Ile Asp Gly Ile Ser Ile Pro Tyr Thr Trp Asn His Thr 395 400 405 Val Phe Tyr Asp Gln Ala Gln Gly Arg Met Pro Phe Leu Val Glu 410 415 420 Thr Leu His Ala Ser Ser Val Glu Ser Asp Tyr Asn Gln Ile Glu 425 430 435 Glu Thr Leu Gly Phe Lys Ile His Ala Ser Ile Ser Lys Gly Asp 440 445 450 Arg Ser Asn Gln Cys Pro Ser Gly Phe Thr Leu Asp Ser Val Gly 455 460 465 Pro Phe Cys Ala Asp Glu Asp Glu Cys Ala Ala Gly Asn Pro Cys 470 475 480 Ser His Ser Cys His Asn Ala Met Gly Thr Tyr Tyr Cys Ser Cys 485 490 495 Pro Lys Gly Leu Thr Ile Ala Ala Asp Gly Arg Thr Cys Gln Asp 500 505 510 Ile Asp Glu Cys Ala Leu Gly Arg His Thr Cys His Ala Gly Gln 515 520 525 Asp Cys Asp Asn Thr Ile Gly Ser Tyr Arg Cys Val Val Arg Cys 530 535 540 Gly Ser Gly Phe Arg Arg Thr Ser Asp Gly Leu Ser Cys Gln Asp 545 550 555 Ile Asn Glu Cys Gln Glu Ser Ser Pro Cys His Gln Arg Cys Phe 560 565 570 Asn Ala Ile Gly Ser Phe His Cys Gly Cys Glu Pro Gly Tyr Gln 575 580 585 Leu Lys Gly Arg Lys Cys Met Asp Val Asn Glu Cys Arg Gln Asn 590 595 600 Val Cys Arg Pro Asp Gln His Cys Lys Asn Thr Arg Gly Gly Tyr 605 610 615 Lys Cys Ile Asp Leu Cys Pro Asn Gly Met Thr Lys Ala Glu Asn 620 625 630 Gly Thr Cys Ile Asp Ile Asp Glu Cys Lys Asp Gly Thr His Gln 635 640 645 Cys Arg Tyr Asn Gln Ile Cys Glu Asn Thr Arg Gly Ser Tyr Arg 650 655 660 Cys Val Cys Pro Arg Gly Tyr Arg Ser Gln Gly Val Gly Arg Pro 665 670 675 Cys Met Asp Ile Asp Glu Cys Glu Asn Thr Asp Ala Cys Gln His 680 685 690 Glu Cys Lys Asn Thr Phe Gly Ser Tyr Gln Cys Ile Cys Pro Pro 695 700 705 Gly Tyr Gln Leu Thr His Asn Gly Lys Thr Cys Gln Asp Ile Asp 710 715 720 Glu Cys Leu Glu Gln Asn Val His Cys Gly Pro Asn Arg Met Cys 725 730 735 Phe Asn Met Arg Gly Ser Tyr Gln Cys Ile Asp Thr Pro Cys Pro 740 745 750 Pro Asn Tyr Gln Arg Asp Pro Val Ser Gly Phe Cys Leu Lys Asn 755 760 765 Cys Pro Pro Asn Asp Leu Glu Cys Ala Leu Ser Pro Tyr Ala Leu 770 775 780 Glu Tyr Lys Leu Val Ser Leu Pro Phe Gly Ile Ala Thr Asn Gln 785 790 795 Asp Leu Ile Arg Leu Val Ala Tyr Thr Gln Asp Gly Val Met His 800 805 810 Pro Arg Thr Thr Phe Leu Met Val Asp Glu Glu Gln Thr Val Pro 815 820 825 Phe Ala Leu Arg Asp Glu Asn Leu Lys Gly Val Val Tyr Thr Thr 830 835 840 Arg Pro Leu Arg Glu Ala Glu Thr Tyr Arg Met Arg Val Arg Ala 845 850 855 Ser Ser Tyr Ser Ala Asn Gly Thr Ile Glu Tyr Gln Thr Thr Phe 860 865 870 Ile Val Tyr Ile Ala Val Ser Ala Tyr Pro Tyr 875 880 20 957 PRT Homo sapiens misc_feature Incyte ID No 2428715CD1 20 Met Gly Ala Ala Ala Val Arg Trp His Leu Cys Val Leu Leu Ala 1 5 10 15 Leu Gly Thr Arg Gly Arg Leu Ala Gly Gly Ser Gly Leu Pro Gly 20 25 30 Ser Val Asp Val Asp Glu Cys Ser Glu Gly Thr Asp Asp Cys His 35 40 45 Ile Asp Ala Ile Cys Gln Asn Thr Pro Lys Ser Tyr Lys Cys Leu 50 55 60 Cys Lys Pro Gly Tyr Lys Gly Glu Gly Lys Gln Cys Glu Asp Ile 65 70 75 Asp Glu Cys Glu Asn Asp Tyr Tyr Asn Gly Gly Cys Val His Glu 80 85 90 Cys Ile Asn Ile Pro Gly Asn Tyr Arg Cys Thr Cys Phe Asp Gly 95 100 105 Phe Met Leu Ala His Asp Gly His Asn Cys Leu Asp Val Asp Glu 110 115 120 Cys Gln Asp Asn Asn Gly Gly Cys Gln Gln Ile Cys Val Asn Ala 125 130 135 Met Gly Ser Tyr Glu Cys Gln Cys His Ser Gly Phe Phe Leu Ser 140 145 150 Asp Asn Gln His Thr Cys Ile His Arg Ser Asn Glu Gly Met Asn 155 160 165 Cys Met Asn Lys Asp His Gly Cys Ala His Ile Cys Arg Glu Thr 170 175 180 Pro Lys Gly Gly Val Ala Cys Asp Cys Arg Pro Gly Phe Asp Leu 185 190 195 Ala Gln Asn Gln Lys Asp Cys Thr Leu Thr Cys Asn Tyr Gly Asn 200 205 210 Gly Gly Cys Gln His Ser Cys Glu Asp Thr Asp Thr Gly Pro Thr 215 220 225 Cys Gly Cys His Gln Lys Tyr Ala Leu His Ser Asp Gly Arg Thr 230 235 240 Cys Ile Glu Lys Asp Glu Ala Ala Ile Glu Arg Ser Gln Phe Asn 245 250 255 Ala Thr Ser Val Ala Asp Val Asp Lys Arg Val Lys Arg Arg Leu 260 265 270 Leu Met Glu Thr Cys Ala Val Asn Asn Gly Gly Cys Asp Arg Thr 275 280 285 Cys Lys Asp Thr Ala Thr Gly Val Arg Cys Ser Cys Pro Val Gly 290 295 300 Phe Thr Leu Gln Pro Asp Gly Lys Thr Cys Lys Asp Ile Asn Glu 305 310 315 Cys Leu Val Asn Asn Gly Gly Cys Asp His Phe Cys Arg Asn Thr 320 325 330 Val Gly Ser Phe Glu Cys Gly Cys Arg Lys Gly Tyr Lys Leu Leu 335 340 345 Thr Asp Glu Arg Thr Cys Gln Asp Ile Asp Glu Cys Ser Phe Glu 350 355 360 Arg Thr Cys Asp His Ile Cys Ile Asn Ser Pro Gly Ser Phe Gln 365 370 375 Cys Leu Cys His Arg Gly Tyr Ile Leu Tyr Gly Thr Thr His Cys 380 385 390 Gly Asp Val Asp Glu Cys Ser Met Ser Asn Gly Ser Cys Asp Gln 395 400 405 Gly Cys Val Asn Thr Lys Gly Ser Tyr Glu Cys Val Cys Pro Pro 410 415 420 Gly Arg Arg Leu His Trp Asn Arg Lys Asp Cys Val Glu Thr Gly 425 430 435 Lys Cys Leu Ser Arg Ala Lys Thr Ser Pro Arg Ala Gln Leu Ser 440 445 450 Cys Ser Lys Ala Gly Gly Val Glu Ser Cys Phe Leu Ser Cys Pro 455 460 465 Ala His Thr Leu Phe Val Pro Asp Ala Pro Thr Thr Pro Ile Lys 470 475 480 Gln Lys Ala Arg Phe Lys Ile Arg Asp Ala Lys Cys His Leu Arg 485 490 495 Pro His Ser Gln Ala Arg Ala Lys Glu Thr Ala Arg Gln Pro Leu 500 505 510 Leu Asp His Cys His Val Thr Phe Val Thr Leu Lys Cys Asp Ser 515 520 525 Ser Lys Lys Arg Arg Arg Gly Arg Lys Ser Pro Ser Lys Glu Val 530 535 540 Ser His Ile Thr Ala Glu Phe Glu Ile Glu Thr Lys Met Glu Glu 545 550 555 Ala Ser Asp Thr Cys Glu Ala Asp Cys Leu Arg Lys Arg Ala Glu 560 565 570 Gln Ser Leu Gln Ala Ala Ile Lys Thr Leu Arg Lys Ser Ile Gly 575 580 585 Arg Gln Gln Phe Tyr Val Gln Val Ser Gly Thr Glu Tyr Glu Val 590 595 600 Ala Gln Arg Pro Ala Lys Ala Leu Glu Gly Gln Gly Ala Cys Gly 605 610 615 Ala Gly Gln Val Leu Gln Asp Ser Lys Cys Val Ala Cys Gly Pro 620 625 630 Gly Thr His Phe Gly Gly Glu Leu Gly Gln Cys Val Pro Cys Met 635 640 645 Pro Gly Thr Tyr Gln Asp Met Glu Gly Gln Leu Ser Cys Thr Pro 650 655 660 Cys Pro Ser Ser Asp Gly Leu Gly Leu Pro Gly Ala Arg Asn Val 665 670 675 Ser Glu Cys Gly Gly Gln Cys Ser Pro Gly Phe Phe Ser Ala Asp 680 685 690 Gly Phe Lys Pro Cys Gln Ala Cys Pro Val Gly Thr Tyr Gln Pro 695 700 705 Glu Pro Gly Arg Thr Gly Cys Phe Pro Cys Gly Gly Gly Leu Leu 710 715 720 Thr Lys His Glu Gly Thr Thr Ser Phe Gln Asp Cys Glu Ala Lys 725 730 735 Val His Cys Ser Pro Gly His His Tyr Asn Thr Thr Thr His Arg 740 745 750 Cys Ile Arg Cys Pro Val Gly Thr Tyr Gln Pro Glu Phe Gly Gln 755 760 765 Asn His Cys Ile Thr Cys Pro Gly Asn Thr Ser Thr Asp Phe Asp 770 775 780 Gly Ser Thr Asn Val Thr His Cys Lys Asn Gln His Cys Gly Gly 785 790 795 Glu Leu Gly Asp Tyr Thr Gly Tyr Ile Glu Ser Pro Asn Tyr Pro 800 805 810 Gly Asp Tyr Pro Ala Asn Ala Glu Cys Val Trp His Ile Ala Pro 815 820 825 Pro Pro Lys Arg Arg Ile Leu Ile Val Val Pro Glu Ile Phe Leu 830 835 840 Pro Ile Glu Asp Glu Cys Gly Asp Val Leu Val Met Arg Lys Ser 845 850 855 Ala Ser Pro Thr Ser Ile Thr Thr Tyr Glu Thr Cys Gln Thr Tyr 860 865 870 Glu Arg Pro Ile Ala Phe Thr Ser Arg Ser Arg Lys Leu Trp Ile 875 880 885 Gln Phe Lys Ser Asn Glu Gly Asn Ser Gly Lys Gly Phe Gln Val 890 895 900 Pro Tyr Val Thr Tyr Asp Glu Asp Tyr Gln Gln Leu Ile Glu Asp 905 910 915 Ile Val Arg Asp Gly Arg Leu Tyr Ala Ser Glu Asn His Gln Glu 920 925 930 Ile Leu Lys Asp Lys Lys Leu Ile Lys Ala Leu Phe Asp Val Leu 935 940 945 Ala His Pro Gln Asn Arg Gly Leu Val Ser Ser Cys 950 955 21 1393 PRT Homo sapiens misc_feature Incyte ID No 3351332CD1 21 Met Gly Ala Ser Arg Asp Arg Gly Leu Ala Ala Leu Trp Cys Leu 1 5 10 15 Gly Leu Leu Gly Gly Leu Ala Arg Val Ala Gly Thr His Tyr Arg 20 25 30 Tyr Leu Trp Arg Gly Cys Tyr Pro Cys His Leu Gly Gln Ala Gly 35 40 45 Tyr Pro Val Ser Ala Gly Asp Gln Arg Pro Asp Val Asp Glu Cys 50 55 60 Arg Thr His Asn Gly Gly Cys Gln His Arg Cys Val Asn Thr Pro 65 70 75 Gly Ser Tyr Leu Cys Glu Cys Lys Pro Gly Phe Arg Leu His Thr 80 85 90 Asp Ser Arg Thr Cys Leu Ala Ile Asn Ser Cys Ala Leu Gly Asn 95 100 105 Gly Gly Cys Gln His His Cys Val Gln Leu Thr Ile Thr Arg His 110 115 120 Arg Cys Gln Cys Arg Pro Gly Phe Gln Leu Gln Glu Asp Gly Arg 125 130 135 His Cys Val Arg Arg Ser Pro Cys Ala Asn Arg Asn Gly Ser Cys 140 145 150 Met His Arg Cys Gln Val Val Arg Gly Leu Ala Arg Cys Glu Cys 155 160 165 His Val Gly Tyr Gln Leu Ala Ala Asp Gly Lys Ala Cys Pro Asp 170 175 180 Val Asp Glu Cys Ala Ala Gly Leu Ala Gln Cys Ala His Gly Cys 185 190 195 Leu Asn Thr Gln Gly Ser Phe Lys Cys Val Cys His Ala Gly Tyr 200 205 210 Glu Leu Gly Ala Asp Gly Arg Gln Cys Tyr Arg Ile Glu Met Glu 215 220 225 Ile Val Asn Ser Cys Glu Ala Asn Asn Gly Gly Cys Ser His Gly 230 235 240 Cys Ser His Thr Ser Ala Gly Pro Leu Cys Thr Cys Pro Arg Gly 245 250 255 Tyr Glu Leu Asp Thr Asp Gln Arg Thr Cys Ile Asp Val Asp Asp 260 265 270 Cys Ala Asp Ser Pro Cys Cys Gln Gln Val Cys Thr Asn Asn Pro 275 280 285 Gly Gly Tyr Glu Cys Gly Cys Tyr Ala Gly Tyr Arg Leu Ser Ala 290 295 300 Asp Gly Cys Gly Cys Glu Asp Val Asp Glu Cys Ala Ser Ser Arg 305 310 315 Gly Gly Cys Glu His His Cys Thr Asn Leu Ala Gly Ser Phe Gln 320 325 330 Cys Ser Cys Glu Ala Gly Tyr Arg Leu His Glu Asp Arg Arg Gly 335 340 345 Cys Ser Pro Leu Glu Glu Pro Met Val Asp Leu Asp Gly Glu Leu 350 355 360 Pro Phe Val Arg Pro Leu Pro His Ile Ala Val Leu Gln Asp Glu 365 370 375 Leu Pro Gln Leu Phe Gln Asp Asp Asp Val Gly Ala Asp Glu Glu 380 385 390 Glu Ala Glu Leu Arg Gly Glu His Thr Leu Thr Glu Lys Phe Val 395 400 405 Cys Leu Asp Asp Ser Phe Gly His Asp Cys Ser Leu Thr Cys Asp 410 415 420 Asp Cys Arg Asn Gly Gly Thr Cys Leu Leu Gly Leu Asp Gly Cys 425 430 435 Asp Cys Pro Glu Gly Trp Thr Gly Leu Ile Cys Asn Glu Thr Cys 440 445 450 Pro Pro Asp Thr Phe Gly Lys Asn Cys Ser Phe Ser Cys Ser Cys 455 460 465 Gln Asn Gly Gly Thr Cys Asp Ser Val Thr Gly Ala Cys Arg Cys 470 475 480 Pro Pro Gly Val Ser Gly Thr Asn Cys Glu Asp Gly Cys Pro Lys 485 490 495 Gly Tyr Tyr Gly Lys His Cys Arg Lys Lys Cys Asn Cys Ala Asn 500 505 510 Arg Gly Arg Cys His Arg Leu Tyr Gly Ala Cys Leu Cys Asp Pro 515 520 525 Gly Leu Tyr Gly Arg Phe Cys His Leu Thr Cys Pro Pro Trp Ala 530 535 540 Phe Gly Pro Gly Cys Ser Glu Glu Cys Gln Cys Val Gln Pro His 545 550 555 Thr Gln Ser Cys Asp Lys Arg Asp Gly Ser Cys Ser Cys Lys Ala 560 565 570 Gly Phe Arg Gly Glu Arg Cys Gln Ala Glu Cys Glu Leu Gly Tyr 575 580 585 Phe Gly Pro Gly Cys Trp Gln Ala Cys Thr Cys Pro Val Gly Val 590 595 600 Ala Cys Asp Ser Val Ser Gly Glu Cys Gly Lys Arg Cys Pro Ala 605 610 615 Gly Phe Gln Gly Glu Asp Cys Gly Gln Glu Cys Pro Val Gly Thr 620 625 630 Phe Gly Val Asn Cys Ser Ser Ser Cys Ser Cys Gly Gly Ala Pro 635 640 645 Cys His Gly Val Thr Gly Gln Cys Arg Cys Pro Pro Gly Arg Thr 650 655 660 Gly Glu Asp Cys Glu Ala Asp Cys Pro Glu Gly Arg Trp Gly Leu 665 670 675 Gly Cys Gln Glu Ile Cys Pro Ala Cys Gln His Ala Ala Arg Cys 680 685 690 Asp Pro Glu Thr Gly Ala Cys Leu Cys Leu Pro Gly Phe Val Gly 695 700 705 Ser Arg Cys Gln Asp Val Cys Pro Ala Gly Trp Tyr Gly Pro Ser 710 715 720 Cys Gln Thr Arg Cys Ser Cys Ala Asn Asp Gly His Cys His Pro 725 730 735 Ala Thr Gly His Cys Ser Cys Ala Pro Gly Trp Thr Gly Phe Ser 740 745 750 Cys Gln Arg Ala Cys Asp Thr Gly His Trp Gly Pro Asp Cys Ser 755 760 765 His Pro Cys Asn Cys Ser Ala Gly His Gly Ser Cys Asp Ala Ile 770 775 780 Ser Gly Leu Cys Leu Cys Glu Ala Gly Tyr Val Gly Pro Arg Cys 785 790 795 Glu Gln Gln Cys Pro Gln Gly His Phe Gly Pro Gly Cys Glu Gln 800 805 810 Leu Cys Gln Cys Gln His Gly Ala Ala Cys Asp His Val Ser Gly 815 820 825 Ala Cys Thr Cys Pro Ala Gly Trp Arg Gly Thr Phe Cys Glu His 830 835 840 Ala Cys Pro Ala Gly Phe Phe Gly Leu Asp Cys Arg Ser Ala Cys 845 850 855 Asn Cys Thr Ala Gly Ala Ala Cys Asp Ala Val Asn Gly Ser Cys 860 865 870 Leu Cys Pro Ala Gly Arg Arg Gly Pro Arg Cys Ala Glu Thr Cys 875 880 885 Pro Ala His Thr Tyr Gly His Asn Cys Ser Gln Ala Cys Ala Cys 890 895 900 Phe Asn Gly Ala Ser Cys Asp Pro Val His Gly Gln Cys His Cys 905 910 915 Ala Pro Gly Trp Met Gly Pro Ser Cys Leu Gln Glu Cys Leu Pro 920 925 930 Arg Asp Val Arg Ala Gly Cys Arg His Ser Gly Gly Cys Leu Asn 935 940 945 Gly Gly Leu Cys Asp Pro His Thr Gly Arg Cys Leu Cys Pro Ala 950 955 960 Gly Trp Thr Gly Asp Lys Cys Gln Ser Pro Cys Leu Arg Gly Trp 965 970 975 Phe Gly Glu Ala Cys Ala Gln Arg Cys Ser Cys Pro Pro Gly Ala 980 985 990 Ala Cys His His Val Thr Gly Ala Cys Arg Cys Pro Pro Gly Phe 995 1000 1005 Thr Gly Ser Gly Cys Glu Gln Ala Cys Pro Pro Gly Ser Phe Gly 1010 1015 1020 Glu Asp Cys Ala Gln Met Cys Gln Cys Pro Gly Glu Asn Pro Ala 1025 1030 1035 Cys His Pro Ala Thr Gly Thr Cys Ser Cys Ala Ala Gly Tyr His 1040 1045 1050 Gly Pro Ser Cys Gln Gln Arg Cys Pro Pro Gly Arg Tyr Gly Pro 1055 1060 1065 Gly Cys Glu Gln Leu Cys Gly Cys Leu Asn Gly Gly Ser Cys Asp 1070 1075 1080 Ala Ala Thr Gly Ala Cys Arg Cys Pro Thr Gly Phe Leu Gly Thr 1085 1090 1095 Asp Cys Asn Leu Thr Cys Pro Gln Gly Arg Phe Gly Pro Asn Cys 1100 1105 1110 Thr His Val Cys Gly Cys Gly Gln Gly Ala Ala Cys Asp Pro Val 1115 1120 1125 Thr Gly Thr Cys Leu Cys Pro Pro Gly Arg Ala Gly Val Arg Cys 1130 1135 1140 Glu Arg Gly Cys Pro Gln Asn Arg Phe Gly Val Gly Cys Glu His 1145 1150 1155 Thr Cys Ser Cys Arg Asn Gly Gly Leu Cys His Ala Ser Asn Gly 1160 1165 1170 Ser Cys Ser Cys Gly Leu Gly Trp Thr Gly Arg His Cys Glu Leu 1175 1180 1185 Ala Cys Pro Pro Gly Arg Tyr Gly Ala Ala Cys His Leu Glu Cys 1190 1195 1200 Ser Cys His Asn Asn Ser Thr Cys Glu Pro Ala Thr Gly Thr Cys 1205 1210 1215 Arg Cys Gly Pro Gly Phe Tyr Gly Gln Ala Cys Glu His Pro Cys 1220 1225 1230 Pro Pro Gly Phe His Gly Ala Gly Cys Gln Gly Leu Cys Trp Cys 1235 1240 1245 Gln His Gly Ala Pro Cys Asp Pro Ile Ser Gly Arg Cys Leu Cys 1250 1255 1260 Pro Ala Gly Phe His Gly His Phe Cys Glu Arg Gly Cys Glu Pro 1265 1270 1275 Gly Ser Phe Gly Glu Gly Cys His Gln Arg Cys Asp Cys Asp Gly 1280 1285 1290 Gly Ala Pro Cys Asp Pro Val Thr Gly Leu Cys Leu Cys Pro Pro 1295 1300 1305 Gly Arg Ser Gly Ala Thr Cys Asn Leu Asp Cys Arg Arg Gly Gln 1310 1315 1320 Phe Gly Pro Ser Cys Thr Leu His Cys Asp Cys Gly Gly Gly Ala 1325 1330 1335 Asp Cys Asp Pro Val Ser Gly Gln Cys His Cys Val Asp Gly Tyr 1340 1345 1350 Met Gly Pro Thr Cys Arg Glu Gly Gly Pro Leu Arg Leu Pro Glu 1355 1360 1365 Asn Pro Ser Leu Ala Gln Gly Ser Ala Gly Thr Leu Pro Ala Ser 1370 1375 1380 Ser Arg Pro Thr Ser Arg Ser Gly Gly Pro Ala Arg His 1385 1390 22 3695 PRT Homo sapiens misc_feature Incyte ID No 6382722CD1 22 Met Ala Lys Arg Leu Cys Ala Gly Ser Ala Leu Cys Val Arg Gly 1 5 10 15 Pro Arg Gly Pro Ala Pro Leu Leu Leu Val Gly Leu Ala Leu Leu 20 25 30 Gly Ala Ala Arg Ala Arg Glu Glu Ala Gly Gly Gly Phe Ser Leu 35 40 45 His Pro Pro Tyr Phe Asn Leu Ala Glu Gly Ala Arg Ile Ala Ala 50 55 60 Ser Ala Thr Cys Gly Glu Glu Ala Pro Ala Arg Gly Ser Pro Arg 65 70 75 Pro Thr Glu Asp Leu Tyr Cys Lys Leu Val Gly Gly Pro Val Ala 80 85 90 Gly Gly Asp Pro Asn Gln Thr Ile Arg Gly Gln Tyr Cys Asp Ile 95 100 105 Cys Thr Ala Ala Asn Ser Asn Lys Ala His Pro Ala Ser Asn Ala 110 115 120 Ile Asp Gly Thr Glu Arg Trp Trp Gln Ser Pro Pro Leu Ser Arg 125 130 135 Gly Leu Glu Tyr Asn Glu Val Asn Val Thr Leu Asp Leu Gly Gln 140 145 150 Val Phe His Val Ala Tyr Val Leu Ile Lys Phe Ala Asn Ser Pro 155 160 165 Arg Pro Asp Leu Trp Val Leu Glu Arg Ser Met Asp Phe Gly Arg 170 175 180 Thr Tyr Gln Pro Trp Gln Phe Phe Ala Ser Ser Lys Arg Asp Cys 185 190 195 Leu Glu Arg Phe Gly Pro Gln Thr Leu Glu Arg Ile Thr Arg Asp 200 205 210 Asp Ala Ala Ile Cys Thr Thr Glu Tyr Ser Arg Ile Val Pro Leu 215 220 225 Glu Asn Gly Glu Ile Val Val Ser Leu Val Asn Gly Arg Pro Gly 230 235 240 Ala Met Asn Phe Ser Tyr Ser Pro Leu Leu Arg Glu Phe Thr Lys 245 250 255 Ala Thr Asn Val Arg Leu Arg Phe Leu Arg Thr Asn Thr Leu Leu 260 265 270 Gly His Leu Met Gly Lys Ala Leu Arg Asp Pro Thr Val Thr Arg 275 280 285 Arg Tyr Tyr Tyr Ser Ile Lys Asp Ile Ser Ile Gly Gly Arg Cys 290 295 300 Val Cys His Gly His Ala Asp Ala Cys Asp Ala Lys Asp Pro Thr 305 310 315 Asp Pro Phe Arg Leu Gln Cys Thr Cys Gln His Asn Thr Cys Gly 320 325 330 Gly Thr Cys Asp Arg Cys Cys Pro Gly Phe Asn Gln Gln Pro Trp 335 340 345 Lys Pro Ala Thr Ala Asn Ser Ala Asn Glu Cys Gln Ser Cys Asn 350 355 360 Cys Tyr Gly His Ala Thr Asp Cys Tyr Tyr Asp Pro Glu Val Asp 365 370 375 Arg Arg Arg Ala Ser Gln Ser Leu Asp Gly Thr Tyr Gln Gly Gly 380 385 390 Gly Val Cys Ile Asp Cys Gln His His Thr Ala Gly Val Asn Cys 395 400 405 Glu Arg Cys Leu Pro Gly Phe Tyr Arg Ser Pro Asn His Pro Leu 410 415 420 Asp Ser Pro His Val Cys Arg Arg Cys Asn Cys Glu Ser Asp Phe 425 430 435 Thr Asp Gly Thr Cys Glu Asp Leu Thr Gly Arg Cys Tyr Cys Arg 440 445 450 Pro Asn Phe Ser Gly Glu Arg Cys Asp Val Cys Ala Glu Gly Phe 455 460 465 Thr Gly Phe Pro Ser Cys Tyr Pro Thr Pro Ser Ser Ser Asn Asp 470 475 480 Thr Arg Glu Gln Val Leu Pro Ala Gly Gln Ile Val Asn Cys Asp 485 490 495 Cys Ser Ala Ala Gly Thr Gln Gly Asn Ala Cys Arg Lys Asp Pro 500 505 510 Arg Val Gly Arg Cys Leu Cys Lys Pro Asn Phe Gln Gly Thr His 515 520 525 Cys Glu Leu Cys Ala Pro Gly Phe Tyr Gly Pro Gly Cys Gln Pro 530 535 540 Cys Gln Cys Ser Ser Pro Gly Val Ala Asp Asp Arg Cys Asp Pro 545 550 555 Asp Thr Gly Gln Cys Arg Cys Arg Val Gly Phe Glu Gly Ala Thr 560 565 570 Cys Asp Arg Cys Ala Pro Gly Tyr Phe His Phe Pro Leu Cys Gln 575 580 585 Leu Cys Gly Cys Ser Pro Ala Gly Thr Leu Pro Glu Gly Cys Asp 590 595 600 Glu Ala Gly Arg Cys Leu Cys Gln Pro Glu Phe Ala Gly Pro His 605 610 615 Cys Asp Arg Cys Arg Pro Gly Tyr His Gly Phe Pro Asn Cys Gln 620 625 630 Ala Cys Thr Cys Asp Pro Arg Gly Ala Leu Asp Gln Leu Cys Gly 635 640 645 Ala Gly Gly Leu Cys Arg Cys Arg Pro Gly Tyr Thr Gly Thr Ala 650 655 660 Cys Gln Glu Cys Ser Pro Gly Phe His Gly Phe Pro Ser Cys Val 665 670 675 Pro Cys His Cys Ser Ala Glu Gly Ser Leu His Ala Ala Cys Asp 680 685 690 Pro Arg Ser Gly Gln Cys Ser Cys Arg Pro Arg Val Thr Gly Leu 695 700 705 Arg Cys Asp Thr Cys Val Pro Gly Ala Tyr Asn Phe Pro Tyr Cys 710 715 720 Glu Ala Gly Ser Cys His Pro Ala Gly Leu Ala Pro Val Asp Pro 725 730 735 Ala Leu Pro Glu Ala Gln Val Pro Cys Met Cys Arg Ala His Val 740 745 750 Glu Gly Pro Ser Cys Asp Arg Cys Lys Pro Gly Phe Trp Gly Leu 755 760 765 Ser Pro Ser Asn Pro Glu Gly Cys Thr Arg Cys Ser Cys Asp Leu 770 775 780 Arg Gly Thr Leu Gly Gly Val Ala Glu Cys Gln Pro Gly Thr Gly 785 790 795 Gln Cys Phe Cys Lys Pro His Val Cys Gly Gln Ala Cys Ala Ser 800 805 810 Cys Lys Asp Gly Phe Phe Gly Leu Asp Gln Ala Asp Tyr Phe Gly 815 820 825 Cys Arg Ser Cys Arg Cys Asp Ile Gly Gly Ala Leu Gly Gln Ser 830 835 840 Cys Glu Pro Arg Thr Gly Val Cys Arg Cys Arg Pro Asn Thr Gln 845 850 855 Gly Pro Thr Cys Ser Glu Pro Ala Arg Asp His Tyr Leu Pro Asp 860 865 870 Leu His His Leu Arg Leu Glu Leu Glu Glu Ala Ala Thr Pro Glu 875 880 885 Gly His Ala Val Arg Phe Gly Phe Asn Pro Leu Glu Phe Glu Asn 890 895 900 Phe Ser Trp Arg Gly Tyr Ala Gln Met Ala Pro Val Gln Pro Arg 905 910 915 Ile Val Ala Arg Leu Asn Leu Thr Ser Pro Asp Leu Phe Trp Leu 920 925 930 Val Phe Arg Tyr Val Asn Arg Gly Ala Met Ser Val Ser Gly Arg 935 940 945 Val Ser Val Arg Glu Glu Gly Arg Ser Ala Ala Cys Ala Asn Cys 950 955 960 Thr Ala Gln Ser Gln Pro Val Ala Phe Pro Pro Ser Thr Glu Pro 965 970 975 Ala Phe Ile Thr Val Pro Gln Arg Gly Phe Gly Glu Pro Phe Val 980 985 990 Leu Asn Pro Gly Thr Trp Ala Leu Arg Val Glu Ala Glu Gly Val 995 1000 1005 Leu Leu Asp Tyr Val Val Leu Leu Pro Ser Ala Tyr Tyr Glu Ala 1010 1015 1020 Ala Leu Leu Gln Leu Arg Val Thr Glu Ala Cys Thr Tyr Arg Pro 1025 1030 1035 Ser Ala Gln Gln Ser Gly Asp Asn Cys Leu Leu Tyr Thr His Leu 1040 1045 1050 Pro Leu Asp Gly Phe Pro Ser Ala Ala Gly Leu Glu Ala Leu Cys 1055 1060 1065 Arg Gln Asp Asn Ser Leu Pro Arg Pro Cys Pro Thr Glu Gln Leu 1070 1075 1080 Ser Pro Ser His Pro Pro Leu Ile Thr Cys Thr Gly Ser Asp Val 1085 1090 1095 Asp Val Gln Leu Gln Val Ala Val Pro Gln Pro Gly Arg Tyr Ala 1100 1105 1110 Leu Val Val Glu Tyr Ala Asn Glu Asp Ala Arg Gln Glu Val Gly 1115 1120 1125 Val Ala Val His Thr Pro Gln Arg Ala Pro Gln Gln Gly Leu Leu 1130 1135 1140 Ser Leu His Pro Cys Leu Tyr Ser Thr Leu Cys Arg Gly Thr Ala 1145 1150 1155 Arg Asp Thr Gln Asp His Leu Ala Val Phe His Leu Asp Ser Glu 1160 1165 1170 Ala Ser Val Arg Leu Thr Ala Glu Gln Ala Arg Phe Phe Leu His 1175 1180 1185 Gly Val Thr Leu Val Pro Ile Glu Glu Phe Ser Pro Glu Phe Val 1190 1195 1200 Glu Pro Arg Val Ser Cys Ile Ser Ser His Gly Ala Phe Gly Pro 1205 1210 1215 Asn Ser Ala Ala Cys Leu Pro Ser Arg Phe Pro Lys Pro Pro Gln 1220 1225 1230 Pro Ile Ile Leu Arg Asp Cys Gln Val Ile Pro Leu Pro Pro Gly 1235 1240 1245 Leu Pro Leu Thr His Ala Gln Asp Leu Thr Pro Ala Thr Ser Pro 1250 1255 1260 Ala Gly Pro Arg Pro Arg Pro Pro Thr Ala Val Asp Pro Asp Ala 1265 1270 1275 Glu Pro Thr Leu Leu Arg Glu Pro Gln Ala Thr Val Val Phe Thr 1280 1285 1290 Thr His Val Pro Thr Leu Gly Arg Tyr Ala Phe Leu Leu His Gly 1295 1300 1305 Tyr Gln Pro Ala His Pro Thr Phe Pro Val Glu Val Leu Ile Asn 1310 1315 1320 Ala Gly Arg Val Trp Gln Gly His Ala Asn Ala Ser Phe Cys Pro 1325 1330 1335 His Gly Tyr Gly Cys Arg Thr Leu Val Val Cys Glu Gly Gln Ala 1340 1345 1350 Leu Leu Asp Val Thr His Ser Glu Leu Thr Val Thr Val Arg Val 1355 1360 1365 Pro Glu Gly Arg Trp Leu Trp Leu Asp Tyr Val Leu Val Val Pro 1370 1375 1380 Glu Asn Val Tyr Ser Phe Gly Tyr Leu Arg Glu Glu Pro Leu Asp 1385 1390 1395 Lys Ser Tyr Asp Phe Ile Ser His Cys Ala Ala Gln Gly Tyr His 1400 1405 1410 Ile Ser Pro Ser Ser Ser Ser Leu Phe Cys Arg Asn Ala Ala Ala 1415 1420 1425 Ser Leu Ser Leu Phe Tyr Asn Asn Gly Ala Arg Pro Cys Gly Cys 1430 1435 1440 His Glu Val Gly Ala Thr Gly Pro Thr Cys Glu Pro Phe Gly Gly 1445 1450 1455 Gln Cys Pro Cys His Ala His Val Ile Gly Arg Asp Cys Ser Arg 1460 1465 1470 Cys Ala Thr Gly Tyr Trp Gly Phe Pro Asn Cys Arg Pro Cys Asp 1475 1480 1485 Cys Gly Ala Arg Leu Cys Asp Glu Leu Thr Gly Gln Cys Ile Cys 1490 1495 1500 Pro Pro Arg Thr Ile Pro Pro Asp Cys Leu Leu Cys Gln Pro Gln 1505 1510 1515 Thr Phe Gly Cys His Pro Leu Val Gly Cys Glu Glu Cys Asn Cys 1520 1525 1530 Ser Gly Pro Gly Ile Gln Glu Leu Thr Asp Pro Thr Cys Asp Thr 1535 1540 1545 Asp Ser Gly Gln Cys Lys Cys Arg Pro Asn Val Thr Gly Arg Arg 1550 1555 1560 Cys Asp Thr Cys Ser Pro Gly Phe His Gly Tyr Pro Arg Cys Arg 1565 1570 1575 Pro Cys Asp Cys His Glu Ala Gly Thr Ala Pro Gly Val Cys Asp 1580 1585 1590 Pro Leu Thr Gly Gln Cys Tyr Cys Lys Glu Asn Val Gln Gly Pro 1595 1600 1605 Lys Cys Asp Gln Cys Ser Leu Gly Thr Phe Ser Leu Asp Ala Ala 1610 1615 1620 Asn Pro Lys Gly Cys Thr Arg Cys Phe Cys Phe Gly Ala Thr Glu 1625 1630 1635 Arg Cys Arg Ser Ser Ser Tyr Thr Arg Gln Glu Phe Val Asp Met 1640 1645 1650 Glu Gly Trp Val Leu Leu Ser Thr Asp Arg Gln Val Val Pro His 1655 1660 1665 Glu Arg Gln Pro Gly Thr Glu Met Leu Arg Ala Asp Leu Arg His 1670 1675 1680 Val Pro Glu Ala Val Pro Glu Ala Phe Pro Glu Leu Tyr Trp Gln 1685 1690 1695 Ala Pro Pro Ser Tyr Leu Gly Asp Arg Val Ser Ser Tyr Gly Gly 1700 1705 1710 Thr Leu Arg Tyr Glu Leu His Ser Glu Thr Gln Arg Gly Asp Val 1715 1720 1725 Phe Val Pro Met Glu Ser Arg Pro Asp Val Val Leu Gln Gly Asn 1730 1735 1740 Gln Met Ser Ile Thr Phe Leu Glu Pro Ala Tyr Pro Thr Pro Gly 1745 1750 1755 His Val His Arg Gly Gln Leu Gln Leu Val Glu Gly Asn Phe Arg 1760 1765 1770 His Thr Glu Thr Arg Asn Thr Val Ser Arg Glu Glu Leu Met Met 1775 1780 1785 Val Leu Ala Ser Leu Glu Gln Leu Gln Ile Arg Ala Leu Phe Ser 1790 1795 1800 Gln Ile Ser Ser Ala Val Ser Leu Arg Arg Val Ala Leu Glu Val 1805 1810 1815 Ala Ser Pro Ala Gly Gln Gly Ala Leu Ala Ser Asn Val Glu Leu 1820 1825 1830 Cys Leu Cys Pro Ala Ser Tyr Arg Gly Asp Ser Cys Gln Glu Cys 1835 1840 1845 Ala Pro Gly Phe Tyr Arg Asp Val Lys Gly Leu Phe Leu Gly Arg 1850 1855 1860 Cys Val Pro Cys Gln Cys His Gly His Ser Asp Arg Cys Leu Pro 1865 1870 1875 Gly Ser Gly Val Cys Val Asp Cys Gln His Asn Thr Glu Gly Ala 1880 1885 1890 His Cys Glu Arg Cys Gln Ala Gly Phe Met Ser Ser Arg Asp Asp 1895 1900 1905 Pro Ser Ala Pro Cys Val Ser Cys Pro Cys Pro Leu Ser Val Pro 1910 1915 1920 Ser Asn Asn Phe Ala Glu Gly Cys Val Leu Arg Gly Gly Arg Thr 1925 1930 1935 Gln Cys Leu Cys Lys Pro Gly Tyr Ala Gly Ala Ser Cys Glu Arg 1940 1945 1950 Cys Ala Pro Gly Phe Phe Gly Asn Pro Leu Val Leu Gly Ser Ser 1955 1960 1965 Cys Gln Pro Cys Asp Cys Ser Gly Asn Gly Asp Pro Asn Leu Leu 1970 1975 1980 Phe Ser Asp Cys Asp Pro Leu Thr Gly Ala Cys Arg Gly Cys Leu 1985 1990 1995 Arg His Thr Thr Gly Pro Arg Cys Glu Ile Cys Ala Pro Gly Phe 2000 2005 2010 Tyr Gly Asn Ala Leu Leu Pro Gly Asn Cys Thr Arg Cys Asp Cys 2015 2020 2025 Thr Pro Cys Gly Thr Glu Ala Cys Asp Pro His Ser Gly His Cys 2030 2035 2040 Leu Cys Lys Ala Gly Val Thr Gly Arg Arg Cys Asp Arg Cys Gln 2045 2050 2055 Glu Gly His Phe Gly Phe Asn Gly Cys Gly Gly Cys Arg Pro Cys 2060 2065 2070 Ala Cys Gly Pro Ala Ala Glu Gly Ser Glu Cys His Pro Gln Ser 2075 2080 2085 Gly Gln Cys His Cys Arg Pro Gly Thr Met Gly Pro Gln Cys Arg 2090 2095 2100 Glu Cys Ala Pro Gly Tyr Trp Gly Leu Pro Glu Gln Gly Cys Arg 2105 2110 2115 Arg Cys Gln Cys Pro Gly Gly Arg Cys Asp Pro His Thr Gly Arg 2120 2125 2130 Cys Asn Cys Pro Pro Gly Leu Ser Gly Glu Arg Cys Asp Thr Cys 2135 2140 2145 Ser Gln Gln His Gln Val Pro Val Pro Gly Gly Pro Val Gly His 2150 2155 2160 Ser Ile His Cys Glu Val Cys Asp His Cys Val Val Leu Leu Leu 2165 2170 2175 Asp Asp Leu Glu Arg Ala Gly Ala Leu Leu Pro Ala Ile His Glu 2180 2185 2190 Gln Leu Arg Gly Ile Asn Ala Ser Ser Met Ala Trp Ala Arg Leu 2195 2200 2205 His Arg Leu Asn Ala Ser Ile Ala Asp Leu Gln Ser Gln Leu Arg 2210 2215 2220 Ser Pro Leu Gly Pro Arg His Glu Thr Ala Gln Gln Leu Glu Val 2225 2230 2235 Leu Glu Gln Gln Ser Thr Ser Leu Gly Gln Asp Ala Arg Arg Leu 2240 2245 2250 Gly Gly Gln Ala Val Gly Thr Arg Asp Gln Ala Ser Gln Leu Leu 2255 2260 2265 Ala Gly Thr Glu Ala Thr Leu Gly His Ala Lys Thr Leu Leu Ala 2270 2275 2280 Ala Ile Arg Ala Val Asp Arg Thr Leu Ser Glu Leu Met Ser Gln 2285 2290 2295 Thr Gly His Leu Gly Leu Ala Asn Ala Ser Ala Pro Ser Gly Glu 2300 2305 2310 Gln Leu Leu Arg Thr Leu Ala Glu Val Glu Arg Leu Leu Trp Glu 2315 2320 2325 Met Arg Ala Arg Asp Leu Gly Ala Pro Gln Ala Ala Ala Glu Ala 2330 2335 2340 Glu Leu Ala Ala Ala Gln Arg Leu Leu Ala Arg Val Gln Glu Gln 2345 2350 2355 Leu Ser Ser Leu Trp Glu Glu Asn Gln Ala Leu Ala Thr Gln Thr 2360 2365 2370 Arg Asp Arg Leu Ala Gln His Glu Ala Gly Leu Met Asp Leu Arg 2375 2380 2385 Glu Ala Leu Asn Arg Ala Val Asp Ala Thr Arg Glu Ala Gln Glu 2390 2395 2400 Leu Asn Ser Arg Asn Gln Glu Arg Leu Glu Glu Ala Leu Gln Arg 2405 2410 2415 Lys Gln Glu Leu Ser Arg Asp Asn Ala Thr Leu Gln Ala Thr Leu 2420 2425 2430 His Ala Ala Arg Asp Thr Leu Ala Ser Val Phe Arg Leu Leu His 2435 2440 2445 Ser Leu Asp Gln Ala Lys Glu Glu Leu Glu Arg Leu Ala Ala Ser 2450 2455 2460 Leu Asp Gly Ala Arg Thr Pro Leu Leu Gln Arg Met Gln Thr Phe 2465 2470 2475 Ser Pro Ala Gly Ser Lys Leu Arg Leu Val Glu Ala Ala Glu Ala 2480 2485 2490 His Ala Gln Gln Leu Gly Gln Leu Ala Leu Asn Leu Ser Ser Ile 2495 2500 2505 Ile Leu Asp Val Asn Gln Asp Arg Leu Thr Gln Arg Ala Ile Glu 2510 2515 2520 Ala Ser Asn Ala Tyr Ser Arg Ile Leu Gln Ala Val Gln Ala Ala 2525 2530 2535 Glu Asp Ala Ala Gly Gln Ala Leu Gln Gln Ala Asp His Thr Trp 2540 2545 2550 Ala Thr Val Val Arg Gln Gly Leu Val Asp Arg Ala Gln Gln Leu 2555 2560 2565 Leu Ala Asn Ser Thr Ala Leu Glu Glu Ala Met Leu Gln Glu Gln 2570 2575 2580 Gln Arg Leu Gly Leu Val Trp Ala Ala Leu Gln Gly Ala Arg Thr 2585 2590 2595 Gln Leu Arg Asp Val Arg Ala Lys Lys Asp Gln Leu Glu Ala His 2600 2605 2610 Ile Gln Ala Ala Gln Ala Met Leu Ala Met Asp Thr Asp Glu Thr 2615 2620 2625 Ser Lys Lys Ile Ala His Ala Lys Ala Val Ala Ala Glu Ala Gln 2630 2635 2640 Asp Thr Ala Thr Arg Val Gln Ser Gln Leu Gln Ala Met Gln Glu 2645 2650 2655 Asn Val Glu Arg Trp Gln Gly Gln Tyr Glu Gly Leu Arg Gly Gln 2660 2665 2670 Asp Leu Gly Gln Ala Val Leu Asp Ala Gly His Ser Val Ser Thr 2675 2680 2685 Leu Glu Lys Thr Leu Pro Gln Leu Leu Ala Lys Leu Ser Ile Leu 2690 2695 2700 Glu Asn Arg Gly Val His Asn Ala Ser Leu Ala Leu Ser Ala Ser 2705 2710 2715 Ile Gly Arg Val Arg Glu Leu Ile Ala Gln Ala Arg Gly Ala Ala 2720 2725 2730 Ser Lys Val Lys Val Pro Met Lys Phe Asn Gly Arg Ser Gly Val 2735 2740 2745 Gln Leu Arg Thr Pro Arg Asp Leu Ala Asp Leu Ala Ala Tyr Thr 2750 2755 2760 Ala Leu Lys Phe Tyr Leu Gln Gly Pro Glu Pro Glu Pro Gly Gln 2765 2770 2775 Gly Thr Glu Asp Arg Phe Val Met Tyr Met Gly Ser Arg Gln Ala 2780 2785 2790 Thr Gly Asp Tyr Met Gly Val Ser Leu Arg Asp Lys Lys Val His 2795 2800 2805 Trp Val Tyr Gln Leu Gly Glu Ala Gly Pro Ala Val Leu Ser Ile 2810 2815 2820 Asp Glu Asp Ile Gly Glu Gln Phe Ala Ala Val Ser Leu Asp Arg 2825 2830 2835 Thr Leu Gln Phe Gly His Met Ser Val Thr Val Glu Arg Gln Met 2840 2845 2850 Ile Gln Glu Thr Lys Gly Asp Thr Val Ala Pro Gly Ala Glu Gly 2855 2860 2865 Leu Leu Asn Leu Arg Pro Asp Asp Phe Val Phe Tyr Val Gly Gly 2870 2875 2880 Tyr Pro Ser Thr Phe Thr Pro Pro Pro Leu Leu Arg Phe Pro Gly 2885 2890 2895 Tyr Arg Gly Cys Ile Glu Met Asp Thr Leu Asn Glu Glu Val Val 2900 2905 2910 Ser Leu Tyr Asn Phe Glu Arg Thr Phe Gln Leu Asp Thr Ala Val 2915 2920 2925 Asp Arg Pro Cys Ala Arg Ser Lys Ser Thr Gly Asp Pro Trp Leu 2930 2935 2940 Thr Asp Gly Ser Tyr Leu Asp Gly Thr Gly Phe Ala Arg Ile Ser 2945 2950 2955 Phe Asp Ser Gln Ile Ser Thr Thr Lys Arg Phe Glu Gln Glu Leu 2960 2965 2970 Arg Leu Val Ser Tyr Ser Gly Val Leu Phe Phe Leu Lys Gln Gln 2975 2980 2985 Ser Gln Phe Leu Cys Leu Ala Val Gln Glu Gly Ser Leu Val Leu 2990 2995 3000 Leu Tyr Asp Phe Gly Ala Gly Leu Lys Lys Ala Val Pro Leu Gln 3005 3010 3015 Pro Pro Pro Pro Leu Thr Ser Ala Ser Lys Ala Ile Gln Val Phe 3020 3025 3030 Leu Leu Gly Gly Ser Arg Lys Arg Val Leu Val Arg Val Glu Arg 3035 3040 3045 Ala Thr Val Tyr Ser Val Glu Gln Asp Asn Asp Leu Glu Leu Ala 3050 3055 3060 Asp Ala Tyr Tyr Leu Gly Gly Val Pro Pro Asp Gln Leu Pro Pro 3065 3070 3075 Ser Leu Arg Arg Leu Phe Pro Thr Gly Gly Ser Val Arg Gly Cys 3080 3085 3090 Val Lys Gly Ile Lys Ala Leu Gly Lys Tyr Val Asp Leu Lys Arg 3095 3100 3105 Leu Asn Thr Thr Gly Val Ser Ala Gly Cys Thr Ala Asp Leu Leu 3110 3115 3120 Val Gly Arg Ala Met Thr Phe His Gly His Gly Phe Leu Arg Leu 3125 3130 3135 Ala Leu Ser Asn Val Ala Pro Leu Thr Gly Asn Val Tyr Ser Gly 3140 3145 3150 Phe Gly Phe His Ser Ala Gln Asp Ser Ala Leu Leu Tyr Tyr Arg 3155 3160 3165 Ala Ser Pro Asp Gly Leu Cys Gln Val Ser Leu Gln Gln Gly Arg 3170 3175 3180 Val Ser Leu Gln Leu Leu Arg Thr Glu Val Lys Thr Gln Ala Gly 3185 3190 3195 Phe Ala Asp Gly Ala Pro His Tyr Val Ala Phe Tyr Ser Asn Ala 3200 3205 3210 Thr Gly Val Trp Leu Tyr Val Asp Asp Gln Leu Gln Gln Met Lys 3215 3220 3225 Pro His Arg Gly Pro Pro Pro Glu Leu Gln Pro Gln Pro Glu Gly 3230 3235 3240 Pro Pro Arg Leu Leu Leu Gly Gly Leu Pro Glu Ser Gly Thr Ile 3245 3250 3255 Tyr Asn Phe Ser Gly Cys Ile Ser Asn Val Phe Val Gln Arg Leu 3260 3265 3270 Leu Gly Pro Gln Arg Val Phe Asp Leu Gln Gln Asn Leu Gly Ser 3275 3280 3285 Val Asn Val Ser Thr Gly Cys Ala Pro Ala Leu Gln Ala Gln Thr 3290 3295 3300 Pro Gly Leu Gly Pro Arg Gly Leu Gln Ala Thr Ala Arg Lys Ala 3305 3310 3315 Ser Arg Arg Ser Arg Gln Pro Ala Arg His Pro Ala Cys Met Leu 3320 3325 3330 Pro Pro His Leu Arg Thr Thr Arg Asp Ser Tyr Gln Phe Gly Gly 3335 3340 3345 Ser Leu Ser Ser His Leu Glu Phe Val Gly Ile Leu Ala Arg His 3350 3355 3360 Arg Asn Trp Pro Ser Leu Ser Met His Val Leu Pro Arg Ser Ser 3365 3370 3375 Arg Gly Leu Leu Leu Phe Thr Ala Arg Leu Arg Pro Gly Ser Pro 3380 3385 3390 Ser Leu Ala Leu Phe Leu Ser Asn Gly His Phe Val Ala Gln Met 3395 3400 3405 Glu Gly Leu Gly Thr Arg Leu Arg Ala Gln Ser Arg Gln Arg Ser 3410 3415 3420 Arg Pro Gly Arg Trp His Lys Val Ser Val Arg Trp Glu Lys Asn 3425 3430 3435 Arg Ile Leu Leu Val Thr Asp Gly Ala Arg Ala Trp Ser Gln Glu 3440 3445 3450 Gly Pro His Arg Gln His Gln Gly Ala Glu His Pro Gln Pro His 3455 3460 3465 Thr Leu Phe Val Gly Gly Leu Pro Ala Ser Ser His Ser Ser Lys 3470 3475 3480 Leu Pro Val Thr Val Gly Phe Ser Gly Cys Val Lys Arg Leu Arg 3485 3490 3495 Leu His Gly Arg Pro Leu Gly Ala Pro Thr Arg Met Ala Gly Val 3500 3505 3510 Thr Pro Cys Ile Leu Gly Pro Leu Glu Ala Gly Leu Phe Phe Pro 3515 3520 3525 Gly Ser Gly Gly Val Ile Thr Leu Asp Leu Pro Gly Ala Thr Leu 3530 3535 3540 Pro Asp Val Gly Leu Glu Leu Glu Val Arg Pro Leu Ala Val Thr 3545 3550 3555 Gly Leu Ile Phe His Leu Gly Gln Ala Arg Thr Pro Pro Tyr Leu 3560 3565 3570 Gln Leu Gln Val Thr Glu Lys Gln Val Leu Leu Arg Ala Asp Asp 3575 3580 3585 Gly Ala Gly Glu Phe Ser Thr Ser Val Thr Arg Pro Ser Val Leu 3590 3595 3600 Cys Asp Gly Gln Trp His Arg Leu Ala Val Met Lys Ser Gly Asn 3605 3610 3615 Val Leu Arg Leu Glu Val Asp Ala Gln Ser Asn His Thr Val Gly 3620 3625 3630 Pro Leu Leu Ala Ala Ala Ala Gly Ala Pro Ala Pro Leu Tyr Leu 3635 3640 3645 Gly Gly Leu Pro Glu Pro Met Ala Val Gln Pro Trp Pro Pro Ala 3650 3655 3660 Tyr Cys Gly Cys Met Arg Arg Leu Ala Val Asn Arg Ser Pro Val 3665 3670 3675 Ala Met Thr Arg Ser Val Glu Val His Gly Ala Val Gly Ala Ser 3680 3685 3690 Gly Cys Pro Ala Ala 3695 23 1255 PRT Homo sapiens misc_feature Incyte ID No 55022490CD1 23 Met Val Arg Gly Gly Arg Trp Glu Gln Ala His Lys Lys Glu Pro 1 5 10 15 Leu Gly Val Trp Gly Pro Leu Pro Cys Val Arg Gly Ala Gln Gly 20 25 30 Thr Leu Gly Asp Arg Asn Gly Gly Thr Gly Gly Trp Arg His Trp 35 40 45 Gly Gly Cys Glu Gly Met Pro Met Pro Ser Ser Ser Gln Asn Val 50 55 60 Cys Thr Asn Ser Gly Ala Ser Val Gly Thr Thr Cys His Ser Lys 65 70 75 Leu Asp Ala Ala Val Asp Gly Thr Arg Cys Gly Glu Asn Lys Trp 80 85 90 Cys Leu Ser Gly Glu Cys Val Pro Val Gly Phe Arg Pro Glu Ala 95 100 105 Val Asp Gly Gly Trp Ser Gly Trp Ser Ala Trp Ser Ile Cys Ser 110 115 120 Arg Ser Cys Gly Met Gly Val Gln Ser Ala Glu Arg Gln Cys Thr 125 130 135 Gln Pro Thr Pro Lys Tyr Lys Gly Arg Tyr Cys Val Gly Glu Arg 140 145 150 Lys Arg Phe Arg Leu Cys Asn Leu Gln Ala Cys Pro Ala Gly His 155 160 165 Pro Ser Phe Arg His Val Gln Cys Ser His Phe Asp Ala Met Leu 170 175 180 Tyr Lys Gly Gln Leu His Thr Trp Val Pro Val Val Asn Asp Val 185 190 195 Asn Pro Cys Glu Leu His Cys Arg Pro Ala Asn Glu Tyr Phe Ala 200 205 210 Glu Lys Leu Arg Asp Ala Val Val Asp Gly Thr Pro Cys Tyr Gln 215 220 225 Val Arg Ala Ser Arg Asp Leu Cys Ile Asn Gly Ile Cys Lys Asn 230 235 240 Val Gly Cys Asp Phe Glu Ile Asp Ser Gly Ala Met Glu Asp Arg 245 250 255 Cys Gly Val Cys His Gly Asn Gly Ser Thr Cys His Thr Val Ser 260 265 270 Gly Thr Phe Glu Glu Ala Glu Gly Leu Gly Tyr Val Asp Val Gly 275 280 285 Leu Ile Pro Ala Gly Ala Arg Glu Ile Arg Ile Gln Glu Val Ala 290 295 300 Glu Ala Ala Asn Phe Leu Ala Leu Arg Ser Glu Asp Pro Glu Lys 305 310 315 Tyr Phe Leu Asn Gly Gly Trp Thr Ile Gln Trp Asn Gly Asp Tyr 320 325 330 Gln Val Ala Gly Thr Thr Phe Thr Tyr Ala Arg Arg Gly Asn Trp 335 340 345 Glu Asn Leu Thr Ser Pro Gly Pro Thr Lys Glu Pro Val Trp Ile 350 355 360 Gln Leu Leu Phe Gln Glu Ser Asn Pro Gly Val His Tyr Glu Tyr 365 370 375 Thr Ile His Arg Glu Ala Gly Gly His Asp Glu Val Pro Pro Pro 380 385 390 Val Phe Ser Trp His Tyr Gly Pro Trp Thr Lys Cys Thr Val Thr 395 400 405 Cys Gly Arg Gly Val Gln Arg Gln Asn Val Tyr Cys Leu Glu Arg 410 415 420 Gln Ala Gly Pro Val Asp Glu Glu His Cys Asp Pro Leu Gly Arg 425 430 435 Pro Asp Asp Gln Gln Arg Lys Cys Ser Glu Gln Pro Cys Pro Ala 440 445 450 Arg Trp Trp Ala Gly Glu Trp Gln Leu Cys Ser Ser Ser Cys Gly 455 460 465 Pro Gly Gly Leu Ser Arg Arg Ala Val Leu Cys Ile Arg Ser Val 470 475 480 Gly Leu Asp Glu Gln Ser Ala Leu Glu Pro Pro Ala Cys Glu His 485 490 495 Leu Pro Arg Pro Pro Thr Glu Thr Pro Cys Asn Arg His Val Pro 500 505 510 Cys Pro Ala Thr Trp Ala Val Gly Asn Trp Ser Gln Cys Ser Val 515 520 525 Thr Cys Gly Glu Gly Thr Gln Arg Arg Asn Val Leu Cys Thr Asn 530 535 540 Asp Thr Gly Val Pro Cys Asp Glu Ala Gln Gln Pro Ala Ser Glu 545 550 555 Val Thr Cys Ser Leu Pro Leu Cys Arg Trp Pro Leu Gly Thr Leu 560 565 570 Gly Pro Glu Gly Ser Gly Ser Gly Ser Ser Ser His Glu Leu Phe 575 580 585 Asn Glu Ala Asp Phe Ile Pro His His Leu Ala Pro Arg Pro Ser 590 595 600 Pro Ala Ser Ser Pro Lys Pro Gly Thr Met Gly Asn Ala Ile Glu 605 610 615 Glu Glu Ala Pro Glu Leu Asp Leu Pro Gly Pro Val Phe Val Asp 620 625 630 Asp Phe Tyr Tyr Asp Tyr Asn Phe Ile Asn Phe His Glu Asp Leu 635 640 645 Ser Tyr Gly Pro Ser Glu Glu Pro Asp Leu Asp Leu Ala Gly Thr 650 655 660 Gly Asp Arg Thr Pro Pro Pro His Ser Arg Pro Ala Ala Pro Ser 665 670 675 Thr Gly Ser Pro Val Pro Ala Thr Glu Pro Pro Ala Ala Lys Glu 680 685 690 Glu Gly Val Leu Gly Pro Trp Ser Pro Ser Pro Trp Pro Ser Gln 695 700 705 Ala Gly Arg Ser Pro Pro Pro Pro Ser Glu Gln Thr Pro Gly Asn 710 715 720 Pro Leu Ile Asn Phe Leu Pro Glu Glu Asp Thr Pro Ile Gly Ala 725 730 735 Pro Asp Leu Gly Leu Pro Ser Leu Ser Trp Pro Arg Val Ser Thr 740 745 750 Asp Gly Leu Gln Thr Pro Ala Thr Pro Glu Ser Gln Asn Asp Phe 755 760 765 Pro Val Gly Lys Asp Ser Gln Ser Gln Leu Pro Pro Pro Trp Arg 770 775 780 Asp Arg Thr Asn Glu Val Phe Lys Asp Asp Glu Glu Pro Lys Gly 785 790 795 Arg Gly Ala Pro His Leu Pro Pro Arg Pro Ser Ser Thr Leu Pro 800 805 810 Pro Leu Ser Pro Val Gly Ser Thr His Ser Ser Pro Ser Pro Asp 815 820 825 Val Ala Glu Leu Trp Thr Gly Gly Thr Val Ala Trp Glu Pro Ala 830 835 840 Leu Glu Gly Gly Leu Gly Pro Val Asp Ser Glu Leu Trp Pro Thr 845 850 855 Val Gly Val Ala Ser Leu Leu Pro Pro Pro Ile Ala Pro Leu Pro 860 865 870 Glu Met Lys Val Arg Asp Ser Ser Leu Glu Pro Gly Thr Pro Ser 875 880 885 Phe Pro Thr Pro Gly Pro Gly Ser Trp Asp Leu Gln Thr Val Ala 890 895 900 Val Trp Gly Thr Phe Leu Pro Thr Thr Leu Thr Gly Leu Gly His 905 910 915 Met Pro Glu Pro Ala Leu Asn Pro Gly Pro Lys Gly Gln Pro Glu 920 925 930 Ser Leu Ser Pro Glu Val Pro Leu Ser Ser Arg Leu Leu Ser Thr 935 940 945 Pro Ala Trp Asp Ser Pro Ala Asn Ser His Arg Val Pro Glu Thr 950 955 960 Gln Pro Leu Ala Pro Ser Leu Ala Glu Ala Gly Pro Pro Ala Asp 965 970 975 Pro Leu Val Val Arg Asn Ala Ser Trp Gln Ala Gly Asn Trp Ser 980 985 990 Glu Cys Ser Thr Thr Cys Gly Leu Gly Ala Val Trp Arg Pro Val 995 1000 1005 Arg Cys Ser Ser Gly Arg Asp Glu Asp Cys Ala Pro Ala Gly Arg 1010 1015 1020 Pro Gln Pro Ala Arg Arg Cys His Leu Arg Pro Cys Ala Thr Trp 1025 1030 1035 His Ser Gly Asn Trp Ser Lys Cys Ser Arg Ser Cys Gly Gly Gly 1040 1045 1050 Ser Ser Val Arg Asp Val Gln Cys Val Asp Thr Arg Asp Leu Arg 1055 1060 1065 Pro Leu Arg Pro Phe His Cys Gln Pro Gly Pro Ala Lys Pro Pro 1070 1075 1080 Ala His Arg Pro Cys Gly Ala Gln Pro Cys Leu Ser Trp Tyr Thr 1085 1090 1095 Ser Ser Trp Arg Glu Cys Ser Glu Ala Cys Gly Gly Gly Glu Gln 1100 1105 1110 Gln Arg Leu Val Thr Cys Pro Glu Pro Gly Leu Cys Glu Glu Ala 1115 1120 1125 Leu Arg Pro Asn Thr Thr Arg Pro Cys Asn Thr His Pro Cys Thr 1130 1135 1140 Gln Trp Val Val Gly Pro Trp Gly Gln Cys Ser Ala Pro Cys Gly 1145 1150 1155 Gly Gly Val Gln Arg Arg Leu Val Lys Cys Val Asn Thr Gln Thr 1160 1165 1170 Gly Leu Pro Glu Glu Asp Ser Asp Gln Cys Gly His Glu Ala Trp 1175 1180 1185 Pro Glu Ser Ser Arg Pro Cys Gly Thr Glu Asp Cys Glu Pro Val 1190 1195 1200 Glu Pro Pro Arg Cys Glu Arg Asp Arg Leu Ser Phe Gly Phe Cys 1205 1210 1215 Glu Thr Leu Arg Leu Leu Gly Arg Cys Gln Leu Pro Thr Ile Arg 1220 1225 1230 Thr Gln Cys Cys Arg Ser Cys Ser Pro Pro Ser His Gly Ala Pro 1235 1240 1245 Ser Arg Gly His Gln Arg Val Ala Arg Arg 1250 1255 24 911 PRT Homo sapiens misc_feature Incyte ID No 6755002CD1 24 Met Ala Gln Leu Phe Leu Pro Leu Leu Ala Ala Leu Val Leu Ala 1 5 10 15 Gln Ala Pro Ala Ala Leu Ala Asp Val Leu Glu Gly Asp Ser Ser 20 25 30 Glu Asp Arg Ala Phe Arg Val Arg Ile Ala Gly Asp Ala Pro Leu 35 40 45 Gln Gly Val Leu Gly Gly Ala Leu Thr Ile Pro Cys His Val His 50 55 60 Tyr Leu Arg Pro Pro Pro Ser Arg Arg Ala Val Leu Gly Ser Pro 65 70 75 Arg Val Lys Trp Thr Phe Leu Ser Arg Gly Arg Glu Ala Glu Val 80 85 90 Leu Val Ala Arg Gly Val Arg Val Lys Val Asn Glu Ala Tyr Arg 95 100 105 Phe Arg Val Ala Leu Pro Ala Tyr Pro Ala Ser Leu Thr Asp Val 110 115 120 Ser Leu Ala Leu Ser Glu Leu Arg Pro Asn Asp Ser Gly Ile Tyr 125 130 135 Arg Cys Glu Val Gln His Gly Ile Asp Asp Ser Ser Asp Ala Val 140 145 150 Glu Val Lys Val Lys Gly Val Val Phe Leu Tyr Arg Glu Gly Ser 155 160 165 Ala Arg Tyr Ala Phe Ser Phe Ser Gly Ala Gln Glu Ala Cys Ala 170 175 180 Arg Ile Gly Ala His Ile Ala Thr Pro Glu Gln Leu Tyr Ala Ala 185 190 195 Tyr Leu Gly Gly Tyr Glu Gln Cys Asp Ala Gly Trp Leu Ser Asp 200 205 210 Gln Thr Val Arg Tyr Pro Ile Gln Thr Pro Arg Glu Ala Cys Tyr 215 220 225 Gly Asp Met Asp Gly Phe Pro Gly Val Arg Asn Tyr Gly Val Val 230 235 240 Asp Pro Asp Asp Leu Tyr Asp Val Tyr Cys Tyr Ala Glu Asp Leu 245 250 255 Asn Gly Glu Leu Phe Leu Gly Asp Pro Pro Glu Lys Leu Thr Leu 260 265 270 Glu Glu Ala Arg Ala Tyr Cys Gln Glu Arg Gly Ala Glu Ile Ala 275 280 285 Thr Thr Gly Gln Leu Tyr Ala Ala Trp Asp Gly Gly Leu Asp His 290 295 300 Cys Ser Pro Gly Trp Leu Ala Asp Gly Ser Val Arg Tyr Pro Ile 305 310 315 Val Thr Pro Ser Gln Arg Cys Gly Gly Gly Leu Pro Gly Val Lys 320 325 330 Thr Leu Phe Leu Phe Pro Asn Gln Thr Gly Phe Pro Asn Lys His 335 340 345 Ser Arg Phe Asn Val Tyr Cys Phe Arg Asp Ser Ala Gln Pro Ser 350 355 360 Ala Ile Pro Glu Ala Ser Asn Pro Ala Ser Asn Pro Ala Ser Asp 365 370 375 Gly Leu Glu Ala Ile Val Thr Val Thr Glu Thr Leu Glu Glu Leu 380 385 390 Gln Leu Pro Gln Glu Ala Thr Glu Ser Glu Ser Arg Gly Ala Ile 395 400 405 Tyr Ser Ile Pro Ile Met Glu Asp Gly Gly Gly Gly Ser Ser Thr 410 415 420 Pro Glu Asp Pro Ala Glu Ala Pro Arg Thr Leu Leu Glu Phe Glu 425 430 435 Thr Gln Ser Met Val Pro Pro Thr Gly Phe Ser Glu Glu Glu Gly 440 445 450 Lys Ala Leu Glu Glu Glu Glu Lys Tyr Glu Asp Glu Glu Glu Lys 455 460 465 Glu Glu Glu Glu Glu Glu Glu Glu Val Glu Asp Glu Ala Leu Trp 470 475 480 Ala Trp Pro Ser Glu Leu Ser Ser Pro Gly Pro Glu Ala Ser Leu 485 490 495 Pro Thr Glu Pro Ala Ala Gln Glu Lys Ser Leu Ser Gln Ala Pro 500 505 510 Ala Arg Ala Val Leu Gln Pro Gly Ala Ser Pro Leu Pro Asp Gly 515 520 525 Glu Ser Glu Ala Ser Arg Pro Pro Arg Val His Gly Pro Pro Thr 530 535 540 Glu Thr Leu Pro Thr Pro Arg Glu Arg Asn Leu Ala Ser Pro Ser 545 550 555 Pro Ser Thr Leu Val Glu Ala Arg Glu Val Gly Glu Ala Thr Gly 560 565 570 Gly Pro Glu Leu Ser Gly Val Pro Arg Gly Glu Ser Glu Glu Thr 575 580 585 Gly Ser Ser Glu Gly Ala Pro Ser Leu Leu Pro Ala Thr Arg Ala 590 595 600 Pro Glu Gly Thr Arg Glu Leu Glu Ala Pro Ser Glu Asp Asn Ser 605 610 615 Gly Arg Thr Ala Pro Ala Gly Thr Ser Val Gln Ala Gln Pro Val 620 625 630 Leu Pro Thr Asp Ser Ala Ser Arg Gly Gly Val Ala Val Val Pro 635 640 645 Ala Ser Gly Asp Cys Val Pro Ser Pro Cys His Asn Gly Gly Thr 650 655 660 Cys Leu Glu Glu Glu Glu Gly Val Arg Cys Leu Cys Leu Pro Gly 665 670 675 Tyr Gly Gly Asp Leu Cys Asp Val Gly Leu Arg Phe Cys Asn Pro 680 685 690 Gly Trp Asp Ala Phe Gln Gly Ala Cys Tyr Lys His Phe Ser Thr 695 700 705 Arg Arg Ser Trp Glu Glu Ala Glu Thr Gln Cys Arg Met Tyr Gly 710 715 720 Ala His Leu Ala Ser Ile Ser Thr Pro Glu Glu Gln Asp Phe Ile 725 730 735 Asn Asn Arg Tyr Arg Glu Tyr Gln Trp Ile Gly Leu Asn Asp Arg 740 745 750 Thr Ile Glu Gly Asp Phe Leu Trp Ser Asp Gly Val Pro Leu Leu 755 760 765 Tyr Glu Asn Trp Asn Pro Gly Gln Pro Asp Ser Tyr Phe Leu Ser 770 775 780 Gly Glu Asn Cys Val Val Met Val Trp His Asp Gln Gly Gln Trp 785 790 795 Ser Asp Val Pro Cys Asn Tyr His Leu Ser Tyr Thr Cys Lys Met 800 805 810 Gly Leu Val Ser Cys Gly Pro Pro Pro Glu Leu Pro Leu Ala Gln 815 820 825 Val Phe Gly Arg Pro Arg Leu Arg Tyr Glu Val Asp Thr Val Leu 830 835 840 Arg Tyr Arg Cys Arg Glu Gly Leu Ala Gln Arg Asn Leu Pro Leu 845 850 855 Ile Arg Cys Gln Glu Asn Gly Arg Trp Glu Ala Pro Gln Ile Ser 860 865 870 Cys Val Pro Arg Arg Pro Ala Arg Ala Leu His Pro Glu Glu Asp 875 880 885 Pro Glu Gly Arg Gln Gly Arg Leu Leu Gly Arg Trp Lys Ala Leu 890 895 900 Leu Ile Pro Pro Ser Ser Pro Met Pro Gly Pro 905 910 25 467 PRT Homo sapiens misc_feature Incyte ID No 7350907CD1 25 Met Pro Gly Arg Trp Arg Trp Gln Arg Asp Met His Pro Ala Arg 1 5 10 15 Lys Leu Leu Ser Leu Leu Phe Leu Ile Leu Met Gly Thr Glu Leu 20 25 30 Thr Gln Val Leu Pro Thr Asn Pro Glu Glu Ser Trp Gln Val Tyr 35 40 45 Ser Ser Ala Gln Asp Ser Glu Gly Arg Cys Ile Cys Thr Val Val 50 55 60 Ala Pro Gln Gln Thr Met Cys Ser Arg Asp Ala Arg Thr Lys Gln 65 70 75 Leu Arg Gln Leu Leu Glu Lys Val Gln Asn Met Ser Gln Ser Ile 80 85 90 Glu Val Leu Asp Arg Arg Thr Gln Arg Asp Leu Gln Tyr Val Glu 95 100 105 Lys Met Glu Asn Gln Met Lys Gly Leu Glu Ser Lys Phe Lys Gln 110 115 120 Val Glu Glu Ser His Lys Gln His Leu Ala Arg Gln Phe Lys Ala 125 130 135 Ile Lys Ala Lys Met Asp Glu Leu Arg Pro Leu Ile Pro Val Leu 140 145 150 Glu Glu Tyr Lys Ala Asp Ala Lys Leu Val Leu Gln Phe Lys Glu 155 160 165 Glu Val Gln Asn Leu Thr Ser Val Leu Asn Glu Leu Gln Glu Glu 170 175 180 Ile Gly Ala Tyr Asp Tyr Asp Glu Leu Gln Ser Arg Val Ser Asn 185 190 195 Leu Glu Glu Arg Leu Arg Ala Cys Met Gln Lys Leu Ala Cys Gly 200 205 210 Lys Leu Thr Gly Ile Ser Asp Pro Val Thr Val Lys Thr Ser Gly 215 220 225 Ser Arg Phe Gly Ser Trp Met Thr Asp Pro Leu Ala Pro Glu Gly 230 235 240 Asp Asn Arg Val Trp Tyr Met Asp Gly Tyr His Asn Asn Arg Phe 245 250 255 Val Arg Glu Tyr Lys Ser Met Val Asp Phe Met Asn Thr Asp Asn 260 265 270 Phe Thr Ser His Arg Leu Pro His Pro Trp Ser Gly Thr Gly Gln 275 280 285 Val Val Tyr Asn Gly Ser Ile Tyr Phe Asn Lys Phe Gln Ser His 290 295 300 Ile Ile Ile Arg Phe Asp Leu Lys Thr Glu Thr Ile Leu Lys Thr 305 310 315 Arg Ser Leu Asp Tyr Ala Gly Tyr Asn Asn Met Tyr His Tyr Ala 320 325 330 Trp Gly Gly His Ser Asp Ile Asp Leu Met Val Asp Glu Ser Gly 335 340 345 Leu Trp Ala Val Tyr Ala Thr Asn Gln Asn Ala Gly Asn Ile Val 350 355 360 Val Ser Arg Leu Asp Pro Val Ser Leu Gln Thr Leu Gln Thr Trp 365 370 375 Asn Thr Ser Tyr Pro Lys Arg Ser Ala Gly Glu Ala Phe Ile Ile 380 385 390 Cys Gly Thr Leu Tyr Val Thr Asn Gly Tyr Ser Gly Gly Thr Lys 395 400 405 Val His Tyr Ala Tyr Gln Thr Asn Ala Ser Thr Tyr Glu Tyr Ile 410 415 420 Asp Ile Pro Phe Gln Asn Lys Tyr Ser His Ile Ser Met Leu Asp 425 430 435 Tyr Asn Pro Lys Asp Arg Ala Leu Tyr Ala Trp Asn Asn Gly His 440 445 450 Gln Ile Leu Tyr Asn Val Thr Leu Phe His Val Ile Arg Ser Asp 455 460 465 Glu Leu 26 1018 PRT Homo sapiens misc_feature Incyte ID No 7474411CD1 26 Met Val Ser His Phe Met Gly Ser Leu Ser Val Leu Cys Phe Leu 1 5 10 15 Leu Leu Leu Gly Phe Gln Phe Val Cys Pro Gln Pro Ser Thr Gln 20 25 30 His Arg Lys Val Pro Gln Arg Met Ala Ala Glu Gly Ala Pro Glu 35 40 45 Asp Asp Gly Gly Gly Gly Ala Pro Gly Val Trp Gly Ala Trp Gly 50 55 60 Pro Trp Ser Ala Cys Ser Arg Ser Cys Ser Gly Gly Val Met Glu 65 70 75 Gln Thr Arg Pro Cys Leu Pro Arg Ser Tyr Arg Leu Arg Gly Gly 80 85 90 Gln Arg Pro Gly Ala Pro Ala Arg Ala Phe Ala Asp His Val Val 95 100 105 Ser Ala Val Arg Thr Ser Val Pro Leu His Arg Ser Arg Asp Glu 110 115 120 Thr Pro Ala Leu Ala Gly Thr Asp Ala Ser Arg Gln Gly Pro Thr 125 130 135 Val Leu Arg Gly Ser Arg His Pro Gln Pro Gln Gly Leu Glu Val 140 145 150 Thr Gly Asp Arg Arg Ser Arg Thr Arg Gly Thr Ile Gly Pro Gly 155 160 165 Lys Tyr Gly Tyr Gly Lys Ala Pro Tyr Ile Leu Pro Leu Gln Thr 170 175 180 Asp Thr Ala His Thr Pro Gln Arg Leu Arg Arg Gln Lys Leu Ser 185 190 195 Ser Arg His Ser Arg Ser Gln Gly Ala Ser Ser Ala Arg His Gly 200 205 210 Tyr Ser Ser Pro Ala His Gln Val Pro Gln His Gly Pro Leu Tyr 215 220 225 Gln Ser Asp Ser Gly Pro Arg Ser Gly Leu Gln Ala Ala Glu Ala 230 235 240 Pro Ile Tyr Gln Leu Pro Leu Thr His Asp Gln Gly Tyr Pro Ala 245 250 255 Ala Ser Ser Leu Phe His Ser Pro Glu Thr Ser Asn Asn His Gly 260 265 270 Val Gly Thr His Gly Ala Thr Gln Ser Phe Ser Gln Pro Ala Arg 275 280 285 Ser Thr Ala Ile Ser Cys Ile Gly Ala Tyr Arg Gln Tyr Lys Leu 290 295 300 Cys Asn Thr Asn Val Cys Pro Glu Ser Ser Arg Ser Ile Arg Glu 305 310 315 Val Gln Cys Ala Ser Tyr Asn Asn Lys Pro Phe Met Gly Arg Phe 320 325 330 Tyr Glu Trp Glu Pro Phe Ala Glu Val Lys Gly Asn Arg Lys Cys 335 340 345 Glu Leu Asn Cys Gln Ala Met Gly Tyr Arg Phe Tyr Val Arg Gln 350 355 360 Ala Glu Lys Val Ile Asp Gly Thr Pro Cys Asp Gln Asn Gly Thr 365 370 375 Ala Ile Cys Val Ser Gly Gln Cys Lys Ser Ile Gly Cys Asp Asp 380 385 390 Tyr Leu Gly Ser Asp Lys Val Val Asp Lys Cys Gly Val Cys Gly 395 400 405 Gly Asp Asn Thr Gly Cys Gln Val Val Ser Gly Val Phe Lys His 410 415 420 Ala Leu Thr Ser Leu Gly Tyr His Arg Val Val Glu Ile Pro Glu 425 430 435 Gly Ala Thr Lys Ile Asn Ile Thr Glu Met Tyr Lys Ser Asn Asn 440 445 450 Tyr Leu Ala Leu Arg Ser Arg Ser Gly Arg Ser Ile Ile Asn Gly 455 460 465 Asn Trp Ala Ile Asp Arg Pro Gly Lys Tyr Glu Gly Gly Gly Thr 470 475 480 Met Phe Thr Tyr Lys Arg Pro Asn Glu Ile Ser Ser Thr Ala Gly 485 490 495 Glu Ser Phe Leu Ala Glu Gly Pro Thr Asn Glu Ile Leu Asp Val 500 505 510 Tyr Met Ile His Gln Gln Pro Asn Pro Gly Val His Tyr Glu Tyr 515 520 525 Val Ile Met Gly Thr Asn Ala Ile Ser Pro Gln Val Pro Pro His 530 535 540 Arg Arg Pro Gly Glu Pro Phe Asn Gly Gln Met Val Thr Glu Gly 545 550 555 Arg Ser Gln Glu Glu Gly Glu Gln Lys Gly Arg Asn Glu Glu Lys 560 565 570 Glu Asp Leu Arg Gly Glu Ala Pro Glu Met Phe Thr Ser Glu Ser 575 580 585 Ala Gln Thr Phe Pro Val Arg His Pro Asp Arg Phe Ser Pro His 590 595 600 Arg Pro Asp Asn Leu Val Pro Pro Ala Pro Gln Pro Pro Arg Arg 605 610 615 Ser Arg Asp His Asn Trp Lys Gln Leu Gly Thr Thr Glu Cys Ser 620 625 630 Thr Thr Cys Gly Lys Gly Ser Gln Tyr Pro Ile Phe Arg Cys Val 635 640 645 His Arg Ser Thr His Glu Glu Ala Pro Glu Ser Tyr Cys Asp Ser 650 655 660 Ser Met Lys Pro Thr Pro Glu Glu Glu Pro Cys Asn Ile Phe Pro 665 670 675 Cys Pro Ala Phe Trp Asp Ile Gly Glu Trp Ser Glu Cys Ser Lys 680 685 690 Thr Cys Gly Leu Gly Met Gln His Arg Gln Val Leu Cys Arg Gln 695 700 705 Val Tyr Ala Asn Arg Ser Leu Thr Val Gln Pro Tyr Arg Cys Gln 710 715 720 His Leu Glu Lys Pro Glu Thr Thr Ser Thr Cys Gln Leu Lys Ile 725 730 735 Cys Ser Glu Trp Gln Ile Arg Thr Asp Trp Thr Ser Cys Ser Val 740 745 750 Pro Cys Gly Val Gly Gln Arg Thr Arg Asp Val Lys Cys Val Ser 755 760 765 Asn Ile Gly Asp Val Val Asp Asp Glu Glu Cys Asn Met Lys Leu 770 775 780 Arg Pro Asn Asp Ile Glu Asn Cys Asp Met Gly Pro Cys Ala Lys 785 790 795 Ser Trp Phe Leu Thr Glu Trp Ser Glu Arg Cys Ser Ala Glu Cys 800 805 810 Gly Ala Gly Val Arg Thr Arg Ser Val Val Cys Met Thr Asn His 815 820 825 Val Ser Ser Leu Pro Leu Glu Gly Cys Gly Asn Asn Arg Pro Ala 830 835 840 Glu Ala Thr Pro Cys Asp Asn Gly Pro Cys Thr Gly Lys Val Glu 845 850 855 Trp Phe Ala Gly Ser Trp Ser Gln Cys Ser Ile Glu Cys Gly Ser 860 865 870 Gly Thr Gln Gln Arg Glu Val Ile Cys Val Arg Lys Asn Ala Asp 875 880 885 Thr Phe Glu Val Leu Asp Pro Ser Glu Cys Ser Phe Leu Glu Lys 890 895 900 Pro Pro Ser Gln Gln Ser Cys His Leu Lys Pro Cys Gly Ala Lys 905 910 915 Trp Phe Ser Thr Glu Trp Ser Met Cys Ser Lys Ser Cys Gln Gly 920 925 930 Gly Phe Arg Val Arg Glu Val Arg Cys Leu Ser Asp Asp Met Thr 935 940 945 Leu Ser Asn Leu Cys Asp Pro Gln Leu Lys Pro Glu Glu Arg Glu 950 955 960 Ser Cys Asn Pro Gln Asp Cys Val Pro Glu Val Asp Glu Asn Cys 965 970 975 Lys Asp Lys Tyr Tyr Asn Cys Asn Val Val Val Gln Ala Arg Leu 980 985 990 Cys Val Tyr Asn Tyr Tyr Lys Thr Ala Cys Cys Ala Ser Cys Thr 995 1000 1005 Arg Val Ala Asn Arg Gln Thr Gly Phe Leu Gly Ser Arg 1010 1015 27 1458 PRT Homo sapiens misc_feature Incyte ID No 4755911CD1 27 Met Gly Lys Glu Gln Glu Leu Val Gln Ala Val Lys Ala Glu Asp 1 5 10 15 Val Gly Thr Ala Gln Arg Leu Leu Gln Arg Pro Arg Pro Gly Lys 20 25 30 Ala Thr Arg Ser Leu Pro Gly Gly Arg Arg Arg Trp Met Asp Gly 35 40 45 Arg Val Asp Gln Pro Arg Val Arg Leu Arg Thr Tyr Ser Arg Val 50 55 60 Ser Val Ser Gly His Leu Cys Gly His Gly Gln Gly Ser Ala Glu 65 70 75 Leu Leu Gly Ser Thr Lys Lys Ile Asn Val Asn Phe Gln Asp Pro 80 85 90 Asp Gly Val Gly Phe Gly Val Lys Gly Gln Leu Pro Ala Ser Pro 95 100 105 Arg Pro Pro Gly Met Arg Pro Leu His Tyr Ala Ala Trp Gln Gly 110 115 120 Arg Lys Glu Pro Met Lys Leu Val Leu Lys Ala Gly Ser Ala Val 125 130 135 Asn Ile Pro Ser Asp Glu Gly His Ile Pro Leu His Leu Ala Ala 140 145 150 Gln His Gly His Tyr Asp Val Ser Glu Met Leu Leu Gln His Gln 155 160 165 Ser Asn Pro Cys Met Val Asp Asn Ser Gly Lys Thr Pro Leu Asp 170 175 180 Leu Ala Cys Glu Phe Gly Arg Val Gly Val Val Gln Leu Leu Leu 185 190 195 Ser Ser Asn Met Cys Ala Ala Leu Leu Glu Pro Arg Pro Gly Asp 200 205 210 Ala Thr Asp Pro Asn Gly Thr Ser Pro Leu His Leu Ala Ala Lys 215 220 225 Asn Gly His Ile Asp Ile Ile Arg Leu Leu Leu Gln Ala Gly Ile 230 235 240 Asp Ile Asn Arg Gln Thr Lys Ser Gly Thr Ala Leu His Glu Ala 245 250 255 Ala Leu Cys Gly Lys Thr Glu Val Val Arg Leu Leu Leu Asp Ser 260 265 270 Gly Ile Asn Ala His Val Arg Asn Thr Tyr Ser Gln Thr Ala Leu 275 280 285 Asp Ile Val His Gln Phe Thr Thr Ser Gln Ala Ser Arg Glu Ile 290 295 300 Lys Gln Leu Leu Arg Glu Ala Ser Ala Ala Leu Gln Val Arg Ala 305 310 315 Thr Lys Asp Tyr Cys Asn Asn Tyr Asp Leu Thr Ser Leu Asn Val 320 325 330 Lys Ala Gly Asp Ile Ile Thr Val Leu Glu Gln His Pro Asp Gly 335 340 345 Arg Trp Lys Gly Cys Ile His Asp Asn Arg Thr Gly Asn Asp Arg 350 355 360 Val Gly Tyr Phe Pro Ser Ser Leu Gly Glu Ala Ile Val Lys Arg 365 370 375 Ala Gly Ser Arg Ala Gly Thr Glu Pro Ser Leu Pro Gln Gly Ser 380 385 390 Ser Ser Ser Gly Pro Ser Ala Pro Pro Glu Glu Ile Trp Val Leu 395 400 405 Arg Lys Pro Phe Ala Gly Gly Asp Arg Ser Gly Ser Ile Ser Gly 410 415 420 Met Ala Gly Gly Arg Gly Ser Gly Gly His Ala Leu His Ala Gly 425 430 435 Ser Glu Gly Val Lys Leu Leu Ala Thr Val Leu Ser Gln Lys Ser 440 445 450 Val Ser Glu Ser Gly Pro Gly Asp Ser Pro Ala Lys Pro Pro Glu 455 460 465 Gly Ser Ala Gly Val Ala Arg Ser Gln Pro Pro Val Ala His Ala 470 475 480 Gly Gln Val Tyr Gly Glu Gln Pro Pro Lys Lys Leu Glu Pro Ala 485 490 495 Ser Glu Gly Lys Ser Ser Glu Ala Val Ser Gln Trp Leu Thr Ala 500 505 510 Phe Gln Leu Gln Leu Tyr Ala Pro Asn Phe Ile Ser Ala Gly Tyr 515 520 525 Asp Leu Pro Thr Ile Ser Arg Met Thr Pro Glu Asp Leu Thr Ala 530 535 540 Ile Gly Val Thr Lys Pro Gly His Arg Lys Lys Ile Ala Ala Glu 545 550 555 Ile Ser Gly Leu Ser Ile Pro Asp Trp Leu Pro Glu His Lys Pro 560 565 570 Ala Asn Leu Ala Val Trp Leu Ser Met Ile Gly Leu Ala Gln Tyr 575 580 585 Tyr Lys Val Leu Val Asp Asn Gly Tyr Glu Asn Ile Asp Phe Ile 590 595 600 Thr Asp Ile Thr Trp Glu Asp Leu Gln Glu Ile Gly Ile Thr Lys 605 610 615 Leu Gly His Gln Lys Lys Leu Met Leu Ala Val Arg Lys Leu Ala 620 625 630 Glu Leu Gln Lys Ala Glu Tyr Ala Lys Tyr Glu Gly Gly Pro Leu 635 640 645 Arg Arg Lys Ala Pro Gln Ser Leu Glu Val Met Ala Ile Glu Ser 650 655 660 Pro Pro Pro Pro Glu Pro Thr Pro Ala Asp Cys Gln Ser Pro Lys 665 670 675 Met Thr Thr Phe Gln Asp Ser Glu Leu Ser Asp Glu Leu Gln Ala 680 685 690 Ala Met Thr Gly Pro Ala Glu Val Gly Pro Thr Thr Glu Lys Pro 695 700 705 Ser Ser His Leu Pro Pro Thr Pro Arg Ala Thr Thr Arg Gln Asp 710 715 720 Ser Ser Leu Gly Gly Arg Ala Arg His Met Ser Ser Ser Gln Glu 725 730 735 Leu Leu Gly Asp Gly Pro Pro Gly Pro Ser Ser Pro Met Ser Arg 740 745 750 Ser Gln Glu Tyr Leu Leu Asp Glu Gly Pro Ala Pro Gly Thr Pro 755 760 765 Pro Arg Glu Ala Arg Pro Gly Arg His Gly His Ser Ile Lys Arg 770 775 780 Ala Ser Val Pro Pro Val Pro Gly Lys Pro Arg Gln Val Leu Pro 785 790 795 Pro Gly Thr Ser His Phe Thr Pro Pro Gln Thr Pro Thr Lys Thr 800 805 810 Arg Pro Gly Ser Pro Gln Ala Leu Gly Gly Pro His Gly Pro Ala 815 820 825 Pro Ala Thr Ala Lys Val Lys Pro Thr Pro Gln Leu Leu Pro Pro 830 835 840 Thr Glu Arg Pro Met Ser Pro Arg Ser Leu Pro Gln Ser Pro Thr 845 850 855 His Arg Gly Phe Ala Tyr Val Leu Pro Gln Pro Val Glu Gly Glu 860 865 870 Val Gly Pro Ala Ala Pro Gly Pro Ala Pro Pro Pro Val Pro Thr 875 880 885 Ala Val Pro Thr Leu Cys Leu Pro Pro Glu Ala Asp Ala Glu Pro 890 895 900 Gly Arg Pro Lys Lys Arg Ala His Ser Leu Asn Arg Tyr Ala Ala 905 910 915 Ser Asp Ser Glu Pro Glu Arg Asp Glu Leu Leu Val Pro Ala Ala 920 925 930 Ala Gly Pro Tyr Ala Thr Val Gln Arg Arg Val Gly Arg Ser His 935 940 945 Ser Val Arg Ala Pro Ala Gly Ala Asp Lys Asn Val Asn Arg Ser 950 955 960 Gln Ser Phe Ala Val Arg Pro Arg Lys Lys Gly Pro Pro Pro Pro 965 970 975 Pro Pro Lys Arg Ser Ser Ser Ala Leu Ala Ser Ala Asn Leu Ala 980 985 990 Asp Glu Pro Val Pro Asp Ala Glu Pro Glu Asp Gly Leu Leu Gly 995 1000 1005 Val Arg Ala Gln Cys Arg Arg Ala Ser Asp Leu Ala Gly Ser Val 1010 1015 1020 Asp Thr Gly Ser Ala Gly Ser Val Lys Ser Ile Ala Ala Met Leu 1025 1030 1035 Glu Leu Ser Ser Ile Gly Gly Gly Gly Arg Ala Ala Arg Arg Pro 1040 1045 1050 Pro Glu Gly His Pro Thr Pro Arg Pro Ala Ser Pro Glu Pro Gly 1055 1060 1065 Arg Val Ala Thr Val Leu Ala Ser Val Lys His Lys Glu Ala Ile 1070 1075 1080 Gly Pro Gly Gly Glu Val Val Asn Arg Arg Arg Thr Leu Ser Gly 1085 1090 1095 Pro Val Thr Gly Leu Leu Ala Thr Ala Arg Arg Gly Pro Gly Glu 1100 1105 1110 Ser Ala Asp Pro Gly Pro Phe Val Glu Asp Gly Thr Gly Arg Gln 1115 1120 1125 Arg Pro Arg Gly Pro Ser Lys Gly Glu Ala Gly Val Glu Gly Pro 1130 1135 1140 Pro Leu Ala Lys Val Glu Ala Ser Ala Thr Leu Lys Arg Arg Ile 1145 1150 1155 Arg Ala Lys Gln Asn Gln Gln Glu Asn Val Lys Phe Ile Leu Thr 1160 1165 1170 Glu Ser Asp Thr Val Lys Arg Arg Pro Lys Ala Lys Glu Arg Glu 1175 1180 1185 Ala Gly Pro Glu Pro Pro Pro Pro Leu Ser Val Tyr His Asn Gly 1190 1195 1200 Thr Gly Thr Val Arg Arg Arg Pro Ala Ser Glu Gln Ala Gly Pro 1205 1210 1215 Pro Glu Leu Pro Pro Pro Pro Pro Pro Ala Glu Pro Pro Pro Thr 1220 1225 1230 Asp Leu Ala His Leu Pro Pro Leu Pro Pro Pro Glu Gly Glu Ala 1235 1240 1245 Arg Lys Pro Ala Lys Pro Pro Val Ser Pro Lys Pro Val Leu Thr 1250 1255 1260 Gln Pro Val Pro Lys Leu Gln Gly Ser Pro Thr Pro Thr Ser Lys 1265 1270 1275 Lys Val Pro Leu Pro Gly Pro Gly Ser Pro Glu Val Lys Arg Ala 1280 1285 1290 His Gly Thr Pro Pro Pro Val Ser Pro Lys Pro Pro Pro Pro Pro 1295 1300 1305 Thr Ala Pro Lys Pro Val Lys Ala Val Ala Gly Leu Pro Ser Gly 1310 1315 1320 Ser Ala Gly Pro Ser Pro Ala Pro Ser Pro Ala Arg Gln Pro Pro 1325 1330 1335 Ala Ala Leu Ala Lys Pro Pro Gly Thr Pro Pro Ser Leu Gly Ala 1340 1345 1350 Ser Pro Ala Lys Pro Pro Ser Pro Gly Ala Pro Ala Leu His Val 1355 1360 1365 Pro Ala Lys Pro Pro Arg Ala Ala Ala Ala Ala Ala Ala Ala Ala 1370 1375 1380 Ala Ala Pro Pro Ala Pro Pro Glu Gly Ala Ser Pro Gly Asp Ser 1385 1390 1395 Ala Arg Gln Lys Leu Glu Glu Thr Ser Ala Cys Leu Ala Ala Ala 1400 1405 1410 Leu Gln Ala Val Glu Glu Lys Ile Arg Gln Glu Asp Ala Gln Gly 1415 1420 1425 Pro Arg Asp Ser Ala Ala Glu Lys Ser Thr Gly Ser Ile Leu Asp 1430 1435 1440 Asp Ile Gly Ser Met Phe Asp Asp Leu Ala Asp Gln Leu Asp Ala 1445 1450 1455 Met Leu Glu 28 323 PRT Homo sapiens misc_feature Incyte ID No 379766CD1 28 Met Ala Ser Trp Thr Ser Pro Trp Trp Val Leu Ile Gly Met Val 1 5 10 15 Phe Met His Ser Pro Leu Pro Gln Thr Thr Ala Glu Lys Ser Pro 20 25 30 Gly Ala Tyr Phe Leu Pro Glu Phe Ala Leu Ser Pro Gln Gly Ser 35 40 45 Phe Leu Glu Asp Thr Thr Gly Glu Gln Phe Leu Thr Tyr Arg Tyr 50 55 60 Asp Asp Gln Thr Ser Arg Asn Thr Arg Ser Asp Glu Asp Lys Asp 65 70 75 Gly Asn Trp Asp Ala Trp Gly Asp Trp Ser Asp Cys Ser Arg Thr 80 85 90 Cys Gly Gly Gly Ala Ser Tyr Ser Leu Arg Arg Cys Leu Thr Gly 95 100 105 Arg Asn Cys Glu Gly Gln Asn Ile Arg Tyr Lys Thr Cys Ser Asn 110 115 120 His Asp Cys Pro Pro Asp Ala Glu Asp Phe Arg Ala Gln Gln Cys 125 130 135 Ser Ala Tyr Asn Asp Val Gln Tyr Gln Gly Arg Tyr Tyr Glu Trp 140 145 150 Leu Pro Arg Tyr Asn Asp Pro Ala Ala Pro Cys Ala Leu Lys Cys 155 160 165 His Ala Gln Gly Gln Asn Leu Val Val Glu Leu Ala Pro Lys Val 170 175 180 Leu Asp Gly Thr Arg Cys Asn Thr Asp Ser Leu Asp Met Cys Ile 185 190 195 Ser Gly Ile Cys Gln Ala Val Gly Cys Asp Arg Gln Leu Gly Ser 200 205 210 Asn Ala Lys Glu Asp Asn Cys Gly Val Cys Ala Gly Asp Gly Ser 215 220 225 Thr Cys Arg Leu Val Arg Gly Gln Ser Lys Ser His Val Ser Pro 230 235 240 Glu Lys Arg Glu Glu Asn Val Ile Ala Val Pro Leu Gly Ser Arg 245 250 255 Ser Val Arg Ile Thr Val Lys Gly Pro Ala Tyr Pro Val Ala Trp 260 265 270 Ala Leu Ala Ile Ser Ser Asn Thr Asn Cys Leu Val Leu Leu Cys 275 280 285 Lys Ala Asn Leu Ala Ser Ser Gly Pro Tyr Phe Ala Leu Ile Pro 290 295 300 Val Asn Pro Thr Thr Met Ala Leu Asn Thr Ala Ile Val Ser Gln 305 310 315 Ser Ala Val Leu Ile Asp Cys Leu 320 29 234 PRT Homo sapiens misc_feature Incyte ID No 553744CD1 29 Met Met Ile His Ser Cys Leu Phe Ser Pro Phe His Ile Ala Phe 1 5 10 15 Ser Thr Pro Ala Ser Gln Leu Phe Ser Pro His Gly Ser Asn Pro 20 25 30 Ser Thr Pro Ala Ala Thr Pro Val Pro Thr Ala Ser Pro Val Lys 35 40 45 Ala Ile Asn His Pro Ser Ala Ser Ala Ala Ala Thr Val Ser Gly 50 55 60 Met Asn Leu Leu Asn Thr Val Leu Pro Val Phe Pro Gly Gln Val 65 70 75 Ser Ser Ala Val His Thr Pro Gln Pro Ser Ile Pro Asn Pro Thr 80 85 90 Val Ile Arg Thr Pro Ser Leu Pro Thr Ala Pro Val Thr Ser Ile 95 100 105 His Ser Thr Thr Thr Thr Pro Val Pro Ser Ile Phe Ser Gly Leu 110 115 120 Val Ser Leu Pro Gly Pro Ser Ala Thr Pro Thr Ala Ala Thr Pro 125 130 135 Thr Pro Gly Pro Thr Pro Arg Ser Thr Leu Gly Ser Ser Glu Ala 140 145 150 Phe Ala Ser Thr Ser Ala Pro Phe Thr Ser Leu Pro Phe Ser Thr 155 160 165 Ser Ser Ser Ala Ala Ser Thr Ser Asn Pro Asn Ser Ala Ser Leu 170 175 180 Ser Ser Val Phe Ala Gly Leu Pro Leu Pro Leu Pro Pro Thr Ser 185 190 195 Gln Gly Leu Ser Asn Pro Thr Pro Val Ile Ala Gly Gly Ser Thr 200 205 210 Pro Ser Val Ala Gly Pro Leu Gly Val Asn Ser Pro Ser Phe Val 215 220 225 Cys Val Lys Arg Phe Ser Asp Ile Gln 230 30 377 PRT Homo sapiens misc_feature Incyte ID No 1825473CD1 30 Met Lys Thr Leu Pro Leu Phe Val Cys Ile Cys Ala Leu Ser Ala 1 5 10 15 Cys Phe Ser Phe Ser Glu Gly Arg Glu Arg Asp His Glu Leu Arg 20 25 30 His Arg Arg His His His Gln Ser Pro Lys Ser His Phe Glu Leu 35 40 45 Pro His Tyr Pro Gly Leu Leu Ala His Gln Lys Pro Phe Ile Arg 50 55 60 Lys Ser Tyr Lys Cys Leu His Lys Arg Cys Arg Pro Lys Leu Pro 65 70 75 Pro Ser Pro Asn Asn Pro Pro Lys Phe Pro Asn Pro His Gln Pro 80 85 90 Pro Lys His Pro Asp Lys Asn Ser Ser Val Val Asn Pro Thr Leu 95 100 105 Val Ala Thr Thr Gln Ile Pro Ser Val Thr Phe Pro Ser Ala Ser 110 115 120 Thr Lys Ile Thr Thr Leu Pro Asn Val Thr Phe Leu Pro Gln Asn 125 130 135 Ala Thr Thr Ile Ser Ser Arg Glu Asn Val Asn Thr Ser Ser Ser 140 145 150 Val Ala Thr Leu Ala Pro Val Asn Ser Pro Ala Pro Gln Asp Thr 155 160 165 Thr Ala Ala Pro Pro Thr Pro Ser Ala Thr Thr Pro Ala Pro Pro 170 175 180 Ser Ser Ser Ala Pro Pro Glu Thr Thr Ala Ala Pro Pro Thr Pro 185 190 195 Ser Ala Thr Thr Gln Ala Pro Pro Ser Ser Ser Ala Pro Pro Glu 200 205 210 Thr Thr Ala Ala Pro Pro Thr Pro Pro Ala Thr Thr Pro Ala Pro 215 220 225 Pro Ser Ser Ser Ala Pro Pro Glu Thr Thr Ala Ala Pro Pro Thr 230 235 240 Pro Ser Ala Thr Thr Pro Ala Pro Leu Ser Ser Ser Ala Pro Pro 245 250 255 Glu Thr Thr Ala Val Pro Pro Thr Pro Ser Ala Thr Thr Leu Asp 260 265 270 Pro Ser Ser Ala Ser Ala Pro Pro Glu Thr Thr Ala Ala Pro Pro 275 280 285 Thr Pro Ser Ala Thr Thr Pro Ala Pro Pro Ser Ser Pro Ala Pro 290 295 300 Gln Glu Thr Thr Ala Ala Pro Ile Thr Thr Pro Asn Ser Ser Pro 305 310 315 Thr Thr Leu Ala Pro Asp Thr Ser Glu Thr Ser Ala Ala Pro Thr 320 325 330 His Gln Thr Thr Thr Ser Val Thr Thr Gln Thr Thr Thr Thr Lys 335 340 345 Gln Pro Thr Ser Ala Pro Gly Gln Asn Lys Ile Ser Arg Phe Leu 350 355 360 Leu Tyr Met Lys Asn Leu Leu Asn Arg Ile Ile Asp Asp Met Val 365 370 375 Glu Gln 31 833 PRT Homo sapiens misc_feature Incyte ID No 7950094CD1 31 Met Ala Pro His Trp Ala Val Trp Leu Leu Ala Ala Arg Leu Trp 1 5 10 15 Gly Leu Gly Ile Gly Ala Glu Val Trp Trp Asn Leu Val Pro Arg 20 25 30 Lys Thr Val Ser Ser Gly Glu Leu Ala Thr Val Val Arg Arg Phe 35 40 45 Ser Gln Thr Gly Ile Gln Asp Phe Leu Thr Leu Thr Leu Thr Glu 50 55 60 Pro Thr Gly Leu Leu Tyr Val Gly Ala Arg Glu Ala Leu Phe Ala 65 70 75 Phe Ser Met Glu Ala Leu Glu Leu Gln Gly Ala Ile Ser Trp Glu 80 85 90 Ala Pro Val Glu Lys Lys Thr Glu Cys Ile Gln Lys Gly Lys Asn 95 100 105 Asn Gln Thr Glu Cys Phe Asn Phe Ile Arg Phe Leu Gln Pro Tyr 110 115 120 Asn Ala Ser His Leu Tyr Val Cys Gly Thr Tyr Ala Phe Gln Pro 125 130 135 Lys Cys Thr Tyr Val Asn Met Leu Thr Phe Thr Leu Glu His Gly 140 145 150 Glu Phe Glu Asp Gly Lys Gly Lys Cys Pro Tyr Asp Pro Ala Lys 155 160 165 Gly His Ala Gly Leu Leu Val Asp Gly Glu Leu Tyr Ser Ala Thr 170 175 180 Leu Asn Asn Phe Leu Gly Thr Glu Pro Ile Ile Leu Arg Asn Met 185 190 195 Gly Pro His His Ser Met Lys Thr Glu Tyr Leu Ala Phe Trp Leu 200 205 210 Asn Glu Pro His Phe Val Gly Ser Ala Tyr Val Pro Glu Ser Val 215 220 225 Gly Ser Phe Thr Gly Asp Asp Asp Lys Val Tyr Phe Phe Phe Arg 230 235 240 Glu Arg Ala Val Glu Ser Asp Cys Tyr Ala Glu Gln Val Val Ala 245 250 255 Arg Val Ala Arg Val Cys Lys Gly Asp Met Gly Gly Ala Arg Thr 260 265 270 Leu Gln Arg Lys Trp Thr Thr Phe Leu Lys Ala Arg Leu Ala Cys 275 280 285 Ser Ala Pro Asn Trp Gln Leu Tyr Phe Asn Gln Leu Gln Ala Met 290 295 300 His Thr Leu Gln Asp Thr Ser Trp His Asn Thr Thr Phe Phe Gly 305 310 315 Val Phe Gln Ala Gln Trp Gly Asp Met Tyr Leu Ser Ala Ile Cys 320 325 330 Glu Tyr Gln Leu Glu Glu Ile Gln Arg Val Phe Glu Gly Pro Tyr 335 340 345 Lys Glu Tyr His Glu Glu Ala Gln Lys Trp Asp Arg Tyr Thr Asp 350 355 360 Pro Val Pro Ser Pro Arg Pro Gly Ser Cys Ile Asn Asn Trp His 365 370 375 Arg Arg His Gly Tyr Thr Ser Ser Leu Glu Leu Pro Asp Asn Ile 380 385 390 Leu Asn Phe Val Lys Lys His Pro Leu Met Glu Glu Gln Val Gly 395 400 405 Pro Arg Trp Ser Arg Pro Leu Leu Val Lys Lys Gly Thr Asn Phe 410 415 420 Thr His Leu Val Ala Asp Arg Val Thr Gly Leu Asp Gly Ala Thr 425 430 435 Tyr Thr Val Leu Phe Ile Gly Thr Gly Asp Gly Trp Leu Leu Lys 440 445 450 Ala Val Ser Leu Gly Pro Trp Val His Leu Ile Glu Glu Leu Gln 455 460 465 Leu Phe Asp Gln Glu Pro Met Arg Ser Leu Val Leu Ser Gln Ser 470 475 480 Lys Lys Leu Leu Phe Ala Gly Ser Arg Ser Gln Leu Val Gln Leu 485 490 495 Pro Val Ala Asp Cys Met Lys Tyr Arg Ser Cys Ala Asp Cys Val 500 505 510 Leu Ala Arg Asp Pro Tyr Cys Ala Trp Ser Val Asn Thr Ser Arg 515 520 525 Cys Val Ala Val Gly Gly His Ser Gly Ser Leu Leu Ile Gln His 530 535 540 Val Met Thr Ser Asp Thr Ser Gly Ile Cys Asn Leu Arg Gly Ser 545 550 555 Lys Lys Val Arg Pro Thr Pro Lys Asn Ile Thr Val Val Ala Gly 560 565 570 Thr Asp Leu Val Leu Pro Cys His Leu Ser Ser Asn Leu Ala His 575 580 585 Ala Arg Trp Thr Phe Gly Gly Arg Asp Leu Pro Ala Glu Gln Pro 590 595 600 Gly Ser Phe Leu Tyr Asp Ala Arg Leu Gln Ala Leu Val Val Met 605 610 615 Ala Ala Gln Pro Arg His Ala Gly Ala Tyr His Cys Phe Ser Glu 620 625 630 Glu Gln Gly Ala Arg Leu Ala Ala Glu Gly Tyr Leu Val Ala Val 635 640 645 Val Ala Gly Pro Ser Val Thr Leu Glu Ala Arg Ala Pro Leu Glu 650 655 660 Asn Leu Gly Leu Val Trp Leu Ala Val Val Ala Leu Gly Ala Val 665 670 675 Cys Leu Val Leu Leu Leu Leu Val Leu Ser Leu Arg Arg Arg Leu 680 685 690 Arg Glu Glu Leu Glu Lys Gly Ala Lys Ala Thr Glu Arg Thr Leu 695 700 705 Val Tyr Pro Leu Glu Leu Pro Lys Glu Pro Thr Ser Pro Pro Phe 710 715 720 Arg Pro Cys Pro Glu Pro Asp Glu Lys Leu Trp Asp Pro Val Gly 725 730 735 Tyr Tyr Tyr Ser Asp Gly Ser Leu Lys Ile Val Pro Gly His Ala 740 745 750 Arg Cys Gln Pro Gly Gly Gly Pro Pro Ser Pro Pro Pro Gly Ile 755 760 765 Pro Gly Gln Pro Leu Pro Ser Pro Thr Arg Leu His Leu Gly Gly 770 775 780 Gly Arg Asn Ser Asn Ala Asn Gly Tyr Val Arg Leu Gln Leu Gly 785 790 795 Gly Glu Asp Arg Gly Gly Leu Gly His Pro Leu Pro Glu Leu Ala 800 805 810 Asp Glu Leu Arg Arg Lys Leu Gln Gln Arg Gln Pro Leu Pro Asp 815 820 825 Ser Asn Pro Glu Glu Ser Ser Val 830 32 1291 PRT Homo sapiens misc_feature Incyte ID No 7479484CD1 32 Met Phe Arg Pro Thr Thr Val Ala Val Asp Glu Asp Gly Gly Glu 1 5 10 15 Glu Asp Lys Asp Glu Ser Ser Thr Asn Ser Gly Ala Ser Ala Val 20 25 30 Ser Ser Cys Gly Phe Gly Ala Asp Phe Ser Thr Asp Lys Gly Gly 35 40 45 Ser Phe Thr Ser Val Gln Ile Thr Asn Thr Thr Gly Leu Ser Gln 50 55 60 Ala Pro Gly Leu Ala Ser Gln Gly Ile Ser Phe Gly Ile Lys Asn 65 70 75 Asn Leu Gly Pro Pro Leu Gln Lys Leu Gly Val Ser Phe Ser Phe 80 85 90 Ala Lys Lys Ala Pro Val Lys Leu Glu Ser Ile Ala Ser Val Phe 95 100 105 Lys Asp His Ala Glu Glu Gly Ser Ser Glu Asp Gly Thr Lys Ala 110 115 120 Asp Glu Lys Ser Ser Asp Gln Gly Val Gln Lys Val Gly Asp Thr 125 130 135 Asp Gly Thr Gly Asn Leu Asp Gly Lys Lys Glu Asp Glu Asp Pro 140 145 150 Gln Asp Gly Gly Ser Leu Ala Ser Thr Leu Ser Lys Leu Lys Arg 155 160 165 Met Lys Arg Glu Glu Gly Thr Gly Ala Thr Glu Pro Glu Tyr Tyr 170 175 180 His Tyr Ile Pro Pro Ala His Cys Lys Val Lys Pro Asn Phe Pro 185 190 195 Phe Leu Leu Phe Met Arg Ala Ser Glu Gln Met Glu Gly Asp His 200 205 210 Ser Ala His Ser Lys Ser Ala Pro Glu Asn Arg Lys Ser Ser Ser 215 220 225 Pro Lys Pro Gln Gly Cys Ser Lys Thr Ala Ala Ser Pro Gly Ala 230 235 240 Glu Arg Thr Val Ser Glu Ala Ser Glu Leu Gln Lys Glu Ala Ala 245 250 255 Val Ala Gly Pro Ser Glu Pro Gly Gly Lys Thr Glu Thr Lys Lys 260 265 270 Gly Ser Gly Gly Gly Glu Asp Glu Gln Ser Val Glu Ser Arg Glu 275 280 285 Thr Ser Glu Ser Pro Met Cys Glu Ser Asn Pro Lys Asp Ile Ser 290 295 300 Gln Ala Thr Pro Ala Thr Lys Ala Gly Gln Gly Pro Lys His Pro 305 310 315 Thr Gly Pro Phe Phe Pro Val Leu Ser Lys Asp Glu Ser Thr Ala 320 325 330 Leu Gln Trp Pro Ser Glu Leu Leu Ile Phe Thr Lys Ala Glu Pro 335 340 345 Ser Ile Ser Tyr Ser Cys Asn Pro Leu Tyr Phe Asp Phe Lys Leu 350 355 360 Ser Arg Asn Lys Asp Ala Lys Ala Lys Gly Thr Glu Lys Pro Lys 365 370 375 Asp Val Ala Gly Ser Ser Lys Asp His Leu Gln Ser Leu Asp Pro 380 385 390 Arg Glu Pro Asn Lys Ser Gln Glu Glu Glu Gln Asp Val Val Leu 395 400 405 Ser Ser Glu Gly Arg Val Asp Glu Pro Ala Ser Gly Ala Ala Cys 410 415 420 Ser Ser Leu Asn Lys Gln Glu Pro Gly Gly Ser His Met Ser Glu 425 430 435 Thr Glu Asp Thr Gly Arg Ser His Pro Ser Lys Lys Glu Pro Ser 440 445 450 Gly Lys Ser His Arg His Lys Lys Lys Lys Lys His Lys Lys Ser 455 460 465 Ser Lys His Lys Arg Lys His Lys Ala Asp Thr Glu Glu Lys Ser 470 475 480 Ser Lys Ala Glu Ser Gly Glu Lys Ser Lys Lys Arg Lys Lys Arg 485 490 495 Lys Arg Lys Lys Asn Lys Ser Ser Ala Ala Ala Asp Ser Glu Arg 500 505 510 Gly Pro Lys Ser Glu Pro Pro Gly Ser Gly Ser Pro Ala Pro Pro 515 520 525 Arg Arg Arg Arg Arg Ala Gln Asp Asp Ser Gln Arg Arg Ser Leu 530 535 540 Pro Ala Glu Glu Gly Asn Ser Gly Lys Lys Asp Asp Gly Gly Gly 545 550 555 Gly Ser Ser Cys Gln Asp His Ser Gly Arg Lys His Lys Gly Glu 560 565 570 Pro Pro Thr Ser Ser Cys Gln Arg Arg Ala Asn Thr Lys His Ser 575 580 585 Ser Arg Ser Ser His Arg Ser Gln Pro Ser Ser Gly Asp Glu Asp 590 595 600 Ser Asp Asp Ala Ser Ser His Arg Leu His Gln Lys Ser Pro Ser 605 610 615 Gln Tyr Ser Glu Glu Glu Glu Glu Glu Glu Glu Glu Glu Glu Glu 620 625 630 Glu Asp Glu Asp Ser Gly Ser Glu His Ser Arg Ser Arg Ser Arg 635 640 645 Ser Gly His Arg His Ser Ser His Arg Ser Ser Arg Arg Ser Tyr 650 655 660 Ser Ser Ser Ser Asp Ala Ser Ser Asp Gln Ser Cys Tyr Ser Arg 665 670 675 Gln His Ser Tyr Ser Asp Asp Ser Tyr Ser Asp Tyr Ser Asp Arg 680 685 690 Ser Arg Arg His Ser Lys Arg Ser His Asp Ser Asp Asp Ser Asp 695 700 705 Tyr Thr Ser Ser Lys His Arg Ser Lys Arg His Lys Tyr Ser Ser 710 715 720 Ser Asp Asp Asp Tyr Ser Leu Ser Cys Ser Gln Ser Arg Ser Arg 725 730 735 Ser Arg Ser His Thr Arg Glu Arg Ser Arg Ser Arg Gly Arg Ser 740 745 750 Arg Ser Ser Ser Cys Ser Arg Ser Arg Ser Lys Arg Arg Ser Arg 755 760 765 Ser Thr Thr Ala His Ser Trp Gln Arg Ser Arg Ser Tyr Ser Arg 770 775 780 Asp Arg Ser Arg Ser Thr Arg Ser Pro Ser Gln Arg Ser Gly Ser 785 790 795 Arg Lys Gly Ser Trp Gly His Glu Ser Pro Glu Glu Arg Arg Ser 800 805 810 Gly Arg Arg Asp Phe Ile Arg Ser Lys Ile Tyr Arg Ser Gln Ser 815 820 825 Pro His Tyr Phe Gln Ser Gly Arg Gly Glu Gly Pro Gly Lys Lys 830 835 840 Glu Asp Gly Arg Gly Asp Asp Ser Lys Gly Ala Gly Leu Pro Ser 845 850 855 Gln Asn Ser Asn Thr Gly Thr Gly Arg Gly Ser Glu Ser Asp Cys 860 865 870 Ser Pro Glu Asp Lys Asn Ser Val Thr Ala Arg Leu Leu Leu Glu 875 880 885 Lys Ile Gln Ser Arg Lys Val Glu Arg Lys Pro Asn Val Cys Glu 890 895 900 Glu Val Leu Ala Thr Pro Asn Lys Ala Gly Leu Lys Tyr Lys Asn 905 910 915 Pro Pro Gln Gly Tyr Phe Gly Pro Lys Leu Pro Pro Ser Leu Gly 920 925 930 Asn Lys Pro Val Leu Pro Met Ile Gly Lys Leu Pro Ala Thr Arg 935 940 945 Lys Ser Asn Lys Lys Cys Glu Glu Ser Gly Leu Glu Arg Gly Glu 950 955 960 Glu Gln Glu His Ser Glu Pro Glu Glu Gly Ser Pro Arg Ser Ser 965 970 975 Asp Ala Pro Phe Gly His Gln Phe Ser Glu Glu Ala Ala Gly Pro 980 985 990 Leu Ser Asp Pro Pro Pro Glu Glu Pro Lys Ser Glu Glu Ala Thr 995 1000 1005 Ala Asp His Ser Val Ala Pro Leu Gly Thr Pro Ala His Thr Asp 1010 1015 1020 Cys Tyr Pro Gly Asp Pro Ala Ile Ser His Asn Tyr Leu Pro Asp 1025 1030 1035 Pro Ser Asp Gly Asp Thr Leu Glu Ser Leu Asp Ser Gly Ser Gln 1040 1045 1050 Pro Gly Pro Val Glu Ser Ser Leu Leu Pro Ile Ala Pro Asp Leu 1055 1060 1065 Glu His Phe Pro Asn Tyr Ala Pro Pro Ser Gly Glu Pro Ser Ile 1070 1075 1080 Glu Ser Thr Asp Gly Thr Glu Asp Ala Ser Leu Ala Pro Leu Glu 1085 1090 1095 Ser Gln Pro Ile Thr Phe Thr Pro Glu Glu Met Glu Lys Tyr Ser 1100 1105 1110 Lys Leu Gln Gln Ala Ala Gln Gln His Ile Gln Gln Gln Leu Leu 1115 1120 1125 Ala Lys Gln Val Lys Ala Phe Pro Ala Ser Thr Ala Leu Ala Pro 1130 1135 1140 Ala Thr Pro Ala Leu Gln Pro Ile His Ile Gln Gln Pro Ala Thr 1145 1150 1155 Ala Ser Ala Thr Ser Ile Thr Thr Val Gln His Ala Ile Leu Gln 1160 1165 1170 His His Ala Ala Ala Ala Ala Ala Ala Ile Gly Ile His Pro His 1175 1180 1185 Pro His Pro Gln Pro Leu Ala Gln Val His His Ile Pro Gln Pro 1190 1195 1200 His Leu Thr Pro Ile Ser Leu Ser His Leu Thr His Ser Ile Ile 1205 1210 1215 Pro Gly His Pro Ala Thr Phe Leu Ala Ser His Pro Ile His Ile 1220 1225 1230 Ile Pro Ala Ser Ala Ile His Pro Gly Pro Phe Thr Phe His Pro 1235 1240 1245 Val Pro His Ala Ala Leu Tyr Pro Thr Leu Leu Ala Pro Arg Pro 1250 1255 1260 Ala Ala Ala Ala Ala Thr Ala Leu His Leu His Pro Leu Leu His 1265 1270 1275 Pro Ile Phe Ser Gly Gln Asp Leu Gln His Pro Pro Ser His Gly 1280 1285 1290 Thr 33 736 PRT Homo sapiens misc_feature Incyte ID No 6780147CD1 33 Met Ala Val Arg Ala Leu Lys Leu Leu Thr Thr Leu Leu Ala Val 1 5 10 15 Val Ala Ala Ala Ser Gln Ala Glu Val Glu Ser Glu Ala Gly Trp 20 25 30 Gly Met Val Thr Pro Asp Leu Leu Phe Ala Glu Gly Thr Ala Ala 35 40 45 Tyr Ala Arg Gly Asp Trp Pro Gly Val Val Leu Ser Met Glu Arg 50 55 60 Ala Leu Arg Ser Arg Ala Ala Leu Arg Ala Leu Arg Leu Arg Cys 65 70 75 Arg Thr Gln Cys Ala Ala Asp Phe Pro Trp Glu Leu Asp Pro Asp 80 85 90 Trp Ser Pro Ser Pro Ala Gln Ala Ser Gly Ala Ala Ala Leu Arg 95 100 105 Asp Leu Ser Phe Phe Gly Gly Leu Leu Arg Arg Ala Ala Cys Leu 110 115 120 Arg Arg Cys Leu Gly Pro Pro Ala Ala His Ser Leu Ser Glu Glu 125 130 135 Met Glu Leu Glu Phe Arg Lys Arg Ser Pro Tyr Asn Tyr Leu Gln 140 145 150 Val Ala Tyr Phe Lys Ile Asn Lys Leu Glu Lys Ala Val Ala Ala 155 160 165 Ala His Thr Phe Phe Val Gly Asn Pro Glu His Met Glu Met Gln 170 175 180 Gln Asn Leu Asp Tyr Tyr Gln Thr Met Ser Gly Val Lys Glu Ala 185 190 195 Asp Phe Lys Asp Leu Glu Thr Gln Pro His Met Gln Glu Phe Arg 200 205 210 Leu Gly Val Arg Leu Tyr Ser Glu Glu Gln Pro Gln Glu Ala Val 215 220 225 Pro His Leu Glu Ala Ala Leu Gln Glu Tyr Phe Val Ala Tyr Glu 230 235 240 Glu Cys Arg Ala Leu Cys Glu Gly Pro Tyr Asp Tyr Asp Gly Tyr 245 250 255 Asn Tyr Leu Glu Tyr Asn Ala Asp Leu Phe Gln Ala Ile Thr Asp 260 265 270 His Tyr Ile Gln Val Leu Asn Cys Lys Gln Asn Cys Val Thr Glu 275 280 285 Leu Ala Ser His Pro Ser Arg Glu Lys Pro Phe Glu Asp Phe Leu 290 295 300 Pro Ser His Tyr Asn Tyr Leu Gln Phe Ala Tyr Tyr Asn Ile Gly 305 310 315 Asn Tyr Thr Gln Ala Val Glu Cys Ala Lys Thr Tyr Leu Leu Phe 320 325 330 Phe Pro Asn Asp Glu Val Met Asn Gln Asn Leu Ala Tyr Tyr Ala 335 340 345 Ala Met Leu Gly Glu Glu His Thr Arg Ser Ile Gly Pro Arg Glu 350 355 360 Ser Ala Lys Glu Tyr Arg Gln Arg Ser Leu Leu Glu Lys Glu Leu 365 370 375 Leu Phe Phe Ala Tyr Asp Val Phe Gly Ile Pro Phe Val Asp Pro 380 385 390 Asp Ser Trp Thr Pro Glu Glu Val Ile Pro Lys Arg Leu Gln Glu 395 400 405 Lys Gln Lys Ser Glu Arg Glu Thr Ala Val Arg Ile Ser Gln Glu 410 415 420 Ile Gly Asn Leu Met Lys Glu Ile Glu Thr Leu Val Glu Glu Lys 425 430 435 Thr Lys Glu Ser Leu Asp Val Ser Arg Leu Thr Arg Glu Gly Gly 440 445 450 Pro Leu Leu Tyr Glu Gly Ile Ser Leu Thr Met Asn Ser Lys Leu 455 460 465 Leu Asn Gly Ser Gln Arg Val Val Met Asp Gly Val Ile Ser Asp 470 475 480 His Glu Cys Gln Glu Leu Gln Arg Leu Thr Asn Val Ala Ala Thr 485 490 495 Ser Gly Asp Gly Tyr Arg Gly Gln Thr Ser Pro His Thr Pro Asn 500 505 510 Glu Lys Phe Tyr Gly Val Thr Val Phe Lys Ala Leu Lys Leu Gly 515 520 525 Gln Glu Gly Lys Val Pro Leu Gln Ser Ala His Leu Tyr Tyr Asn 530 535 540 Val Thr Glu Lys Val Arg Arg Ile Met Glu Ser Tyr Phe Arg Leu 545 550 555 Asp Thr Pro Leu Tyr Phe Ser Tyr Ser His Leu Val Cys Arg Thr 560 565 570 Ala Ile Glu Glu Val Gln Ala Glu Arg Lys Asp Asp Ser His Pro 575 580 585 Val His Val Asp Asn Cys Ile Leu Asn Ala Glu Thr Leu Val Cys 590 595 600 Val Lys Glu Pro Pro Ala Tyr Thr Phe Arg Asp Tyr Ser Ala Ile 605 610 615 Leu Tyr Leu Asn Gly Asp Phe Asp Gly Gly Asn Phe Tyr Phe Thr 620 625 630 Glu Leu Asp Ala Lys Thr Val Thr Ala Glu Val Gln Pro Gln Cys 635 640 645 Gly Arg Ala Val Gly Phe Ser Ser Gly Thr Glu Asn Pro His Gly 650 655 660 Val Lys Ala Val Thr Arg Gly Gln Arg Cys Ala Ile Ala Leu Trp 665 670 675 Phe Thr Leu Asp Pro Arg His Ser Glu Arg Asp Arg Val Gln Ala 680 685 690 Asp Asp Leu Val Lys Met Leu Phe Ser Pro Glu Glu Met Asp Leu 695 700 705 Ser Gln Glu Gln Pro Leu Asp Ala Gln Gln Gly Pro Pro Glu Pro 710 715 720 Ala Gln Glu Ser Leu Ser Gly Ser Glu Ser Lys Pro Lys Asp Glu 725 730 735 Leu 34 1896 PRT Homo sapiens misc_feature Incyte ID No 7204554CD1 34 Met Pro Leu Pro Pro Arg Ser Leu Gln Val Leu Leu Leu Leu Leu 1 5 10 15 Leu Leu Leu Leu Leu Leu Pro Gly Met Trp Ala Glu Ala Gly Leu 20 25 30 Pro Arg Ala Gly Gly Gly Ser Gln Pro Pro Phe Arg Thr Phe Ser 35 40 45 Ala Ser Asp Trp Gly Leu Thr His Leu Val Val His Glu Gln Thr 50 55 60 Gly Glu Val Tyr Val Gly Ala Val Asn Arg Ile Tyr Lys Leu Ser 65 70 75 Gly Asn Leu Thr Leu Leu Arg Ala His Val Thr Gly Pro Val Glu 80 85 90 Asp Asn Glu Lys Cys Tyr Pro Pro Pro Ser Val Gln Ser Cys Pro 95 100 105 His Gly Leu Gly Ser Thr Asp Asn Val Asn Lys Leu Leu Leu Leu 110 115 120 Asp Tyr Ala Ala Asn Arg Leu Leu Ala Cys Gly Ser Ala Ser Gln 125 130 135 Gly Ile Cys Gln Phe Leu Arg Leu Asp Asp Leu Phe Lys Leu Gly 140 145 150 Glu Pro His His Arg Lys Glu His Tyr Leu Ser Ser Val Gln Glu 155 160 165 Ala Gly Ser Met Ala Gly Val Leu Ile Ala Gly Pro Pro Gly Gln 170 175 180 Gly Gln Ala Lys Leu Phe Val Gly Thr Pro Ile Asp Gly Lys Ser 185 190 195 Glu Tyr Phe Pro Thr Leu Ser Ser Arg Arg Leu Met Ala Asn Glu 200 205 210 Glu Asp Ala Asp Met Phe Gly Phe Val Tyr Gln Asp Glu Phe Val 215 220 225 Ser Ser Gln Leu Lys Ile Pro Ser Asp Thr Leu Ser Lys Phe Pro 230 235 240 Ala Phe Asp Ile Tyr Tyr Val Tyr Ser Phe Arg Ser Glu Gln Phe 245 250 255 Val Tyr Tyr Leu Thr Leu Gln Leu Asp Thr Gln Leu Thr Ser Pro 260 265 270 Asp Ala Ala Gly Glu His Phe Phe Thr Ser Lys Ile Val Arg Leu 275 280 285 Cys Val Asp Asp Pro Lys Phe Tyr Ser Tyr Val Glu Phe Pro Ile 290 295 300 Gly Cys Glu Gln Ala Gly Val Glu Tyr Arg Leu Val Gln Asp Ala 305 310 315 Tyr Leu Ser Arg Pro Gly Arg Ala Leu Ala His Gln Leu Gly Leu 320 325 330 Ala Glu Asp Glu Asp Val Leu Phe Thr Val Phe Ala Gln Gly Gln 335 340 345 Lys Asn Arg Val Lys Pro Pro Lys Glu Ser Ala Leu Cys Leu Phe 350 355 360 Thr Leu Arg Ala Ile Lys Glu Lys Ile Lys Glu Arg Ile Gln Ser 365 370 375 Cys Tyr Arg Gly Glu Gly Lys Leu Ser Leu Pro Trp Leu Leu Asn 380 385 390 Lys Glu Leu Gly Cys Ile Asn Ser Pro Leu Gln Ile Asp Asp Asp 395 400 405 Phe Cys Gly Gln Asp Phe Asn Gln Pro Leu Gly Gly Thr Val Thr 410 415 420 Ile Glu Gly Thr Pro Leu Phe Val Asp Lys Asp Asp Gly Leu Thr 425 430 435 Ala Val Ala Ala Tyr Asp Tyr Arg Gly Arg Thr Val Val Phe Ala 440 445 450 Gly Thr Arg Ser Gly Arg Ile Arg Lys Ile Leu Val Asp Leu Ser 455 460 465 Asn Pro Gly Gly Arg Pro Ala Leu Ala Tyr Glu Ser Val Val Ala 470 475 480 Gln Glu Gly Ser Pro Ile Leu Arg Asp Leu Val Leu Ser Pro Asn 485 490 495 His Gln Tyr Leu Tyr Ala Met Thr Glu Lys Gln Val Thr Arg Val 500 505 510 Pro Val Glu Ser Cys Val Gln Tyr Thr Ser Cys Glu Leu Cys Leu 515 520 525 Gly Ser Arg Asp Pro His Cys Gly Trp Cys Val Leu His Ser Ile 530 535 540 Cys Ser Arg Arg Asp Ala Cys Glu Arg Ala Asp Glu Pro Gln Arg 545 550 555 Phe Ala Ala Asp Leu Leu Gln Cys Val Gln Leu Thr Val Gln Pro 560 565 570 Arg Asn Val Ser Val Thr Met Ser Gln Val Pro Leu Val Leu Gln 575 580 585 Ala Trp Asn Val Pro Asp Leu Ser Ala Gly Val Asn Cys Ser Phe 590 595 600 Glu Asp Phe Thr Glu Ser Glu Ser Val Leu Glu Asp Gly Arg Ile 605 610 615 His Cys Arg Ser Pro Ser Ala Arg Glu Val Ala Pro Ile Thr Arg 620 625 630 Gly Gln Gly Asp Gln Arg Val Val Lys Leu Tyr Leu Lys Ser Lys 635 640 645 Glu Thr Gly Lys Lys Phe Ala Ser Val Asp Phe Val Phe Tyr Asn 650 655 660 Cys Ser Val His Gln Ser Cys Leu Ser Cys Val Asn Gly Ser Phe 665 670 675 Pro Cys His Trp Cys Lys Tyr Arg His Val Cys Thr His Asn Val 680 685 690 Ala Asp Cys Ala Phe Leu Glu Gly Arg Val Asn Val Ser Glu Asp 695 700 705 Cys Pro Gln Ile Leu Pro Ser Thr Gln Ile Tyr Val Pro Val Gly 710 715 720 Val Val Lys Pro Ile Thr Leu Ala Ala Arg Asn Leu Pro Gln Pro 725 730 735 Gln Ser Gly Gln Arg Gly Tyr Glu Cys Leu Phe His Ile Pro Gly 740 745 750 Ser Pro Ala Arg Val Thr Ala Leu Arg Phe Asn Ser Ser Ser Leu 755 760 765 Gln Cys Gln Asn Ser Ser Tyr Ser Tyr Glu Gly Asn Asp Val Ser 770 775 780 Asp Leu Pro Val Asn Leu Ser Val Val Trp Asn Gly Asn Phe Val 785 790 795 Ile Asp Asn Pro Gln Asn Ile Gln Ala His Leu Tyr Lys Cys Pro 800 805 810 Ala Leu Arg Glu Ser Cys Gly Leu Cys Leu Lys Ala Asp Pro Arg 815 820 825 Phe Glu Cys Gly Trp Cys Val Ala Glu Arg Arg Cys Ser Leu Arg 830 835 840 His His Cys Ala Ala Asp Thr Pro Ala Ser Trp Met His Ala Arg 845 850 855 His Gly Ser Ser Arg Cys Thr Asp Pro Lys Ile Leu Lys Leu Ser 860 865 870 Pro Glu Thr Gly Pro Arg Gln Gly Gly Thr Arg Leu Thr Ile Thr 875 880 885 Gly Glu Asn Leu Gly Leu Arg Phe Glu Asp Val Arg Leu Gly Val 890 895 900 Arg Val Gly Lys Val Leu Cys Ser Pro Val Glu Ser Glu Tyr Ile 905 910 915 Ser Ala Glu Gln Ile Val Cys Glu Ile Gly Asp Ala Ser Ser Val 920 925 930 Arg Ala His Asp Ala Leu Val Glu Val Cys Val Arg Asp Cys Ser 935 940 945 Pro His Tyr Arg Ala Leu Ser Pro Lys Arg Phe Thr Phe Val Thr 950 955 960 Pro Thr Phe Tyr Arg Val Ser Pro Ser Arg Gly Pro Leu Ser Gly 965 970 975 Gly Thr Trp Ile Gly Ile Glu Gly Ser His Leu Asn Ala Gly Ser 980 985 990 Asp Val Ala Val Ser Val Gly Gly Arg Pro Cys Ser Phe Ser Trp 995 1000 1005 Arg Asn Ser Arg Glu Ile Arg Cys Leu Thr Pro Pro Gly Gln Ser 1010 1015 1020 Pro Gly Ser Ala Pro Ile Ile Ile Asn Ile Asn Arg Ala Gln Leu 1025 1030 1035 Thr Asn Pro Glu Val Lys Tyr Asn Tyr Thr Glu Asp Pro Thr Ile 1040 1045 1050 Leu Arg Ile Asp Pro Glu Trp Ser Ile Asn Ser Gly Gly Thr Leu 1055 1060 1065 Leu Thr Val Thr Gly Thr Asn Leu Ala Thr Val Arg Glu Pro Arg 1070 1075 1080 Ile Arg Ala Lys Tyr Gly Gly Ile Glu Arg Glu Asn Gly Cys Leu 1085 1090 1095 Val Tyr Asn Asp Thr Thr Met Val Cys Arg Ala Pro Ser Val Ala 1100 1105 1110 Asn Pro Val Arg Ser Pro Pro Glu Leu Gly Glu Arg Pro Asp Glu 1115 1120 1125 Leu Gly Phe Val Met Asp Asn Val Arg Ser Leu Leu Val Leu Asn 1130 1135 1140 Ser Thr Ser Phe Leu Tyr Tyr Pro Asp Pro Val Leu Glu Pro Leu 1145 1150 1155 Ser Pro Thr Gly Leu Leu Glu Leu Lys Pro Ser Ser Pro Leu Ile 1160 1165 1170 Leu Lys Gly Arg Asn Leu Leu Pro Pro Ala Pro Gly Asn Ser Arg 1175 1180 1185 Leu Asn Tyr Thr Val Leu Ile Gly Ser Thr Pro Cys Thr Leu Thr 1190 1195 1200 Val Ser Glu Thr Gln Leu Leu Cys Glu Ala Pro Asn Leu Thr Gly 1205 1210 1215 Gln His Lys Val Thr Val Arg Ala Gly Gly Phe Glu Phe Ser Pro 1220 1225 1230 Gly Thr Leu Gln Val Tyr Ser Asp Ser Leu Leu Thr Leu Pro Ala 1235 1240 1245 Ile Val Gly Ile Gly Gly Gly Gly Gly Leu Leu Leu Leu Val Ile 1250 1255 1260 Val Ala Val Leu Ile Ala Tyr Lys Arg Lys Ser Arg Asp Ala Asp 1265 1270 1275 Arg Thr Leu Lys Arg Leu Gln Leu Gln Met Asp Asn Leu Glu Ser 1280 1285 1290 Arg Val Ala Leu Glu Cys Lys Glu Ala Phe Ala Glu Leu Gln Thr 1295 1300 1305 Asp Ile His Glu Leu Thr Asn Asp Leu Asp Gly Ala Gly Ile Pro 1310 1315 1320 Phe Leu Asp Tyr Arg Thr Tyr Ala Met Arg Val Leu Phe Pro Gly 1325 1330 1335 Ile Glu Asp His Pro Val Leu Lys Glu Met Glu Val Gln Ala Asn 1340 1345 1350 Val Glu Lys Ser Leu Thr Leu Phe Gly Gln Leu Leu Thr Lys Lys 1355 1360 1365 His Phe Leu Leu Thr Phe Ile Arg Thr Leu Glu Ala Gln Arg Ser 1370 1375 1380 Phe Ser Met Arg Asp Arg Gly Asn Val Ala Ser Leu Ile Met Thr 1385 1390 1395 Ala Leu Gln Gly Glu Met Glu Tyr Ala Thr Gly Val Leu Lys Gln 1400 1405 1410 Leu Leu Ser Asp Leu Ile Glu Lys Asn Leu Glu Ser Lys Asn His 1415 1420 1425 Pro Lys Leu Leu Leu Arg Arg Thr Glu Ser Val Ala Glu Lys Met 1430 1435 1440 Leu Thr Asn Trp Phe Thr Phe Leu Leu Tyr Lys Phe Leu Lys Glu 1445 1450 1455 Cys Ala Gly Glu Pro Leu Phe Met Leu Tyr Cys Ala Ile Lys Gln 1460 1465 1470 Gln Met Glu Lys Gly Pro Ile Asp Ala Ile Thr Gly Glu Ala Arg 1475 1480 1485 Tyr Ser Leu Ser Glu Asp Lys Leu Ile Arg Gln Gln Ile Asp Tyr 1490 1495 1500 Lys Thr Leu Thr Leu Asn Cys Val Asn Pro Glu Asn Glu Asn Ala 1505 1510 1515 Pro Glu Val Pro Val Lys Gly Leu Asp Cys Asp Thr Val Thr Gln 1520 1525 1530 Ala Lys Glu Lys Leu Leu Asp Ala Ala Tyr Lys Gly Val Pro Tyr 1535 1540 1545 Ser Gln Arg Pro Lys Ala Ala Asp Met Asp Leu Glu Trp Arg Gln 1550 1555 1560 Gly Arg Met Ala Arg Ile Ile Leu Gln Asp Glu Asp Val Thr Thr 1565 1570 1575 Lys Ile Asp Asn Asp Trp Lys Arg Leu Asn Thr Leu Ala His Tyr 1580 1585 1590 Gln Val Thr Asp Gly Ser Ser Val Ala Leu Val Pro Lys Gln Thr 1595 1600 1605 Ser Ala Tyr Asn Ile Ser Asn Ser Ser Thr Phe Thr Lys Ser Leu 1610 1615 1620 Ser Arg Tyr Glu Ser Met Leu Arg Thr Ala Ser Ser Pro Asp Ser 1625 1630 1635 Leu Arg Ser Arg Thr Pro Met Ile Thr Pro Asp Leu Glu Ser Gly 1640 1645 1650 Thr Lys Leu Trp His Leu Val Lys Asn His Asp His Leu Asp Gln 1655 1660 1665 Arg Glu Gly Asp Arg Gly Ser Lys Met Val Ser Glu Ile Tyr Leu 1670 1675 1680 Thr Arg Leu Leu Ala Thr Lys Gly Thr Leu Gln Lys Phe Val Asp 1685 1690 1695 Asp Leu Phe Glu Thr Ile Phe Ser Thr Ala His Arg Gly Ser Ala 1700 1705 1710 Leu Pro Leu Ala Ile Lys Tyr Met Phe Asp Phe Leu Asp Glu Gln 1715 1720 1725 Ala Asp Lys His Gln Ile His Asp Ala Asp Val Arg His Thr Trp 1730 1735 1740 Lys Ser Asn Cys Leu Pro Leu Arg Phe Trp Val Asn Val Ile Lys 1745 1750 1755 Asn Pro Gln Phe Val Phe Asp Ile His Lys Asn Ser Ile Thr Asp 1760 1765 1770 Ala Cys Leu Ser Val Val Ala Gln Thr Phe Met Asp Ser Cys Ser 1775 1780 1785 Thr Ser Glu His Lys Leu Gly Lys Asp Ser Pro Ser Asn Lys Leu 1790 1795 1800 Leu Tyr Ala Lys Asp Ile Pro Asn Tyr Lys Ser Trp Val Glu Arg 1805 1810 1815 Tyr Tyr Ala Asp Ile Ala Lys Met Pro Ala Ile Ser Asp Gln Asp 1820 1825 1830 Met Ser Ala Tyr Leu Ala Glu Gln Ser Arg Leu His Leu Ser Gln 1835 1840 1845 Phe Asn Ser Met Ser Ala Leu His Glu Ile Tyr Ser Tyr Ile Thr 1850 1855 1860 Lys Tyr Lys Asp Glu Ile Leu Ala Ala Leu Glu Lys Asp Glu Gln 1865 1870 1875 Ala Arg Arg Gln Arg Leu Arg Ser Lys Leu Glu Gln Val Val Asp 1880 1885 1890 Thr Met Ala Leu Ser Ser 1895 35 215 PRT Homo sapiens misc_feature Incyte ID No 6833247CD1 35 Met Gly Leu Glu Lys Pro Gln Ser Lys Leu Glu Gly Gly Met His 1 5 10 15 Pro Gln Leu Ile Pro Ser Val Ile Ala Val Val Phe Ile Leu Leu 20 25 30 Leu Ser Val Cys Phe Ile Ala Ser Cys Leu Val Thr His His Asn 35 40 45 Phe Ser Arg Cys Lys Arg Gly Thr Gly Val His Lys Leu Glu His 50 55 60 His Ala Lys Leu Lys Cys Ile Lys Glu Lys Ser Glu Leu Lys Ser 65 70 75 Ala Glu Gly Ser Thr Trp Asn Cys Cys Pro Ile Asp Trp Arg Ala 80 85 90 Phe Gln Ser Asn Cys Tyr Phe Pro Leu Thr Asp Asn Lys Thr Trp 95 100 105 Ala Glu Ser Glu Arg Asn Cys Ser Gly Met Gly Ala His Leu Met 110 115 120 Thr Ile Ser Thr Glu Ala Glu Gln Asn Phe Ile Ile Gln Phe Leu 125 130 135 Asp Arg Arg Leu Ser Tyr Phe Leu Gly Leu Arg Asp Glu Asn Ala 140 145 150 Lys Gly Gln Trp Arg Trp Val Asp Gln Thr Pro Phe Asn Pro Arg 155 160 165 Arg Val Phe Trp His Lys Asn Glu Pro Asp Asn Ser Gln Gly Glu 170 175 180 Asn Cys Val Val Leu Val Tyr Asn Gln Asp Lys Trp Ala Trp Asn 185 190 195 Asp Val Pro Cys Asn Phe Glu Ala Ser Arg Ile Cys Lys Ile Pro 200 205 210 Gly Thr Thr Leu Asn 215 36 579 PRT Homo sapiens misc_feature Incyte ID No 4148119CD1 36 Met Gly Arg Pro Thr Gln Trp Pro Ser Leu Leu Leu Leu Leu Leu 1 5 10 15 Leu Pro Gly Pro Pro Pro Val Ala Gly Leu Glu Asp Ala Ala Phe 20 25 30 Pro His Leu Gly Glu Ser Leu Gln Pro Leu Pro Arg Ala Cys Pro 35 40 45 Leu Arg Cys Ser Cys Pro Arg Val Asp Thr Val Asp Cys Asp Gly 50 55 60 Leu Asp Leu Arg Val Phe Pro Asp Asn Ile Thr Arg Ala Ala Gln 65 70 75 His Leu Ser Leu Gln Asn Asn Gln Leu Gln Glu Leu Pro Tyr Asn 80 85 90 Glu Leu Ser Arg Leu Ser Gly Leu Arg Thr Leu Asn Leu His Asn 95 100 105 Asn Leu Ile Ser Ser Glu Gly Leu Pro Asp Glu Ala Phe Glu Ser 110 115 120 Leu Thr Gln Leu Gln His Leu Cys Val Ala His Asn Lys Leu Ser 125 130 135 Val Ala Pro Gln Phe Leu Pro Arg Ser Leu Arg Val Ala Asp Leu 140 145 150 Ala Ala Asn Gln Val Met Glu Ile Phe Pro Leu Thr Phe Gly Glu 155 160 165 Lys Pro Val Leu Arg Ser Val Tyr Leu His Asn Asn Gln Leu Ser 170 175 180 Asn Ala Gly Leu Pro Pro Asp Ala Phe Arg Gly Ser Glu Ala Ile 185 190 195 Ala Thr Leu Ser Leu Ser Asn Asn Gln Leu Ser Tyr Leu Pro Pro 200 205 210 Ser Leu Pro Pro Ser Leu Glu Arg Leu His Leu Gln Asn Asn Leu 215 220 225 Ile Ser Lys Val Pro Arg Gly Ala Leu Ser Arg Gln Thr Gln Leu 230 235 240 Arg Glu Leu Tyr Leu Gln His Asn Gln Leu Thr Asp Ser Gly Leu 245 250 255 Asp Ala Thr Thr Phe Ser Lys Leu His Ser Leu Glu Tyr Leu Asp 260 265 270 Leu Ser His Asn Gln Leu Thr Thr Val Pro Ala Gly Leu Pro Arg 275 280 285 Thr Leu Ala Ile Leu His Leu Gly Arg Asn Arg Ile Arg Gln Val 290 295 300 Glu Ala Ala Arg Leu His Gly Ala Arg Gly Leu Arg Tyr Leu Leu 305 310 315 Leu Gln His Asn Gln Leu Gly Ser Ser Gly Leu Pro Ala Gly Ala 320 325 330 Leu Arg Pro Leu Arg Gly Leu His Thr Leu His Leu Tyr Gly Asn 335 340 345 Gly Leu Asp Arg Val Pro Pro Ala Leu Pro Arg Arg Leu Arg Ala 350 355 360 Leu Val Leu Pro His Asn His Val Ala Ala Leu Gly Ala Arg Asp 365 370 375 Leu Val Ala Thr Pro Gly Leu Thr Glu Leu Asn Leu Ala Tyr Asn 380 385 390 Arg Leu Ala Ser Ala Arg Val His His Arg Ala Phe Arg Arg Leu 395 400 405 Arg Ala Leu Arg Ser Leu Asp Leu Ala Gly Asn Gln Leu Thr Arg 410 415 420 Leu Pro Met Gly Leu Pro Thr Gly Leu Arg Thr Leu Gln Leu Gln 425 430 435 Arg Asn Gln Leu Arg Met Leu Glu Pro Glu Pro Leu Ala Gly Leu 440 445 450 Asp Gln Leu Arg Glu Leu Ser Leu Ala His Asn Arg Leu Arg Val 455 460 465 Gly Asp Ile Gly Pro Gly Thr Trp His Glu Leu Gln Ala Leu Gln 470 475 480 Met Leu Asp Leu Ser His Asn Glu Leu Ser Phe Val Pro Pro Asp 485 490 495 Leu Pro Glu Ala Leu Glu Glu Leu His Leu Glu Gly Asn Arg Ile 500 505 510 Gly His Val Gly Pro Glu Ala Phe Leu Ser Thr Pro Arg Leu Arg 515 520 525 Ala Leu Phe Leu Arg Ala Asn Arg Leu His Met Thr Ser Ile Ala 530 535 540 Ala Glu Ala Phe Leu Gly Leu Pro Asn Leu Arg Val Val Asp Thr 545 550 555 Ala Gly Asn Pro Glu Gln Val Leu Ile Arg Leu Pro Pro Thr Thr 560 565 570 Pro Arg Gly Pro Arg Ala Gly Gly Pro 575 37 1211 DNA Homo sapiens misc_feature Incyte ID No 1888682CB1 37 ccgggacggt cacatcccgc tgcaggggcg ggcggaggcc gccgcactgc ctcccgcacc 60 ggggacccag gccagcgtcc gggcaacgcc ccctgctccc ggacagactc cgtggcccgc 120 tcgagccctg ggggctccgc agacccgcgc ccgctccgcc cgcagctcgg ccccgcgctg 180 cccgcgtcgc cgggcccgcg ccgggatggg gtaggggcag cgccaccgag tcgggcgatg 240 ggccgccctc tgggcaccga gcagcccccc gaggcctgac caaccgcgag gaccggcgga 300 ggagccccgc ctggatgtca agcggatgcc aagcggatgc cacagttccc cccccagcgg 360 actccgtggg gacatggctt cgctggtgcc cctttcccca tatctaagcc ccacggtcct 420 cctgctggtc agctgtgacc tgggcttcgt gcgagcagac cggcctccct ctcctgtgaa 480 tgtgacggtc actcacctca gagccaactc ggccactgtg tcctgggacg tcccagaagg 540 caacatcgtc attggctact ccatttccca gcaacggcag aatggccccg ggcagcgtgt 600 gattcgggag gtgaacacca ccacccgggc ctgtgccctc tggggcctgg ctgaagacag 660 tgactacaca gtgcaggtca ggagcatcgg ccttcgggga gagagtcccc cagggccccg 720 ggtgcacttc cgaactctca agggttctga ccggctacct tcaaacagtt caagcccagg 780 tgacatcaca gtggaaggtc tggatggaga gcggccactg cagactgggg aagtggtcat 840 cattgtggtg gtgttgctca tgtgggctgc tgtaattggg ctgttctgcc gtcagtatga 900 catcatcaag gacaatgact ccaacaacaa tcccaaggag aagggaaagg ggccggaaca 960 gagtcctcag ggaaggccag tggggacaag acagaaaaag tcaccatcta tcaacaccat 1020 cgacgtttga gtgaagaaac acacccagaa gagagatgca ctaacaactg gggataggga 1080 tggggtcagg gggagcccaa gatggtgatc tgcccgagac tcccagaggg tattgccact 1140 cccacaatct caggcctggt acccatcctc tttccactgt gagcagagcc agaaggtagg 1200 tctgttcaga g 1211 38 1523 DNA Homo sapiens misc_feature Incyte ID No 1794980CB1 38 ggcggctggc ggcgcgggca ggcaggcggg gaggacaggc tgggggcggc gaccgcgagg 60 ggccgcgcgc ggagggcgcc tggtgcagca tgggcggccc gcgggcttgg gcgctgctct 120 gcctcgggct cctgctcccg ggaggcggcg ctgcgtggag catcggggca gctccgttct 180 ccggacgcag gaactggtgc tcctatgtgg tgacccgcac catctcatgc catgtgcaga 240 atggcaccta ccttcagcga gtgctgcaga actgcccctg gcccatgagc tgtccgggga 300 gcagctacag aactgtggtg agacccacat acaaggtgat gtacaagata gtgaccgccc 360 gtgagtggag gtgctgccct gggcactcag gagtgagctg cgaggaagtt gcagcttcct 420 ctgcctcctt ggagcccatg tggtcgggca gtaccatgcg gcggatggcg cttcggccca 480 cagccttctc aggttgtctc aactgcagca aagtgtcaga gctgacagag cggctgaagg 540 tgctggaggc caagatgacc atgctgactg tcatagagca gccagtacct ccaacaccag 600 ctacccctga ggaccctgcc ccgctctggg gtccccctcc tgcccagggc agccccggag 660 atggaggcct ccaggaccaa gtcggtgctt gggggcttcc cgggcccacc ggccccaagg 720 gagatgccgg cagtcggggc ccaatgggga tgagaggccc accaggtcca cagggccccc 780 cagggagccc tggccgggct ggagctgtgg gcacccctgg agagagggga cctcctgggc 840 caccagggcc tcctggcccc cctgggcccc cagcccctgt tgggccaccc catgcccgga 900 tctcccagca tggagaccca ttgctgtcca acaccttcac tgagaccaac aaccactggc 960 cccagggacc cactgggcct ccaggccctc cagggcccat gggtccccct gggcctcctg 1020 gccccacagg tgtccctggg agtcctggtc acataggacc cccaggcccc actggaccca 1080 aaggaatctc tggccaccca ggagagaagg gcgagagagg actgcgtggg gagcctggcc 1140 cccaaggctc tgctgggcag cggggggaac ctggccctaa gggagaccct ggtgagaaga 1200 gccactgggg ggaggggttg caccagctac gcgaggcttt gaagatttta gctgagaggg 1260 ttttaatctt ggaaacaatg attgggctct atgaaccaga gctggggtct ggggcgggcc 1320 ctgccggcac aggcaccccc agcctccttc ggggcaagag gggcggacat gcaaccaact 1380 accggatcgt ggcccccagg agccgggacg agagaggctg agttggtggc ggcccctgag 1440 gcagaccagg ccaggcttcc cctcctacct ggactcggcc agctgcctcc agggaccgcc 1500 cgtccataat tcaggagcgt ccc 1523 39 1368 DNA Homo sapiens misc_feature Incyte ID No 5533958CB1 39 ctgccgggtg tgccgggtgt ccagcgaacc cctttcccaa accttcgggg agaagggagg 60 tgggaggagg caaagaaact acaggcaggg agctggaagg gggggtgggg ggggcaggag 120 acaagaaatc aagacaccag gcagcaggac acacacacac tcacatacac tcacacacat 180 agagaccaac agatagacag ctacctaaag cctgaaagac tgacagcaac acagaaaaaa 240 agaaacaggc agaaagagag acaaagacag aaatagaaac agactaacac acagagtcaa 300 aaatacagag acagaaagac agggagaaag agaaacagaa aattagacac caaagacata 360 cgaacaggga ggaaggccga ctgaaagaaa gacggagaag aggagagaga agccagggcc 420 gagcgtgcca gcaggcggat ggagggcggc ctggtggagg aggagacgta gtggcctggg 480 ctgagctggg tgggccggga gaagcgggtg cctcagagtg ggggtggggg catgggaggg 540 gcaggcattc tgctgctgct gctggctggg gcgggggtgg tggtggcctg gagaccccca 600 aagggaaagt gtcccctgcg ctgctcctgc tctaaagaca gcgccctgtg tgagggctcc 660 ccggacctgc ccgtcagctt ctctccgacc ctgctgtcac tctcactcgt caggacggga 720 gtcacccagc tgaaggccgg cagcttcctg agaattccgt ctctgcacct gctcctcttc 780 acctccaact ccttctccgt gattgaggac gatgcatttg cgggcctgtc ccacctgcag 840 tacctcttca tcgaggacaa tgagattggc tccatctcta agaatgccct cagaggactt 900 cgctcgctta cacacctaag cctggccaat aaccatctgg agaccctccc cagattcctg 960 ttccgaggcc tggacaccct tactcacgtg gacctccgcg ggaacccgtt ccagtgtgac 1020 tgccgcgtcc tctggctcct gcagtggatg cccaccgtga atgccagcgt ggggaccggc 1080 gcctgtgcgg gccccgcctc cctgagccac atgcagctcc accacctcga ccccaagact 1140 ttcaagtgca gagccatagg tggggggctt tcccgatggg gtgggaggcg ggagatctgg 1200 gggaaaggct gccagggcca agaggctcgt ctcactccct gccctgccat ttcccggagt 1260 gggaagaccc tgagcaagca gcactgcctt cctgagcccc agttttctca tctgtaaagt 1320 gggggtaata aacagtgata taggagtgcc atggaaaaaa aaaaaaaa 1368 40 3157 DNA Homo sapiens misc_feature Incyte ID No 60210196CB1 40 tggtcgttcc tcggtttgcc atccattggg cccctgccct ccatccccgt ggaggcccct 60 tgtctgggtg ttcgcactca acgtcgatgt gttgataatg gtgccttttt cgtgaagaaa 120 ctgcctgagt ctcacttcca gaagtttata ggtccacccg ttctctccag cgtccgccag 180 cccagatctc gcatgcgcat ctgtgtctgc ccctctttgc cttctgcctg tccctgggtg 240 cccctcaggg tcagaatcac cctttccgcc cgcactggcc cccacatcac ctgtcttgtc 300 cccactggcc ttccctgagg actctgttcc ggcccctttc ccttctcctt gggattgttg 360 ttggagtcat tgtccttgat gatgtcatac tgacggcaga acagcccaat tacagctgaa 420 acacaataca gtctgagccc agagagccgc ggggaccatg gagccggtgc cgctgcagga 480 cttcgtgcgc gccttggacc ccgcctccct cccgcgcgtg ctgcgggtct gctcgggggt 540 ctacttcgag ggctccatct atgagatctc tgggaatgag tgctgcctct ccacggggga 600 cctgatcaag gtcacccagg tccgcctcca gaaggtggtc tgtgagaacc cgaagaccag 660 ccagaccatg gagctcgccc ccaacttcca gggctacttc acccccctca acaccccaca 720 gagctatgaa accctggagg agctggtctc tgccacaact cagagctcca agcagctgcc 780 cacttgcttc atgtcgaccc acaggattgt cacagagggc agggtggtga ctgaggacca 840 gctcctcatg cttgaggctg tggtgatgca cctcgggatc cgctctgccc gctgtgtcct 900 gggcatggag ggtcagcagg tcatcctgca cctgccccta tcccagaagg ggcccttctg 960 gacatgggag cctagtgccc ctcgaactct gctccaggtc ctacaggatc cagccctgaa 1020 agacctcgtc ctcacctgcc ccaccctgcc ctggcattcc ctgatcctgc ggccccagta 1080 tgagatccaa gccatcatgc acatgcgcag gaccattgtc aagatccctt ctaccctgga 1140 ggtcgacgtg gaggacgtca ccgcctcctc ccggcacgtc cactttatca aaccgctgct 1200 gctgagcgag gtcctggcct gggaaggccc tttccccctg tccatggaga tcctggaggt 1260 tcctgagggc cgccccatct tcctcagccc gtgggtgggc tccttgcaaa aaggccagag 1320 gctttgcgtc tatggcctag cctcaccacc ctggcgggtc ctggcctcaa gcaagggccg 1380 caaggtgccc aggcacttcc tggtgtcagg gggctaccaa ggcaagctgc ggcggcggcc 1440 aagggagttc cccacggcct atgacctcct aggtgctttc cagccaggcc ggccactccg 1500 ggtggtggcc acaaaggact gtgagggcga gagggaggag aatcccgagt tcacgtccct 1560 ggctgtgggt gaccggctgg aggtgctggg gcctggccag gcccatgggg cccagggcag 1620 tgacgtggat gtcttggttt gtcagcggct gagtgaccag gctggggagg atgaggagga 1680 agagtgcaaa gaggaggcag agagcccaga gcgggtcctg ctgcccttcc acttccctgg 1740 cagtttcgtg gaggagatga gtgacagccg gcgctacagc ctggcagatc tgactgccca 1800 gttttcactg ccttgtgagg tcaaggtggt ggccaaggac accagccacc ccactgaccc 1860 tctgacctcc ttcctgggcc tgcggctgga ggagaagatc acagagccat tcttggtggt 1920 gagcctagac tctgagcctg ggatgtgctt tgagatccct ccccggtggc tggacctgac 1980 tgttgtgaag gccaaggggc agccagactt gccagagggg tctctcccca tagccacagt 2040 ggaggagctg acagacacct tctattatcg tcttcggaag ttaccagcct gtgagatcca 2100 agccccccca cccaggcccc ctaaaaatca gggcctcagc aagcagagga gacacagcag 2160 tgagggaggc gtcaagtctt ctcaagtctt aggattgcag caacacgctc ggctgcccaa 2220 acccaaggcg aagaccttgc cagagttcat caaggatggc tccagtacgt acagcaagat 2280 tcctgcccac aggaagggcc acaggcccgc taagccccaa aggcaggatc tagatgatga 2340 tgaacatgat tatgaagaaa tacttgagca atttcagaaa accatctaag tgctggagga 2400 accacgcttc ctaactgctg cttctcaggg aatccgacac cagccaacca ttttaagcct 2460 ctaaaagacc tcgggcaagt ctcacagaaa ctgagctgca gacggggagt agctttgtgg 2520 aaactgattt gatggacact gcaccagctt ccttcaggtt ctagattctt gctacttagg 2580 gcgggctggt ttggacctaa catctcgcac gtgactccct cagcctcaga gccttgggat 2640 gcagagcagc tggcagggtt cctctcaatc ctgcaacccc agctgtccca ccggtggatg 2700 cagaggggaa tccgaggcca tcaaccttgg tgacagcagc gcagtgccaa tgctgatcac 2760 actgcatggg agattttgtt aacgtctgcc acccccactc tcacccccaa gctctaagcc 2820 cccgggaggc ctggactgtc ttcctcatct ctgtagcacc aagcctgata gatctgtata 2880 tggtaaacag gggtttaacc acatgtggtt aacatggatt aatgtgggaa tttggcttca 2940 agaacacaac cttaggacct tgggccccaa aagctggtgg tgaaatgaga ggagccaatt 3000 taagaagacc cttatggaga cctgaggctg cagaaactgg taggtttcat caggtggtta 3060 aagtcgtcaa agttgtaagt gactaaccaa gattatttca ttttaaaacc acagaataaa 3120 aatgacacct gagcttctct aaaaaaaaaa aaaaaaa 3157 41 3264 DNA Homo sapiens misc_feature Incyte ID No 815125CB1 41 ggagccgggg cagccagaag aggtgggaaa agcggaggag gacgcccagg aggaggcggc 60 ggcggcggcc gggaagtgaa aggtctcgca aagttcagcg gcggctgcgg gcgccgagcc 120 ccgggctagc ggcagacgag cccgcagggc cgctccgcgg ggcagcgcag ccaggccggc 180 tatggtcccg gggctcccgc cgccccccag gtgcccggga cccgccaggc cgggtgcgcg 240 agggtcaccc cacctccccg cgcggtcccg gcccctggct cccagctgcc ggcgaccgct 300 gaccgagccc ggcgccccag gaggaggaag aaaccagggc cccgttccct cccgaggacg 360 gcggcgcttc atcccgcagc ccagaggtct cggctccctc cggcacccgc ccggcccggc 420 tgctcccggc tcctcccggc catggggagc tgcgcgcggc tgctgctgct ctggggctgc 480 acggtggtgg ccgcaggact gagtggagta gctggagtga gttcccgctg tgaaaaagcc 540 tgcaaccctc ggatgggaaa tttggctttg gggcgaaaac tctgggcaga caccacctgc 600 ggtcagaatg ctaccgaact gtactgcttc tacagtgaga acacggatct gacttgtcgg 660 cagcccaaat gtgacaagtg caatgctgcc tatcctcacc tggctcacct gccatctgcc 720 atggcagact catccttccg gtttcctcgc acatggtggc agtctgcgga ggatgtgcac 780 agagaaaagg tccagttaga cctggaagct gaattctact tcactcacct aattgtgatg 840 ttcaagtccc ccaggccagc tgccatggtg ctggaccgct cccaggactt tgggaaaaca 900 tggaagcctt ataagtactt tgcgactaac tgctccgcta catttggcct ggaagatgat 960 gttgtcaaga agggcgctat ttgtacttct aaatactcca gtccttttcc atgcactgga 1020 ggagaggtta ttttcaaagc tttgtcacca ccatacgata cagagaaccc ttacagtgcc 1080 aaagttcagg agcagctgaa gatcaccaac cttcgcgtgc agctgctgaa acgacagtct 1140 tgtccctgtc agagaaatga cctgaacgaa gagcctcaac attttacaca ctatgcaatc 1200 tatgatttca ttgtcaaggg cagctgcttc tgcaatggcc acgctgatca atgcatacct 1260 gttcatggct tcagacctgt caaggcccca ggaacattcc acatggtcca tgggaagtgt 1320 atgtgtaagc acaacacagc aggcagccac tgccagcact gtgccccgtt atacaatgac 1380 cggccatggg aggcagctga tggcaaaacg ggggctccca acgagtgcag aacctgcaag 1440 tgtaatgggc atgctgatac ctgtcacttc gacgttaatg tgtgggaggc atcagggaat 1500 cgtagtggtg gtgtctgtga tgactgtcag cacaacacag aaggacagta ttgccagagg 1560 tgcaagccag gcttctatcg tgacctgcgg agacccttct cagctccaga tgcttgcaaa 1620 ccgtgttcct gccatccagt aggatcagct gtccttcctg ccaactcagt gaccttctgc 1680 gaccccagca atggtgactg cccttgcaag cctggggtgg cagggcgacg ttgtgacagg 1740 tgcatggtgg gatactgggg cttcggagac tatggctgtc gaccatgtga ctgtgcaggg 1800 agctgtgacc ctatcaccgg agactgcatc agcagccaca cagacataga ctggtatcat 1860 gaagttcctg acttccgtcc cgtgcacaat aagagcgaac cagcctggga gtgggaggat 1920 gcgcaggggt tttctgcact tctacactca ggtaaatgcg aatgtaagga acagacatta 1980 ggaaatgcca aggcattctg tggaatgaaa tattcatatg tgctaaaaat aaagatttta 2040 tcagctcatg ataaaggtac tcatgttgag gtcaatgtga agattaaaaa ggtcttaaaa 2100 tctaccaaac tgaagatttt ccgaggaaag cgaacattat atccagaatc atggacggac 2160 agaggatgca cttgtccaat cctcaatcct ggtttggaat accttgtagc aggacatgag 2220 gatataagaa caggcaaact aattgtgaat atgaaaagct ttgtccagca ctggaaacct 2280 tctcttggaa gaaaagtcat ggatatttta aaaagagagt gcaagtagca ttaagatgga 2340 tagcacataa tggcacttgt ctatgtacaa aacacaaact ttagagcaag aagacctcag 2400 acaggaaact ggaatttttt aaagtgccaa aacatataga aatgtttgaa tgcatgggtc 2460 ttatctaatt tatctcttct ggacccatgt ttaaatacag ttttatttca tgaagagaaa 2520 tgaaaacccc tacactgata tctgttttct atgggactga ttctgaaatt cttaactatt 2580 aagaatattt taatagcagc atgacattta gcagtaatcc attaagggca gtacctctaa 2640 caaggacgcc ttccagcttc agctatgtta cttacgtttg atgctactta aagtaatgaa 2700 tgacgtttta aggaatccct aaccctacta tcagaaaagg tgtttgttaa agagccttct 2760 cttgtgtgtt acgcatgaac tttggtctgt aggtgttaaa tggaacctct ccatgtgtat 2820 atagtatttc cttgtataaa gcactttact acctaccact tgtgttgtga acgtttggtg 2880 actgctgttg aaagaaggaa aagggtgtgt gagaaagcct actgaagcag cagcactgcc 2940 actacatgtg gacaaaagtg aacatataaa agaagttgtg ctatttaact ctgaatactt 3000 ggagaaacta ggtgaagatg caaccagaaa ggagaatatg tatgcgtgaa gtctcagctt 3060 tgagctggag gctagattcc aagatgacag ccatgatgaa actttttaaa aaactaaacc 3120 agaagagact ttaaaataag agaaagaaat cataaatgta gacatatgct tggctaaagg 3180 ggaaatggac tttaaatttt aaagagctca tttgcaatgc acttgtatac acttcaaaaa 3240 ttattgtaga cacagcattt gtta 3264 42 3383 DNA Homo sapiens misc_feature Incyte ID No 1386915CB1 42 tgcgatctag aacgtccgac ctctcctctc ccagccagtc gtggctggcc tttcaaagtg 60 tgcagttgtc tcctccctgt ccagccccat cgtcgcccag gaccagctgg gccgcggtct 120 gacctgaggc tgctgctcag cgccggggcg ctggcgctct ccattcgagc accttccagc 180 ataccgctcg gctccgggag ccgctctgca aagttgagca gctcagagcg caagctttgc 240 ctctcgactt ctccctcctt gggtccccgg cgcccccgcc tcccacgatc cctttcacta 300 ggagcagcca gtcccagcgg gctggcaact tgcacccctt cctagtcatc ctccctgaaa 360 cgcgaccatg ctgttaaggg gcgtcctcct ggcgttgcaa gccctgcagc tcgccggtgc 420 cctcgacctg cccgctgggt cctgtgcctt tgaagagagc acttgcggct ttgactccgt 480 gttggcctct ctgccgtgga ttttaaatga ggaaggccat tacatttatg tggatacctc 540 ctttggcaag cagggggaga aagctgtgct gctaagtcct gacttacagg ctgaggaatg 600 gagctgcctc cgtttggtct accagataac cacatcttcg gagtctctgt cagatcccag 660 ccagctgaac ctctacatga gatttgaaga tgaaagcttt gatcgcttgc tttggtcagc 720 taaggaacct tcagacagct ggctcatagc cagcttggat ttgcaaaaca gttccaagaa 780 attcaagatt ttaatagaag gtgtactagg acagggaaac acagccagca tcgcactatt 840 tgaaatcaag atgacaaccg gctactgtat tgaatgtgac tttgaagaaa atcatctctg 900 tggctttgtg aaccgctgga atcccaatgt gaactggttt gttggaggag gaagtattcg 960 gaatgtccac tccattctcc cacaggatca caccttcaag agtgaactgg gccactacat 1020 gtacgtggac tcagtttatg tgaagcactt ccaggaggtg gcacagctca tctccccgtt 1080 gaccacggcc cccatggctg gctgcctgtc attttattac cagatccagc aggggaatga 1140 caatgtcttt tccctttaca ctcgggatgt ggctggcctt tacgaggaaa tctggaaagc 1200 agacaggcca gggaatgctg cctggaacct tgcggaggtc gagttcaatg ctccttaccc 1260 catggaggtt atttttgaag ttgctttcaa tggtcccaag ggaggttatg ttgccctgga 1320 tgatatttca ttctctcctg ttcactgcca gaatcagaca gaacttctgt tcagtgccgt 1380 ggaagccagc tgcaattttg agcaagatct ctgcaacttt taccaagata aagaaggtcc 1440 aggttggacc cgagtgaaag taaaaccaaa catgtatcgg gctggagacc acactacagg 1500 cttagggtat tacctgctag ccaacacaaa gttcacatct cagcctggct acattggaag 1560 gctctatggg ccctccctac caggaaactt gcagtattgt ctgcgttttc attatgccat 1620 ctatggattt ttaaaaatga gtgacaccct agcagtttac atctttgaag agaaccatgt 1680 ggttcaagag aagatctggt ctgtgttgga gtccccaagg ggtgtttgga tgcaagctga 1740 aatcaccttt aagaagccca tgcctaccaa ggtggttttc atgagcctat gcaaaagttt 1800 ctgggactgt gggcttgtag ccctggatga cattacaata caattgggaa gctgctcatc 1860 ttcagagaaa cttccacctc cacctggaga gtgtactttc gagcaagatg aatgtacatt 1920 tactcaggag aaaagaaacc ggagcagctg gcacaggagg aggggagaaa ctcccacttc 1980 ctacacagga ccaaagggag atcacactac tggggtaggc tactacatgt acattgaggc 2040 ctcccatatg gtgtatggac aaaaagcacg cctcttgtcc aggcctctgc gaggagtctc 2100 tggaaaacac tgcttgacct ttttctacca catgtatgga gggggcactg gcctgctgag 2160 tgtttatctg aaaaaggaag aagacagtga agagtccctc ttatggagga gaagaggtga 2220 acagagcatt tcctggctac gagcactgat tgaatacagc tgtgagaggc aacaccagat 2280 aatttttgaa gccattcgag gagtatcaat aagaagtgat attgccattg atgatgttaa 2340 atttcaggca ggaccctgtg gagaaatgga agatacaact caacaatcat caggatattc 2400 tgaggactta aatgaaattg agtattaaga aatgatctgc attggattta ctagacgaaa 2460 accatacctc tcttcaatca aaatgaaaac aaagcaaatg aatactggac agtcttaaca 2520 attttataag ttataaaatg actttagagc accctccttc attacttttg caaaaacata 2580 ctgactcagg gctctttttt tctttttgca tatgacaact gttactagaa atacaggcta 2640 ctggttttgc atagatcatt catcttaatt ttggtaccag ttaaaaatac aaatgtacta 2700 tattgtagtc attttaaagt acacaaaggg cacaatcaaa atgagatgca ctcatttaaa 2760 tctgcattca gtgaatgtat tgggagaaaa ataggtcttg caggtttcct tttgaatttt 2820 aagtatcata aatatttttt aagtaaataa tacggggtgt cagtaatatc tgcagaatga 2880 atgcagtctt tcatgctaat gagttagtct ggaaaaataa agtcttattt tctatgtttt 2940 attcatagaa atggagtatt aatttttaat attttcacca tatgtgataa caaaggatct 3000 ttcatgaatg tccaagggta agtcagtatt aattaatgct gtattacaag gcaatgctac 3060 cttctttatt ccccctttga actacctttg aagtcactat gagcacatgg atagaaattt 3120 aacttttttt tgtaaagcaa gcttaaaatg tttatgtata catacccagc aacttttata 3180 aatgtgttaa acaattttac tgatttttat aataaatatt ttggtaagat tttgaataat 3240 atgaattcag gcagatatac taaactgctt ttatttactt gtttagaaaa ttgtatatat 3300 atgtttgtgt atcctaacag ctgctatgaa attataaaat tacctaataa aaataatttg 3360 aaaatcttaa aaaaaaaaaa aaa 3383 43 2741 DNA Homo sapiens misc_feature Incyte ID No 1344495CB1 43 ggcagctgcg ggtcgcgggt cgcgggtcgc gagtcgccgg tcgccggtcg cggcggagcc 60 tgggcgctga gtgaagaaaa tgaggcacga ggaattgtta accaagacct tccaaggccc 120 agctgttgtg tgtgggactc cgaccagcca cgtatacatg tttaagaatg gcagtgggga 180 ctcgggggac tcttctgaag aagagtctca ccgtgtggtt ttgcggcccc ggggcaagga 240 gcgccacaag agcggtgtcc accagcctcc ccaggcggga gcaggtgacg tggtgctgct 300 gcagcgggag ctggcccagg aggacagcct caacaagctg gcgctgcagt atggctgcaa 360 agttgcagat atcaagaaag tcaacaactt catcagagaa caagacttat atgctttgaa 420 atctgttaag attccagtga gaaaccatgg gatcctgatg gagacccaca aagaactgaa 480 accccttctg agcccgtctt ccgagaccac agtgaccgtg gaactgccag aggcagacag 540 agcaggcgcg ggcaccggtg cccaggccgg ccaactgatg ggcttcttta aggggattga 600 ccaggatatt gagcgtgcag tgcagtcaga aatctttcta catgaaagtt actgcatgga 660 cacctcccat cagccactgc tcccggcacc tccgaagacg cctatggatg gtgcagattg 720 tggcattcag tggtggaatg ctgttttcat catgctgctg attggtattg tcttgcctgt 780 cttttatttg gtctacttta aaatacaagc tagtggtgag acccctaata gcttgaacac 840 aactgtcatc cccaatggct cgatggcaat gggtacagtt ccagggcaag cccccagact 900 agcagttgca gtgccagccg tcacttctgc agacagccag ttcagtcaga ccacccaagc 960 ggggagctaa gctttgtttt taaagactcg gcccagcttt agcaattggc tgttgatgtg 1020 cctcagctgt cactggcgat gtcctagggg tgctgcattt tgcttccggg gaaggatgga 1080 cacttttcag aagtcactgc agtattccca attgcactgg ccctgggcat ggccttaccc 1140 agtctaagct ggcaggatct aaaacagcag cgacctcggc ccctatccag agaggtgcag 1200 caagagagcc atttccctgt gacatttagt ggactggcca gttcatagca gcactgtgag 1260 gacccccaag ttggacgtgc tcggagggaa agatttatgg cctctgtcga gggacctgca 1320 gcgtgagagc cagtggcatc tgcgcggctt gcctggctct tgctgtatcc tcacttcctg 1380 tggagcgggg attggctctg agaaggagtg ttctctgtct gcctggcaaa ggtgctgtgg 1440 aataggcttg gcatgccacc ctgttttaga gagtgacagt tacagttgta acaagcctac 1500 ttcatattgg ccccctcagt tagccttttt gaggcaatgc catttctaga gttgaaaaag 1560 ccctggaccc aaactgcggc actgttgaat aaagggcagt cctactcctg tccttttaga 1620 gtggcttagt gtgacacaca ggcatctccc aggccaagca cacacaggct gcgcccagtt 1680 ccgcaggagc cgtcccacag cgtggctctc tggattctcc cacttgtcct ccttggaagg 1740 agctcttgct ggccagtgtt tggaggggag gatgagtgcc tgtcactgag gcctcactat 1800 ggttggcgtc tgaagctggg cggtcgtcag gcctgtgctg agagccgcag cccctgtgca 1860 cacctaacac agggcgctcc ccctgctgct tccctggctc agttcttcgg agctccagag 1920 tgagaaggcc gcttcgtcct ttttctctgg gtgatgccct tagaataaca ctatatgcaa 1980 tgtaactcac aatgttccag gaccaaagac ttgatggagg ggctagaggc gacccttgtt 2040 gtaaaaggcg atcagaacac ctgagggagg aaggggcttg cagttttccc agcccttctc 2100 gctgccaagg cagcagtggt gctgtggatg ggctggggac tgcgggacag agcctgctac 2160 tacttgggag ttggtgctgc cctgtggcat ggaggggtgg gaggggctga gatggctgct 2220 ggcccggcct ccaagagttc tggacaggag gcagacactg cccagatgct cggtggaggg 2280 acagtgatgg cctttgactc atgaggcctg gagaaaagta tcaaaggtct caccatgtaa 2340 gagtgatttc cgatttctct cctttcagtt gtgtgaaaaa acagctggcc tgggttccat 2400 tagcaaatta aatcatcttc aatcttaaat tagagaccag aatgatcttc aggataaaaa 2460 gaacttctga atctctgcaa taggaaatgt ttcgatcatg caagtgcttt cccagccaaa 2520 tgtctgtgct ctctgtgtca ctgagggcca caggttcctc taacatctgt cactgtcact 2580 tcaccaggca ggccttggag ttccatgaca aaatcacttt tgtcagacaa agaatgtatc 2640 ctttactttt ctcaaatgga ataaaattat ttcttctgtg gaggaaaatt gattccccct 2700 ttttatttaa tttttttttg gagacagtct cactccttcc c 2741 44 2076 DNA Homo sapiens misc_feature Incyte ID No 1485774CB1 44 cggggctcca gccaggagcc ctgctgccca gggcatggcc aaacctttct tccgactcca 60 gaagtttctc cgccgaacac agttcctgct gttcttcctc acggctgcct acctgatgac 120 cggcagcctg ctgctgctgc agcgggtccg cgtggctctc ccacagggcc cccgggcacc 180 cggccccctg cagaccttgc cagtggccgc cgtggcgctg ggcgtgggct tgctggacag 240 cagagccctg cacgaccctc gagtcagccc agagctgctg ctgggtgtgg acatgctgca 300 gagccccctg acccggcccc ggcccggccc ccgctggctc cggagccgca actcggagct 360 gcgtcagttg cgtcgccgct ggttccacca cttcatgagt gactcccagg gaccgcccgc 420 cctgggcccc gaggctgcca ggcccgccat ccacagccga ggcacctaca ttggatgctt 480 cagtgacgat ggccatgaga ggactctgaa aggagctgtg ttttatgact tgagaaagat 540 gactgtctcc cactgccagg atgcgtgtgc tgagcggtcc tatgtctacg ccggcttgga 600 ggccggggcg gagtgttact gcgggaaccg gctgccagcg gtgagcgtgg ggctggaaga 660 gtgtaaccat gagtgcaaag gcgagaaggg ctctgtgtgc ggggctgtgg accggctctc 720 cgtgtaccgt gtggacgagc tgcagccggg ctccaggaag cggcggaccg ccacctaccg 780 cggatgcttc cgactgccag agaacatcac acatgccttc cccagctccc tgatacaggc 840 caatgtgacc gtggggactt gctcgggctt ttgttcccag aaagagttcc ccttggccat 900 tctcaggggc tgggaatgct actgtgctta ccctaccccc cggttcaacc tgcgggatgc 960 catggacagc tcagtatgtg gccaggaccc tgaggcacag aggctggcag aatactgtga 1020 ggtctaccag acacctgtgc aagacactcg ttgtacagac aggaggttcc tgcctaacaa 1080 atccaaagtg tttgtggctt tgtcaagctt cccaggagcc gggaacacgt gggcacggca 1140 cctcattgag catgccactg gcttctatac agggagctac tactttgatg gaaccctcta 1200 caacaaaggg ttcaagggcg aaaaggacca ctggcggagc cgacgcacca tctgtgtcaa 1260 aacccacgag agtggcagga gggagattga gatgtctgat tcagccatcc tgctaatccg 1320 gaacccatac aggtccctgg tggcagaatt caacagaaaa tgtgccgggc acctgggata 1380 tgcagctgac cgcaactgga agagcaaaga gtggccggac tttgtcaaca gctacgcctc 1440 gtggtggtcc tcgcacgtcc tggactggct caagtacggg aagcggctgc tggtggtgca 1500 ctacgaggag ctgcggcgca gcctggtgcc cacgttacgg gagatggtgg ccttcctcaa 1560 cgtgtctgtg agcgaggagc ggctgctctg cgtggagaac aacaaggagg gcagcttccg 1620 gcggcgcggc cggcgctccc acgaccctga gcccttcacc ccggagatga aagacttgat 1680 caatggctac atccggacgg tggaccaagc cctgcgtgac cacaactgga cggggctgcc 1740 cagggagtat gtgcccagat gataggcctg gcccacgccg ccgcccccgc tgagtgacgc 1800 aatcgcacca cggggctgcg ctccccactc tgatgctcag gcccgtggcc tcactgggac 1860 gaacggtggg tggggggctc accctggtgc tgcctcccgc acaaggagac ctggacacaa 1920 cagacacaca tcacaaggcg aacacaaatg gacacacata cctggccatg aacccacacc 1980 tcctcagaca ctcagacacc actccaggct catagcccgt cttgatgcag agaagccccc 2040 acgtgggtgt gccaggcacc ccagatacaa atgttt 2076 45 2957 DNA Homo sapiens misc_feature Incyte ID No 7289372CB1 45 cataagattg ctttacacca gggttcctga aatcaaggaa aatactggcc aaaatcaccg 60 accccattct accttcaatt acctagattc tgcgtccccg gcgctaggta cccaatcctg 120 gctgtccgac cacaggatcc ccggcaggga cgggtcacag tgctctcacc cctcgaccat 180 tttcgaaaaa accttcctct gcaaacgcat tgcgccctcc ccatgggtcc gcgggcgggg 240 actccaggcc cgagcagtcg gtgtgaagtt ctgtgttctg aactggggct gagcaagatg 300 cgatggtctc ntaccgctgg gccgcccgta gcgacggcag gagtaggggt attgatctcc 360 acggaagccc caaaccctcg ccatcgagag acccccatgg cccggggtga tggctgtggg 420 gcttggtgct cccagagagc tcagtggcta cagaatgggt ggggattctg cgtgtctccc 480 ggagcctgaa cccctttcct ggttatggcc ggtagctgtc tccagggact aacgtgggca 540 gcgcaggggg gcggaaaccg ggttttagcc aaatgcctcg acatcgccgc gcctccgcct 600 cctcgtcgct gaaagaaatg tcggggtttc atcagagcta gggagcgaca gtcgggaaca 660 gcgagtctgc cgaagccggc tgttgtgtga gggtgtgaga cggcggggcg gtgaggggcc 720 accgcggctt gggggatagt gcgtgtgggg ttgaccgtgt gtctgcttga gaggctgtga 780 agatatgggg ggcagatatg ggagaaatgc tcgggcctga agtccccagc ccaccgtgct 840 caagagtagc ggacgttttg ccaccatcct tgtctgtgct actgtctgct gcagcttccg 900 tgccccgttc tcctggagca gggcgtaaaa gcggcttgca ttcaattagc agcgaagctc 960 gcgggcgctg gcgggacagg cgcgtgaggc cacaacacat gcgtgtatct tgcttgggct 1020 atcttccctg ctctgccacg ccgggtctgg agaaggggtt tcagccccag gacatttact 1080 gagagtcggc gaatattggg agccgcgatg ttcccccttc gggccctgtg gttggtctgg 1140 gcgcttctag gagtggccgg atcatgcccg gagccgtgcg cctgcgtgga caagtacgct 1200 caccagttcg cggactgcgc ttacaaagag ttgcgtgagg tgccggaagg actgcctgcc 1260 aacgtgacga cgcttagtct gtccgcgaac aagatcactg tgctgcggcg cggggccttc 1320 gccgacgtca cacaggtcac gtcgctgtgg ctggcgcaca atgaggtgcg caccgtggag 1380 ccaggcgcac tggccgtgct gagtcagctc aagaacctcg atctgagcca caacttcata 1440 tccagctttc cgtggagcga cctgcgcaac ctgagcgcgc tgcagctgct caaaatgaac 1500 cacaaccgcc tgggctctct gccccgggac gcactcggtg cgctacccga cctgcgttcc 1560 ctgcgcatca acaacaaccg gctgcgtacg ctggcgcctg gcaccttcga cgcgcttagc 1620 gcgctgtcac acttgcaact ctatcacaat cccttccact gcggctgcgg ccttgtgtgg 1680 ctgcaggcct gggccgcgag cacccgggtg tccttacccg agcccgactc cattgcttgt 1740 gcctcgcctc ccgcgctgca gggggtgccg gtgtaccgcc tgcccgccct gccctgtgca 1800 ccgcccagcg tgcatctgag tgccgagcca ccgcttgaag cacccggcac cccactgcgc 1860 gcaggactgg cgttcgtgtt acactgcatc gccgacggcc accctacgcc tcgcctgcaa 1920 tggcaacttc agatccccgg tggcaccgta gtcttagagc caccggttct gagcggggag 1980 gacgacgggg ttggggcgga ggaaggagag ggagaaggag atggggattt gctgacgcag 2040 acccaagccc aaacgccgac tccagcaccc gcttggccgg cgcccccagc cacaccgcgc 2100 ttcctggccc tcgcaaatgg ctccctgttg gtgcccctcc tgagtgccaa ggaggcgggc 2160 gtctacactt gccgtgcaca caatgagctg ggcgccaact ctacgtcaat acgcgtggcg 2220 gtggcagcaa ccgggccccc aaaacacgcg cctggcgccg ggggagaacc cgacggacag 2280 gccccgacct ctgagcgcaa gtccacagcc aagggccggg gcaacagcgt cctgccttcc 2340 aaacccgagg gcaaaatcaa aggccaaggc ctggccaagg tcagcattct cggggagacc 2400 gagacggagc cggaggagga cacaagtgag ggagaggagg ccgaagacca gatcctcgcg 2460 gacccggcgg aggagcagcg ctgtggcaac ggggacccct ctcggtacgt ttctaaccac 2520 gcgttcaacc agagcgcaga gctcaagccg cacgtcttcg agctgggcgt catcgcgctg 2580 gatgtggcgg agcgcgaggc gcgggtgcag ctgactccgc tggctgcgcg ctggggccct 2640 gggcccggcg gggctggcgg agccccgcga cccgggcggc gacccctgcg cctactctat 2700 ctgtgtccag cggggggcgg cgcggcagtg cagtggtccc gcgtagagga aggcgtcaac 2760 gcctactggt tccgcggcct gcggccgggt accaactact ccgtgtgcct ggcgctggcg 2820 ggcgaagcct gccacgtgca agtggtgttt ccaccaagaa ggagctccca tcgctgctgg 2880 tcatagtggc agtgagcgta tccctcctgg tgctggccac agtgcccctt ctgggcgccg 2940 cctgttgcca tctgctg 2957 46 1223 DNA Homo sapiens misc_feature Incyte ID No 1672338CB1 46 ggcacctgga gggccgcact cccgttccag ccaggctgag ccttctgtcc cctgcctctg 60 gggcctggga accccccttc ttctttctcc tgaatggcac ccccgcccta gaatccagac 120 accgagtttc ccactgtggc tggttcaagg gtatgtgaga gctccctggt gacagtctgt 180 ggctgagcat ggccctccca gccctgggcc tggacccctg gagcctcctg ggccttttcc 240 tcttccaact gcttcagctg ctgctgccga cgacgaccgc ggggggaggc gggcaggggc 300 ccatgcccag ggtcagatac tatgcagggg atgaacgtag ggcacttagc ttcttccacc 360 agaagggcct ccaggatttt gacactctgc tcctgagtgg tgatggaaat actctctacg 420 tgggggctcg agaagccatt ctggccttgg atatccagga tccaggggtc cccaggctaa 480 agaacatgat accgtggcca gccagtgaca gaaaaaagag tgaatgtgcc tttaagaaga 540 agagcaatga gacacagtgt ttcaacttca tccgtgtcct ggtttcttac aatgtcaccc 600 atctctacac ctgcggcacc ttcgccttca gccctgcttg taccttcatt gtgagttctc 660 tggtgcccag cgctcaggcc cccaagcatc ccttctcaca tctacccacg actttcctct 720 gtagctctgg aaaactctgg ccttccagat gcaggaccct catgaacttc ctggccccag 780 accaatttcc ctctatgtcc ctttcccttc cttcctcaag cccctcattt cccagatgtg 840 agaccttggc gttctggccc cccagcctct ctccccattt aggaacttca agattcctac 900 ctgttgccca tctcggagga caaggtcatg gagggaaaag gccaaagccc ctttgacccc 960 gctcacaagc atacggctgt cttggtgggt gagtatcagg tttcccactt catcccaaca 1020 tctactttct ccagtcacgc tgtgaaatat ggaatattac agagttttcc aaaaggcagg 1080 ggaaactggg tgtggtgatg cgtgcatatg gtcccagtta tttggaagct gaagttgaag 1140 gatgcttgag tttaggggtt tgagtctagc ctgggcaaca cagcgagatc gtctcaaaaa 1200 aaaaaaaaaa aaaaaaaaaa aaa 1223 47 2888 DNA Homo sapiens misc_feature Incyte ID No 184661CB1 47 cgcacgacgt aaatcctgcg gctacatgag cggctcggaa ttcggctcga gcccggcccg 60 ggcagctgcg gctcgggatc cgtcgagggg aggccgagct tgccaagctg gcgcccagcg 120 gggtcatggt gcccggcgcc cgcggcggcg gcgcactggc gcgggctgcc gggcggggcc 180 tcctggcttt gctgctcgcg gtctccgccc cgctccggct gcaggcggag gagctgggtg 240 atggctgtgg acacctagtg acttatcagg atagtggcac aatgacatct aagaattatc 300 ccgggaccta ccccaatcac actgtttgcg aaaagacaat tacagtacca aaggggaaaa 360 gactgattct gaggttggga gatttggata tcgaatccca gacctgtgct tctgactatc 420 ttctcttcac cagctcttca gatcaatatg gtccatactg tggaagtatg actgttccca 480 aagaactctt gttgaacaca agtgaagtaa ccgtccgctt tgagagtgga tcccacattt 540 ctggccgggg ttttttgctg acctatgcga gcagcgacca tccagattta ataacatgtt 600 tggaacgagc tagccattat ttgaagacag aatacagcaa attctgccca gctggttgta 660 gagacgtagc aggagacatt tctgggaata tggtagatgg atatagagat acctctttat 720 tgtgcaaagc tgccatccat gcaggaataa ttgctgatga actaggtggc cagatcagtg 780 tgcttcagcg caaagggatc agtcgatatg aagggattct ggccaatggt gttctttcga 840 gggatggttc cctgtcagac aagcgatttc tgtttacctc caatggttgc agcagatcct 900 tgagttttga acctgacggg caaatcagag cttcttcctc atggcagtcg gtcaatgaga 960 gtggagacca agttcactgg tctcctggcc aagcccgact tcaggaccaa ggcccatcat 1020 gggcttcggg cgacagtagc aacaaccaca aaccacgaga gtggctggag atcgatttgg 1080 gggagaaaaa gaaaataaca ggaattagga ccacaggatc tacacagtcg aacttcaact 1140 tttatgttaa gagttttgtg atgaacttca aaaacaataa ttctaagtgg aagacctata 1200 aaggaattgt gaataatgaa gaaaaggtgt ttcagggtaa ctctaacttt cgggacccag 1260 tgcaaaacaa tttcatccct cccatcgtgg ccagatatgt gcgggttgtc ccccagacat 1320 ggcaccagag gatagccttg aaggtggagc tcattggttg ccagattaca caaggtaatg 1380 attcattggt gtggcgcaag acaagtcaaa gcaccagtgt ttcaactaag aaagaagatg 1440 agacaatcac aaggcccatc ccctcggaag aaacatccac aggaataaac attacaacgg 1500 tggctattcc attggtgctc cttgttgtcc tggtgtttgc tggaatgggg atctttgcag 1560 cctttagaaa gaagaagaag aaaggaagtc cgtatggatc agcagaggct cagaaaacag 1620 actgttggaa gcagattaaa tatccctttg ccagacatca gtcagctgag tttaccatca 1680 gctatgataa tgagaaggag atgacacaaa agttagatct catcacaagt gatatggcag 1740 attaccagca gcccctcatg attggcaccg ggacagtcac gaggaagggc tccaccttcc 1800 ggcccatgga cacggatgcc gaggaggcag gggtgagcac cgatgccggc ggccactatg 1860 actgcccgca gcgggccggc cgccacgagt acgcgctgcc ctggcgcccc cggagcccga 1920 gtacgccacg cccatcgtgg agcggcacgt gctgcgcgcc cacacgttct ctgcgcagag 1980 cggctaccgc gtcccagggc cccagcccgg ccacaaacac tccctctcct cgggcggctt 2040 ctcccccgta gcgggtgtgg gcgcccagga cggagactat caaaggccac acagcgcaca 2100 gcctgcgggc aggggctacg accggcccaa agctgtcagc gccctcgcca ccgaaagcgg 2160 acaccctgac tctcagaagc ccccaacgca tcccgggacg agtgacagct attctgcccc 2220 cagagactgc ctcacacccc tcaaccagac ggccatgact gcccttttgt gaacacaatg 2280 tgaaagaagc ctgctgtggt actgagcgtc gggctgtcac aaggcactgg aagaagggag 2340 cctgctggtc cagagtgtgc gtgtgtatcg gtgtgtgtgt acacttgcat gtgtgtgtgt 2400 gatccagtag gatcctagag acaacctgtc atactgttta caaaattgtg cagctggttt 2460 cgtgctgacc cttagggtgc gtctgttggg ttttgttggg ctagaaaaat gaaaattttt 2520 agatggcgtt ttcattcctc tgactgatat tgagctgctt tggtgttaaa ggtgtaatgt 2580 gtacagagtt gtatttaaca ataataaaag taacttaagt ttgctctatc agattttagt 2640 tctgcacaga ggttaagtgg gaaaatgcag ctgttgcaaa atgtatataa atagtatgtt 2700 catttttttc agtatattat ctgatactgt gttagcagca ggtctgtctt aaacctagtc 2760 ttgttgttat ttgagtcatt tcctctcctt tgataactag aactgaaagc atttttaaca 2820 ttcttctcct ggaagaaatg aattacttga agcatgaaaa gcacaccagg gtggttgttt 2880 atttagca 2888 48 3142 DNA Homo sapiens misc_feature Incyte ID No 3719737CB1 48 tgcgcgcagg ctcacaggcc ctgggagtga gctggtgccc ggcgacctgg cacccgcgcc 60 tggatatggg gcgtctacat cgtcccagga gcagcaccag ctacaggaac ctgccgcatc 120 tgtttctgtt tttcctcttc gtgggaccct tcagctgcct cgggagttac agccgggcca 180 ccgagcttct gtacagccta aacgagggac tacccgcggg ggtgctcatc ggcagcctgg 240 ccgaggacct gcggctgctg cccaggtctg cagggaggcc ggacccgcag tcgcagctgc 300 cagagcgcac cggtgctgag tggaaccccc ctctctcctt cagcctggcc tcccggggac 360 tgagtggcca gtacgtgacc ctagacaacc gctctgggga gctgcacact tcagctcagg 420 agatcgacag ggaggccctg tgtgttgaag ggggtggagg gactgcgtgg agcggcagcg 480 tttccatctc ctcctctcct tctgactctt gtcttttgct gctggatgtg cttgtcctgc 540 ctcaggaata cttcaggttt gtgaaggtga agatcgccat cagagacatc aatgacaacg 600 ccccgcagtt ccctgtttcc cagatctcgg tgtgggtccc ggaaaatgca cctgtaaaca 660 cccgactggc catagagcat cctgctgtgg acccagatgt aggcattaat ggggtacaga 720 cctatcgctt actggactac catggtatgt tcaccctgga cgtggaggag aatgagaatg 780 gggagcgcac cccctaccta attgtcatgg gtgctttgga cagggaaacc caggaccagt 840 atgtgagcat catcatagct gaggatggtg ggtctccacc acttttgggc agtgccactc 900 tcaccattgg catcagtgac attaatgaca attgccctct cttcacagac tcacaaatca 960 atgtcactgt gtatgggaat gctacagtgg gcaccccaat tgcagctgtc caggctgtgg 1020 ataaagactt ggggaccaat gctcaaatta cttattctta cagtcagaaa gttccacaag 1080 catctaagga tttatttcac ctggatgaaa acactggagt cattaaactt ttcagtaaga 1140 ttggaggaag tgttctggag tcccacaagc tcaccatcct tgctaatgga ccaggctgca 1200 tccctgctgt aatcactgct cttgtgtcca ttattaaagt tattttcaga ccccctgaaa 1260 ttgtccctcg ttacatagca aacgagatag atggtgttgt ttatctgaaa gaactggaac 1320 ccgttaacac tcccattgcg tttttcacca taagagatcc agaaggtaaa tacaaggtta 1380 actgctacct ggatggtgaa gggccgttta ggttatcacc ttacaaacca tacaataatg 1440 aatatttact agagaccaca aaacctatgg actatgagct acagcagttc tatgaagtag 1500 ctgtggtggc ttggaactct gagggatttc atgtcaaaag ggtcattaaa gtgcaacttt 1560 tagatgacaa tgataatgct ccaattttcc ttcaaccctt aatagaacta accatcgaag 1620 agaacaactc acccaatgcc tttttgacta agctgtatgc tacagatgcc gacagcgagg 1680 agagaggcca agtttcatat tttctgggac ctgatgctcc atcatatttt tccttagaca 1740 gtgtcacagg aattctgaca gtttctactc agctggaccg agaagagaaa gaaaagtaca 1800 gatacactgt cagagctgtt gactgtggga agccacccag agaatcagta gccactgtgg 1860 ccctcacagt gttggataaa aatgacaaca gtcctcggtt tatcaacaag gacttcagct 1920 tttttgtgcc tgaaaacttt ccaggctatg gtgagattgg agtaattagt gtaacagatg 1980 ctgacgctgg acgaaatgga tgggtcgccc tctctgtggt gaaccagagt gatatttttg 2040 tcatagatac aggaaagggt atgctgaggg ctaaagtctc tttggacaga gagcagcaaa 2100 gctcctatac tttgtgggtt gaagctgttg atgggggtga gcctgccctc tcctctacag 2160 caaaaatcac aattctcctt ctagatatca atgacaaccc tcctcttgtt ttgtttcctc 2220 agtctaatat gtcttatctg ttagtactgc cttctactct gccaggctcc ccggttacag 2280 aagtctatgc tgtcgacaaa gacacaggca tgaatgctgt catagcttac agcatcatag 2340 ggagaagagg tcctaggcct gagtccttca ggattgaccc taaaactggc aacattactt 2400 tggaagaggc attgctgcag acagattatg ggctccatcg cttactggtg aaagtgagtg 2460 atcatggtta tcccgagcct ctccactcca cagtcatggt gaacctattt gtcaatgaca 2520 ctgtcagtaa tgagagttac attgagagtc ttttaagaaa agaaccagag attaatatag 2580 aggagaaaga accacaaatc tcaatagaac cgactcatag gaaggtagaa tctgtgtctt 2640 gtatgcccac cttagtagct ctgtctgtaa taagcttggg ttccatcaca ctggtcacag 2700 ggatgggcat atacatctgt ttaaggaaag gggaaaagca tcccagggaa gatgaaaatt 2760 tggaagtaca gattccactg aaaggaaaaa ttgacttgca tatgcgagag agaaagccaa 2820 tggatatttc taatatttga tatttcatgg tggaataaca cagagaaatg ttttaactga 2880 ctttggatct tcatcaccta aaaaagagtg tgttgatggc agttccaatg aaggacaact 2940 aatttataac ttgttctata ttgtaaatag ctgtttacag gtttttaaat ttaaattcag 3000 aggttataaa atgtgtacag catttttaag tgaaaattag tactaacagc tataggactt 3060 gtatttaaaa aaaaaaaaaa aaagcttgga catggtttgc agctttcata caccaagcag 3120 atgtttgata aaacctgggg gt 3142 49 4749 DNA Homo sapiens misc_feature Incyte ID No 5773251CB1 49 gtgcttgcag tggtggaatt cctagagcgt taaatattca gtgataagtg ggcagggttg 60 aggctgaaaa gatagatagg ggccaggtca aagtgggtta atttatgtgc tgtttgtacc 120 aacaagcttg gactttggta ttgtgacagg cagttaggag gcattcaaga cttaagcaga 180 gtgacatggt aaaattactc cagaaaacgt tcaaattata tttgatgatc cactaccaat 240 ttcatacagt cagccagaga aggtgaatgg agagtccaag agcagcagta ccagcgagag 300 tggggacagt gataacatga ggatttccag ctgcagcgat gaaagtagta acagcaacag 360 cagtcgtaag agtgacaatc attcaccagc tgtggtcact accactgtga gcagcaaaaa 420 gcagccatca gttcttgtta catttccaaa ggaagagaga aaatctgttt ctggcaaggc 480 ttcaataaaa ttgtcagaaa ctatcagtga agggaccagt aattctctat ctacttgtac 540 aaaatctggt ccatctcccc tttcttctcc aaatgggaag ttaacagtag caagtcctaa 600 gcgtgggcaa aagagggaag aaggatggaa agaagttgta agaaggtcaa agaaagtcgg 660 aggctggctt tggctgcgaa aagagaaaaa agaaaagaga agagaaggaa gaaaaaggaa 720 gaacaaagaa ggaaactaga agaaattgaa gccaaaaata aaagagaact ttgaactcca 780 agctgctcaa gaaaaagaaa agcttaaagt tgaagatgag cctgaagtct tgacagaacc 840 tccaagtgcc acaaccacta ctaccatagg tatatctgca acctggacaa ctttggcagg 900 ttctcatggt aaaagaaata ataccataac tacaaccagt tcaaagagga aaaacaggaa 960 aaataaaatt actccagaaa acgttcaaat tatatttgat gatccactac caatttcata 1020 cagtcagcca gagaaggtga atggagagtc caagagcagc agtaccagcg agagtgggga 1080 cagtgataac atgaggattt ccagctgcag cgatgaaagt agtaacagca acagcagtcg 1140 taagagtgac aatcattcac cagctgtggt cactaccact gtgagcagca aaaagcagcc 1200 atcagttctt gttacatttc caaaggaaga gagaaaatct gtttctggca aggcttcaat 1260 aaaattgtca gaaactatca gtgaagggac cagtaattct ctatctactt gtacaaaatc 1320 tggtccatct cccctttctt ctccaaatgg gaagttaaca gtagcaagtc ctaagcgtgg 1380 gcaaaagagg gaagaaggat ggaaagaagt tgtaagaagg tcaaagaaag tatctgttcc 1440 atcaactgtg atatccagag tgattggaag aggaggctgt aatatcaatg ctattcggga 1500 gtttactggt gcacacatag atattgataa acagaaagac aagactggag accggataat 1560 cactataagg ggtggcactg aatcaacaag acaagcaact caattgatta atgctttgat 1620 caaggatcca gacaaagaaa ttgatgaact tattccaaag aatcgtttga aaagctcctc 1680 agcaaattcc aaaatagggt catcagcacc taccaccact gctgctaaca cttccttaat 1740 gggaattaaa atgacaactg tagctctgtc atcaacatct caaactgcca cagcactcac 1800 tgtgcctgca atttcttctg catccactca caaaaccatt aagaacccag tgaataatgt 1860 gaggcctggt tttccagttt ctcttccatt agcatatcct cctccacagt ttgcacatgc 1920 tttgcttgct gctcagactt tccagcagat ccgtccacca aggttgccca tgacccactt 1980 tggaggtact tttccaccag ctcaatccac ttggggtccg tttcctgtca ggcctttgag 2040 ccctgccaga gctactaact cgcctaagcc tcacatggtg cctcgccata gcaatcagaa 2100 tagcagtggt tctcaggtga attcagcagg ttctttaact tcaagcccaa caactacaac 2160 cagttcatca gcttcaacgg tgcctggtac atctacaaat ggcagtccaa gttcaccttc 2220 tgtccgaagg cagctttttg tcacagttgt gaagacatcc aatgccacca caacaacagt 2280 cacaaccacg gcaagcaaca acaacactgc acccacaaat gccacatatc ctatgcctac 2340 tgccaaagaa cactatccag tatcatcccc atcttcccca tcaccaccag cccagccagg 2400 aggggtttct agaaacagcc ctttggattg tggatcagca tctccaaata aagtggcatc 2460 ttcctccgaa caggaagcag gtagtccacc agtagtagaa acaacaaaca ctagacctcc 2520 aaacagcagc agttcttctg ggagttcatc agctcattct aatcagcaac aacctccggg 2580 atctgtttct caggaaccaa gaccacctct tcagcagtct caggttcctc ccccggaagt 2640 tagaatgact gttcctcctt tagcaacaag ttctgctcca gtggcggtgc cttctactgc 2700 cccagtgact taccctatgc ctcagacacc aatgggatgc ccccagccta ctcctaaaat 2760 ggaaacccct gctattagac caccccctca tggcacaact gcccctcaca agaattcagc 2820 ttcagtgcaa aattcatctg ttgcagtcct tagtgtcaat cacattaaaa gacctcacag 2880 tgttccctct tctgtccagc taccttcgac cttaagtaca caaagtgctt gtcagaattc 2940 agtacatcca gcaaataagc ctattgctcc caatttcagt gcccccttac catttgggcc 3000 ctttagcaca ttgtttgaaa acagccctac ttctgctcat gccttctggg gaggatctgt 3060 tgtttcatct cagtcaacac cagaatctat gctatcagga aaatcctcat atttgccaaa 3120 ttcagatcct ttacatcagt ctgatacttc caaagctcca ggttttagac caccattaca 3180 gagacctgct ccaagtccct caggtattgt caatatggac tcgccatatg gttctgtaac 3240 accttcttca acacatttgg gaaactttgc ttcaaacatt tcaggaggtc agatgtacgg 3300 acctggggca ccccttggag gagcacccgc agctgctaac tttaacagac aacatttttc 3360 cccgcttagt ttgttgactc cgtgttcatc agcatcaaat gattcttctg cacagtcagt 3420 atcctcggga gttcgtgcac catctcctgc cccatcatca gtaccgttag ggtcagaaaa 3480 gcccagcaat gtgtctcagg acaggaaagt tccagtccct attgggactg aacgttctgc 3540 acgtatcagg caaactggaa cgtcagctcc atctgttatt gggagcaatt tgtctacatc 3600 agtaggacat agtggcatct ggtcctttga agggattggt ggcaatcaag acaaagtaga 3660 ctggtgtaac cctgggatgg gaaatcctat gatccacaga ccgatgtctg acccaggagt 3720 attttcacaa catcaagcaa tggagcgaga tagtacagga attgtaactc cttctggtac 3780 attccatcag catgttcctg caggctacat ggactttcct aaagttgggg gtatgccttt 3840 ttctgtgtat gggaatgcaa tgattcctcc agtagcacct atccctgatg gtgctggagg 3900 acccatattt aatggccctc atgctgcaga cccttcttgg aactcactga taaagatggt 3960 ttccagctcc acggaaaata atggccctca aacggtgtgg actggaccct gggcacctca 4020 catgaacagt gtgcatatga accagcttgg ctgatgagga tcagcttgtt agcctgcaga 4080 ttccttttca tttggaggaa atcacaagtg gccgaaaaaa aaaattatgc tcccaaatca 4140 ttctactgat gtgcttgact gaagtgtgta ggctttttgc agaagatctt actaactgac 4200 ctattttctg tgaacatttg tgactgccca ttccccatca tcatccgttt taccttagtt 4260 agcatttttc ttatcatttt tctttttttc tttccctctt cccctttgga cataactttc 4320 tgttgaagct gttctttggc tggttggttt tagtactgta aactgcttct gagcaaacac 4380 ggaaatttag caaaattatg taaacttgat cctgaagttt tagaatggca aataaatgta 4440 caattgttta cataacagaa aaggctaagc agaaagtaaa tttcaatatg tcagtataga 4500 ggctctactt tatgtagact taaattaatg tgagatatgt accttcatat tcagaaatct 4560 ggatgtttcc ttcatacatt aaactattaa taagcataac ttttctactg gtgtaattta 4620 agtataaagt aaaataatgg gcattatcat tggatgtttc cccacattgg cttttaaaat 4680 acccatcttg ctttcttttt ggtttatttg tagcaaggca catatagaag aagaaatttc 4740 tggcttttc 4749 50 4155 DNA Homo sapiens misc_feature Incyte ID No 5426470CB1 50 gccgtcgggg cgggcgtctg gcgagctgca gagaccagat taaaggattt acctgaagag 60 aaagcattct attcatcaga gactggacaa gagttactct tgcatttggc aattaaagat 120 gatgtttcca tggaaacagt tgatcctgct ttcattcatt ggctgcttag gaggtgagct 180 tctcttacaa ggccctgtat ttatcaaaga acccagcaac agcattttcc ctgttggttc 240 agaagataaa aaaataactt tgcattgtga agcaagaggc aatccatcac ctcattacag 300 atggcagctg aatggaagtg atattgatat gagtatggaa catcgttata agttgaatgg 360 aggaaatctt gtggttatta atcccaacag aaattgggat acaggaactt accaatgttt 420 tgcaacaaat tcacttggaa caattgtcag cagagaagcc aaacttcagt ttgcctatct 480 tgaaaatttt aaaaccaaaa tgaggagtac agtgtctgtg cgtgaaggcc agggagttgt 540 gctgctctgc ggccccccac cacactctgg agaactgtca tatgcttgga tcttcaatga 600 atacccatcg tttgttgaag aagatagtcg gagatttgtc tcccaggaga cagggcacct 660 ctacatatct aaggtggagc cgtctgatgt gggaaattac acatgtgtgg tgacaagtat 720 ggtgacaaat gcccgagtgc tgggctctcc aactcctttg gtgctacgtt ctgatggtgt 780 gatgggtgaa tatgaaccta aaatagaagt tcagtttcca gaaactcttc cagcagctaa 840 aggttcgact gtgaaattgg aatgttttgc ccttggaaat cccatacctc agattaattg 900 gagaagaagt gatgggctgc cattttccag caaaattaaa ttaaggaagt tcagtggtgt 960 gcttgaaatc cccaacttcc aacaggaaga tgcaggttcc tatgaatgca ttgctgagaa 1020 ttcacgagga aaaaatgttg ccagagggcg tctcacttac tatgcaaagc cccattgggt 1080 tcaactcata aaggatgtgg aaatagccgt ggaggacagt ctttattggg aatgcagggc 1140 aagcggcaag cccaagcctt cctaccgatg gctgaaaaat ggagcagccc tggtgctaga 1200 ggagagaaca cagatagaaa atggtgccct tacaatatca aacctaagtg tgactgattc 1260 tggcatgttc caatgcatag cagaaaacaa acatggcctt gtttattcca gtgctgagct 1320 caaagttgtt gcttctgctc cagatttttc aaagaatcca atgaagaagt tggttcaggt 1380 gcaggtgggc agcctggtca gcttggattg taaacccaga gcctccccaa gggcactctc 1440 ttcctggaag aagggggatg tgagcgtgca ggagcatgaa agaatttctt tgttaaacga 1500 tggaggactc aaaatagcca atgtgactaa agctgatgct ggaacttaca cctgcatggc 1560 agaaaaccag tttgggaaag caaatggcac aacacatttg gttgttacgg aaccaacaag 1620 aataactttg gcaccatcta acatggatgt ttctgttggt gaaagcgtca tattgccctg 1680 ccaggtacaa catgacccgc tgttagacat catctttacc tggtatttca atggggccct 1740 tgcagatttt aagaaagatg gatctcactt tgagaaagtt ggtgggagtt catctggtga 1800 tttaatgatc agaaacattc agctgaaaca cagtgggaaa tatgtttgta tggtgcaaac 1860 gggggtggac agtgtttcat ctgctgctga cctcatagta agaggttcac ctggaccacc 1920 agaaaatgtg aaggtagatg aaattacaga cacaacagcc caactctctt ggaaagaagg 1980 taaagacaac catagcccag ttatatccta ttctatccag gctcggacac ctttctccgt 2040 gggttggcaa accgtcacaa cagtgcctga ggtcatcgat gggaagacgc acacagccac 2100 tgtagttgag ttaaacccat gggtggaata tgaatttcgg gttgtagcca gtaacaaaat 2160 tggaggtgga gaaccaagtt taccctcaga aaaagtaaga actgaagagg cagttccaga 2220 agtgcctcct tctgaagtca atggaggagg cggaagccgg tctgaacttg tgataacctg 2280 ggatccagtc cctgaagaac tacagaatgg tgaaggtttt gggtatgttg ttgctttccg 2340 ccctcttggg gttaccacct ggatccagac agtggtgaca tcccctgaca ccccaagata 2400 tgtctttagg aatgaaagca tcgtgccata ttcaccatat gaagttaaag tgggtgttta 2460 taataacaaa ggtgaaggac catttagccc agtgacaaca gtgttctctg cagaagaaga 2520 gcctacagtg gccccatctc aagtctctgc aaatagccta tcttcctcag aaattgaggt 2580 ttcatggaac accattcctt ggaagttgag caatggacat ttactgggct atgaggtgcg 2640 gtactggaat gggggtggaa aggaggaatc atccagtaag atgaaagtgg caggaaatga 2700 gacatcagcc agactacggg gcctgaagag caacctggcc tattacacgg ctgtccgggc 2760 ttacaacagt gccggcgctg ggccttttag cgccacagtt aatgtaacca ccaagaaaac 2820 gcctcccagt cagccaccag gaaatgttgt ttggaatgcc acagacacta aagtgttact 2880 taattgggag caagttaaag ccatggagaa tgagtcagaa gtaacaggat ataaagtttt 2940 ctataggact agcagtcaaa ataacgtaca agtactgaac acaaataaaa cttcagctga 3000 acttgtgctg cccattaaag aggactacat tattgaagtc aaggccacaa cagatggagg 3060 ggatgggacc agtagtgaac agatcaggat tccacgaata accagtatgg atgcaagagg 3120 atccacttca gccatctcga atgtccaccc tatgtcaagt tatatgccta tagtactgtt 3180 cttaattgta tatgtcctgt ggtgatatta actccttttt attatttatt ggaaagttat 3240 ttggttacca aaaaaagtgc tttcatgaaa tgcagtgatt atgcatgttt ttttcaactc 3300 ttatttttaa ctttctactt cattataggt aaatatgaat ataattaaaa aaacagtaaa 3360 tccttttagg ggaatctgaa atgccttaat attaacttga taaaccaaag gaatttacat 3420 attacatact tcagactttt gatataaatg ttcttaaact atgagtttaa gcactgccta 3480 tggataaaga ctcacacact ctcacatgta cacacacacg catgagaatt tctttttaca 3540 ttgaaaaact ctttcattta attcaaatgc tattttccca ttataatagc attatttgga 3600 agacttaacc agtatcaatt tgaaatgctg atttaagtcc ccaaggatga aaaatacatt 3660 ttaaaaatta ttttgttgga gaggagtggc atgtgattca aaagagcatt gttggaaaat 3720 gctactgtgg ggcttagaag aatgatgttt ggtttggtat gctgctaact agttgtaaga 3780 ctttacaaat cactttgcca tctgtacctc tcaattattc ctctataaaa tatggagata 3840 ataataccta tctgatcaga ctttgcccca tgaattagtt tttaaaagat aaagactgaa 3900 gtatgaaagt gcttttgtca ccccaaatgc aattgaccca tgcaaaatat tagcatgaat 3960 ttatttaatc acataaaagt catgaagacc agccagattt tcaagcttca ttctgtttca 4020 ttcagttata ttccaaaatt caaatgatca cattttattc tttctcaaaa aaaaaaaagt 4080 ttttttaaat taaaaaagga attgtttcct tcacagctat gaataagctt tcaggtttta 4140 ttaaaaccta gagga 4155 51 1327 DNA Homo sapiens misc_feature Incyte ID No 7087904CB1 51 gcgagctgaa agctgctgga gagtgagcag ccctagcagg gatggacatg atgctgttgg 60 tgcagggtgc ttgttgctcg aaccagtggc tggcggcggt gctcctcagc ctgtgctgcc 120 tgctaccctc ctgcctcccg gctggacaga gtgtggactt cccctgggcg gccgtggaca 180 acatgatggt cagaaaaggg gacacggcgg tgcttaggtg ttatttggaa gatggagctt 240 caaagggtgc ctggctgaac cggtcaagta ttatttttgc gggaggtgat aagtggtcag 300 tggatcctcg agtttcaatt tcaacattga ataaaaggga ctacagcctc cagatacaga 360 atgtagatgt gacagatgat ggcccataca cgtgttctgt tcagactcaa catacaccca 420 gaacaatgca ggtgcatcta actgtgcaag ttcctcctaa gatatatgac atctcaaatg 480 atatgaccgt caatgaagga accaacgtca ctcttacttg tttggccact gggaaaccag 540 agccttccat ttcttggcga cacatctccc catcagcaaa accatttgaa aatggacaat 600 atttggacat ttatggaatt acaagggacc aggctgggga atatgaatgc agtgcggaaa 660 atgatgtgtc attcccagat gtgaggaaag taaaagttgt tgtcaacttt gctcctacta 720 ttcaggaaat taaatctggc accgtgaccc ccggacgcag tggcctgata agatgtgaag 780 gtgcaggtgt gccgcctcca gcctttgaat ggtacaaagg agagaagaag ctcttcaatg 840 gccaacaagg aattattatt caaaatttta gcacaagatc cattctcact gttaccaacg 900 tgacacagga gcacttcggc aattatactt gtgtggctgc caacaagcta ggcacaacca 960 atgcgagcct gcctcttaac cctccaagta cagcccagta tggaattacc gggagcgctg 1020 atgttctttt ctcctgctgg taccttgtgt tgacactgtc ctctttcacc agcatattct 1080 acctgaagaa tgccattcta caataaattc aaagacccat aaaaggcttt taaggattct 1140 ctgaaagtgc tgatggctgg atccaatctg gtacagttgt taaaagcgcg tgggatttat 1200 cagcagtgct acctgggatg accgctttgg aaaatgccct tatttatcct tatccaccct 1260 tttgaaagaa ctccttgagg cgacattgcc tttaaacgac gcgaatctaa gatacggccg 1320 ttgcacc 1327 52 5529 DNA Homo sapiens misc_feature Incyte ID No 7477312CB1 52 atgcagctga gccgcgccgc cgccgccgcc gccgccgccc ctgcggagcc cccggagccg 60 ctgtcccccg cgccggcccc ggccccggcc ccccccggcc ccctcccgcg cagcgcggcc 120 gacggggctc cggcgggggg gaaggggggg ccggggcgcc gcgcgcggag tccccgggcg 180 ctccgttccc cggcgcgagc ggccccggcc cgggccccgg cgcggggatg gacggccccg 240 gggccagggg ccagcgccgt ggtcgtgcgc gtcggcatcc cggacctgca gcagacgaag 300 tgcctgcgcc tggacccggc cgcgcccgtg tgggccgcca agcagcgcgt gctctgcgcc 360 ctcaaccaca gcctccagga cgcgctcaac tatgggcttt tccagccgcc ctcccggggc 420 cgcgccggca agttcctgga tgaggagcgg ctcctgcagg agtacccgcc caacctggac 480 acgcccctgc cctacctgga gtttcgatac aagcggcgag tttatgccca gaacctcatc 540 gatgataagc agtttgcaaa gcttcacaca aaggcgaacc tgaagaagtt catggactac 600 gtccagctgc atagcacgga caaggtggca cgcctgttgg acaaggggct ggaccccaac 660 ttccatgacc ctgactcagg agagtgcccc ctgagcctcg cagcccagct ggacaacgcc 720 acggacctgc taaaggtgct gaagaatggt ggtgcccacc tggacttccg cactcgcgat 780 gggctcactg ccgtgcactg tgccacacgc cagcggaatg cggcagcact gacgaccctg 840 ctggacctgg gggcttcacc tgactacaag gacagccgcg gcttgacacc cctctaccac 900 agcgccctgg ggggtgggga tgccctctgc tgtgagctgc ttctccacga ccacgctcag 960 ctggggacca ccgacgagaa tggctggcag gagatccacc aggcctgccg ctttgggcac 1020 gtgcagcatc tggagcacct gctgttctat ggggcagaca tgggggccca gaacgcctcg 1080 gggaacacag ccctgcacat ctgtgccctc tacaaccagg agagctgtgc tcgtgtcctg 1140 ctcttccgtg gagctaacag ggatgtccgc aactacaaca gccagacagc cttccaggtg 1200 gccatcatcg cagggaactt tgagcttgca gaggttatca agacccacaa agactcggat 1260 gttggacagg acagtcatga cttgctacat cctatgccca ctggggtccc agagtggggc 1320 ctgtacacag aagaggaact ggaaggaggt gccgccttct ctgtaccatt cagggaaacc 1380 cccagctatg cgaagcggcg gcgactggct ggccccagtg gcttggcatc ccctcggcct 1440 ctgcagcgct cagccagcga tatcaacctg aagggggagg cacagccagc agcttctcct 1500 ggaccctcgc tgagaagcct cccccaccag ctgctgctcc agcggctgca agaggagaaa 1560 gatcgtgacc gggatgccga ccaggagagc aacatcagtg gccctttagc aggcagggcc 1620 ggccaaagca agatcaggag ctgtattcga attcgagctc ggttccccgc gccccctgcg 1680 ccccccgcac cgccgccccg gggcccgaag cggaaacttt acagcgccgt ccccggccgc 1740 aagttcatcg ccgtgaaggc gcacagcccg cagggtgaag gcgagatccc gctgcaccgc 1800 ggcgaggccg tgaaggtgct cagcattggg gagggcggtt tctgggaggg aaccgtgaaa 1860 ggccgcacgg gctggttccc ggccgactgc gtggaggaag tgcagatgag gcagcatgac 1920 acacggcctg aaacgcggga ggaccggacg aagcggctct ttcggcacta cacagtgggc 1980 tcctacgaca gcctcacctc acacagcgat tatgtcattg atgacaaagt ggctgtcctg 2040 cagaaacggg accacgaggg ctttggtttt gtgctccggg gagccaaagc agagaccccc 2100 atcgaggagt tcacgcccac gccagccttc ccggcgctgc agtatctcga gtcggtggac 2160 gtggagggtg tggcctggag ggccgggctg cgcacgggag acttcctcat cgaggtgaac 2220 ggggtgaacg tggtgaaggt cggacacaag caggtggtgg ctctgattcg ccagggtggc 2280 aaccgcctcg tcatgaaggt tgtgtctgtg acaaggaagc cagaagagga cggggctcgg 2340 cgcagagccc caccgccccc caagagggcc cccagcacca cactgaccct gcgctccaag 2400 tccatgacag ctgagctcga ggaacttgag aagctggacg agatgctggc agccgccgca 2460 gagccaacgc tgcggccaga catcgcagac gcagactcca gagccgccac cgtcaaacag 2520 aggcccacca gtcggaggat cacacccgcc gagattagct cattgtttga acgccagggc 2580 ctcccaggcc cagagaagct gccgggctcc ttgcggaagg ggattccacg gaccaagtct 2640 gtaggggagg acgagaagct ggcgtccctg ctggaagggc gcttcccgcg gagcacctcg 2700 atgcaagacc cggtgcgcga gggtcgcggc atcccgcccc cgccgcagac cgcgccgcct 2760 cccccgcccg cgccctacta cttcgactcg gggccgcccc cggccttctc gccgccgccc 2820 ccgccgggcc gcgcctacga cacggtgcgc tccagcttca agcccggcct ggaggcgcgc 2880 ctgggcgcgg gcgctgccgg cctgtacgag ccgggcgcgg ccctcggccc gctgccgtat 2940 cccgagcggc agaagcgcgc gcgctccatg atcatcctgc aggactcggc gcccgagtcg 3000 ggcgacgccc ctcgaccccc gcccgcggcc accccgcccg agcgacccaa gcgccggccg 3060 cggccgcccg gccccgacag cccctacgcc aacctgggcg ccttcagcgc cagcctcttc 3120 gctccgtcca agccgcagcg ccgcaagagc cccctggtga agcagctgca ggtggaggac 3180 gcgcaggagc gcgcggccct ggccgtgggc agccccggtc ccggcggcgg cagcttcgcc 3240 cgcgagccct ccccgaccca ccgcggtccg cgcccgggtg gcctcgacta cggcgcgggc 3300 gatggcccgg ggctcgcgtt cggcggcccg ggcccggcca aggaccggcg gctggaggag 3360 cggcgccgct ccactgtgtt cctgtccgtg ggggccatcg agggcagcgc ccccggcgcg 3420 gatctgccat ccctacagcc ctcccgctcc atcgacgagc gcctcctggg gaccggcccc 3480 accgccggcc gcgacctgct gctgccctcc ccggtgtctg ccctgaagcc gttggtcagc 3540 ggcccgagcc tggggccctc gggttccacc ttcatccacc cactcaccgg caaacccctg 3600 gaccccagct cacccctggc ccttgccctg gctgcccgag agcgagctct ggcctcccag 3660 gcgccctccc ggtcccccac acccgtgcac agtcccgacg ccgaccgccc cggacccctg 3720 tttgtggatg tacaggcccg ggacccagag cgagggtccc tggcttcccc ggctttctcc 3780 ccacggagcc cagcctggat tcctgtgcct gctcgcaggg aggcagagaa ggtcccccgg 3840 gaggagcgga agtcacccga ggacaagaag tccatgatcc tcagcgtcct ggacacatcc 3900 ctgcagcggc cagctggcct catcgttgtg cacgccacca gcaacgggca ggagcccagc 3960 aggctggggg gggccgaaga ggagcgcccg ggcaccccgg agttggcccc ggcccccatg 4020 cagtcagcgg ctgtggcaga gcccctgccc agcccccggg cccagccccc tggtggcacc 4080 ccggcagacg ccgggccagg ccagggcagc tcagaggaag agccagagct ggtgtttgct 4140 gtgaacctgc cacctgccca gctgtcgtcc agcgatgagg agaccaggga ggagctggcc 4200 cgaattgggt tggtgccacc ccctgaagag tttgccaacg gggtcctgct ggccacccca 4260 ctcgctggcc cgggcccctc gcccaccacg gtgcccagcc cggcctcagg gaagcccagc 4320 agtgagccac cccctgcccc tgagtctgca gccgactctg gggtggagga ggctgacaca 4380 cgcagctcca gcgaccccca cctggagacc acaagcacca tctccacggt gtccagcatg 4440 tccaccttga gctcggagag cggggaactc actgacaccc acacctcctt cgctgacgga 4500 cacacttttc tactcgagaa gccaccagtg cctcccaagc ccaagctcaa gtccccgctg 4560 gggaaggggc cggtgacctt cagggacccg ctgctgaagc agtcctcgga cagcgagctc 4620 atggcccagc agcaccacgc cgcctctgcc gggctggcct ctgccgccgg gcctgcccgc 4680 cctcgctacc tcttccagag aaggtccaag ctatgggggg accccgtgga gagccggggg 4740 ctccctgggc ctgaagacga caaaccaact gtgatcagtg agctcagctc ccgcctgcag 4800 cagctgaaca aggacacgcg ttccctgggg gaggaaccag ttggtggcct gggcagcctg 4860 ctggaccctg ccaagaagtc gcccatcgca gcagctcggc tcttcagcag cctcggtgag 4920 ctgagctcca tttcagcgca gcgcagcccc gggggcccgg gcggcggggc ctcgtactcg 4980 gtgaggccca gtggccgcta ccccgtggcg agacgcgccc cgagcccggt gaagcccgcg 5040 tcgctggagc gggtggaggg gctgggggcg ggcgcggggg gcgcagggcg gcccttcggc 5100 ctcacgcccc ccaccatcct caagtcgtcc agcctctcca tcccgcacga gcccaaggag 5160 gtgcgcttcg tggtgcgcag cgtgagcgcg cgcagtcgct ccccctcgcc gtcgccgctg 5220 ccctcgcccg cgtccggccc cggccccggc gcccccggcc cacgccgacc cttccagcag 5280 aagccgctgc agctctggag caagttcgac gtgggcgact ggctggagag catccaccta 5340 ggcgagcacc gcgaccgctt cgaggaccat gagatagaag gcgcgcacct acccgcgctt 5400 accaaggacg acttcgtgga gctgggcgtc acgcgcgtgg gccaccgcat gaacatcgag 5460 cgcgcgctca ggcagctgga cggcagctga cgccccaccc ccactcccgc cccaggccga 5520 gcccgcggc 5529 53 1623 DNA Homo sapiens misc_feature Incyte ID No 2739431CB1 53 tgatatttga agaagtgttt tcatctatcc aagaaaaata tgatgtctcc atcccaagcc 60 tcactcttat tcttaaatgt atgtattttt atttgtggag aagctgtaca aggtaactgt 120 gtacatcatt ctacggactc ttcagtagtt aacattgtag aagatggatc taatgcaaaa 180 gatgaaagta aaagtaatga tactgtttgt aaggaagact gtgaggaatc atgtgatgtt 240 aaaactaaaa ttacacgaga agaaaaacat ttcatgtgta gaaatttgca aaattctatt 300 gtttcctaca caagaagtac caaaaaacta ctaaggaata tgatggatga gcaacaagct 360 tccttggatt atttatctaa tcaggtaatg tgtgacatgg attacagagg aggtggatgg 420 actgtgatac agaaaagaat tgatgggata attgatttcc agaggttgtg gtgtgattat 480 ctggatggat ttggagatct tctaggagaa ttttggctag gactgaaaaa gattttttat 540 atagtaaatc agaaaaatac cagttttatg ctgtatgtgg ctttggaatc tgaagatgac 600 actcttgctt atgcatcata tgataatttt tggctagagg atgaaacgag attttttaaa 660 atgcacttag gacggtattc aggaaatgct ggtgatgcat tccggggtct caaaaaagaa 720 gataatcaaa atgcaatgcc ttttagcaca tcagatgttg ataatgatgg gtgtcgccct 780 gcatgcctgg tcaatggtca gtctgtgaag agctgcagtc acctccataa caagaccggc 840 tggtggttta acgagtgtgg tctagcaaat ctaaatggca ttcatcactt ctctggaaaa 900 ttgcttgcaa ctggaattca atggggcacg tggaccaaaa acaactcacc tgtcaagatt 960 aaatctgttt caatgaaaat tagaagaatg tacaatccat attttaaata atctcattta 1020 acattgtaat gcaagttcta caatgataat atattaaaga tttttaaaag tttatctttt 1080 cacttagtgt ttcaaacata ttaggcaaaa tttaactgta gatggcattt agatgttatg 1140 agtttaatta gaaaacttca attttgtagt attctataaa agaaaacatg gcttattgta 1200 tgtttttact tctgactata ttaacaatat acaatgaaat ttgtttcaag tgaactacaa 1260 cttgtcttcc taaaatttat agtgatttta aaggattttg ccttttcttt gaagcatttt 1320 taaaccataa tatgttgtaa ggaaaattga agggaatatt ttacttattt ttatacttta 1380 tatgattata taatctacag ataatttcta ctgaagacag ttacaataaa taactttatg 1440 cagattaata tataagctac acatgatgta aaaaccttac tatttctagg tgatgccata 1500 ccattttaaa agtagtaaga gtttgctgcc caaatagttt ttcttgtttt catatctaat 1560 catggttaac tattttgtta ttgtttgtaa taaatatatg tacttttata tcctgaaaaa 1620 aaa 1623 54 2242 DNA Homo sapiens misc_feature Incyte ID No 7473606CB1 54 ccacaagggc ctgactgagc gagcgagcat ggacggccgc ggggctttct ggacagtggc 60 cattcccaga gccaggcagg aaggcctcgg gaggctgggg ctcccgttcc cggtgaagcg 120 gacgccgcca gcgccccaga acccaggagg aagcacacag gccccacaga gagtggttgg 180 caagagtcac tcggggatta ggatgccggc caaatcgcgg aatttgaggc tggaatccaa 240 gctcaacagg aaagtagtga aatacaaatg gggaaaacag ggctctggag cggggaggga 300 gctggtgccg gcatttccca ccaacgccgg tttaggaaga cgggaccgat gccggccgcc 360 ccctgctgga ggggatgtgg catctcacgg gctgccaggg agcggggttg gctactcctg 420 caaccagcgt gaagagggtc tcaggggagg ctgtggtggg atcccccacg tgcccttgtt 480 cctctcaccg ttacctctgg atgcctcggg gcaaaggcct tcttccacct atagacagag 540 tctacgcagg ggtcttggaa cccgggcaca ccagtcccca gctaacgaaa tccccgagtt 600 gggggatttg agagggtcac gtttggccca agaacccgca gtcctctttg gtcttcggcc 660 ctctatttct aagcgtgggc ttctggcacg gcggctctgg gcacagccca tgctgctttc 720 gggctgggtg gtttcaacga cgacaacaat tatcacagtg acggtgacct tcaccccaac 780 aggactgctg tgtgtgaagc actcaagagg gcccctacaa ccaacctgcc aggagtcggc 840 tcctgaaaac agggtcggaa aagcgctaat tactttttcc aaaggctgga gggcttcact 900 ccggctggcg ccgccgccta gcgcgctcct gcttcgccgc cacggtccgg gggggctgcc 960 ggtcccgggt accatgtgtg acggcgccct gctgcctccg ctcgtcctgc ccgtgctgct 1020 gctgctggtt tggggactgg acccgggcac aggtagcgcc ccctcccaca gccctcttca 1080 ccccgcgtcc tgcggctacc ttccctctgc gttctcgcgg cgtcctggcg gcccgggggc 1140 ggcggcggga ccgctgacgg cgcccgagcg gaggaggcgc gggccgcggc cggagtacgg 1200 gaatcgggtg gctccgtggc aggcgcgccg ccgccgggtc tccgctcgcc gatgcgcggc 1260 gccgttccgg gaggtgctcg cgcggctgcg ccggagaccc tccccgggtg gcgcgggcca 1320 gcgtggagct gtcggcgacg cggcggccga cgtggaggtg gtgctcccgt ggcgggtgcg 1380 ccccgacgac gtgcacctgc cgccgctgcc cgcagccccc gggccccgac ggcggcgacg 1440 cccccgcacg cccccagccg ccccgcgcgc ccggcccgga gagcgcgccc tgctgctgca 1500 cctgccggcc ttcgggcgcg acctgtacct tcagctgcgc cgcgacctgc gcttcctgtc 1560 ccgaggcttc gaggtggagg aggcgggcgc ggcccggcgc cgcggccgcc ccgccgagct 1620 gtgcttctac tcgggccgtg tgctcggcca ccccggctcc ctcgtctcgc tcagcgcctg 1680 cggcgccgcc ggcggcctgg ttggcctcat tcagcttggg caggagcagg tgctaatcca 1740 gcccctcaac aactcccagg gcccattcag tggacgagaa catctgatca ggcgcaaatg 1800 gtccttgacc cccagccctt ctgctgaggc ccagagacct gagcagctct gcaaggttct 1860 aacagttcca cagtgtctgg gcctcacctg ggaggacttg aaatctggag gctggagtga 1920 tctggaggtg cctcattcat gtgtctggcc tggaggtgga tgacttgaag acaaggacaa 1980 caacgtggag cgtctacctg tggcctctgc agcttggcgt ccataccttg gtggcagaca 2040 tacttcttct atggccacca gggctcccaa tgcaagagtt cccgcaagcc cagcaggagc 2100 tgtgctgcct ttgaggatca gcctcagaaa tcctagagca tcactctgaa ggtactctgt 2160 tggctgaagc ggttagaaac ctacccaggt tcaagggcag agagatagac cccaccgctc 2220 aatgtcaaag aatttggggg gc 2242 55 3751 DNA Homo sapiens misc_feature Incyte ID No 3534918CB1 55 ttcatggagc atggagcgct tggcagcctt ggggaacatg cagcgaaagt tgtgggaaag 60 gtactcagac aagagcaaga ctttgtaata acccaccacc agcgtttggt gggtcctact 120 gtgatggagc agaaacacag atgcaagttt gcaatgaaag aaattgtcca attcatggca 180 agtgggcgac ttgggccagt tggagtgcct gttctgtgtc atgtggagga ggtgccagac 240 agagaacaag gggctgctcc gaccctgtgc cccagtatgg aggaaggaaa tgcgaaggga 300 gtgatgtcca gagtgatttt tgcaacagtg acccttgccc aagtgagtgt tggaaatacc 360 catggtaact ggagtccttg gagtggctgg ggaacatgca gccggacgtg taacggaggg 420 cagatgcggc ggtaccgcac atgtgataac cctcctccct ccaatggggg aagagcttgt 480 gggggaccag actcccagat ccagaggtgc aacactgaca tgtgtcctgt ggatggaagt 540 tggggaagct ggcatagttg gagccagtgc tctgcctcct gtggaggagg tgaaaagact 600 cggaagcggc tgtgcgacca tcctgtgcca gttaaaggtg gccgtccctg tcccggagac 660 actactcagg tgaccaggtg caatgtacaa gcatgtccag gtgggcccca gcgagccaga 720 ggaagtgtta ttggaaatat taatgatgtt gaatttggaa ttgctttcct taatgccaca 780 ataactgata gccctaactc tgatactaga ataatacgtg ccaaaattac caatgtacct 840 cgtagtcttg gttcagcaat gagaaagata gtttctattc taaatcccat ttattggaca 900 acagcaaagg aaataggaga agcagtcaat ggctttaccc tcaccaatgc agtcttcaaa 960 agagaaactc aagtggaatt tgcaactgga gaaatcttgc agatgagtca tattgcccgg 1020 ggcttggatt ccgatggttc tttgctgcta gatatcgttg tgagtggcta tgtcctacag 1080 cttcagtcac ctgctgaagt cactgtaaag gattacacag aggactacat tcaaacaggt 1140 cctgggcagc tgtacgccta ctcaacccgg ctgttcacca ttgatggcat cagcatccca 1200 tacacatgga accacaccgt tttctatgat caggcacagg gaagaatgcc tttcttggtt 1260 gaaacacttc atgcatcctc tgtggaatct gactataacc agatagaaga gacactgggt 1320 tttaaaattc atgcttcaat atccaaagga gatcgcagta atcagtgccc ctccgggttt 1380 accttagact cagttggacc tttttgtgct gatgaggatg aatgtgcagc agggaatccc 1440 tgctcccata gctgccacaa tgccatgggg acttactact gctcctgccc taaaggcctc 1500 accatagctg cagatggaag aacttgtcaa gatattgatg agtgtgcttt gggtaggcat 1560 acctgccacg ctggtcagga ctgtgacaat acgattggat cttatcgctg tgtggtccgt 1620 tgtggaagtg gctttcgaag aacctctgat gggctgagtt gtcaagatat taatgaatgt 1680 caagaatcca gcccctgtca ccagcgctgt ttcaatgcca taggaagttt ccattgtgga 1740 tgtgaacctg ggtatcagct caaaggcaga aaatgcatgg atgtgaacga gtgtagacaa 1800 aatgtatgca gaccagatca gcactgtaag aacacccgtg gtggctataa gtgcattgat 1860 ctttgtccaa atggaatgac caaggcagaa aatggaacct gtattgatat tgatgaatgt 1920 aaagatggga cccatcagtg cagatataac cagatatgtg agaatacaag aggcagctat 1980 cgttgtgtat gcccaagagg ttatcggtct caaggagttg gaagaccctg catggatatt 2040 gatgaatgtg aaaatacaga tgcctgccag catgagtgta agaatacctt tggaagttat 2100 cagtgcatct gcccacctgg ctatcaactc acacacaatg gaaagacatg ccaagatatc 2160 gatgaatgtc tggagcagaa tgtgcactgt ggacccaatc gcatgtgctt caacatgaga 2220 ggaagctacc agtgcatcga tacaccctgt ccacccaact accaacggga tcctgtttca 2280 gggttctgcc tcaagaactg tccacccaat gatttggaat gtgccttgag cccatatgcc 2340 ttggaataca aactcgtctc cctcccattt ggaatagcca ccaatcaaga tttaatccgg 2400 ctggttgcat acacacagga tggagtgatg catcccagga caactttcct catggtagat 2460 gaggaacaga ctgttccttt tgccttgagg gatgaaaacc tgaaaggagt ggtgtataca 2520 acacgaccac tacgagaagc agagacctac cgcatgaggg tccgagcctc atcctacagt 2580 gccaatggga ccattgaata tcagaccaca ttcatagttt atatagctgt gtccgcctat 2640 ccatactaag gaactctcca aagcctattc cacatattta aaccgcatta atcatggcaa 2700 tcaagccccc ttccagatta ctgtctcttg aacagttgca atcttggcag cttgaaaatg 2760 gtgctacact ctgttttgtg tgccttcctt ggtacttctg aggtattttc atgatcccac 2820 catggtcata tcttgaagta tggtctagaa aagtccctta ttattttatt tattacactg 2880 gagcagttac ttcccaaaga ttattctgaa catctaacag gacatatcag tgatggttta 2940 cagtagtgta gtacctaaga tcattttcct gaaagccaaa ccaaacaacg aaaaacaaga 3000 acaactaatt cagaatcaaa tagagttttt gagcatttga ctatttttag aatcataaaa 3060 ttagttacta agtattttga tcaaagctta taaaataact tacggagatt tttgtaagta 3120 ttgatacatt ataataggac ttgcctattt tcatttttaa gaagaaaaac accactcatt 3180 ttataaaata tagtacagct actataaggc ttgtttgatc ccaaatggtg cttatcttga 3240 ttgaacattc agaacaagga tattattttc agtgattttg tgagatcagc tgaaccactt 3300 atgataataa taataaaaaa gactgctttg ccctcacgtc agttgtacat ggcatggaac 3360 tttaaaaatt ttaatataaa ctttcatcca gttagcttca taacttttac gttccagaat 3420 tttgtttatt ttcctgtcaa tgaaagcaat ttttaaagat accagtggga caggtttggt 3480 tttttaaaaa tctcatgtgt tcaaattaac ataaatatta cacgtcaata cactgtacat 3540 ggtggtaata gactctaagc aattgccaag atgtattcta tttttatgaa gtgtatatat 3600 attaccttag tgtgcatttt ctatataata tcttgatgga ctcttttata aaattatttt 3660 ataaaaaaca atgttacact aaaatcagcc taaataaatt ttcacaactt tttttcataa 3720 ccaaaaacaa caaacaacaa aaccggggcc g 3751 56 3579 DNA Homo sapiens misc_feature Incyte ID No 2428715CB1 56 gggtcgacca cgcgtcgggg caggtggcga gcagcgagca gcgcctgcgg gagcggccgg 60 tcggtcgggt ccccgcgccc cgcacgcccg cacgcccagc ggggcccgca ttgagcatgg 120 gcgcggcggc cgtgcgctgg cacttgtgcg tgctgctggc cctgggcaca cgcgggcggc 180 tggccggggg cagcgggctc ccagggtcag tcgacgtgga tgagtgctca gagggcacag 240 atgactgcca catcgatgcc atctgtcaga acacgcccaa gtcctacaaa tgcctctgca 300 agccaggcta caagggggaa ggcaagcagt gtgaagacat tgacgagtgt gagaatgact 360 actacaatgg gggctgtgtc cacgagtgca tcaacatccc ggggaactac aggtgtacct 420 gctttgatgg cttcatgctg gcacacgatg gacacaactg cctggatgtg gacgagtgtc 480 aggacaataa tggtggctgc cagcagatct gcgtcaatgc catgggcagc tacgagtgtc 540 agtgccacag tggcttcttc cttagtgaca accagcatac ctgcatccac cgctccaatg 600 agggtatgaa ctgcatgaac aaagaccatg gctgtgccca catctgccgg gagacgccca 660 aaggtggggt ggcctgcgac tgcaggcccg gctttgacct tgcccaaaac cagaaggact 720 gcacactaac ctgtaattat ggaaacggag gctgccagca cagctgtgag gacacagaca 780 caggccccac gtgtggttgc caccagaagt acgccctcca ctcagacggt cgcacgtgca 840 tcgagaagga tgaggctgca attgagcgct ctcagttcaa tgccacgtca gtagctgatg 900 tggacaagcg ggtgaaacgg cggctactca tggagacgtg cgcagtcaat aacggaggct 960 gcgaccggac atgcaaggac acagccactg gcgtgcgatg cagctgcccc gttggattca 1020 cactgcagcc ggacgggaag acatgcaaag acatcaacga gtgcctggtc aacaacggag 1080 gctgcgacca cttctgccgc aacaccgtgg gcagcttcga gtgcggctgc cggaagggct 1140 acaagctgct caccgacgag cgcacctgcc aggacatcga cgagtgctcc ttcgagcgga 1200 cctgtgacca catctgcatc aactccccgg gcagcttcca gtgcctgtgt caccgcggct 1260 acatcctcta cgggacaacc cactgcggag atgtggacga gtgcagcatg agcaacggga 1320 gctgtgacca gggctgcgtc aacaccaagg gcagctacga gtgcgtctgt cccccgggga 1380 ggcggctcca ctggaaccgg aaggattgcg tggagacagg caagtgtctt tctcgtgcca 1440 agacctcccc ccgggcccag ctgtcctgca gcaaggcagg cggtgtggag agctgcttcc 1500 tttcctgccc ggctcacaca ctcttcgtgc cagatgcccc caccaccccc atcaaacaga 1560 aggcccgctt caagatccga gatgccaagt gccacctccg gccccacagc caggcacgag 1620 caaaggagac cgccaggcag ccgctgctgg accactgcca tgtgactttc gtgaccctca 1680 agtgtgactc ctccaagaag aggcgccgtg gccgcaagtc cccatccaag gaggtgtccc 1740 acatcacagc agagtttgag atcgagacaa agatggaaga ggcctcagac acatgcgaag 1800 cggactgctt gcggaagcga gcagaacaga gcctgcaggc cgccatcaag accctgcgca 1860 agtccatcgg ccggcagcag ttctatgtcc aggtctcagg cactgagtac gaggtagccc 1920 agaggccagc caaggcgctg gaggggcagg gggcatgtgg cgcaggccag gtgctacagg 1980 acagcaaatg cgttgcctgt gggcctggca cccacttcgg tggtgagctc ggccagtgtg 2040 tgccatgtat gccaggaaca taccaggaca tggaaggcca gctcagttgc acaccgtgcc 2100 ccagcagcga cgggcttggt ctgcctggtg cccgcaacgt gtcggaatgt ggaggccagt 2160 gttctccagg cttcttctcg gccgatggct tcaagccctg ccaggcctgc cccgtgggca 2220 cgtaccagcc tgagcccggg cgcaccggct gcttcccctg tggagggggt ttgctcacca 2280 aacacgaagg caccacctcc ttccaggact gcgaggctaa agtgcactgc tcccccggcc 2340 accactacaa caccaccacc caccgctgca tccgctgccc cgtcggcacc taccagcccg 2400 agtttggcca gaaccactgc atcacctgtc cgggcaacac cagcacagac ttcgatggct 2460 ccaccaacgt cacacactgc aaaaaccagc actgcggcgg cgagcttggt gactacaccg 2520 gctacatcga gtcccccaac taccctggcg actacccagc caacgctgaa tgcgtctggc 2580 acatcgcacc tcccccaaag cgcaggatcc tcatcgtggt ccctgagatc ttcctgccca 2640 tcgaggatga gtgcggcgat gttctggtca tgaggaagag tgcctctccc acgtccatca 2700 ccacctatga gacctgccag acctacgaga ggcccatcgc cttcacctcc cgctcccgca 2760 agctctggat ccagttcaaa tccaatgaag gcaacagcgg caaaggcttc caagtgccct 2820 atgtcaccta cgatgaggac taccagcaac tcatagagga catcgtgcgc gatgggcgcc 2880 tgtacgcctc ggagaaccac caggaaattt tgaaagacaa gaagctgatc aaggccctct 2940 tcgacgtgct ggcgcatccc cagaaccgcg gcttagtttc ctcatgttaa aagaaaatac 3000 ttatcctccc tgtggcacag ggttttgttt aaaagattag acaagatgat acaaccattt 3060 tggaaataat ttggcagctt cttataaaca tatactttac aggtaagcca gcaattgcac 3120 tcctagctgc acccacgaga aatgaaaata tgtccataca aagatttata cacaaatgtt 3180 tatagcagct ttattcataa taatcaaaaa ctgaaaacaa ctcaaacatc catcaacagg 3240 cagatggata aacaaattat ggtatgtcca tgcaacggaa tacaactcac tgatgaaaag 3300 gaataaacca caaatgcctg caacgccatg atgaatctca aaacatgctg agtgtagaga 3360 agccagacac aagagtagat actcctatac aattccactt acatggaaat ctagaaaaga 3420 caattcgaat atatagtggc aaaaagcaga agagtggttg cctggaacca gggtgggaat 3480 gaagattaac tgcccagagg cataaaaaat ggggtggtgg gggcggtgat ggaaaagtgc 3540 tatgccttca ctgtaccttt gtcaaaactt gttgaactg 3579 57 5178 DNA Homo sapiens misc_feature Incyte ID No 3351332CB1 57 gggaacccag aaccagcccg agccgcctgc cccgtcgccc ggccgccggc ttagggcgca 60 gcgcggttgg tcctcgcccc ctcccgcccg ccggcctacc aggccatggg ggcgtcccgg 120 gaccgcgggc tggccgcgct ctggtgcctt gggctcctgg ggggcctggc gcgcgtcgcg 180 ggcacgcact accgctacct ctggaggggc tgctacccat gtcacctggg ccaggccggc 240 taccccgtga gcgccggtga ccagaggcca gatgtggacg aatgccgaac ccacaacggt 300 ggctgccagc accggtgcgt gaacacccca ggctcctacc tctgtgagtg caagcccggc 360 ttccggctcc acactgacag caggacctgc ctggccatta actcctgcgc cctgggcaat 420 ggcggctgcc agcaccactg tgtccagctc acaatcactc ggcatcgctg ccagtgccgg 480 cccgggttcc agctccagga ggacggcagg cattgtgtcc gtagaagccc gtgtgccaac 540 aggaacggca gctgcatgca caggtgccag gtggtccggg gcctcgcccg ctgtgagtgc 600 cacgtgggct atcagctagc agcggacggc aaggcctgtc cagatgtgga cgaatgtgcc 660 gcagggctgg cccagtgtgc ccatggctgc ctcaacaccc aggggtcctt caagtgcgtg 720 tgtcacgcgg gctatgagct gggcgccgat ggccggcagt gctaccggat tgagatggaa 780 atcgtgaaca gctgtgaggc caacaacggc ggctgctccc atggctgcag ccacaccagt 840 gctgggcccc tgtgcacatg tccccgcggc tacgagctgg acacagatca gaggacctgc 900 atcgatgtcg acgactgtgc agacagcccg tgctgccagc aggtgtgcac caacaaccct 960 ggcgggtacg agtgcggctg ctacgccggc taccggctca gtgccgatgg ctgcggctgt 1020 gaggatgtgg atgagtgcgc ctccagccgt ggcggctgcg agcaccactg caccaacctg 1080 gccggctcct tccagtgctc ctgcgaggcc ggctaccggc tgcacgagga ccgtaggggc 1140 tgcagccccc tggaggagcc gatggtggac ctggacggcg agctgccttt cgtgcggccc 1200 ctgccccaca ttgccgtgct ccaggacgag ctgccgcaac tcttccagga tgacgacgtc 1260 ggggccgatg aggaagaggc agagttgcgg ggcgaacaca cgctcacaga gaagtttgtc 1320 tgcctggatg actcctttgg ccatgactgc agcttgacct gtgatgactg caggaacgga 1380 gggacctgcc tcctgggcct ggatggctgt gattgccccg agggctggac tgggctcatc 1440 tgcaatgaga cttgtcctcc ggacaccttt gggaagaact gcagcttctc ctgcagctgt 1500 cagaatggtg ggacctgcga ctctgtcacg ggggcctgcc gctgcccccc gggtgtcagt 1560 ggaactaact gtgaggatgg ctgccccaag ggctactatg gcaagcactg tcgcaagaaa 1620 tgcaactgtg ccaaccgggg ccggtgccac cgcctctacg gggcctgcct ctgcgaccca 1680 gggctctacg gccgcttctg ccacctcacc tgcccgccgt gggcctttgg gccgggctgc 1740 tcggaggagt gccagtgtgt gcagccccac acgcagtcct gtgacaagag ggatggcagc 1800 tgctcctgca aggctggctt ccggggcgag cgctgtcagg cagagtgtga gctgggctac 1860 tttgggccgg ggtgctggca ggcatgcacc tgcccagtgg gcgtggcctg tgactccgtg 1920 agcggcgagt gtgggaagcg gtgtcctgct ggcttccagg gagaggactg tggccaagag 1980 tgcccggtgg ggacgtttgg cgtgaactgc tcgagctcct gctcctgtgg gggggccccc 2040 tgccacgggg tcacggggca gtgccggtgt ccgccgggga ggactgggga agactgtgag 2100 gcagattgtc ccgagggccg ctgggggctg ggctgccagg agatctgccc agcatgccag 2160 cacgctgccc gctgcgaccc tgagaccgga gcctgcctgt gcctccctgg cttcgtcggc 2220 agccgctgcc aggacgtgtg cccagcaggc tggtatggtc ccagctgcca gacaaggtgc 2280 tcttgtgcca atgatgggca ctgccaccca gccaccggac actgcagctg tgcccccggg 2340 tggaccggct ttagctgcca gagagcctgt gatactgggc actggggacc tgactgcagc 2400 cacccctgca actgcagcgc tggccacggg agctgtgatg ccatcagcgg cctgtgtctg 2460 tgtgaggctg gctacgtggg cccgcggtgc gagcagcagt gtccccaggg ccactttggg 2520 cccggctgtg agcagctgtg ccagtgtcag catggagcag cctgtgacca cgtcagcggg 2580 gcctgcacct gcccggccgg ctggaggggc accttctgcg agcatgcctg cccggccggc 2640 ttctttggat tggactgtcg cagtgcctgc aactgcaccg ccggagctgc ctgtgatgcc 2700 gtgaatggct cctgcctctg ccccgctggc cgccggggcc cccgctgtgc cgagacctgc 2760 ccagcccaca cctacgggca caattgcagc caggcctgtg cctgctttaa cggggcctcc 2820 tgtgaccctg tccacgggca gtgccactgt gcccctggct ggatggggcc ctcctgcctg 2880 caggagtgcc tcccccggga cgtcagagct ggctgccggc acagcggcgg ttgcctcaac 2940 gggggcctgt gtgacccgca cacgggccgc tgcctctgcc cagccggctg gactggggac 3000 aagtgtcaga gcccctgcct gcggggctgg tttggagagg cctgtgccca gcgctgcagc 3060 tgcccgcctg gcgctgcctg ccaccacgtc actggggcct gccgctgtcc ccctggcttc 3120 actggctccg gctgcgagca ggcctgccca cccggcagct ttggggagga ctgtgcgcag 3180 atgtgccagt gtcccggtga gaacccggcc tgccaccctg ccaccgggac ctgctcatgt 3240 gctgctggct accacggccc cagctgccag caacgatgtc cgcccgggcg gtatgggcca 3300 ggctgtgaac agctgtgtgg gtgtctcaac gggggctcct gtgatgcggc cacgggggcc 3360 tgccgctgcc ccactgggtt cctcgggacg gactgcaacc tcacctgtcc gcagggccgc 3420 ttcggcccca actgcaccca cgtgtgtggg tgtgggcagg gggcggcctg cgaccctgtg 3480 accggcacct gcctctgccc cccggggaga gccggcgtcc gctgtgagcg aggctgcccc 3540 cagaaccggt ttggcgtggg ctgcgagcac acctgctcct gcagaaatgg gggcctgtgc 3600 cacgccagca acggcagctg ctcctgtggc ctgggctgga cggggcggca ctgcgagctg 3660 gcctgtcccc ctgggcgcta cggagccgcc tgccatctgg agtgctcctg ccacaacaac 3720 agcacgtgtg agcctgccac gggcacctgc cgctgcggcc ccggcttcta tggccaggcc 3780 tgcgagcacc cctgtccccc tggcttccac ggggctggct gccaggggtt gtgctggtgt 3840 caacatggag ccccctgcga ccccatcagt ggccgatgcc tctgccctgc cggcttccac 3900 ggccacttct gtgagagggg gtgtgagcca ggttcatttg gagagggctg ccaccagcgc 3960 tgtgactgtg acgggggggc accctgtgac cctgtcaccg gtctctgcct ttgcccacca 4020 gggcgctcag gagccacctg taacctggat tgcagaaggg gccagtttgg gcccagctgc 4080 accctgcact gtgactgcgg gggtggggct gactgcgacc ctgtcagtgg gcagtgtcac 4140 tgtgtggatg gctacatggg gcccacgtgc cgggaaggtg ggcccctccg gctccccgag 4200 aacccgtcct tagcccaggg ctcagcgggc acactgcccg cctccagcag acccacatcc 4260 cggagcggtg gaccagcgag gcactagtag aggcagtccc gtggagcccg cctctccagt 4320 cccagccaga ggggaccctg gcctttggtg accactgaga aggacacttc acgggcccag 4380 agctcctggt actgcccttc ctttgagggc cgtggagggc tgtggacagc ccagcaacct 4440 gtcgctcttg gaggctggtg tggccttgag gagggaagcc tcgcatggcc gctggaagag 4500 aggcgcctcc tggcctggct ctgcagaacc caggggcacg ctctgggcct gggctgagga 4560 agtcccgctc tccccgcggc tctgagttgg actgaggaca ggtgtgggcg ccagtgtggg 4620 tgcaggcgca ggtgcaggca cagggccact gtcctccagg caggcttttt ggtgctaggc 4680 cctgggactg gaagtcgccc agcccgtatt tatgtaaagg tatttatggg ccactgcaca 4740 tgcccgctgc agccctggga tcagctggaa gctgcctgtc atctcctgcc caatccccag 4800 aaaccctgat tcaggtctgc aggctcctgc gggctcacca ggctgctggc tccggtacca 4860 tgtaaaccta ggaaggtaaa ggagcaggca acctcctcgt ggcctgtgtg tttgctgtgt 4920 tacgtggact ctgtgtgggc tcctccctgg ggcccggcca gcataacggt gcacccaggg 4980 acctcccagt gcacccgggg ccctttgcag gggtgggggt gccacacaag tgaagaagtt 5040 gggactcatc tcagttccca gtgctattga ggagaacgct ggggctgcat tcattaccgc 5100 tgagacccag agactggctg ttcccagaga atggcccagg gggaggaggg ctggtgtgga 5160 agggcaactt ggactgag 5178 58 11367 DNA Homo sapiens misc_feature Incyte ID No 6382722CB1 58 atggcgaagc ggctctgcgc ggggagcgca ctgtgtgttc gcggcccccg gggccccgcg 60 ccgctgctgc tggtcgggct ggcgctgctg ggcgcggcgc gggcgcggga ggaggcgggc 120 ggcggcttca gcctgcaccc gccctacttc aacctggccg agggcgcccg catcgccgcc 180 tccgcgacct gcggagagga ggccccggcg cgcggctccc cgcgccccac cgaggacctt 240 tactgcaagc tggtaggggg ccccgtggcc ggcggcgacc ccaaccagac catccggggc 300 cagtactgcg acatctgcac ggctgccaac agcaacaagg cacaccccgc gagcaatgcc 360 atcgatggca cggagcgctg gtggcagagt ccaccgctgt cccgcggcct ggagtacaac 420 gaggtcaacg tcaccctgga cctgggccag gtcttccacg tggcctacgt cctcatcaag 480 tttgccaact caccccggcc ggacctctgg gtgctggagc ggtccatgga cttcggccgc 540 acctaccagc cctggcagtt ctttgcctcc tctaagaggg actgtctgga gcggttcggg 600 ccacagacgc tggagcgcat cacacgggac gacgcggcca tctgcaccac cgagtactca 660 cgcatcgtgc ccctggagaa cggagagatc gtggtgtccc tggtgaacgg acgtccgggc 720 gccatgaatt tctcctactc gccgctgcta cgtgagttca ccaaggccac caacgtccgc 780 ctgcgcttcc tgcgtaccaa cacgctgctg ggccatctca tggggaaggc gctgcgggac 840 cccacggtca cccgccggta ttattacagc atcaaggata tcagcatcgg aggccgctgt 900 gtctgccacg gccacgcgga tgcctgcgat gccaaagacc ccacggaccc gttcaggctg 960 cagtgcacct gccagcacaa cacctgcggg ggcacctgcg accgctgctg ccccggcttc 1020 aatcagcagc cgtggaagcc tgcgactgcc aacagtgcca acgagtgcca gtcctgtaac 1080 tgctacggcc atgccaccga ctgttactac gaccctgagg tggaccggcg ccgcgccagc 1140 cagagcctgg atggcaccta tcagggtggg ggtgtctgta tcgactgcca gcaccacacc 1200 gccggcgtca actgtgagcg ctgcctgccc ggcttctacc gctctcccaa ccaccctctc 1260 gactcgcccc acgtctgccg ccgctgcaac tgcgagtccg acttcacgga tggcacctgc 1320 gaggacctga cgggtcgatg ctactgccgg cccaacttct ctggggagcg gtgtgacgtg 1380 tgtgccgagg gcttcacggg cttcccaagc tgctacccga cgccctcgtc ctccaatgac 1440 accagggagc aggtgctgcc agctggccag attgtgaatt gtgactgcag cgcggcaggg 1500 acccagggca acgcctgccg gaaggaccca agggtgggac gctgtctgtg caaacccaac 1560 ttccaaggca cccattgtga gctctgcgcg ccagggttct acggccccgg ctgccagccc 1620 tgccagtgtt ccagccctgg agtggccgat gaccgctgtg accctgacac aggccagtgc 1680 aggtgccgag tgggcttcga gggggccaca tgtgatcgct gtgcccccgg ctactttcac 1740 ttccctctct gccagttgtg tggctgcagc cctgcaggaa ccttgcccga gggctgcgat 1800 gaggccggcc gctgcctatg ccagcctgag tttgctggac ctcattgtga ccggtgccgc 1860 cctggctacc atggtttccc caactgccaa gcatgcacct gcgaccctcg gggagccctg 1920 gaccagctct gtggggcggg aggtttgtgc cgctgccgcc ccggctacac aggcactgcc 1980 tgccaggaat gcagccccgg ctttcacggc ttccccagct gtgtcccctg ccactgctct 2040 gctgaaggct ccctgcacgc agcctgtgac ccccggagtg ggcagtgcag ctgccggccc 2100 cgtgtgacgg ggctgcggtg tgacacgtgt gtgcccggtg cctacaactt cccctactgc 2160 gaagctggct cttgccaccc tgccggtctg gccccagtgg atcctgccct tcctgaggca 2220 caggttccct gtatgtgccg ggctcacgtg gaggggccga gctgtgaccg ctgcaaacct 2280 gggttctggg gactgagccc cagcaacccc gagggctgta cccgctgcag ctgcgacctc 2340 aggggcacac tgggtggagt tgctgagtgc cagccgggca ccggccagtg cttctgcaag 2400 ccccacgtgt gcggccaggc ctgcgcgtcc tgcaaggatg gcttctttgg actggatcag 2460 gctgactatt ttggctgccg cagctgccgg tgtgacattg gcggtgcact gggccagagc 2520 tgtgaaccga ggacgggcgt ctgccggtgc cgccccaaca cccagggccc cacctgcagc 2580 gagcctgcga gggaccacta cctcccggac ctgcaccacc tgcgcctgga gctggaggag 2640 gctgccacac ctgagggtca cgccgtgcgc tttggcttca accccctcga gttcgagaac 2700 ttcagctgga ggggctacgc gcagatggca cctgtccagc ccaggatcgt ggccaggctg 2760 aacctgacct cccccgacct tttctggctc gtcttccgat acgtcaaccg gggggccatg 2820 agtgtgagcg ggcgggtctc tgtgcgagag gagggcaggt cggccgcctg tgccaactgc 2880 acagcacaga gtcagcccgt ggccttccca cccagcacgg agcctgcctt catcaccgtg 2940 ccccagaggg gcttcggaga gccctttgtg ctgaaccctg gcacctgggc cctgcgtgtg 3000 gaggccgaag gggtgctcct ggactacgtg gttctgctgc ctagcgcata ctacgaggcg 3060 gcgctcctgc agctgcgggt gactgaggcc tgcacatacc gtccctctgc ccagcagtct 3120 ggcgacaact gcctcctcta cacacacctc cccctggatg gcttcccctc ggccgccggg 3180 ctggaggccc tgtgtcgcca ggacaacagc ctgccccggc cctgccccac ggagcagctc 3240 agcccgtcgc acccgccact gatcacctgc acgggcagtg atgtggacgt ccagcttcaa 3300 gtggcagtgc cacagccagg ccgctatgcc ctagtggtgg agtacgccaa tgaggatgcc 3360 cgccaggagg tgggcgtggc tgtgcacacc ccacagcggg ccccccagca ggggctgctc 3420 tccctgcacc cctgcctgta cagcaccctg tgccggggca ctgcccggga tacccaggac 3480 cacctggctg tcttccacct ggactcggag gccagcgtga ggctcacagc cgagcaggca 3540 cgcttcttcc tgcacggggt cactctggtg cccattgagg agttcagccc ggagttcgtg 3600 gagccccggg tcagctgcat cagcagccac ggcgcctttg gccccaacag tgccgcctgt 3660 ctgccctcgc gcttcccaaa gccgccccag cccatcatcc tcagggactg ccaggtgatc 3720 ccgctgccgc ccggcctccc gctgacccac gcgcaggatc tcactccagc cacgtcccca 3780 gctggacccc gacctcggcc ccccaccgct gtggaccctg atgcagagcc caccctgctg 3840 cgtgagcccc aggccaccgt ggtcttcacc acccatgtgc ccacgctggg ccgctatgcc 3900 ttcctgctgc acggctacca gccagcccac cccaccttcc ccgtggaagt cctcatcaac 3960 gccggccgcg tgtggcaggg ccacgccaac gccagcttct gtccacatgg ctacggctgc 4020 cgcaccctgg tggtgtgtga gggccaggcc ctgctggacg tgacccacag cgagctcact 4080 gtgaccgtgc gtgtgcccga gggccggtgg ctctggctgg attatgtact cgtggtccct 4140 gagaacgtct acagctttgg ctacctccgg gaggagcccc tggataaatc ctatgacttc 4200 atcagccact gcgcagccca gggctaccac atcagcccca gcagctcatc cctgttctgc 4260 cgaaacgctg ctgcttccct ctccctcttc tataacaacg gagcccgtcc atgtggctgc 4320 cacgaagtag gtgctacagg ccccacgtgt gagcccttcg ggggccagtg tccctgccat 4380 gcccatgtca ttggccgtga ctgctcccgc tgtgccaccg gatactgggg cttccccaac 4440 tgcaggccct gtgactgcgg tgcccgcctc tgtgacgagc tcacgggcca gtgcatctgc 4500 ccgccacgca ccatcccgcc cgactgcctg ctgtgccagc cccagacctt tggctgccac 4560 cccctggtcg gctgtgagga gtgtaactgc tcagggcccg gcatccagga gctcacagac 4620 cctacctgtg acacagacag cggccagtgc aagtgcagac ccaacgtgac tgggcgccgc 4680 tgtgatacct gctctccggg cttccatggc tacccccgct gccgcccctg tgactgtcac 4740 gaggcgggca ctgcgcctgg cgtgtgtgac cccctcacag ggcagtgcta ctgtaaggag 4800 aacgtgcagg gccccaaatg tgaccagtgc agccttggga ccttctcact ggatgctgcc 4860 aaccccaaag gttgcacccg ctgcttctgc tttggggcca cggagcgctg ccggagctcg 4920 tcctacaccc gccaggagtt cgtggatatg gagggatggg tgctgctgag cactgaccgg 4980 caggtggtgc cccacgagcg gcagccaggg acggagatgc tccgtgcaga cctgcggcac 5040 gtgcctgagg ctgtgcccga ggctttcccc gagctgtact ggcaggcccc accctcctac 5100 ctgggggacc gggtgtcatc ctacggtggg accctccgtt atgaactgca ctcagagacc 5160 cagcggggag atgtctttgt ccccatggag agcaggccgg atgtggtgct gcagggcaac 5220 cagatgagca tcacattcct ggagccggca taccccacgc ctggccacgt tcaccgtggg 5280 cagctgcagc tggtggaggg gaacttccgg catacggaga ctcgcaacac tgtgtcccgc 5340 gaggagctca tgatggtgct ggccagcctg gagcagctgc agatccgtgc cctcttctca 5400 cagatctcct cggctgtctc cctgcgcagg gtggcactgg aggtggccag cccagcaggc 5460 cagggggccc tggccagcaa tgtggagctg tgcctgtgcc ccgccagcta ccggggggac 5520 tcatgccagg aatgtgcccc cggcttctat cgggacgtca aaggtctctt cctgggccga 5580 tgtgtccctt gtcagtgcca tggacactca gaccgctgcc tccctggctc tggcgtctgt 5640 gtggactgcc agcacaacac cgaaggggcc cactgtgagc gctgccaggc tggcttcatg 5700 agcagcaggg acgaccccag cgccccctgt gtcagctgcc cctgccccct ctcagtgcct 5760 tccaacaact tcgccgaggg ctgtgtcctg cgaggcggcc gcacccagtg cctctgcaaa 5820 cctggttatg caggtgcctc ctgcgagcgg tgtgcgcccg gattctttgg gaacccactg 5880 gtgctgggca gctcctgcca gccatgcgac tgcagcggca acggtgaccc caacttgctc 5940 ttcagcgact gcgaccccct gacgggcgcc tgccgtggct gcctgcgcca caccactggg 6000 ccccgctgcg agatctgtgc ccccggcttc tacggcaacg ccctgctgcc cggcaactgc 6060 acccggtgcg actgtacccc atgtgggaca gaggcctgcg acccccacag cgggcactgc 6120 ctgtgcaagg cgggcgtgac tgggcggcgc tgtgaccgct gccaggaggg acattttggt 6180 ttcaatggct gcgggggctg ccgcccgtgt gcttgtggac cggccgccga gggctccgag 6240 tgccaccccc agagcggaca gtgccactgc cgaccaggga ccatgggacc ccagtgccgc 6300 gagtgtgccc ctggctactg ggggctccct gagcagggct gcaggcgctg ccagtgccct 6360 gggggccgct gtgaccctca cacgggccgc tgcaactgcc ccccggggct cagcggggag 6420 cgctgcgaca cctgcagcca gcagcatcag gtgcctgttc caggcgggcc tgtgggccac 6480 agcatccact gtgaagtgtg tgaccactgt gtggtcctgc tcctggatga cctggaacgg 6540 gccggcgccc tcctccccgc cattcacgag caactgcgtg gcatcaatgc cagctccatg 6600 gcctgggccc gtctgcacag gctgaacgcc tccatcgctg acctgcagag ccagctccgg 6660 agccccctgg gcccccgcca tgagacggca cagcagctgg aggtgctgga gcagcagagc 6720 acaagcctcg ggcaggacgc acggcggcta ggcggccagg ccgtggggac ccgagaccag 6780 gcgagccaat tgctggccgg caccgaggcc acactgggcc atgcgaagac gctgttggcg 6840 gccatccggg ctgtggaccg caccctgagc gagctcatgt cccagacggg ccacctgggg 6900 ctggccaatg cctcggctcc atcaggtgag cagctgctcc ggacactggc cgaggtggag 6960 cggctgctct gggagatgcg ggcccgggac ctgggggccc cgcaggcagc agctgaggct 7020 gagttggctg cagcacagag attgctggcc cgggtgcagg agcagctgag cagcctctgg 7080 gaggagaacc aggcactggc cacacaaacg cgcgaccggc tggcccagca cgaggccggc 7140 ctcatggacc tgcgagaggc tttgaaccgg gcagtggacg ccacacggga ggcccaggag 7200 ctcaacagcc gcaaccagga gcgcctggag gaagccctgc aaaggaagca ggagctgtcc 7260 cgggacaatg ccaccctgca ggccactctg catgcggcta gggacaccct ggccagcgtc 7320 ttcagattgc tgcacagcct ggaccaggct aaggaggagc tggagcgcct cgccgccagc 7380 ctggacgggg ctcggacccc actgctgcag aggatgcaga ccttctcccc ggcgggcagc 7440 aagctgcgtc tagtggaggc cgccgaggcc cacgcacagc agctgggcca gctggcactc 7500 aatctgtcca gcatcatcct ggacgtcaac caggaccgcc tcacccagag ggccatcgag 7560 gcctccaacg cctacagccg catcctgcag gccgtgcagg ctgccgagga tgctgctggc 7620 caggccctgc agcaggcgga ccacacgtgg gcgacggtgg tgcggcaggg cctggtggac 7680 cgagcccagc agctcctggc caacagcact gcactagaag aggccatgct ccaggaacag 7740 cagaggctgg gccttgtgtg ggctgccctc cagggtgcca ggacccagct ccgagatgtc 7800 cgggccaaga aggaccagct ggaggcgcac atccaggcgg cgcaggccat gcttgccatg 7860 gacacagacg agacaagcaa gaagatcgca catgccaagg ctgtggctgc tgaagcccag 7920 gacaccgcca cccgtgtgca gtcccagctg caggccatgc aggagaatgt ggagcggtgg 7980 cagggccagt acgagggcct gcggggccag gacctgggcc aggcagtgct tgacgcaggc 8040 cactcagtgt ccaccctgga gaagacgctg ccccagctgc tggccaagct gagcatcctg 8100 gagaaccgtg gggtgcacaa cgccagcctg gccctgtccg ccagcattgg ccgcgtgcga 8160 gagctcattg cccaggcccg gggggctgcc agtaaggtca aggtgcccat gaagttcaac 8220 gggcgctcag gggtgcagct gcgcacccca cgggatcttg ccgaccttgc tgcctacact 8280 gccctcaagt tctacctgca gggcccagag cctgagcctg ggcagggtac cgaggatcgc 8340 tttgtgatgt acatgggcag ccgccaggcc actggggact acatgggtgt gtctctgcgt 8400 gacaagaagg tgcactgggt gtatcagctg ggtgaggcgg gccctgcagt cctaagcatc 8460 gatgaggaca ttggggagca gttcgcagct gtcagcctgg acaggactct ccagtttggc 8520 cacatgtccg tcacagtgga gagacagatg atccaggaaa ccaagggtga cacggtggcc 8580 cctggggcag aggggctgct caacctgcgg ccagacgact tcgtcttcta cgtcgggggg 8640 taccccagta ccttcacgcc ccctcccctg cttcgcttcc ccggctaccg gggctgcatc 8700 gagatggaca cgctgaatga ggaggtggtc agcctctaca acttcgagag gaccttccag 8760 ctggacacgg ctgtggacag gccttgtgcc cgctccaagt cgaccgggga cccgtggctc 8820 acggacggct cctacctgga cggcaccggc ttcgcccgca tcagcttcga cagtcagatc 8880 agcaccacca agcgcttcga gcaggagctg cggctcgtgt cctacagcgg ggtgctcttc 8940 ttcctgaagc agcagagcca gttcctgtgc ttggccgtgc aagaaggcag cctcgtgctg 9000 ttgtatgact ttggggctgg cctgaaaaag gccgtcccac tgcagccccc accgcccctg 9060 acctcggcca gcaaggcgat ccaggtgttc ctgctggggg gcagccgcaa gcgtgtgctg 9120 gtgcgtgtgg agcgggccac ggtgtacagc gtggagcagg acaatgatct ggagctggcc 9180 gacgcctact acctgggggg cgtgccgccc gaccagctgc ccccgagcct gcgacggctc 9240 ttccccaccg gaggctcagt ccgtggctgc gtcaaaggca tcaaggccct gggcaagtat 9300 gtggacctca agcggctgaa cacgacaggc gtgagcgccg gctgcaccgc cgacctgctg 9360 gtggggcgcg ccatgacttt ccatggccac ggcttccttc gcctggcgct ctcgaacgtg 9420 gcaccgctca ctggcaacgt ctactccggc ttcggcttcc acagcgccca ggacagtgcc 9480 ctgctctact accgggcgtc cccggatggg ctatgccagg tgtccctgca gcagggccgt 9540 gtgagcctac agctcctgag gactgaagtg aaaactcaag cgggcttcgc cgatggtgcc 9600 ccccattacg tcgccttcta cagcaatgcc acgggagtct ggctgtatgt cgatgaccag 9660 ctccagcaga tgaagcccca ccggggacca ccccccgagc tccagccgca gcctgagggg 9720 cccccgaggc tcctcctggg aggcctgcct gagtctggca ccatttacaa cttcagtggc 9780 tgcatcagca acgtcttcgt gcagcggctc ctgggcccac agcgcgtatt tgatctgcag 9840 cagaacctgg gcagcgtcaa tgtgagcacg ggctgtgcac ccgccctgca agcccagacc 9900 ccgggcctgg ggcctagagg actgcaggcc accgcccgga aggcctcccg ccgcagccgt 9960 cagcccgccc ggcatcctgc ctgcatgctg cccccacacc tcaggaccac ccgagactcc 10020 taccagtttg ggggttccct gtccagtcac ctggagtttg tgggcatcct ggcccgacat 10080 aggaactggc ccagtctctc catgcacgtc ctcccgcgaa gctcccgagg cctcctcctc 10140 ttcactgccc gtctgaggcc cggcagcccc tccctggcgc tcttcctgag caatggccac 10200 ttcgttgcac agatggaagg cctcgggact cggctccgcg cccagagccg ccagcgctcc 10260 cggcctggcc gctggcacaa ggtctccgtg cgctgggaga agaaccggat cctgctggtg 10320 acggacgggg cccgggcctg gagccaggag gggccgcacc ggcagcacca gggggcagag 10380 cacccccagc cccacaccct ctttgtgggc ggcctcccgg ccagcagcca cagctccaaa 10440 cttccggtga ccgtcgggtt cagcggctgt gtgaagagac tgaggctgca cgggaggccc 10500 ctgggggccc ccacacggat ggcaggggtc acaccctgca tcttgggccc cctggaggcg 10560 ggcctgttct tcccaggcag cgggggagtt atcactttag acctcccagg agctacactg 10620 cctgatgtgg gcctggaact ggaggtgcgg cccctggcag tcaccggact gatcttccac 10680 ttgggccagg cccggacgcc cccctacttg cagttgcagg tgaccgagaa gcaagtcctg 10740 ctgcgggcgg atgacggagc aggggagttc tccacgtcag tgacccgccc ctcagtgctg 10800 tgtgatggcc agtggcaccg gctagcggtg atgaaaagcg ggaatgtgct ccggctggag 10860 gtggacgcgc agagcaacca caccgtgggc cccttgctgg cggctgcagc tggtgcccca 10920 gcccctctgt acctcggggg cctgcctgag cccatggccg tgcagccctg gccccccgcc 10980 tactgcggct gcatgaggag gctggcggtg aaccggtccc ccgtcgccat gactcgctct 11040 gtggaggtcc acggggcagt gggggccagt ggctgcccag ccgcctagga cacagccaac 11100 cccggcccct ggtcaggccc ctgcagctgc ctcacaccgc cccttgtgct cgcctcatag 11160 gtgtctattt ggactctaag ctctacgggt gacagatctt gtttctgaag atggtttaag 11220 ttatagcttc ttaaacgaaa gaataaaata ctgcaaaatg tttttatatt tggcccttcc 11280 acccattttt aattgtgaga gatttgtcac caatcatcac tggttcctcc ttaaaaatta 11340 aaaagtaact tctgtgtaaa aaaaaaa 11367 59 4255 DNA Homo sapiens misc_feature Incyte ID No 55022490CB1 59 gcggcacaga cccagctctg aattctgggt caaccatgga ccaactgtga cccttcggac 60 aagtcccttc gcctctctgg agctggccta taagagggaa aaggaacccc tgtggagagg 120 gtctatttat cctggcgaag atcgcctgaa gtgatcttct aacaggagtg tttccagagg 180 aggggctggg ccgggagagg tgtggacagc tggggaccgc tctgagcagc gcagccccgg 240 gcgccccaca ccaccacatg gtccggggag gaaggtggga gcaggcacac aagaaggaac 300 ctctgggggt ctgggggccc ctgccatgtg tgaggggtgc ccaggggacc cttggggaca 360 ggaacggggg cacgggtggg tggcggcact ggggagggtg tgagggtatg cccatgccct 420 cctcctcgca gaatgtctgc acaaactctg gtgcatctgt ggggaccacc tgtcactcca 480 agctggatgc agctgtggac ggcacccggt gtggggagaa taagtggtgt ctcagtgggg 540 agtgcgtacc cgtgggcttc cggcccgagg ccgtggatgg tggctggtct ggctggagcg 600 cctggtccat ctgctcacgg agctgtggca tgggcgtaca gagcgccgag cggcagtgca 660 cgcagcctac gcccaaatac aaaggcagat actgtgtggg tgagcgcaag cgcttccgcc 720 tctgcaacct gcaggcctgc cctgctggcc acccctcctt ccgccacgtc cagtgcagcc 780 actttgacgc tatgctctac aagggccagc tgcacacatg ggtgcccgtg gtcaatgacg 840 tgaacccctg cgagctgcac tgccggcccg cgaatgagta ctttgccgag aagctgcggg 900 acgccgtggt cgatggcacc ccctgctacc aggtccgagc cagccgggac ctctgcatca 960 acggcatctg taagaacgtg ggctgtgact tcgagattga ctccggtgct atggaggacc 1020 gctgtggtgt gtgccacggc aacggctcca cctgccacac cgtgagcggg accttcgagg 1080 aggccgaggg cctggggtat gtggatgtgg ggctgatccc agccggcgca cgcgagatcc 1140 gcatccaaga ggttgccgag gctgccaact tcctggcact gcggagtgag gacccggaga 1200 agtacttcct caatggtggc tggaccatcc agtggaacgg ggactaccag gtggcaggga 1260 ccaccttcac atacgcacgc aggggcaact gggagaacct cacgtccccg ggtcccacca 1320 aggagcctgt ctggatccag ctgctgttcc aggagagcaa ccctggggtg cactacgagt 1380 acaccatcca cagggaggca ggtggccacg acgaggtccc gccgcccgtg ttctcctggc 1440 attatgggcc ctggaccaag tgcacagtca cctgcggcag aggtgtgcag aggcagaatg 1500 tgtactgctt ggagcggcag gcagggcccg tggacgagga gcactgtgac cccctgggcc 1560 ggcctgatga ccaacagagg aagtgcagcg agcagccctg ccctgccagg tggtgggcag 1620 gtgagtggca gctgtgctcc agctcctgcg ggcctggggg cctctcccgc cgggccgtgc 1680 tctgcatccg cagcgtgggg ctggatgagc agagcgccct ggagccaccc gcctgtgaac 1740 accttccccg gccccctact gaaacccctt gcaaccgcca tgtaccctgt ccggccacct 1800 gggctgtggg gaactggtct cagtgctcag tgacatgtgg ggagggcact cagcgccgaa 1860 atgtcctctg caccaatgac accggtgtcc cctgtgacga ggcccagcag ccagccagcg 1920 aagtcacctg ctctctgcca ctctgtcggt ggcccctggg cacactgggc cctgaaggct 1980 caggcagcgg ctcctccagc cacgagctct tcaacgaggc tgacttcatc ccgcaccacc 2040 tggccccacg cccttcaccc gcctcatcac ccaagccagg caccatgggc aacgccattg 2100 aggaggaggc tccagagctg gacctgccgg ggcccgtgtt tgtggacgac ttctactacg 2160 actacaattt catcaatttc cacgaggatc tgtcctacgg gccctctgag gagcccgatc 2220 tagacctggc ggggacaggg gaccggacac ccccaccaca cagccgtcct gctgcgccct 2280 ccacgggtag ccctgtgcct gccacagagc ctcctgcagc caaggaggag ggggtactgg 2340 gaccttggtc cccgagccct tggcctagcc aggccggccg ctccccaccc ccaccctcag 2400 agcagacccc tgggaaccct ttgatcaatt tcctgcctga ggaagacacc cccatagggg 2460 ccccagatct tgggctcccc agcctgtcct ggcccagggt ttccactgat ggcctgcaga 2520 cacctgccac ccctgagagc caaaatgatt tcccagttgg caaggacagc cagagccagc 2580 tgccccctcc atggcgggac aggaccaatg aggttttcaa ggatgatgag gaacccaagg 2640 gccgcggagc accccacctg cccccgagac ccagctccac gctgccccct ttgtcccctg 2700 ttggcagcac ccactcctct cctagtcctg acgtggcgga gctgtggaca ggaggcacag 2760 tggcctggga gccagctctg gagggtggcc tggggcctgt ggacagtgaa ctgtggccca 2820 ctgttggggt ggcttctctc cttcctcctc ccatagcccc tctgccagag atgaaggtca 2880 gggacagttc cctggagccg gggactccct ccttcccaac cccaggacca ggctcatggg 2940 acctgcagac tgtggcagtg tgggggacct tcctccccac aaccctgact ggcctcgggc 3000 acatgcctga gcctgccctg aacccaggac ccaagggtca gcctgagtcc ctcagccctg 3060 aggtgcccct gagctctagg ctgctgtcca caccagcttg ggacagcccc gccaacagcc 3120 acagagtccc tgagacccag ccgctggctc ccagcctggc tgaagcgggg ccccccgcgg 3180 acccgttggt tgtcaggaac gccagctggc aagcgggaaa ctggagcgag tgctctacca 3240 cctgtggcct gggtgcggtc tggaggccgg tgcgctgtag ctccggccgg gatgaggact 3300 gcgcccccgc tggccggccc cagcctgccc gccgctgcca cctgcggccc tgtgccacct 3360 ggcactcagg caactggagt aagtgctccc gcagctgcgg cggaggttcc tcagtgcggg 3420 acgtgcagtg tgtggacaca cgggacctcc ggccactgcg gcccttccat tgtcagcccg 3480 ggcctgccaa gccgcctgcg caccggccct gcggggccca gccctgcctc agctggtaca 3540 catcttcctg gagggagtgc tccgaggcct gtggcggtgg tgagcagcag cgtctagtga 3600 cctgcccgga gccaggcctc tgcgaggagg cgctgagacc caacaccacc cggccctgca 3660 acacccaccc ctgcacgcag tgggtggtgg ggccctgggg ccagtgctca gccccctgtg 3720 gtggtggtgt ccagcggcgc ctggtcaagt gtgtcaacac ccagacaggg ctgcccgagg 3780 aagacagtga ccagtgtggc cacgaggcct ggcctgagag ctcccggccg tgtggcaccg 3840 aggattgtga gcccgtcgag cctccccgct gtgagcggga ccgcctgtcc ttcgggttct 3900 gcgagacgct gcgcctactg ggccgctgcc agctgcccac catccgcacc cagtgctgcc 3960 gctcgtgctc tccgcccagc cacggcgccc cctcccgagg ccatcagcgg gttgcccgcc 4020 gctgactgtg ccaggatgca cagaccgacc gacagacctc agtgcccacc acgggctgtg 4080 gcggagctcc cgccccctgc gccctaatgg tgctaacccc ctctcactac ccagcagcag 4140 gctggggacc tcctccccct caaaaaaggt atttttttat tctaacagtt tgtgtaacat 4200 ttattatgat tttacataaa tgagcatcta ccattccaaa aaaaaaaaaa aaaaa 4255 60 3438 DNA Homo sapiens misc_feature Incyte ID No 6755002CB1 60 tgtgcgccgg gagggccggc gccctcttcc gaatgtcctg cggccccagc ctctcctcac 60 gctcgcgcag tctccgccgc agtctcagct gcagctgcag gactgagccg tgcacccgga 120 ggagaccccc ggaggaggcg acaaacttcg cagtgccgcg acccaacccc agccctgggt 180 agcctgcagc atggcccagc tgttcctgcc cctgctggca gccctggtcc tggcccaggc 240 tcctgcagct ttagcagatg ttctggaagg agacagctca gaggaccgcg cttttcgcgt 300 gcgcatcgcg ggcgacgcgc cactgcaggg cgtgctcggc ggcgccctca ccatcccttg 360 ccacgtccac tacctgcggc caccgccgag ccgccgggct gtgctgggct ctccgcgggt 420 caagtggact ttcctgtccc ggggccggga ggcagaggtg ctggtggcgc ggggagtgcg 480 cgtcaaggtg aacgaggcct accggttccg cgtggcactg cctgcgtacc cagcgtcgct 540 caccgacgtc tccctggcgc tgagcgagct gcgccccaac gactcaggta tctatcgctg 600 tgaggtccag cacggcatcg atgacagcag cgacgctgtg gaggtcaagg tcaaaggggt 660 cgtctttctc taccgagagg gctctgcccg ctatgctttc tccttttctg gggcccagga 720 ggcctgtgcc cgcattggag cccacatcgc caccccggag cagctctatg ccgcctacct 780 tgggggctat gagcaatgtg atgctggctg gctgtcggat cagaccgtga ggtatcccat 840 ccagacccca cgagaggcct gttacggaga catggatggc ttccccgggg tccggaacta 900 tggtgtggtg gacccggatg acctctatga tgtgtactgt tatgctgaag acctaaatgg 960 agaactgttc ctgggtgacc ctccagagaa gctgacattg gaggaagcac gggcgtactg 1020 ccaggagcgg ggtgcagaga ttgccaccac gggccaactg tatgcagcct gggatggtgg 1080 cctggaccac tgcagcccag ggtggctagc tgatggcagt gtgcgctacc ccatcgtcac 1140 acccagccag cgctgtggtg ggggcttgcc tggtgtcaag actctcttcc tcttccccaa 1200 ccagactggc ttccccaata agcacagccg cttcaacgtc tactgcttcc gagactcggc 1260 ccagccttct gccatccctg aggcctccaa cccagcctcc aacccagcct ctgatggact 1320 agaggctatc gtcacagtga cagagaccct ggaggaactg cagctgcctc aggaagccac 1380 agagagtgaa tcccgtgggg ccatctactc catccccatc atggaggacg gaggaggtgg 1440 aagctccact ccagaagacc cagcagaggc ccctaggacg ctcctagaat ttgaaacaca 1500 atccatggta ccgcccacgg ggttctcaga agaggaaggt aaggcattgg aggaagaaga 1560 gaaatatgaa gatgaagaag agaaagagga ggaagaagaa gaggaggagg tggaggatga 1620 ggctctgtgg gcatggccca gcgagctcag cagcccgggc cctgaggcct ctctccccac 1680 tgagccagca gcccaggaga agtcactctc ccaggcgcca gcaagggcag tcctgcagcc 1740 tggtgcatca ccacttcctg atggagagtc agaagcttcc aggcctccaa gggtccatgg 1800 accacctact gagactctgc ccactcccag ggagaggaac ctagcatccc catcaccttc 1860 cactctggtt gaggcaagag aggtggggga ggcaactggt ggtcctgagc tatctggggt 1920 ccctcgagga gagagcgagg agacaggaag ctccgagggt gccccttccc tgcttccagc 1980 cacacgggcc cctgagggta ccagggagct ggaggccccc tctgaagata attctggaag 2040 aactgcccca gcagggacct cagtgcaggc ccagccagtg ctgcccactg acagcgccag 2100 ccgaggtgga gtggccgtgg tccccgcatc aggtgactgt gtccccagcc cctgccacaa 2160 tggtgggaca tgcttggagg aggaggaagg ggtccgctgc ctatgtctgc ctggctatgg 2220 gggggacctg tgcgatgttg gcctccgctt ctgcaacccc ggctgggacg ccttccaggg 2280 cgcctgctac aagcactttt ccacacgaag gagctgggag gaggcagaga cccagtgccg 2340 gatgtacggc gcgcatctgg ccagcatcag cacacccgag gaacaggact tcatcaacaa 2400 ccggtaccgg gagtaccagt ggatcggact caacgacagg accatcgaag gcgacttctt 2460 gtggtcggat ggcgtccccc tgctctatga gaactggaac cctgggcagc ctgacagcta 2520 cttcctgtct ggagagaact gcgtggtcat ggtgtggcat gatcagggac aatggagtga 2580 cgtgccctgc aactaccacc tgtcctacac ctgcaagatg gggctggtgt cctgtgggcc 2640 gccaccggag ctgcccctgg ctcaagtgtt cggccgccca cggctgcgct atgaggtgga 2700 cactgtgctt cgctaccggt gccgggaagg actggcccag cgcaatctgc cgctgatccg 2760 atgccaagag aacggtcgtt gggaggcccc ccagatctcc tgtgtgccca gaagacctgc 2820 ccgagctctg cacccagagg aggacccaga aggacgtcag gggaggctac tgggacgctg 2880 gaaggcgctg ttgatccccc cttccagccc catgccaggt ccctaggggg caaggccttg 2940 aacactgccg gccacagcac tgccctgtca cccaaatttt ccctcacacc ctgcgctccc 3000 gccaccacag gaagtgacaa catgacgagg ggtggtgctg gagtccaggt gacagttcct 3060 gaaggggctt ctgggaaata cctaggaggc tccagcccag cccaggccct ctccccctac 3120 cctgggcacc agatcttcca tcagggccgg agtaaatccc taagtgcctc aactgccctc 3180 tccctggcag ccatcttgtc ccctctattc ctctagggag cactgtgccc actctttctg 3240 ggttttccaa gggaatgggc ttgcaggatg gagtgtctgt aaaatcaaca ggaaataaaa 3300 ctgtgtatga gcccagggta gggggagagg gcctgggctg ggctggagcc tcctaggtat 3360 ttcccagaag ccccttcagg aactgtcacc tggactccag caccacccct cgtcatgttg 3420 tcacttcctg tggtggcg 3438 61 1683 DNA Homo sapiens misc_feature Incyte ID No 7350907CB1 61 ggcgtgggga cacgagccag gcgccgccgc cggagccagc ggagccgggg ccagagccgg 60 agcgcgtccg cgtccacgca gccgccggcc ggccagcacc cagggccctg catgccaggt 120 cgttggaggt ggcagcgaga catgcacccg gcccggaagc tcctcagcct cctcttcctc 180 atcctgatgg gcactgaact cactcaagtg ctgcccacca accctgagga gagctggcag 240 gtgtacagct ctgcccagga cagcgagggc aggtgtatct gcacagtggt cgccccacag 300 cagaccatgt gttcacggga tgcccgcaca aaacagctga ggcagctact ggagaaggtg 360 cagaacatgt ctcaatccat agaggtcttg gacaggcgga cccagagaga cttgcagtac 420 gtggagaaga tggagaacca aatgaaagga ctggagtcca agttcaaaca ggtggaggag 480 agtcataagc aacacctggc caggcagttt aaggcgataa aagcgaaaat ggatgaactt 540 aggcctttga tacctgtgtt ggaagagtac aaggccgatg ccaaattggt attgcagttt 600 aaagaggagg tccagaatct gacgtcagtg cttaacgagc tgcaagagga aattggcgcc 660 tatgactacg atgaacttca gagcagagtg tccaatcttg aagaaaggct ccgtgcatgc 720 atgcaaaaac tagcttgcgg gaagttgacg ggcatcagtg accccgtgac tgtcaagacc 780 tccggctcga ggttcggatc ctggatgaca gaccctctcg cccctgaagg cgataaccgg 840 gtgtggtaca tggacggcta tcacaacaac cgcttcgtac gtgagtacaa gtccatggtt 900 gacttcatga acacggacaa tttcacctcc caccgtctcc cccacccctg gtcgggcacg 960 gggcaggtgg tctacaacgg ttctatctac ttcaacaagt tccagagcca catcatcatc 1020 aggtttgacc tgaagacaga gaccatcctc aagacccgca gcctggacta tgccggttac 1080 aacaacatgt accactacgc ctggggtggc cactcggaca tcgacctcat ggtggacgag 1140 agcgggctgt gggccgtgta cgccaccaac cagaacgctg gcaacatcgt ggtcagtagg 1200 ctggaccccg tgtccctgca gaccctgcag acctggaaca cgagctaccc caagcgcagc 1260 gccggggagg ccttcatcat ctgcggcacg ctgtacgtca ccaacggcta ctcagggggt 1320 accaaggtcc actatgcata ccagaccaat gcctccacct atgaatacat cgacatccca 1380 ttccagaaca aatactccca catctccatg ctggactaca accccaagga ccgggccctg 1440 tatgcctgga acaacggcca ccagatcctc tacaacgtga ccctcttcca cgtcatccgc 1500 tccgacgagt tgtagctccc tcctcctgga agccaagggc ccacgtcctc accacaaagg 1560 gactcctgtg aaactgctgc caaaaagata ccaataacac taacaatacc gatcttgaaa 1620 aatcatcagc agtgcggatt ctgacatcga gggatggcat tacctccgtg tttctccctt 1680 tcg 1683 62 6886 DNA Homo sapiens misc_feature Incyte ID No 7474411CB1 62 cggggcacag cgggagcccg tgcaggcggg cgcggggcgg ctgggcggcg gtggcggccg 60 tccatgcggc ggcgctcggg gctgcccggc gccgggaacc acgcgggggc gaggcgaggc 120 gaggcggccg ccggtcgctc cgggacgcgg accgccagga cttgaacgca actcccaatt 180 gcagaaaatt ggcaacgtct ctgaagagcc cttgcttttg cctggacccc cagcatcatg 240 gtttcccatt tcatggggtc tctcagtgtc ctgtgtttcc ttctgctgct tggattccag 300 ttcgtctgcc cacagccctc cactcaacac aggaaggtcc cgcagcggat ggcggcggag 360 ggcgcccccg aggacgacgg cggcggcggc gccccgggag tgtggggcgc ctggggcccc 420 tggtcggcct gctcgcgtag ctgcagcggc ggcgtgatgg agcagacgcg gccctgcctg 480 ccccgctcct accgcctgcg cggcggccag cggcctggcg cccctgcgcg cgccttcgcg 540 gaccacgtgg tgtcggcggt gcgcacgtcg gtgccactgc accggagccg cgacgagacg 600 ccagcgctgg ccggtacgga cgccagccgc cagggcccca cggtgctgcg aggcagccgg 660 cacccacagc cccagggcct cgaagtcact ggggacagaa ggagcaggac ccgtggtacc 720 attggccctg gcaagtatgg ctatggtaag gccccatata tcttaccact gcagacagac 780 actgcacaca cgccacagag gctccggaga cagaagctct catcccgcca ttccaggtcc 840 cagggagcat cttctgctag gcatggctac agttcaccag cccaccaggt cccccaacat 900 gggcctttgt accaaagtga cagtggccct cgctctggac tgcaggctgc ggaggccccc 960 atctaccagc tacctttgac ccatgatcaa ggctaccctg cagcttcaag tctctttcac 1020 agcccagaaa caagcaacaa ccacggtgtg gggacccatg gggcaactca gagcttctct 1080 cagcctgccc gatctacagc aatctcatgc atcggggcct atcggcagta caagctgtgc 1140 aacaccaacg tatgtccaga aagcagtaga agtatccggg aggtacagtg tgcatcctac 1200 aacaacaagc cattcatggg ccggttttat gagtgggaac catttgcaga agtaaaaggc 1260 aatcgcaaat gtgagttgaa ctgccaggca atgggctacc gcttctatgt acggcaagct 1320 gagaaagtca tcgatggcac cccctgtgac cagaacggca cggccatctg tgtgtctggg 1380 cagtgcaaga gcattggctg tgatgactac ttaggctccg acaaagtcgt ggacaaatgt 1440 ggggtgtgtg gaggagacaa cacgggctgt caggttgtgt cgggcgtgtt taagcatgcc 1500 ctcaccagcc tgggctacca ccgcgtcgtg gagattcccg agggagccac gaaaatcaac 1560 atcacggaga tgtacaagag caacaactat ttggccctga gaagtcgttc tggacgctcc 1620 atcatcaatg ggaactgggc aattgatcga ccaggaaaat acgagggcgg agggaccatg 1680 ttcacctaca agcgtccaaa tgagatttcg agcactgccg gagagtcctt tttggcggaa 1740 ggtcccacca acgagatctt ggatgtctac atgatacacc agcagccaaa cccaggcgtg 1800 cactacgagt acgtgatcat ggggaccaac gccatcagcc cccaggtgcc accccacagg 1860 agaccagggg aacccttcaa tggccagatg gtgacagaag gcaggagcca ggaggaggga 1920 gaacagaaag ggaggaacga ggagaaggaa gacttgcgtg gggaggcccc tgagatgttc 1980 acctcagaat cggcacagac cttcccagtc aggcatccag acagattttc tccccatcga 2040 ccggacaact tggtgccacc agcaccgcag cccccacggc gcagccggga tcacaactgg 2100 aagcagcttg ggacaacaga atgttccacg acctgtggga aaggatcgca gtaccctatt 2160 ttccgctgtg tgcacagaag cactcatgaa gaggctcctg agagttactg tgactccagc 2220 atgaagccga cccccgagga ggagccctgc aacatcttcc cttgcccagc cttctgggac 2280 atcggggagt ggtctgagtg cagcaagacc tgtggcctgg gcatgcagca ccgccaggtt 2340 ctgtgccgcc aggtgtacgc caaccgcagc ctgacggtgc agccctaccg ctgccagcac 2400 ctggagaaac ctgagaccac cagcacctgc caactcaaga tctgcagcga gtggcagatc 2460 cggaccgact ggacctcgtg ctcggtgccc tgtggcgtgg gacagaggac ccgtgatgtg 2520 aagtgtgtga gcaacattgg ggatgtggtt gacgatgagg aatgcaacat gaagctccgg 2580 ccgaatgaca ttgagaactg cgacatggga ccctgtgcca agagctggtt cctcaccgag 2640 tggagcgaaa ggtgctcagc ggagtgtggg gccggagtgc ggacacgctc ggtggtgtgc 2700 atgaccaacc atgtcagcag cctgcccctg gagggctgtg ggaacaaccg gccggcagag 2760 gccaccccat gtgacaacgg accctgcacg ggcaaggtgg agtggtttgc cgggagctgg 2820 agtcagtgtt ccatcgagtg tgggagcggg acgcaacaga gggaggtgat ttgtgttaga 2880 aagaatgcag acacctttga agtgttggac ccctctgaat gttctttcct ggagaaaccc 2940 cccagccagc aatcctgcca cctcaagcct tgcggagcca aatggtttag caccgaatgg 3000 agcatgtgtt ccaagagctg ccagggtggc tttcgggtcc gggaagtgcg gtgtctgtct 3060 gatgacatga ctctaagtaa cctctgtgac cctcagttga aaccagaaga gagagaatct 3120 tgtaaccctc aggactgtgt ccctgaagtt gatgaaaact gcaaggacaa gtactacaac 3180 tgcaacgtgg tggtccaggc aagactctgt gtctacaact actacaagac cgcctgctgt 3240 gcctcctgca cccgtgtggc caacaggcag acgggcttcc tggggagcag ataacactcc 3300 tgcaccccca tcagtagggc agcatcactg ccttcccggg ggcttcagca gtgcgcctgg 3360 ctggctgctg ctccaccacg ggccccctgg cccaggcgct gccaaccaac ttagtcacca 3420 cccctgcctc cggtgaatgc accccgtggt acccaggggc tttttacaca agatgtttga 3480 aagccacagt cagtccttta agcatcacca tgtactgatg atcccctcct tggacctggc 3540 atctgctaat ggtgcccttt gaaagtcaag cagtgggaag tacatggagc tctcagccct 3600 gctcccatct ggcaccttca agtcagcaga tgggccactg actgagcact gccccgtccc 3660 tggtgctact ggtctttcta aacttagcac cctggagagt ccaaggaggc agcgccccca 3720 acccagcgcc ccactaagcc ttgctgacac gcgtgcatcc ctctgtgacc tcagcccaga 3780 tgtgcctgtt ttcattctca aagacattag actgttttcc tgccctatga cacagatagc 3840 tcacatgaat attgtgcttt atttagcagg tgtactcaca gatactagct ccttagcagc 3900 tcacaacatc ccagaatggg aggcaggggg tgactcatta tccccatttt actgacaggg 3960 aaactgaggc tcaacttaag taattgacct gccaggtata ttcacccatc cagtggaaga 4020 gctgagtccc cgccccagtc atctaccagt atccagcctg gggcctgtac ttagatgtga 4080 aaggtgctgc ttcatttctg accaagagac tgagaagttt cccagaatgc aaacaaagcc 4140 caggcccctg aaatctttcc ggtcaagcct ttatcccagc actcagttgt tttggatgtc 4200 tgttcctact tgcccttacc cccaaagtta cagatcctag ttacaggact ctgccagctt 4260 tgttaaactg tccgtgagac aagaaagcca ttggggaaac caggtgattg cctgaaattc 4320 ttactccgtt ccaagtgctg ttcctcccag gaaatcaaag gccagggtcc ttatggccgt 4380 ggagccttcc cgaccacaga gccaacttgt gaagcacaca gctctgcagc ctgggctctg 4440 ccctgcctca gccgcctccc ccacgctctt caccacgttc ctggagagtc cggccaacct 4500 gtcccagcca aaacactgct gtattagaaa aagtctcttt ctggtctttc tggttttgtt 4560 tatgaatttc cctctgtggc cacaaattcc tcccctcccc catgactcac agtccatatg 4620 gcccaccccc agacttgagc accaagctct gcattaatgc agttggcctg cgacaaggag 4680 ctgtggaccc ttccccatct cttccaattc actttcccca actatccagt tccagaggcc 4740 gcaggcctgg aaggatgcag tgcatattga aaggtggacc ctctgaaaac agttaagagg 4800 aatatatgta tgttttgccc attaagaaaa aatggcaagc taaacaaatg ttaaacttac 4860 agaaaatttg tcttatggtc ctgagcatat ttccctttta gagcaagcct ggattcttag 4920 caaagtgttt cccccatttg ctcttttagc tgacaaatct gccactgtga tgatggtttg 4980 cagcttttgg aagcagtatg gcaacctggc ctgacatgct ctttaggctt ccactaacct 5040 ggggctttca gaaattctat ttggcctttc tgtgggtagc tttccagctt ctcttctagg 5100 gagccccagg catcatttcc caaaagcatc cccatctcct gattctcttg gaactcctac 5160 agataagcat cctggcagag gcccaggctc ccaaaccgac aaagtgaaaa gagaccagag 5220 aggccaagca tattgactgg tgctgttcag ggcctgctct tttccactca ccacttgttt 5280 tgctgcttgt cacgaggaga gttgttcctg tatgtggctg ctctcagatc tttccaagca 5340 agccagtcat ttgaagaggt tttcttttca tgctggaggg caggctaaga tcaatgagtg 5400 gaagagagaa aggctgtttt agctcaagtt aaaggaacac cttctagcca tcaaagccgc 5460 ccaacagagg caagggccac cacacatgag agagcgctct gtccttaaag ggaattctct 5520 gttgagtggg aggtgaacac cctggttctt ccaactcagg aattctcgtg gctgggctgg 5580 gtcagtgatg gctttgtctc tttatgtcta aagtgcccta tggctgctga aggttaccta 5640 accattcttt aaaaggagaa tgaccctcca tgggaatggc cagcctgcca actgtgcaat 5700 tgaagaagac ccgatggatc aaccccatgt ctcccttggg gagaaagtgc ataaaccagg 5760 ggtctctttt tttttttttt caacaaacca ttgagctgtt cttggagttc atctctggag 5820 aggttataca ttattagaag tttgattatt attatagttt gatcaattta tttgtcttag 5880 agatccaatt tttactaatt ccctagtttt ttatttcagc atctgaatgt ctttctccct 5940 agcacagtgc atacaatcag ggccttgggt atttccagtg ataactttcc ttggagagga 6000 tctaagaaaa gcccagattt cggtagccat ctccctccaa atatgtctct ttctgctttc 6060 ttagtgccca ttatttcccc ttctcctttc ttctgtcact gccatctcct tcttggtctt 6120 cccattgttc tttaactggc tgtaatgtgg aattgatatt tacattttga tacggttttt 6180 ttcttggcct gtgtacggga ttgcctcatt tcctgctctg aattttaaaa ttagatatta 6240 aagctgtcat atggtttcct cacaaaagtc aacaaagtcc aaacaaaaat agtttgccgt 6300 tttactttca tccattgaaa aaggaaattg tgcctcttgc agcctaggca aaggacattt 6360 agtactatcg attctttcca ccctcacgat gacttgcggt tctctctgta gaaaagggat 6420 ggcctaagaa atacaactaa aaaaacaaac aaaaacacca aaagaaaaaa aaaagccatt 6480 taaagccagc cactagaggg agtcagttca gttccgtaaa ggtatgctca gtgcccgctg 6540 cctgcaagct gttggggacc ccagggaggg caaggcagcc tgtccccgcc cccagggaac 6600 tagaacatga caagaattct ccgcactgtg cctacctgtc cctttaactt acctctctgg 6660 cccagagttc ttggagggta aaccttctat ttctcttatg tactcatcta cttattctca 6720 aagtatttag cattcaacac tcttttggct ttaaaaagaa tgggccttac aaagggacag 6780 aacacgagaa gacacgagct aggtgtattt catcaagtat gtggcacgag aaatccagat 6840 attaccagga cctgtctaac caatgtgggg ttactttcat cggatg 6886 63 4457 DNA Homo sapiens misc_feature Incyte ID No 4755911CB1 63 atggggaagg agcaggagct ggtgcaggcg gtgaaggcgg aggacgtagg gaccgcgcag 60 aggctgctgc agaggccgcg gcccgggaag gccacgcgta gcctccctgg gggccgccgg 120 agatggatgg atgggcgtgt ggaccagccg cgtgtgcggc tgcgcacgta tagccgtgtc 180 agtgtgtcag ggcacctgtg cgggcacgga cagggctctg cagagctcct gggttccacc 240 aagaagatca atgtcaactt ccaggacccg gatggggttg ggtttggggt caagggtcag 300 ctcccagcat cccctcgccc cccaggcatg cggccgctgc actatgcggc ctggcagggc 360 cggaaggagc ccatgaagct ggtgctgaag gcgggctcgg ccgtgaacat cccgtctgat 420 gagggccaca tccccctgca cctggcggcc cagcatggtc actatgatgt gtctgagatg 480 ctgctacagc accagtctaa cccgtgcatg gtggacaact cggggaagac gcccctggac 540 ctggcctgcg agttcggccg cgttggggtg gtccagctgc tcctcagcag caatatgtgt 600 gcggcgctgc tggagccccg gccgggagac gccaccgacc ccaacggcac cagccctttg 660 cacctcgcag ctaaaaacgg ccacatcgac atcatcaggc tcctcctcca agccggcatc 720 gacattaacc gccagaccaa gtccggcacg gccctgcacg aggctgcgct ctgcggaaag 780 acagaggtgg tgcggctgct gctggatagc gggatcaatg cccacgtgag gaacacctac 840 agccagacag ccctggacat cgtgcaccag ttcaccacgt cccaggccag cagggagatc 900 aagcagctgt tgcgagaggc ctcagcggcc ctgcaggtcc gggcgaccaa ggattattgc 960 aacaattacg acctgaccag cctcaacgtg aaggcagggg acatcatcac agtcctcgag 1020 cagcatccgg atggccggtg gaagggctgc atccatgaca accggacggg caatgaccgg 1080 gtgggctact tcccgtcctc cctgggcgag gccattgtca agcgagcagg ttcccgagca 1140 ggcactgaac caagcctgcc ccagggaagc agctcatcgg gaccctctgc acccccagag 1200 gagatctggg tgctgaggaa gccttttgca ggtggggacc gaagcggcag cattagcggc 1260 atggctggcg gccggggcag cgggggtcac gccctacacg cgggctctga aggcgtcaag 1320 ctcctggcaa cggtgctttc ccagaagtcc gtctctgagt ccggcccggg ggacagcccc 1380 gccaagcctc cggaaggctc tgcaggtgtg gcccggtccc agcctccagt ggcccacgcc 1440 gggcaggtct atggggagca gccgcccaag aagctggagc cagcatcgga gggcaagagc 1500 tctgaggccg tgagccagtg gctcaccgcg ttccagctgc agctctacgc ccccaacttc 1560 atcagcgccg gctacgacct gcccaccatc agccgcatga ctcccgagga cctcacggcc 1620 attggtgtca ccaagccggg ccaccggaag aagatcgcgg cagagatcag cggcctaagc 1680 atccctgact ggctgcctga gcacaaaccc gctaacctgg ccgtgtggct gtccatgatc 1740 ggcctggccc agtactacaa ggtgttggtg gacaatggct acgagaacat tgatttcatc 1800 accgacatca cctgggagga cctgcaggag atcggcatca ccaagctggg gcaccagaag 1860 aagctgatgc tcgctgtgag gaagctggca gagctgcaga aggctgaata cgccaagtat 1920 gaggggggcc ccctgcgccg gaaggcgccc cagtctcttg aagtgatggc catcgagtcg 1980 ccgcccccgc ctgagcccac accggccgac tgccagtccc ctaaaatgac caccttccag 2040 gacagcgagc tcagtgacga gctgcaggct gccatgactg gcccggctga ggtggggccc 2100 accactgaga agccctccag ccacctgcca cccaccccga gggccaccac gcggcaggac 2160 tccagcctgg gtggtcgggc acggcacatg agcagctcgc aggagctgct gggagatggg 2220 ccccctgggc ccagcagccc catgtctcga agccaggagt acctcctgga tgagggcccc 2280 gcccccggca ccccgcccag ggaggcccgg cccggccgcc acggccacag catcaagagg 2340 gccagcgtgc cccccgtgcc tggcaagcca cggcaggtcc tcccaccagg cactagccac 2400 ttcacgcccc cccagacgcc caccaaaacc cgaccaggct ctccccaggc ccttggggga 2460 cctcatggtc cagccccagc tacggccaag gtgaagccca ccccgcagct gctgccgccg 2520 acagagcgcc ccatgtcacc ccgctccctg cctcagtcac cgacgcaccg cggctttgcc 2580 tacgtgctgc cccagcccgt ggagggcgag gtggggccgg ctgccccggg gcctgcgccc 2640 ccacccgtgc cgacggctgt gcccacactg tgcctgcccc ctgaggccga cgcggagccg 2700 gggcggccca agaagcgggc ccacagcctg aatcgctatg cggcgtccga cagcgagccg 2760 gagcgggacg agctgctggt gcctgcggct gccggcccct atgccacggt ccagcggcgc 2820 gtgggccgca gccactcagt gagggcgccc gcaggtgccg acaagaacgt caaccgcagc 2880 cagtcctttg ccgtgcggcc ccgaaagaag gggcccccgc cgcccccacc caagcgctcc 2940 agctcggccc tggctagtgc caacctggcg gatgagccgg tgcctgacgc cgagcctgag 3000 gatggcctgc tgggggtccg ggcacagtgc cggcgggcca gtgacctggc cggcagcgtg 3060 gacacgggta gtgccggcag tgtgaagagc atcgcggcca tgctggagct gtcctccatt 3120 gggggtgggg gccgggctgc ccgcaggcct cctgagggcc accccactcc ccgccctgcc 3180 agcccagagc cgggccgggt ggccaccgtg ctggcctcag tgaaacacaa agaggccatc 3240 gggcctggcg gggaggtggt gaaccggcgc cgcacgctca gcgggccagt caccggactt 3300 ctggccactg cccgccgggg gcctggggag tcggcagacc caggcccctt tgtggaggat 3360 ggcactggcc ggcagcggcc tcggggtccc tccaagggcg aggcgggtgt cgaaggcccg 3420 cccttggcca aggtggaagc cagcgccaca ctcaagaggc gcatccgggc caagcagaac 3480 cagcaggaga acgtcaagtt catcctgacc gagtctgaca cggtcaagcg caggcccaag 3540 gccaaggagc gggaggccgg gcctgagcca ccaccgccac tgtccgtgta ccataatggc 3600 actggcaccg tgcgccgccg accggcctcg gagcaggctg ggcctccgga gctgcctcca 3660 ccgcccccgc ctgccgaacc cccgcccacc gacctggcgc acctaccccc attgcccccg 3720 cccgagggcg aagcccggaa gccggccaag ccgcctgtct ctcccaagcc cgtcctgacg 3780 cagcctgtgc ccaagctcca gggctcgccc acacccacct ccaagaaggt gccgctgcca 3840 ggccctggca gcccagaggt gaagcgcgcc cacggcacgc caccgcccgt gtctcccaag 3900 ccgccgccgc cgcccacagc gcccaagccc gtcaaggcgg tcgcggggct gccttcgggc 3960 agcgccggcc cttcacccgc accctcgccc gcgcgacagc cgcccgccgc cctcgccaag 4020 ccgcccggta cgccgccctc gctgggcgcc agccccgcca agcccccgtc ccccggcgcg 4080 cccgcgctgc acgtgcccgc caagcccccg cgagccgccg ccgccgccgc cgccgccgcc 4140 gccgcgcccc ccgccccgcc cgaaggcgcc tcgccagggg acagcgcccg gcagaaactg 4200 gaggagacaa gcgcgtgcct ggccgcggcg ctgcaggcgg tggaggagaa gatccggcag 4260 gaggacgcgc agggcccgcg cgactcggcg gcggaaaaga gcactggcag catcctggac 4320 gacatcggca gcatgttcga cgacctggcc gaccagctgg atgccatgct ggagtgaacg 4380 ccgcctggcc gggccctccc gcgccgcccg ggccctcccc gcacactgac ctatacctca 4440 ggatgggcgc gtctggg 4457 64 1943 DNA Homo sapiens misc_feature Incyte ID No 379766CB1 64 ggcggcggcg actgcggcgc cgcgggctgg aggccggcgt cggggaaggt cctggtgccg 60 gattccgcac gaggtgttga cgggcggctt ctgccaactt ctccccagcg cgcgccgagc 120 ccgcgcggcc ccggggctgc acgtcccaga tacttctgcg gcgcaaggct acaactgaga 180 cccggaggag actagacccc atggcttcct ggacgagccc ctggtgggtg ctgataggga 240 tggtcttcat gcactctccc ctcccgcaga ccacagctga gaaatctcct ggagcctatt 300 tccttcccga gtttgcactt tctcctcagg gaagttttct ggaagacaca acaggggagc 360 agttcctcac ttatcgctat gatgaccaga cctcaagaaa cactcgttca gatgaagaca 420 aagatggcaa ctgggatgct tggggcgact ggagtgactg ctcccggacc tgtgggggag 480 gagcatcata ttctctgcgg agatgtttga ctggaaggaa ttgtgaaggg cagaacattc 540 ggtacaagac atgcagcaat catgactgcc ctccagatgc agaagatttc agagcccagc 600 agtgctcagc ctacaatgat gtccagtatc aggggcgtta ctatgaatgg cttccacgat 660 ataatgatcc tgctgccccg tgtgcactca agtgtcatgc acaaggacaa aacttggtgg 720 tggagctggc acctaaggta ctggatggaa ctcgttgcaa cacggactcc ttggacatgt 780 gtatcagtgg catctgtcag gcagtgggct gcgatcggca actgggaagc aatgccaagg 840 aggacaactg tggagtctgt gccggcgatg gctccacctg caggcttgta cggggacaat 900 caaagtcaca cgtttctcct gaaaaaagag aagaaaatgt aattgctgtt cctttgggaa 960 gtcgaagtgt gagaattaca gtgaaaggac ctgcttatcc tgtggcctgg gctttagcca 1020 tctcttccaa taccaattgc ctagtgttat tatgtaaagc taatttggcc agctctggtc 1080 cttattttgc actcattcca gtaaacccaa ccactatggc acttaatact gccattgtca 1140 gtcagtctgc agtattgatt gactgccttt agagctctct tttgtgtgcc ttgtccactc 1200 ttcagtcact gagagagaga ccaaagaaca gagaccaaca ccctgtactt ggcatggcca 1260 ttagtcactg gagttagatg aatcacactg tatctaagag agaagactca gggagaaggg 1320 cttagcacaa cacagaaaag ctttaaacac tcttaccttt gactggaatt acacacacac 1380 acacacacac acacacatac acacacacac atacacacac acacactaag gctttcccac 1440 aaagccatga tgcatcctta aaaataacac acagctctga aaagtgaatg tcgggggtga 1500 agagagccct cctacactcc ttttcctagt gatgacaagg ttgtgggggc atggctgact 1560 gtgaggagca gaagatgaga gggagatatc attttacttc tttgtactgc aataataaaa 1620 agaacagata gaatggaagg aagaggccag gggcagtggc tcatacctgt aatcccagca 1680 ctttgggagg ctgaggcagg tggatcacct gaggtcagga gttcgagacc agcctggcca 1740 acatggagaa actccgtctc tattaagaat acaaaaatta gccaggcgtg gtggtgggca 1800 cctataatca cagctacccg ggaggttgag gcaggagaat cacttgaact tgtggggcgg 1860 aggtcgcagt gagccaagat tgcaccactt cactccagcc tgggcgagaa agtgaactct 1920 gtctcaaaaa aaaaaaaaaa aaa 1943 65 4111 DNA Homo sapiens misc_feature Incyte ID No 553744CB1 65 gcgatctagg gcggggcaac tgtacagatg aacaatctgg aatattaaat tcaactcaca 60 gagtggcaac aaacaatact ggagagctgg gcatgaatcc tggaaagcct tgtatggccc 120 tgcaagggaa gccatgttct gaaagctcct atgaggggga ctgactgact ctagataagt 180 agattgaaag aattagaggt aaagtcagtg cagcagcact aatcacaatt aaaataaatg 240 ctttaatttt taaaaagcgg aaaaacatga aaggacactt cgcaagcttc tcaaaacttc 300 ctgtgatttg gagggctatt ttgagcagag tctagacgaa aactggatct gactggctcc 360 agagtaaaga tctgagaaat ggaacccagc aatttagata ttacaagagc ctgttatact 420 tgtcattttt tatttggtat ttgttaaata ttacaaaaat ggttatgctt tttaattcaa 480 aatttgacgt ttcagcatga tgatacattc ttgccttttt tcccccttcc atatagcatt 540 ttccacccca gcaagtcaac tcttttctcc tcatggttct aatccttcaa cacctgctgc 600 aactcctgtt cctactgcat ccccagtcaa ggcaattaat catccatcag catcagcagc 660 tgccaccgtt tctggaatga acctgctgaa tactgtcctt cctgtgttcc cagggcaggt 720 ctcctcagcc gttcacacac ctcagccatc aataccaaac ccaacagtta tcagaacccc 780 ttcattgccc actgcacctg ttacatccat ccacagtaca accaccactc ctgttccttc 840 cattttttct ggcctagtgt cactgccagg tccttctgcc actcctaccg cagccactcc 900 taccccagga cctacaccac ggtccactct tggttccagt gaagcatttg cttctacttc 960 tgcacctttc actagcctcc ccttttccac cagctcttct gctgcttcta ccagcaaccc 1020 aaattctgct tcattgtcat cagtttttgc agggctccct ttgcccttac caccaacatc 1080 ccaaggccta tccaacccga ctcctgtaat tgctggtggc tctactccca gcgttgccgg 1140 tccacttggt gtgaacagtc catcttttgt ctgcgttaaa aggttttctg acatccaatg 1200 acaccaattt aatcaactcc tctgctttat cctctgctgt cacaagtggg ctggcttcac 1260 tatcttctct tactcttcag aactctgact cttctgcttc agcccctaac aagtgctatg 1320 ccccatcagc catccctacc ccacagagga cttccactcc agggttggcc ctgttcccag 1380 gcctgccgtc tcccgtggct aactcaactt ccactcccct gacattgcct gtacagtctc 1440 ctttagccac tgctgcatca gcttccacgt cagtgccagt tagctgtggc tcctcagcct 1500 cccttttgcg tggcccccac ccaggtacct cagatctgca tatttcatct acccctgctg 1560 caacaactct tcctgttatg atcaaaactg agcccacaag tcctactccc tcggccttca 1620 aaggtccatc tcattctggg aatccctctc atggcacttt aggtttgtca gggacattgg 1680 gccgtgcata tacttcaaca tccgtgccca tcagtttatc tgcttgcctt aatcctgcat 1740 tgtcaggtct ctccagcttg agtactcctt taaatggttc aaatcctctt tcctctattt 1800 cccttccacc acatggttcc tccactccca ttgcaccagt attcactgct cttccttctt 1860 ttacttcttt gaccaacaat tttcctttaa ctggcaaccc atctcttaat ccgtcagtat 1920 ctctcccagg gtcattaata gccacctcat ctaccgctgc cacctccaca tctctccctc 1980 atcctagctc aacggcagct gttctctcag ggctttctgc ttcagcacca gtctcagcag 2040 cacctttccc cctcaacctg tccactgctg ttccctcact tttctctgtt actcaaggac 2100 ctctgtcatc ttcaaatccc tcctatccag gcttttctgt ctctaatacc ccaagcgtta 2160 cccctgctct tccctcattc ccggggctgc aggcgccctc tacagtcgca gctgtcacac 2220 cactacctgt ggctgccaca gccccatccc cagctccagt cctcccagga ttcgcctcag 2280 cattcagttc caatttcaac tccgctcttg ttgcacaagc cggtttatca tctggacttc 2340 aagctgcagg cagttctgtt tttccaggcc ttttgtccct cccgggtatc cctgggtttc 2400 ctcagaatcc ttcacaatca tccttgcaag aattacagca taatgcggct gcgcagtcag 2460 cattgttaca gcaggtccat tcagcttcgg ctctggaaag ctatccagct cagcctgatg 2520 ggtttcctag ttatccttca gcgccaggaa caccattttc tttgcaacca agcctgtccc 2580 agagtgggtg gcagtgaata cttttaactt ttattctcct tcagagcaac atcagaattg 2640 cctgagaact gcaatgaaca atctgacaaa tgtgaagctg gccaaaagtc ggaaaatgag 2700 aatgagggta atcctggaga aattgtgaca acaatttgaa aattgtggtt gcattttaaa 2760 gtgtgaacac tcccctatgt aaatatgctg acaataaatt gtatggagaa tggtatttaa 2820 aaagtgtttg gagacttttc acctgtccta taaaattttg aattgtgtat gtgatctaca 2880 tagaaagaat attaaagagt aggttgaact ctttatagcc gaatacagcc ttaaatatgc 2940 ttgtatagca tccactggca gaagtaatag ttgtgcctca gacttggggg ttgcatgtgg 3000 ccctggggga gttactaccc ttggtatgca tgagcggttc ctattagcat cagtgggaac 3060 tcagtactct gtatgtatcc acaaaaggga acttgagacc cacagttatt cttaatttct 3120 gatattaaca accgtacata ctgctgaatt taactcaaaa tatttcaggt aagtgaaagt 3180 ggtgcttaat gtagactata gaatgacttt caggtgtttt caactgaaag tatatatcca 3240 gaactgcatc cttatagaaa tacaagtaag acttaggata atttgccttc aaaacagttt 3300 tcctaatctc agcagtatcc agtgagtgaa gaacacttga ctgactcttg ggccacctct 3360 gttacttact gtactatgga agctcctggt gaatgtttac aattatggga tgtagtattt 3420 ctatttgtac tttaagtcaa atgcttatat gaaatatgtg acaacaaata gagaagactg 3480 gctctgttag taattatgca gtatgtactc tatttaagga tctgtggtag tataacatga 3540 gtgaatgtca ttaattttga agtaataact gccacatgtg ggaagtaggg gagtaaggag 3600 aatgaattcc aatctgtgat taaaagtgta aactatagac tctactgtag tacatttcag 3660 gatctagaag ttttactttt ataaagatgg tgtccggaag atgttgctaa tgtattttac 3720 ttcaacatag ggaacaaact ttttaagtat attaataaac ctgtatggtt agtttttaac 3780 agttttttaa aataaactat ggatatgaca aatattctgt gttttactaa gtgcttggat 3840 aggctttcta attttgtata cgtgctagag ttaattattg aacattttta tccaaattta 3900 gttgtaactc tgtttatact actgattgct cattcgttta aatgatattt taatgtaaaa 3960 gtcataacca acatatgaac agacagattt atgtctttaa acacagaatg taagctatag 4020 tttaatctga taccagttgc tggaagttgc catttgtttt tcttaaatct atacccataa 4080 aacttctttt aagattaaaa aaaaaaaaaa a 4111 66 1604 DNA Homo sapiens misc_feature Incyte ID No 1825473CB1 66 gatcttaaat ctaatagatt tcctatttcc aaaaagctcg actggagtgt tataaaacct 60 gaaaattctc ttgtgctttc tcttcttttg cttctagtta ccatcctcaa aggattggct 120 aaaagcaagc aactggattg aacaccctaa gaagaaagat tcacactgca ccaggagaca 180 tcagaaagaa tgaaaactct gccgctgttt gtgtgcatct gtgcactgag tgcttgcttc 240 tcgttcagtg aaggtcgaga aagggatcat gaactacgtc acagaaggca tcatcaccaa 300 tcacccaaat ctcactttga attaccacat tatcctggac tgctagctca ccagaagccg 360 ttcattagaa agtcctataa atgtctgcac aaacgctgta ggcctaagct tccaccttca 420 cctaataacc cccccaaatt cccaaatcct caccagccac ctaaacatcc agataaaaat 480 agcagtgtgg tcaaccctac cttagtggct acaacccaaa ttccatctgt gactttccca 540 tcagcttcca ccaaaattac tacccttcca aatgtgactt ttcttcccca gaatgccacc 600 accatatctt caagagaaaa tgttaacaca agctcttctg tagctacatt agcaccagtg 660 aattccccag ctccacaaga caccacagct gccccaccca caccttctgc aactacacca 720 gctccaccat cttcctcagc tccaccagag accacagctg ccccacccac accttctgca 780 actacacaag ctccaccatc ttcctcagct ccaccagaga ccacagctgc cccacccaca 840 cctcctgcaa ctacaccagc tccaccatct tcctcagctc caccagagac cacagctgcc 900 ccacccacac cttctgcaac tacaccagct ccactatctt cctcagctcc accagagacc 960 acagctgtcc cacccacacc ttctgcaact accctagacc catcatccgc ctcagctcca 1020 ccagagacca cagctgcccc acccacacct tctgcaacta caccagctcc accgtcttcc 1080 ccagctccac aagagaccac agctgcccca attaccacac ctaattcttc cccaactact 1140 cttgcacctg acacttctga aacttcagct gcacccacac accagactac tacttcggtc 1200 actactcaaa ctactactac taaacaacca acttcagctc ctggccaaaa taaaatttct 1260 cgatttcttt tatatatgaa gaatctacta aacagaatta ttgacgacat ggtggagcaa 1320 tagtatattg tatgttgtaa agtgttctgt catttacaag atgtgattca tgagtgcaga 1380 actaccacct ttcttttagc accaatccca acatgaaatt atattactca gatttaaagc 1440 actatcatta atctttcaat ctaattattc accaccacaa gacctattaa caagacaaaa 1500 tgcctctatc ccacaagcca gatgcaggtc tggggttcaa aataactctt tggatcctac 1560 agagatagcc tactgagggc agagaaagtc cttagataaa gaga 1604 67 2646 DNA Homo sapiens misc_feature Incyte ID No 7950094CB1 67 gcgagcgcgg gcaggcggcg acgcgggggc aggggtggac ggcggtcaga gccgaacgcg 60 agggcggcgc ccggggactg gagctgcgcg caataggaca gctggcctga agctcagagc 120 cggggcgtgc gccatggccc cacactgggc tgtctggctg ctggcagcaa ggctgtgggg 180 cctgggcatt ggggctgagg tgtggtggaa ccttgtgccg cgtaagacag tgtcttctgg 240 ggagctggcc acggtagtac ggcggttctc ccagaccggc atccaggact tcctgacact 300 gacgctgacg gagcccactg ggcttctgta cgtgggcgcc cgagaggccc tgtttgcctt 360 cagcatggag gccctggagc tgcaaggagc gatctcctgg gaggcccccg tggagaagaa 420 gactgagtgt atccagaaag ggaagaacaa ccagaccgag tgcttcaact tcatccgctt 480 cctgcagccc tacaatgcct cccacctgta cgtctgtggc acctacgcct tccagcccaa 540 gtgcacctac gtcaacatgc tcaccttcac tttggagcat ggagagtttg aagatgggaa 600 gggcaagtgt ccctatgacc cagctaaggg ccatgctggc cttcttgtgg atggtgagct 660 gtactcggcc acactcaaca acttcctggg cacggaaccc attatcctgc gtaacatggg 720 gccccaccac tccatgaaga cagagtacct ggccttttgg ctcaacgaac ctcactttgt 780 aggctctgcc tatgtacctg agagtgtggg cagcttcacg ggggacgacg acaaggtcta 840 cttcttcttc agggagcggg cagtggagtc cgactgctat gccgagcagg tggtggctcg 900 tgtggcccgt gtctgcaagg gcgatatggg gggcgcacgg accctgcaga ggaagtggac 960 cacgttcctg aaggcgcggc tggcatgctc tgccccgaac tggcagctct acttcaacca 1020 gctgcaggcg atgcacaccc tgcaggacac ctcctggcac aacaccacct tctttggggt 1080 ttttcaagca cagtggggtg acatgtacct gtcggccatc tgtgagtacc agttggaaga 1140 gatccagcgg gtgtttgagg gcccctataa ggagtaccat gaggaagccc agaagtggga 1200 ccgctacact gaccctgtac ccagccctcg gcctggctcg tgcattaaca actggcatcg 1260 gcgccacggc tacaccagct ccctggagct acccgacaac atcctcaact tcgtcaagaa 1320 gcacccgctg atggaggagc aggtggggcc tcggtggagc cgccccctgc tcgtgaagaa 1380 gggcaccaac ttcacccacc tggtggccga ccgggttaca ggacttgatg gagccaccta 1440 tacagtgctg ttcattggca caggagacgg ctggctgctc aaggctgtga gcctggggcc 1500 ctgggttcac ctgattgagg agctgcagct gtttgaccag gagcccatga gaagcctggt 1560 gctatctcag agcaagaagc tgctctttgc cggctcccgc tctcagctgg tgcagctgcc 1620 cgtggccgac tgcatgaagt atcgctcctg tgcagactgt gtcctcgccc gggaccccta 1680 ttgcgcctgg agcgtcaaca ccagccgctg tgtggccgtg ggtggccact ctggatctct 1740 actgatccag catgtgatga cctcggacac ttcaggcatc tgcaacctcc gtggcagtaa 1800 gaaagtcagg cccactccca aaaacatcac ggtggtggcg ggcacagacc tggtgctgcc 1860 ctgccacctc tcctccaact tggcccatgc ccgctggacc tttgggggcc gggacctgcc 1920 tgcggaacag cccgggtcct tcctctacga tgcccggctc caggccctgg ttgtgatggc 1980 tgcccagccc cgccatgccg gggcctacca ctgcttttca gaggagcagg gggcgcggct 2040 ggctgctgaa ggctaccttg tggctgtcgt ggcaggcccg tcggtgacct tggaggcccg 2100 ggcccccctg gaaaacctgg ggctggtgtg gctggcggtg gtggccctgg gggctgtgtg 2160 cctggtgctg ctgctgctgg tgctgtcatt gcgccggcgg ctgcgggaag agctggagaa 2220 aggggccaag gctactgaga ggaccttggt gtaccccctg gagctgccca aggagcccac 2280 cagtcccccc ttccggccct gtcctgaacc agatgagaaa ctttgggatc ctgtcggtta 2340 ctactattca gatggctccc ttaagatagt acctgggcat gcccggtgcc agcccggtgg 2400 ggggccccct tcgccacctc caggcatccc aggccagcct ctgccttctc caactcggct 2460 tcacctgggg ggtgggcgga actcaaatgc caatggttac gtgcgcttac aactaggagg 2520 ggaggaccgg ggagggctcg ggcaccccct gcctgagctc gcggatgaac tgagacgcaa 2580 actgcagcaa cgccagccac tgcccgactc caaccccgag gagtcatcag tatgagggga 2640 accccc 2646 68 3876 DNA Homo sapiens misc_feature Incyte ID No 7479484CB1 68 atgttccgac caaccacggt ggctgtagac gaggatggtg gagaagagga taaagatgag 60 tcatcaacca acagtggtgc aagtgctgtt tcttcttgtg gctttggagc cgacttctcc 120 acagataaag ggggctcctt cacgtcagta cagatcacta ataccactgg actgtcacag 180 gctcctggct tagcctccca aggtattagc tttggcatta agaataatct gggaccccca 240 ctgcagaaat tgggagtatc attttccttt gccaagaaag ctcccgtcaa acttgaatca 300 atagcatccg ttttcaagga ccatgcagag gaagggagct cagaagatgg aacgaaggct 360 gatgagaaga gctctgacca aggggtgcag aaggtgggag atactgatgg cactggtaat 420 cttgatggaa agaaagaaga tgaagaccct caggatggag ggtcccttgc ctcaacactg 480 tccaagttga aaaggatgaa acgggaagaa ggaacagggg ctacagagcc agaatattac 540 cactacatcc ccccagcaca ctgcaaggtc aaacctaatt tccccttctt actctttatg 600 agagccagtg aacagatgga aggggatcat agtgcacact caaagagtgc ccccgagaac 660 agaaaaagca gctctcccaa gccgcaaggc tgtagtaaga cagcagcaag cccaggggca 720 gaaagaacag tgagtgaagc ttctgagctg caaaaggaag ccgctgtggc tgggccttca 780 gagcctggag gtaaaactga aacaaagaaa ggctccggag gaggggaaga tgagcagagt 840 gtagagagta gggagacgtc agagagcccg atgtgtgagt ccaatcctaa agacatttct 900 caggccaccc cagcaacaaa agcaggccag ggacccaagc atcctactgg tccattcttt 960 ccagttttaa gcaaggatga aagcactgcc ctccagtggc catcagaact actcattttc 1020 accaaagcag agccttccat ctcctacagt tgtaatcctt tatactttga ctttaaactt 1080 tcaagaaaca aagatgctaa agctaaaggg acagaaaagc caaaagatgt cgcaggctcc 1140 tcaaaggatc atctccagag ccttgatcct agagaaccga ataaaagcca ggaagaggag 1200 caggatgtag tgctctcttc agaaggcaga gtggatgaac ctgcatcagg ggctgcctgt 1260 agcagcctga acaagcagga gcctgggggt agccatatgt cagaaactga agacactggg 1320 agaagccatc ctagcaagaa agaaccatca ggcaagtctc acagacacaa gaagaaaaag 1380 aaacacaaaa aatccagcaa gcacaaacgt aaacacaagg ctgacacgga agagaagagt 1440 tctaaggcag agtctgggga gaaatctaag aagcgcaaga aacgaaaacg gaagaagaac 1500 aaatcatcag ccgcagctga ttctgaacgc ggacccaaat cagaacctcc tggaagcggc 1560 agcccggcac caccgagaag gcggcgccga gctcaagatg attcccagcg gagatccctt 1620 cctgctgaag aaggaaacag tggcaagaag gatgatggtg ggggtggtag cagttgccaa 1680 gatcacagtg ggaggaaaca caaaggtgaa ccaccaactt cctcctgcca gcggagagct 1740 aacaccaaac atagcagccg gtccagccat cggagccaac ccagtagtgg tgatgaggat 1800 agtgatgatg cttcctcaca ccgactgcac cagaagtctc catcccagta cagtgaggag 1860 gaggaagagg aggaggagga agaagaggag gaagatgaag actccggtag tgagcattct 1920 cgtagccgct ctcggtctgg ccatcgccat tcctcacatc gttcctcccg gcgctcttat 1980 tctagcagct ctgatgcctc ttcagaccag agctgctata gtagacagca cagttactct 2040 gatgatagct atagtgacta tagcgaccga tcacgaaggc actctaagcg ctctcacgat 2100 tcagatgatt cagactatac cagctccaaa cacaggtcta aacgacacaa atactcatca 2160 tctgatgatg actatagcct cagttgcagc cagtcccgaa gccgatctcg gagtcataca 2220 agggagcgat caagatcccg gggtcgaagc cgcagtagca gctgtagtcg cagtcgaagc 2280 aagaggagaa gtcgcagcac cacagcccac agctggcagc gaagccgaag ctatagccgg 2340 gaccggagcc gcagcaccag gagcccttct cagagatcag gctccagaaa gggctcatgg 2400 ggtcatgaga gcccagagga aaggcgctct ggccgccggg atttcattcg ttcaaagatc 2460 taccgctctc aatcccccca ctatttccaa tcaggtcggg gagaaggtcc tggaaagaaa 2520 gaagatggca gaggagatga cagtaaagga gcaggcctgc cctcccagaa tagcaatact 2580 ggcacaggaa gggggtcaga aagtgactgc agtcctgaag ataagaattc tgttactgcc 2640 agactgctgc tagagaagat ccagtccagg aaagtggaga ggaaacccaa tgtgtgcgag 2700 gaggtgctgg ccacccctaa taaggctggg ctcaagtaca agaacccccc acaaggttac 2760 tttgggccta agctcccccc gtctcttggt aataagcctg ttcttccaat gatagggaag 2820 cttccagcta cccggaagtc caataagaaa tgtgaagagt ctggcttaga aaggggagaa 2880 gagcaggaac attcagagcc agaagaaggg tccccaagga gtagtgatgc tccatttggg 2940 catcagttct cagaggaagc agctggtccc ttatcagacc ctcccccaga agagccaaag 3000 tctgaagaag ctactgctga tcactctgtg gctccgctag gcaccccagc ccacactgac 3060 tgctaccctg gggatccagc catctcccat aactacctcc cggaccccag tgatggggat 3120 actctggagt ctctggatag tggcagtcaa ccaggccctg tggaatccag cttgctgcct 3180 atagccccag accttgagca cttccccaat tatgcacctc ccagtgggga acctagtatt 3240 gaatcaacag atgggactga ggatgcctcc ttggctcctc tcgagagcca gcccatcacc 3300 ttcacccctg aggagatgga gaagtacagc aagctccagc aggctgcaca gcagcacatc 3360 cagcagcagc ttctggccaa acaagtgaag gcctttccag cctccaccgc cctagctcca 3420 gccacaccag ccctgcagcc catccacatt cagcagccag ccacagcctc tgccacctcc 3480 atcaccactg ttcagcatgc catcctacag catcatgctg cagccgctgc tgccgccatt 3540 ggcattcacc ctcaccccca ccctcagccg cttgctcaag tacatcatat tccccagccc 3600 catctaaccc ctatttcttt gtcccatctc actcactcaa ttatccctgg ccaccctgcc 3660 acctttcttg ctagccaccc tatccatata attcctgcct cagccatcca tcctgggccc 3720 ttcacctttc atcccgtccc acacgctgcc ctctacccca ccctgcttgc cccacggcct 3780 gctgcagcag ctgccacagc cctccatctt cacccactgc ttcaccccat cttctcaggt 3840 caggacctgc agcaccctcc cagccatggg acttga 3876 69 2583 DNA Homo sapiens misc_feature Incyte ID No 6780147CB1 69 ggtggcgggt ggctggcggt tccgttaggt ctgagggagc gatggcggta cgcgcgttga 60 agctgctgac cacactgctg gctgtcgtgg ccgctgcctc ccaagccgag gtcgagtccg 120 aggcaggatg gggcatggtg acgcctgatc tgctcttcgc cgaggggacc gcagcctacg 180 cgcgcgggga ctggcccggg gtggtcctga gcatggaacg ggcgctgcgc tcccgggcag 240 ccctccgcgc ccttcgcctg cgctgccgca cccagtgtgc cgccgacttc ccgtgggagc 300 tggaccccga ctggtccccc agcccggccc aggcctcggg cgccgccgcc ctgcgcgacc 360 tgagcttctt cgggggcctt ctgcgtcgcg ctgcctgcct gcgccgctgc ctcgggccgc 420 cggccgccca ctcgctcagc gaagagatgg agctggagtt ccgcaagcgg agcccctaca 480 actacctgca ggtcgcctac ttcaagatca acaagttgga gaaagctgtt gctgcagcac 540 acaccttctt cgtgggcaat cctgagcaca tggaaatgca gcagaaccta gactattacc 600 aaaccatgtc tggagtgaag gaggccgact tcaaggatct tgagactcaa ccccatatgc 660 aagaatttcg actgggagtg cgactctact cagaggaaca gccacaggaa gctgtgcccc 720 acctagaggc ggcgctgcaa gaatactttg tggcctatga ggagtgccgt gccctctgcg 780 aagggcccta tgactacgat ggctacaact accttgagta caacgctgac ctcttccagg 840 ccatcacaga tcattacatc caggtcctca actgtaagca gaactgtgtc acggagcttg 900 cttcccaccc aagtcgagag aagccctttg aagacttcct cccatcgcat tataattatc 960 tgcagtttgc ctactataac attgggaatt atacacaggc tgttgaatgt gccaagacct 1020 atcttctctt cttccccaat gacgaggtga tgaaccaaaa tttggcctat tatgcagcta 1080 tgcttggaga agaacacacc agatccatcg gcccccgtga gagtgccaag gagtaccgac 1140 agcgaagcct actggaaaaa gaactgcttt tcttcgctta tgatgttttt ggaattccct 1200 ttgtggatcc ggattcatgg actccagaag aagtgattcc caagagattg caagagaaac 1260 agaagtcaga acgggaaaca gccgtacgca tctcccagga gattgggaac cttatgaagg 1320 aaatcgagac ccttgtggaa gagaagacca aggagtcact ggatgtgagc agactgaccc 1380 gggaaggtgg ccccctgctg tatgaaggca tcagtctcac catgaactcc aaactcctga 1440 atggttccca gcgggtggtg atggacggcg taatctctga ccacgagtgt caggagctgc 1500 agagactgac caatgtggca gcaacctcag gagatggcta ccggggtcag acctccccac 1560 atactcccaa tgaaaagttc tatggtgtca ctgtcttcaa agccctcaag ctggggcaag 1620 aaggcaaagt tcctctgcag agtgcccacc tgtactacaa cgtgacggag aaggtgcggc 1680 gcatcatgga gtcctacttc cgcctggata cgcccctcta cttttcctac tctcatctgg 1740 tgtgccgcac tgccatcgaa gaggtccagg cagagaggaa ggatgatagt catccagtcc 1800 acgtggacaa ctgcatcctg aatgccgaga ccctcgtgtg tgtcaaagag cccccagcct 1860 acaccttccg cgactacagc gccatccttt acctaaatgg ggacttcgat ggcggaaact 1920 tttatttcac tgaactggat gccaagaccg tgacggcaga ggtgcagcct cagtgtggaa 1980 gagccgtggg attctcttca ggcactgaaa acccacatgg agtgaaggct gtcaccaggg 2040 ggcagcgctg tgccatcgcc ctgtggttca ccctggaccc tcgacacagc gagcgggaca 2100 gggtgcaggc agatgacctg gtgaagatgc tcttcagccc agaagagatg gacctctccc 2160 aggagcagcc cctggatgcc cagcagggcc cccccgaacc tgcacaagag tctctctcag 2220 gcagtgaatc gaagcccaag gatgagctat gacagcgtcc aggtcagacg gatgggtgac 2280 tagacccatg gagaggaact cttctgcact ctgagctggc cagcccctcg gggctgcaga 2340 gcagtgagcc tacatctgcc actcagccga ggggaccctg ctcacagcct tctacatggt 2400 gctactgctc ttggagtgga catgaccaga caccgcaccc cctggatctg gctgagggct 2460 caggacacag gcccagccac ccccaggggc ctccacaggc cgctgcataa cagcgataca 2520 gtacttaagt gtctgtgtag acaaccaaag aataaatgat tcatggtttt ttttaaaaaa 2580 aaa 2583 70 6147 DNA Homo sapiens misc_feature Incyte ID No 7204554CB1 70 tgatatatag ggccatgctt atctagcatg catgctcgag acgcgcgcat atgtgctgga 60 aagggcgggg cgcgccccgg ggcggcgggg ctgaagctcc tggcaccatg atgctcaccc 120 cagcaggacc agagcaccga ggcccaaggc cccagcctgc catgccgctg ccaccgcgga 180 gcctgcaggt gctcctgctg ctgctgctgt tgctgctgct gctgccgggc atgtgggctg 240 aggcaggctt gcccagggca ggcgggggtt cacagccccc cttccgcacc ttctcggcca 300 gcgactgggg cctcacccac ctagtggtgc atgagcagac aggcgaggtg tatgtgggcg 360 cagtgaaccg catctataag ctgtcgggga acctgacact gctgcgggcc cacgtcacgg 420 gccctgtgga ggacaacgag aagtgctacc cgccgcccag cgtgcagtcc tgcccccacg 480 gcctgggcag tactgacaac gtcaacaagc tgctgctgct ggactatgcc gctaaccgcc 540 tgctggcctg tggcagcgcc tcccagggca tctgccagtt cctgcgtctg gacgatctct 600 tcaaactggg tgagccacac caccgtaagg agcactacct gtccagcgtg caggaggcag 660 gcagcatggc gggcgtgctc attgccgggc caccgggcca gggccaggcc aagctcttcg 720 tgggcacacc catcgatggc aagtccgagt acttccccac actgtccagc cgtcggctca 780 tggccaacga ggaggatgcc gacatgttcg gcttcgtgta ccaggatgag tttgtgtcat 840 cacagctcaa gatcccttcg gacacgctgt ccaagttccc ggcctttgac atctactatg 900 tgtacagctt ccgcagcgag cagtttgtct actacctcac gctgcagcta gacacacagc 960 tgacctcgcc tgatgccgcc ggcgagcact tcttcacgtc caagatcgtg cggctctgtg 1020 tggacgaccc caaattctac tcgtacgttg agttccccat tggctgcgag caggcgggtg 1080 tggagtaccg cctggtgcag gatgcctacc tgagccggcc cggccgtgcc ctggcccacc 1140 agctgggcct ggctgaggac gaggacgtgc tgttcactgt gttcgcccag ggccagaaga 1200 accgcgtgaa gccaccaaag gagtcagcac tgtgcctgtt cacgctcagg gccatcaagg 1260 agaagattaa ggagcgcatc cagtcctgct accgtggtga gggcaagctc tccctgccgt 1320 ggctgctcaa caaggagctg ggctgcatca actcgcccct gcagatcgat gacgacttct 1380 gcgggcagga cttcaaccag cccctggggg gcacagtcac cattgagggg acgcccctgt 1440 tcgtggacaa ggatgatggc ctgaccgccg tggctgccta tgactatcgg ggccgcactg 1500 tggtattcgc cggcacgcga agtggccgca tccgcaagat cctggtggac ctctcaaacc 1560 ccggtggccg gcctgccctg gcctacgaga gcgtcgtggc ccaggagggc agccccatcc 1620 tgcgagacct cgtcctcagc cccaaccacc agtacctcta cgccatgacc gagaagcagg 1680 tgacgcgggt gcctgtggag agctgtgtgc agtacacgtc ctgtgagctg tgtctggggt 1740 cacgggaccc ccactgtggc tggtgtgtcc tgcacagcat ctgctcgcgg cgggacgcct 1800 gtgagcgagc agacgagccc cagcgctttg ctgcggacct gctgcagtgt gtgcagctga 1860 ctgtgcagcc ccgcaatgtg tctgtcacca tgtcccaggt cccacttgtg ctgcaggcct 1920 ggaacgtgcc tgacctctca gctggcgtca actgctcctt cgaggacttc acggaatctg 1980 agagcgtcct ggaggatggc cggatccact gccgctcacc ctccgcccgg gaggtggcgc 2040 ccatcacgcg gggccaggga gaccagcggg tggtgaaact ctacctaaag tccaaggaga 2100 cagggaagaa gtttgcgtct gtggacttcg tcttctacaa ctgcagcgtc caccagtcct 2160 gcctgtcctg tgtcaacggc tcctttccct gccactggtg caaataccgc cacgtgtgca 2220 cacacaacgt ggctgactgc gccttcctgg agggccgtgt caacgtgtct gaggactgcc 2280 cacagatcct gccctccacg cagatctacg tgccagtggg agtggtaaaa cccatcaccc 2340 tggccgcacg gaacctgcca cagccacagt caggccagcg tggatatgag tgcctcttcc 2400 acatcccggg cagcccggcc cgtgtcaccg ccctgcgctt caacagctcc agcctgcagt 2460 gccagaattc ctcgtactcc tacgagggga acgatgtcag cgacctgcca gtgaacctgt 2520 cagtcgtgtg gaacggcaac tttgtcattg acaacccaca gaacatccag gcgcacctct 2580 acaagtgccc ggccctgcgc gagagctgcg gcctctgcct caaggccgac ccgcgcttcg 2640 agtgcggatg gtgcgtggcc gagcgccgct gctccctgcg acaccactgc gctgccgaca 2700 cacctgcatc gtggatgcac gcgcgtcacg gcagcagtcg ctgcaccgac cccaagatcc 2760 tcaagctgtc ccccgagacg ggcccgaggc agggcggcac gcggctcact atcacaggcg 2820 agaacctggg cctgcgattc gaagacgtgc gtctgggcgt gcgcgtgggc aaggtgctgt 2880 gcagccctgt ggagagcgag tacatcagtg cggagcagat cgtctgtgag atcggggacg 2940 ccagctccgt gcgtgcccat gacgccctgg tggaggtgtg tgtgcgggac tgctcaccac 3000 actaccgcgc cctgtcaccc aagcgcttca ccttcgtgac accaaccttc taccgtgtga 3060 gcccctcccg tgggcctctg tcagggggca cctggattgg catcgaggga agccacctga 3120 acgcaggcag tgatgtggct gtgtcggtcg gtggccggcc ctgctccttc tcctggagga 3180 actcccgtga gatccggtgc ctgacacccc ccgggcagag ccctggcagc gctcccatca 3240 tcatcaacat caaccgcgcc cagctcacca accctgaggt gaagtacaac tacaccgagg 3300 accccaccat cctgaggatc gaccccgagt ggagcatcaa cagcggtggg accctcctga 3360 cggtcacagg caccaacctg gccactgtcc gtgaaccccg aatccgggcc aagtatggag 3420 gcattgagag ggagaacggc tgcctggtgt acaatgacac caccatggta tgccgcgccc 3480 cgtctgtggc caaccctgtg cgcagcccac cagagctggg ggagcggccg gatgagctgg 3540 gcttcgtcat ggacaacgtg cgctccctgc ttgtgctcaa ctccacctcc ttcctctact 3600 accctgaccc cgtactggag ccactcagcc ccactggcct gctggagctg aagcccagct 3660 ccccactcat cctcaagggc cggaacctct tgccacctgc acccggcaac tcccgactca 3720 actacacggt gctcatcggc tccacaccct gtaccctcac cgtgtcggag acgcaactgc 3780 tgtgcgaggc gcccaacctc actgggcagc acaaggtcac ggtgcgggca ggtggcttcg 3840 agttctcgcc agggacactg caggtgtact cggacagcct gctgacgctg cctgccattg 3900 tgggcattgg cggaggcggg ggtctcctgc tgctggtcat cgtggctgtg ctcatcgcct 3960 acaagcgcaa gtcacgagat gctgaccgca cactcaagcg gctgcagctc cagatggaca 4020 acctggagtc ccgcgtggcc ctcgaatgca aggaagcctt tgcagagctg cagacagaca 4080 tccacgagct gaccaatgac ctggacggtg ccggcatccc cttccttgac taccggacat 4140 atgccatgcg ggtgctcttt cctgggatcg aggaccaccc tgtgctcaag gagatggagg 4200 tgcaggccaa tgtggagaag tcgctgacac tgttcgggca gctgctgacc aagaagcact 4260 tcctgctgac cttcatccgc acgctggagg cacagcgcag cttctccatg cgcgaccgcg 4320 ggaatgtggc ctcgctcatc atgacggccc tgcagggcga gatggaatac gccacaggcg 4380 tgctcaagca gctgctttcc gacctcatcg agaagaacct ggagagcaag aaccacccca 4440 agctgctact gcgccggact gagtcggtgg cagagaagat gctaactaac tggttcacct 4500 tcctcttgta taagttcctc aaggagtgcg ctggggagcc gctgttcatg ctgtactgcg 4560 ccatcaagca gcagatggag aagggcccca ttgacgccat cacgggtgag gcacgctact 4620 ccctgagtga ggacaagctc atccggcagc agattgacta caagacactg accctgaact 4680 gtgtgaaccc tgagaatgag aatgcacctg aggtgccggt gaaggggctg gactgtgaca 4740 cggtcaccca ggccaaggag aagctgctgg acgctgccta caagggcgtg ccctactccc 4800 agcggcccaa ggccgcggac atggacctgg agtggcgcca gggccgcatg gcgcgcatca 4860 tcctgcagga cgaggacgtc accaccaaga ttgacaacga ttggaagagg ctgaacacac 4920 tggctcacta ccaggtgaca gacgggtcct cggtggcact ggtgcccaag cagacgtccg 4980 cctacaacat ctccaactcc tccaccttca ccaagtccct cagcagatac gagagcatgc 5040 tgcgcacggc cagcagcccc gacagcctgc gctcgcgcac gcccatgatc acgcccgacc 5100 tggagagcgg caccaagctg tggcacctgg tgaagaacca cgaccacctg gaccagcgtg 5160 agggtgaccg cggcagcaag atggtctcgg agatctactt gacacggcta ctggccacca 5220 agggcacact gcagaagttt gtggacgacc tgtttgagac catcttcagc acggcacacc 5280 ggggctcagc cctgccgctg gccatcaagt acatgttcga cttcctggat gagcaggccg 5340 acaagcacca gatccacgat gctgacgtgc gccacacctg gaagagcaac tgcctgcccc 5400 tgcgcttctg ggtgaacgtg atcaagaacc cacagtttgt gttcgacatt cacaagaaca 5460 gcatcacgga cgcctgcttg tcggtggtgg cccagacctt catggactcc tgctccacct 5520 ctgagcacaa gctgggcaag gactcaccct ccaacaagct gctctacgcc aaggacatcc 5580 ccaactacaa gagctgggtg gagaggtact atgcagacat cgccaagatg ccagccatca 5640 gcgaccagga catgagtgcg tatctggctg agcagtcccg cctgcacctg agccagttca 5700 acagcatgag cgccttgcac gagatctact cctacatcac caagtacaag gatgagatcc 5760 tggcagccct ggagaaggat gagcaggcgc ggcggcagcg gctgcggagc aagctggagc 5820 aggtggtgga cacgatggcc ctgagcagct gagccccagc tgtgatcatc cagcatgatg 5880 cagcgtgagg acagctgagc agggaccggg acagccctca ccgcatgcgt gtggagtgtc 5940 cggtggtgct cgggccgccg cagtgcagcg actgcccggc cctccctccc ctgcctcacc 6000 cggtcgggtc ccggctcttc ctgtgtggag gtgatggtac ctgccacacc acagctgcgc 6060 acacagctgc ttgctcaggg gccgggacag cactgggtgc tcaggctggc caaggacctt 6120 cattgcctgg gcaagagctg cccagtg 6147 71 888 DNA Homo sapiens misc_feature Incyte ID No 6833247CB1 71 cgagcttact tatactggta cctttctaat ctcactacaa tatgtaacat tggtgttcga 60 tctcaagtat ttctgaatat attcccctat ccacagaaat atactctggg ggaaaaaaaa 120 tagaacaaat tcttgccgtc ctgaccattg aacaagagac taattagaca atggggctag 180 aaaaacctca aagtaaactg gaaggaggca tgcatcccca gctgatacct tcggttattg 240 ctgtagtttt catcttactt ctcagtgtct gttttattgc aagttgtttg gtgactcatc 300 acaacttttc acgctgtaag agaggcacag gagtgcacaa gttagagcac catgcaaagc 360 tcaaatgcat caaagagaaa tcagaactga aaagtgctga agggagcacc tggaactgtt 420 gtcctattga ctggagagcc ttccagtcca actgctattt tcctcttact gacaacaaga 480 cgtgggctga gagtgaaagg aactgttcag ggatgggggc ccatctgatg accatcagca 540 cggaagctga gcagaacttt attattcagt ttctggatag acggctttcc tatttccttg 600 gacttagaga tgagaatgcc aaaggtcagt ggcgttgggt ggaccagacg ccatttaacc 660 cacgcagagt attctggcat aagaatgaac ccgacaactc tcagggagaa aactgtgttg 720 ttcttgttta taaccaagat aaatgggcct ggaatgatgt tccttgtaac tttgaagcaa 780 gtaggatttg taaaatacct ggaacaacat tgaactagaa actcagaaag tggtccttgt 840 gatggaaaga gaaaagaaaa accaattaga ataaggcaga atgtacgt 888 72 3582 DNA Homo sapiens misc_feature Incyte ID No 4148119CB1 72 ctggccacac cgaaagagag cccacccaag tctgaggaac cacacccgga gcagttccga 60 aaagcgaggg agacttcccc tgatctggaa agggtgccag gcacttcagc accatcggca 120 gccccagccc ctcacccacg gcaagagagg cagagcggct ctcaccgggt ccagaccggc 180 ccagcccacc ataatggtca aaagaaggcc aagctctgga aggtgggaac aactgaggca 240 gatggggaca gtaaagccag atggaccgcg cttgagcctt catctccacc agggacccag 300 gccaccttcc cagttccata cctcttcagc ctcaggtccc tcttgactga gcccagcgtc 360 accgccccca agaaagttcc ccaatcaccc tgtcccacgc tgggccacct gcttccctcc 420 ctgaaggctg tccctaagct gtgggtattt atcctactaa ggaggctggg acagagtcct 480 gacctgcacc catctgttcc caacccacca gccttcaaac aagggggctc ctcctccccg 540 gggcagctct ggcctctgct gggggccagt cgaggcagat agaagggtga gcctaaccaa 600 tgacccaacg cccccttccc aattaactac cgccttccaa cggaatccaa gggaatccct 660 catccccaaa acttcaccgc ggaaggatct gcggggactg acaggcagaa gccaggcaca 720 gggatatccg aacagcctca gtcttgctac ccaactctgc cttcaagaca ttccaatctg 780 atgggaagag tcctgtctgg gaagctccct gtctgatggg agacagccct gtccacatgg 840 aggtctcagt ctgacggagg aaacagcctg gccagccagg cccaggccga caggggagac 900 acagtccctg cccaaggagc ttccaagcta agggcggaac cacagccaag cccagggagc 960 tcccaggcta agggcggaga ctgtcccagc ccagggagct cccagtcaaa agggggagac 1020 acagcactgc ccttacaaag ctaccagcct cacggagaag gcgcagtccc tgtccacaga 1080 gacacagcct tgccccagtt actgcccacc tgcaagagat ccacatttct gccctccaga 1140 gctcccaaac tgatggggga gagagacatc atcccccagc tctgggagtt tccagtctga 1200 tggaggagac agagcctgct tcggtaactc tcactctgcg ggggaagact cagccctatc 1260 cagggagctc ccacactttc aatggggagg cccacccagt ggccgagcct gctgctgctc 1320 ctgctgttgc cggggccccc gcccgtcgcc ggcttggaag acgctgcctt cccccacctg 1380 ggggagagct tgcagcccct gccccgggcc tgtcccctgc gctgctcctg cccccgagtc 1440 gacactgtgg actgtgatgg cttggacctt cgagtgttcc cggacaacat caccagagcc 1500 gctcagcacc tctccctgca gaacaaccag ctccaggaac tcccctacaa tgagctgtcc 1560 cgcctcagtg gcctgcgaac cctcaacctc cacaacaacc tcatctcctc cgaaggcctg 1620 cctgacgagg ccttcgagtc cctcacccag ctgcagcacc tctgcgtggc tcacaacaag 1680 ctctcagtgg cccctcagtt tctgccccgg tccctccgtg tcgcggatct ggctgccaac 1740 caagtgatgg agatcttccc cctcaccttt ggggagaagc cggtactcag gtccgtgtac 1800 ctccacaaca accagctgag caacgctggc ctgccccccg acgccttccg cggctccgag 1860 gccatcgcca ccctcagcct ctccaacaac cagctcagct acctgccgcc cagcctgccg 1920 ccctcactcg agcggctcca cctgcagaac aatctcatct ccaaggtgcc ccgaggagcc 1980 ctgagccgcc agactcaact ccgtgagctc tacctccagc acaaccagct gacagacagt 2040 ggcctggatg ccaccacctt cagcaagctg catagccttg aatacctgga tctctcccac 2100 aaccagctga ccacagtgcc cgccggcctg ccccggaccc tggctatcct gcacctgggc 2160 cgcaaccgca tccggcaggt ggaggcggct cggctgcacg gggcgcgtgg tctgcgctat 2220 ttgttgctgc agcacaacca gctggggagc tcagggctgc ccgccggggc tctgcggccg 2280 ctgcggggcc tgcacacgct gcacctctat ggcaatgggc tggaccgcgt gcctccagcc 2340 ctgccccgcc gcctgcgtgc cctggtgctg ccccacaacc acgtggccgc gctgggtgcc 2400 cgtgacctgg tcgccacacc gggcctgacg gagcttaacc tggcctataa ccgcctggcc 2460 agcgcccgtg tgcaccaccg ggccttccgc cggttgcgtg ccctgcgcag cctcgacctg 2520 gcagggaatc agctaacccg gctgcccatg ggcctgccca ctggcctgcg caccctgcag 2580 ctgcaacgca accagctgcg gatgctcgag cccgagcctc tggccggcct ggaccaactg 2640 cgggagctca gcctggcgca caaccggctc cgggtcggcg acatcgggcc aggcacctgg 2700 catgagctcc aagccctcca gatgctggac ctcagccaca atgagctgtc ctttgtgccc 2760 ccggacctgc ctgaggccct agaggagctg cacctcgagg gcaaccgcat cggccacgtg 2820 ggccccgagg ccttcctcag cacaccccgc ctgcgtgccc tcttcctcag ggccaacagg 2880 cttcacatga cgagcatcgc ggctgaggcc ttcctggggc tcccaaacct gcgtgtggtg 2940 gacacggcag ggaatccgga gcaggtcctg atccggctgc ctcccaccac cccacgtggg 3000 ccacgggcag ggggcccctg atcctagaga ggcccagcag agcagctcag actcctggga 3060 ctccgctggg ccgtggactg aggagacaac gcccaccagg ggcccttggt ctggctctcc 3120 tgggcctcca gggctgggcc tgctctgcct gccactggcc gagacacaga ggcacacagc 3180 tggcatactc caggctcaca gaccacgccg gcctggcggg acacacccta ccccaaactc 3240 ccaacacaga tggaggcagc aacaataaag ccaaaccctt ccagcactca gcacggacca 3300 ggcacccttc gggggctctg tccacggact cctccccaca accagtccag ctggggaaac 3360 tgaggctctg ggatgctaag tgggtcagga ctgaattttg aggtcttgag gcacacactg 3420 gggtcaccaa acagcaccct gtgcgaccta gccacgtgtg attgcaggga cgcccaaggc 3480 cacccactga aaaaacactg ggtgacagat atagggaccc tcacatgtat ccccccccac 3540 agcaagcatg ggaatgaaat gcatccttca aaaaaaaaaa aa 3582 

What is claimed is:
 1. An isolated polypeptide selected from the group consisting of: a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-36, b) a naturally occurring polypeptide comprising an amino acid sequence at least 90%o identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-36, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-36, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-36.
 2. An isolated polypeptide of claim 1 selected from the group consisting of SEQ ID NO:1-36.
 3. An isolated polynucleotide encoding a polypeptide of claim
 1. 4. An isolated polynucleotide encoding a polypeptide of claim
 2. 5. An isolated polynucleotide of claim 4 selected from the group consisting of SEQ ID NO:37-72.
 6. A recombinant polynucleotide comprising a promoter sequence operably linked to a polynucleotide of claim
 3. 7. A cell transformed with a recombinant polynucleotide of claim
 6. 8. A transgenic organism comprising a recombinant polynucleotide of claim
 6. 9. A method for producing a polypeptide of claim 1, the method comprising: a) culturing a cell under conditions suitable for expression of the polypeptide, wherein said cell is transformed with a recombinant polynucleotide, and said recombinant polynucleotide comprises a promoter sequence operably linked to a polynucleotide encoding the polypeptide of claim 1, and b) recovering the polypeptide so expressed.
 10. An isolated antibody which specifically binds to a polypeptide of claim
 1. 11. An isolated polynucleotide selected from the group consisting of: a) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:37-72, b) a naturally occurring polynucleotide comprising a polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO:37-72, c) a polynucleotide complementary to a polynucleotide of a), d) a polynucleotide complementary to a polynucleotide of b), and e) an RNA equivalent of a)-d).
 12. An isolated polynucleotide comprising at least 60 contiguous nucleotides of a polynucleotide of claim
 11. 13. A method for detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide of claim 11, the method comprising: a) hybridizing the sample with a probe comprising at least 20 contiguous nucleotides comprising a sequence complementary to said target polynucleotide in the sample, and which probe specifically hybridizes to said target polynucleotide, under conditions whereby a hybridization complex is formed between said probe and said target polynucleotide or fragments thereof, and b) detecting the presence or absence of said hybridization complex, and, optionally, if present, the amount thereof.
 14. A method of claim 13, wherein the probe comprises at least 60 contiguous nucleotides.
 15. A method for detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide of claim 11, the method comprising: a) amplifying said target polynucleotide or fragment thereof using polymerase chain reaction amplification, and b) detecting the presence or absence of said amplified target polynucleotide or fragment thereof, and, optionally, if present, the amount thereof.
 16. A composition comprising a polypeptide of claim 1 and a pharmaceutically acceptable excipient.
 17. A composition of claim 16, wherein the polypeptide has an amino acid sequence selected from the group consisting of SEQ ID NO:1-36.
 18. A method for treating a disease or condition associated with decreased expression of functional ECMCAD, comprising administering to a patient in need of such treatment the composition of claim
 16. 19. A method for screening a compound for effectiveness as an agonist of a polypeptide of claim 1, the method comprising: a) exposing a sample comprising a polypeptide of claim 1 to a compound, and b) detecting agonist activity in the sample.
 20. A composition comprising an agonist compound identified by a method of claim 19 and a pharmaceutically acceptable excipient.
 21. A method for treating a disease or condition associated with decreased expression of functional ECMCAD, comprising administering to a patient in need of such treatment a composition of claim
 20. 22. A method for screening a compound for effectiveness as an antagonist of a polypeptide of claim 1, the method comprising: a) exposing a sample comprising a polypeptide of claim 1 to a compound, and b) detecting antagonist activity in the sample.
 23. A composition comprising an antagonist compound identified by a method of claim 22 and a pharmaceutically acceptable excipient.
 24. A method for treating a disease or condition associated with overexpression of functional ECMCAD, comprising administering to a patient in need of such treatment a composition of claim
 23. 25. A method of screening for a compound that specifically binds to the polypeptide of claim 1, said method comprising the steps of: a) combining the polypeptide of claim 1 with at least one test compound under suitable conditions, and b) detecting binding of the polypeptide of claim 1 to the test compound, thereby identifying a compound that specifically binds to the polypeptide of claim
 1. 26. A method of screening for a compound that modulates the activity of the polypeptide of claim 1, said method comprising: a) combining the polypeptide of claim 1 with at least one test compound under conditions permissive for the activity of the polypeptide of claim 1, b) assessing the activity of the polypeptide of claim 1 in the presence of the test compound, and c) comparing the activity of the polypeptide of claim 1 in the presence of the test compound with the activity of the polypeptide of claim 1 in the absence of the test compound, wherein a change in the activity of the polypeptide of claim 1 in the presence of the test compound is indicative of a compound that modulates the activity of the polypeptide of claim
 1. 27. A method for screening a compound for effectiveness in altering expression of a target polynucleotide, wherein said target polynucleotide comprises a sequence of claim 5, the method comprising: a) exposing a sample comprising the target polynucleotide to a compound, under conditions suitable for the expression of the target polynucleotide, b) detecting altered expression of the target polynucleotide, and c) comparing the expression of the target polynucleotide in the presence of varying amounts of the compound and in the absence of the compound.
 28. A method for assessing toxicity of a test compound, said method comprising: a) treating a biological sample containing nucleic acids with the test compound; b) hybridizing the nucleic acids of the treated biological sample with a probe comprising at least 20 contiguous nucleotides of a polynucleotide of claim 11 under conditions whereby a specific hybridization complex is formed between said probe and a target polynucleotide in the biological sample, said target polynucleotide comprising a polynucleotide sequence of a polynucleotide of claim 11 or fragment thereof; c) quantifying the amount of hybridization complex; and d) comparing the amount of hybridization complex in the treated biological sample with the amount of hybridization complex in an untreated biological sample, wherein a difference in the amount of hybridization complex in the treated biological sample is indicative of toxicity of the test compound.
 29. A diagnostic test for a condition or disease associated with the expression of ECMCAD in a biological sample comprising the steps of: a) combining the biological sample with an antibody of claim 10, under conditions suitable for the antibody to bind the polypeptide and form an antibody:polypeptide complex; and b) detecting the complex, wherein the presence of the complex correlates with the presence of the polypeptide in the biological sample.
 30. The antibody of claim 10, wherein the antibody is: a) a chimeric antibody, b) a single chain antibody, c) a Fab fragment, d) a F(ab′)₂ fragment, or e) a humanized antibody.
 31. A composition comprising an antibody of claim 10 and an acceptable excipient.
 32. A method of diagnosing a condition or disease associated with the expression of ECMCAD in a subject, comprising administering to said subject an effective amount of the composition of claim
 31. 33. A composition of claim 31, wherein the antibody is labeled.
 34. A method of diagnosing a condition or disease associated with the expression of ECMCAD in a subject, comprising administering to said subject an effective amount of the composition of claim
 33. 35. A method of preparing a polyclonal antibody with the specificity of the antibody of claim 10 comprising: a) immunizing an animal with a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-36, or an immunogenic fragment thereof, under conditions to elicit an antibody response: b) isolating antibodies from said animal; and c) screening the isolated antibodies with the polypeptide, thereby identifying a polyclonal antibody which binds specifically to a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-36.
 36. An antibody produced by a method of claim
 35. 37. A composition comprising the antibody of claim 36 and a suitable carrier.
 38. A method of making a monoclonal antibody with the specificity of the antibody of claim 10 comprising: a) immunizing an animal with a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-36, or an immunogenic fragment thereof, under conditions to elicit an antibody response; b) isolating antibody producing cells from the animal; c) fusing the antibody producing cells with immortalized cells to form monoclonal antibody-producing hybridoma cells; d) culturing the hybridoma cells: and e) isolating from the culture monoclonal antibody which binds specifically to a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-36.
 39. A monoclonal antibody produced by a method of claim
 38. 40. A composition comprising the antibody of claim 39 and a suitable carrier.
 41. The antibody of claim 10, wherein the antibody is produced by screening a Fab expression library.
 42. The antibody of claim 10, wherein the antibody is produced by screening a recombinant immunoglobulin library.
 43. A method for detecting a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-36 in a sample, comprising the steps of: a) incubating the antibody of claim 10 with a sample under conditions to allow specific binding of the antibody and the polypeptide; and b) detecting specific binding, wherein specific binding indicates the presence of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-36 in the sample.
 44. A method of purifying a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-36 from a sample, the method comprising: a) incubating the antibody of claim 10 with a sample under conditions to allow specific binding of the antibody and the polypeptide; and b) separating the antibody from the sample and obtaining the purified polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-36.
 45. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:1.
 46. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:2.
 47. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:3.
 48. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:4.
 49. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:5.
 50. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:6.
 51. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:7.
 52. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:8.
 53. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:9.
 54. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:10.
 55. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:11.
 56. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:12.
 57. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:13.
 58. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:14.
 59. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:15.
 60. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:16.
 61. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:17.
 62. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO18.
 63. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO19.
 64. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:20.
 65. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:21.
 66. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:22.
 67. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:23.
 68. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:24.
 69. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:25.
 70. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:26.
 71. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:27.
 72. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:28.
 73. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:29.
 74. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:30.
 75. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:31.
 76. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:32.
 77. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:33.
 78. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:34.
 79. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:35.
 80. A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:36.
 81. A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID NO:37.
 82. A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID NO:38.
 83. A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID NO:39.
 84. A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID NO:40.
 85. A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID NO:41.
 86. A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID NO:42.
 87. A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID NO:43.
 88. A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID NO:44.
 89. A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID NO:45.
 90. A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID NO:46.
 91. A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID NO:47.
 92. A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID NO:48.
 93. A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID NO:49.
 94. A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID NO:50.
 95. A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID NO:51.
 96. A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID NO:52.
 97. A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID NO:53.
 98. A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID NO:54.
 99. A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID NO:55.
 100. A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID NO:56.
 101. A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID NO:57.
 102. A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID NO:58.
 103. A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID NO:59.
 104. A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID NO:60.
 105. A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID NO:61.
 106. A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID NO:62.
 107. A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID NO:63.
 108. A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID NO:64.
 109. A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID NO:65.
 110. A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID NO:66.
 111. A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID NO:67.
 112. A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID NO:68.
 113. A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID NO:69.
 114. A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID NO:70.
 115. A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID NO:71.
 116. A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID NO:72. 